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ABSTRACT 
Low vitamin B12 concentrations have been shown to be risk factors for metabolic traits in 
numerous observational studies; however, the relationship has remained inconsistent. It is 
possible that certain genotypes might jointly contribute to obesity and vitamin B12 deficiency, 
and these may be modulated by lifestyle factors (dietary factors and physical activity levels) 
across different ethnic groups. The implementation of a genetic approach to establish the 
relationship between vitamin B12 and obesity could be a more desirable option over 
observational studies, as results are less prone to confounding factors. Hence, the main aims of 
this thesis were to examine for the first time the association of common vitamin B12-related 
single nucleotide polymorphisms (SNPs) and metabolic SNPs with vitamin B12 concentrations 
and metabolic outcomes in multiple ethnic groups. In addition, the interaction between these 
SNPs and dietary factors (protein, carbohydrate and fat) on vitamin B12 concentrations and 
metabolic traits was investigated. A total of five studies with different study designs were used. 
These studies included a case-control study (Chennai Urban Rural Study; CURES, Asian India, 
n=900), three cross-sectional cohort studies [Genetics of obesity and Diabetes study (GOOD 
study; Sinhalese Sri Lankan adults, n=109), The Minangkabau Indonesia Study on Nutrition 
and Genetics (MINANG study; Indonesian women; n=118) and Brazilian adolescents (n=113)] 
and a 16 week-dietary randomized, single-blind, parallel-group dietary intervention [Dietary 
Intervention and VAScular function (DIVAS study; British adults, n=119)]. Gene-diet 
interactions were observed in the Sri Lankan and Indonesian populations between the vitamin 
B12-related SNPs and protein energy intake (%) on markers of central obesity (waist 
circumference (P=0.002) and body fat percentage (P= 0.034), respectively). In the Brazilian 
adolescent population, the metabolic and vitamin B12 related SNPs showed a significant 
interaction with carbohydrate and protein intakes on oxidised low density lipoprotein 
cholesterol (P=0.005) and homocysteine concentrations (P = 0.007), respectively, which are 
well-known independent risk factors for cardiovascular disease. Additionally, in the Indonesian 
population, an interaction was observed between vitamin B12-related SNPs and dietary fibre 
intake (g) on glycated haemoglobin levels (P =0.042), a marker of long-term glycaemic status. 
Furthermore, for the first time, a novel association between two obesity-related SNPs and 
vitamin B12 concentrations (P = 0.018) was observed in the Indian population. In summary, 
these studies in multiple ethnic groups show that the relationship between B12 deficiency and 
metabolic outcomes may be influenced by dietary factors such as protein and fibre intake. 
However, in the Indian population, we found that vitamin B12 concentrations may be 
influenced by a genetic predisposition to obesity, but without a dietary influence. Given the 
limited sample size in some of the cohorts, replication of the study findings is highly warranted. 
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cis-monounsaturated fatty acids; n–6 PUFA, polyunsaturated fatty acid; TE, total energy; TAG, 
triacylglycerol; TC, Total Cholesterol; high-density lipoprotein, HDL; low-density lipoprotein 
(LDL) 
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Chapter 1      
Introduction to the thesis 
1.1  Introduction 
Vitamin B12 is an essential water soluble micronutrient, which participates as a 
cofactor for the synthesis of DNA, fatty acids, and myelin [1]. Vitamin B12 deficiency was 
previously thought to be limited to populations with a low intake of vitamin B12-rich foods 
(mainly vegetarians) and older adults, due to their impaired absorption of the vitamin through 
food [2]. However, alarmingly high prevalence rates of low plasma vitamin B12 status have 
been recognized to exist in the Indian subcontinent, Mexico, Central and South America, and 
selected areas in Africa [3]. Symptoms of vitamin B12 deficiency include haematological and 
neurological impairment. Additionally, observational studies have shown that low vitamin B12 
concentrations are accompanied by a wide range of chronic diseases and conditions, including 
obesity, insulin dysregulation and adverse cardiometabolic outcomes [4-10].  
 Metabolic diseases such as type 2 diabetes and obesity are world-wide health problems, 
which are now increasingly diagnosed earlier in life. The metabolic diseases are generally 
caused by the interaction between environmental factors (dietary factors and sedentary 
lifestyle) and a genetic predisposition to the development of metabolic diseases [11]. Whilst 
dietary factors are an important contributor to metabolic disorders, this relationship differs 
across countries, due to the variation in food consumed worldwide [12]. Studies have shown 
that the intrauterine imbalance of vitamin B12 and folate can affect DNA methylation and 
‘programme’ the offspring to develop metabolic disorders later in life [13] providing evidence 
for interactions between genes and nutrients in the development of metabolic disease.   
Many candidate genes have been studied in relation to their potential role in vitamin 
B12 metabolism, and an association between these genes and vitamin B12 concentrations have 
22 
been confirmed [14]. To date only two Mendelian Randomization studies (an analytical tool 
used to measure the causal relations between modifiable risk factors and a clinically relevant 
outcome, using measured variation in genes of known function [15]) have explored the 
relationship between a genetically determined decrease in serum vitamin B12 concentrations 
on body mass index (BMI) [16] and cardiometabolic risk [17] highlighting the need for more 
studies. Vitamin B12 levels, which are not a homogenous phenotype, are responsive to changes 
in diet and are dependent on the quality and consumption of animal protein [18]. Therefore, 
controlling diet is recommended in preventing vitamin B12 deficiency [19]. Given that the 
genetic make-up varies from individual to individual, it is vital to examine the interactive 
effects between dietary factors and genetics on vitamin B12 concentrations and metabolic 
traits, which will ultimately allow us to personalise diet according to each ethnic sub-group 
[12]. Furthermore, other modifiable factors (e.g. physical activity), which could interact with 
genetic factors should be taken into account. 
The following chapter will (i) explain the nutritional aspects of vitamin B12 (ii) focus 
on the importance of maintaining adequate vitamin B12 concentrations (iii) describe the 
symptoms associated with vitamin B12 deficiency (iv) explain the role of genes in influencing 
circulating vitamin B12 concentrations and (vi) explain the need for a nutrigenetics approach 
to study the role of genes and diet in the development of vitamin B12 deficiency and metabolic 
traits.  
1.2 Vitamin B12 function 
Vitamin B12 in the body is crucial for normal erythropoiesis [20]. Both folate and vitamin 
B12 are required for DNA synthesis, which codes for the production of billions of erythrocytes 
daily. Deficiency of either folate or vitamin B12 leads to the inhibition of purine and 
thymidylate synthesis, which impairs DNA synthesis. As a result erythroblast apoptosis and 
anaemia persists [20]. Additionally, vitamin B12 is an essential co-factor important for cell 
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metabolism, thus a deficiency will have serious clinical consequences. The intracellular 
conversion of vitamin B12 into two active co-enzymes, methylcobalamin (cytoplasm) and 
adenosylcobalamin (mitochondria) is essential for the homeostasis of methionine and 
methylmalonic acid, respectively [21, 22].  
In the cytoplasm, methylcobalamin participates as a co-factor for the enzyme 
methionine synthase; which converts homocysteine to methionine. This reaction also depends 
on folate, where the methyl group of methyltetrahydrofolate is transferred to homocysteine, to 
produce methionine and tetrahydrofolate (Figure 1) [23]. A deficiency of vitamin B12 may 
lead to the increase in homocysteine concentration, which is a known marker of cardiovascular 
disease (CVD) [24]. Furthermore, methionine synthase is important for purine and pyrimidine 
synthesis [23].  
 
Figure 1  Synthesis of methionine 
This chemical reaction is catalysed by methionine synthase. Methylcobalamin is a co-factor 
which serves as an intermediate in the transfer of a methyl group from 
methyltetrahydrofolate to homocysteine.  
 In mammals, the mitochondrial conversion of methylmalonyl-CoA to succinyl-CoA is 
catalysed by methylmalonyl-CoA mutase an enzyme which utilizes vitamin B12 (5-deoxy 
adenosyl cobalamin) as a co-enzyme [25, 26]. Subsequently, succinyl-CoA, which is important 
for lipid and carbohydrate synthesis, enters the Krebs cycle (Figure 2) [27]. A defect in the 
conversion of methylmalonyl-CoA to succinyl-CoA can cause the build-up of methylmalonyl-
CoA which gets converts into methylmalonic acid (MMA), which has detrimental implications 
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on the nervous system. Accumulated MMA is thought to be a myelin destabiliser, where 
excessive MMA leads to the incorporation of abnormal fatty acids into the myelin sheath [28, 
29].  
 
Figure 2 Succinyl-CoA synthesis 
 This chemical reaction is catalysed by methylmalonyl coenzyme A mutase (MUT). 5-deoxy-
adenosyl cobalamin is a co-factor which serves as an intermediate for the conversion of 
methylmalonyl-coA to succinyl-coA.  
1.3  Metabolism of vitamin B12 
While ingesting food, the salivary and oesophageal glands release transcobalamin-I 
(TCN1, also known as haptocorrin), which binds strongly to vitamin B12. The function of 
TCN1 is to protect vitamin B12 from acid degradation in the stomach [30]. Once vitamin B12 
reaches the duodenum, proteolytic enzymes from the pancreas release vitamin B12 from 
TCN1. Vitamin B12 then forms a new complex with intrinsic factor (IF), which is secreted by 
the gastric epithelium. The vitamin B12-IF complex interacts with the cubam receptor 
(consisting of cubilin and a receptor-associated protein) present on the apical surface of the 
distal ileal epithelium, at which the complex enters by endocytosis in the ileum [25].  Upon 
internalization, IF is degraded in enterocyte lysosomes, releasing the free vitamin B12 to the 
cytosol  in the form of hydroxocobalamin [31]. Next, hydroxocobalamin is either transformed 
into methylcobalamin in the cytoplasm or to adenosylcobalamin in the mitochondria [32]. 
Alternatively, vitamin B12 is transported into portal circulation by the ABC drug transport 
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protein (ABCC1), also known as multidrug resistance protein (MRP1) [25, 33]. Vitamin B12 
then binds to transcobalamin II (TC), which is then secreted into circulation and is transported 
as holotranscobalamin (holoTC) in serum and is distributed to tissues including the liver by 
receptor-mediated endocytosis [33].  
 In healthy adults, approximately 50-90% of vitamin B12 is stored in the liver as 
adenosylcobalamin (2000-5000 µg) [34, 35]. The remainder of vitamin B12 is stored in muscle, 
skin and blood plasma [36]. Approximately, 2-5 µg of vitamin B12 is lost daily as a result of 
cellular metabolism, irrespective of how much vitamin B12 is stored in the body [36]. Vitamin 
B12 is also excreted into bile (500 µg - 5000 µg) and is reabsorbed across the ileal enterocyte. 
Very small amounts of vitamin B12 absorption (1%–2% of an oral dose) occur by passive 
diffusion, and this route of absorption especially important for populations with limited or no 
intrinsic factor present (e.g., patients with gastric bypass surgery) [2]. 
1.4  Dietary sources and Bioavailability of vitamin B12 
1.4.1 Bioavailability of vitamin B12 
The intake of dietary vitamin B12 cannot be used as a sole measure of nutritional status. It 
is important to take into consideration how much of the vitamin B12 from the food source can 
be used systematically through normal body functions [37]. At present, the bioavailability of 
vitamin B12 is assumed to be between 40-50% for healthy adults with normal gastrointestinal 
functioning [37].  
Absorption of vitamin B12 are traditionally assessed by measuring faecal extraction of 
radioactivity, after consuming 100g of a food item labelled with radioactive vitamin B12 [38]. 
In healthy humans, the absorption of vitamin B12 has shown to vary according to the type and 
quantity of protein consumed within the diet [19]. Studies assessing bioavailability of B12 from 
different food sources in healthy participants showed that the absorption of vitamin B12 was 
better in milk (65%) and chicken (61-65%), in comparison to eggs (24-36%) [38-41].  
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A further issue to take into consideration, when discussing bioavailability, is that IF-
vitamin B12 receptors (present on the distal ileal epithelium), can be saturated and absorb a 
certain amount of vitamin B12 [38]. It is thought that  approximately 1.5-2.0 µg of vitamin B12 
can be absorbed from a meal, however other studies have reported higher absorption rates (up 
to 6 µg from a single meal) [37]. Bioavailability of vitamin B12 increases as the vitamin B12 
content in food increases up to a certain point, and then it decreases if the vitamin B12 content 
is higher than the absorption capacity of the IF-vitamin B12 receptors [38].  
Consuming processed food, improving hygiene and reheating cooked foods are some 
factors which reduce the bioavailability of vitamin B12 in foods [19]. Furthermore, the 
overgrowth of intestinal bacteria (because of poor dietary intake, antibiotics and stress), leads 
to the competitive uptake of vitamin B12 by bacteria and interferes with the bioavailability of 
vitamin B12 [42]. 
1.4.2 Nutritional Aspects of vitamin B12 
Vitamin B12 is synthesized from bacteria growing in soil, sewage, water and the 
intestinal lumen of animals. Vitamin B12 enters animal tissues when animals ingest vitamin 
B12-producing bacteria present on legumes/roots or produced in the animal’s rumen [38]. 
Although, micro-organisms in the human colon synthesize vitamin B12, humans cannot absorb 
it, as the majority of vitamin B12 is absorbed in the small intestine [43]. Consequently, the 
main sources of biologically active vitamin B12 vitamers are derived from animal products, 
such as milk, eggs, seafood and poultry [38]. Excellent sources of vitamin B12 include the 
livers of ruminant animals as well as shellfish, fish and fish roe (Table 1) [38, 43]. 
Table 1: Contents of uncooked foods containing a high vitamin B12 content 
Sources of B12 Vitamin B12 content (µg/100 g) a 
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Beef liver 60-122b 
Shellfish1 2-58 
Fish2 3.0-8.0 
Fish roe3 18 
The data has been extracted from a national Food composition data bank (The Danish National 
Food Institute, 2015). The data should be treated as an estimate, given that the food data base 
did not disclose how the levels of vitamin B12 were obtained. 
1 Clam, scallop, mussel, shrimp and oyster 
2 Salmon, trout, mackerel, and tuna 
3 Roe from Atlantic cod, lumpfish, and rainbow trout 
aThe adult UK Recommended Nutrient Intake (RNI) for vitamin B12 is 1.5 µg/day [44] 
bThe efficiency of absorption from liver is approximately 11% compared with 50% for other 
food [45]. 
It is believed that individuals following a vegan/vegetarian diet are more susceptible to 
vitamin B12 deficiency [46]. Any vitamin B12 present on plant-derived products are usually 
because of bacterial contamination. However, some plants such as dried purple laver (nori), 
mushroom fruiting bodies fermented soybeans (Tempe), and tea leaves have been found to 
contain vitamin B12 [46, 47]. Most blue-green algae (cyanobacteria) and certain edible 
shellfish contain vitamin B12 analogues which are inactive in mammals and may inhibit 
cobalamin-dependent enzymes [48]. As a result, vegetarians and vegans are reliant on vitamin 
supplements containing vitamin B12, and foods such as breakfast cereals, soy milk and 
nutritional yeast products which are fortified with vitamin B12 [43]. 
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1.4.3 Methods for the analysis of vitamin B12 in food 
Several methods have been used to determine the vitamin B12 content in foods 
including microbiological assays, chemiluminescence assays, polarographic, 
spectrophotometric and high-performance liquid chromatography [49]. The microbiological 
assay has been the most commonly used assay technique for foods, utilizing certain vitamin 
B12–requiring microorganisms, such as Lactobacillus delbrueckii subsp.lactis ATCC7830 
[19]. However, it is no longer the reference method due to the high measurement uncertainty 
of vitamin B12 [50]. Furthermore, this assay requires overnight incubation and may give false 
results if any inactive vitamin B12 analogues are present in the foods [38]. Currently, 
radioisotope dilution assay (RIDA) with labelled vitamin B12 and hog IF (pigs) have been used 
to determine vitamin B12 content in food [19]. Previous reports have suggested that the RIDA 
method is able to detect higher concentrations of vitamin B12 in foods compared to the 
microbiological assay method [19, 49]. New techniques employing more specific monoclonal 
antibodies and specific binding proteins are expected to advance the detection of vitamin B12 
in food products [51]. 
1.4.4 Recommended dietary intake of vitamin B12 
The recommended dietary intake (RDI) of vitamin B12 varies between countries. The 
European Union recommends 1 µg of vitamin B12, whilst the government of the United 
Kingdom and United States recommends a daily intake of 1.5 µg and 2.4 µg, respectively [23]. 
The requirements of vitamin B12 also varies according to age and whether a woman is pregnant 
or lactating, as shown in Table 2. 
Table 2: Recommended Dietary Allowance (RDA)/ Recommended Nutrient Intake 
(RNI) for vitamin B12  
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Age or condition Vitamin B12 requirement 
(µg/day) in healthy U.S 
and Canadian populations 
[45] 
Age or 
condition 
Vitamin B12 
requirement 
(µg/day) in a healthy 
UK population [44] 
Pregnant 2.6 Pregnant 1.5 
Breast-feeding 2.8 Breast-feeding 2.0 
0-6 mo 0.4 0-6 mo 0.3 
7-12 mo 0.5 7-12 mo 0.4 
1-3 yr 0.9 1-3 yr 0.5 
4-8 yr 1.2 4-6 yr 0.8 
9-13 yr 1.8 7-10 yr 1.0 
14-18 yr 2.4 11-14 yr 1.2 
19-50 yr 2.4 15+ yr 1.5 
51+ yr 2.4 
 
The RNI of vitamin B12 for healthy British adult men and women is 1.5 µg/day and is based 
on the estimated average requirement (EAR) of vitamin B12 which is 1.25 µg/day for over 15 
year olds (with no different recommendations for  pregnant women)[44]. Although the daily 
requirement of vitamin B12 for people over the age of 50 is the same as younger adults (1.5 
µg/day), this serves many problems. Individuals over the age of 51 years are at greater risk of 
vitamin B12 malabsorption, due to inadequate stomach acid and gastritis. As a result, the US 
institute of Medicine has recommended that individuals over 51 should take vitamin B12 
supplements or consume a greater amount of fortified vitamin B12 products [45, 50]. The 
storage of vitamin B12 in the body is approximately 1000 - 5000 µg, which is relatively high 
[23]. Therefore, vitamin B12 deficiency may not appear for several years, until stores deplete. 
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However, an inadequate dietary consumption of vitamin B12 is recommended to prevent the 
onset of vitamin B12 deficiency.  
For pregnant women in the UK, the RNI (1.5 µg/day) does not take into consideration 
the foetal deposition of vitamin B12 (0.10-0.2 µg/day). Furthermore, there is evidence that the 
maternal absorption of vitamin B12 is more efficient during pregnancy. During lactation, the 
RNI is further increased to 2.0 µg/day to take account of the approximate secretion of 0.33 µg 
vitamin B12/day in breast milk [38, 45].  
1.5  Vitamin B12 deficiency 
1.5.1 Symptoms of vitamin B12 deficiency 
The clinical manifestations of vitamin B12 deficiency vary in severity and can affect 
multiple systems in the body. The following section summarizes the current knowledge of the 
adverse functional effects of vitamin B12 deficiency.  
1.5.2 Prevalence of vitamin B12 deficiency from world-wide studies 
According to the World Health Organization (WHO), vitamin B12 deficiency may be 
considered a global public health problem affecting millions of individuals [52]. However, the 
incidence and prevalence of vitamin B12 deficiency worldwide is unknown due to the limited 
population-based data available (Table 3).  
Developed countries such as the United States, Germany and the United Kingdom have 
relatively constant mean vitamin B12 concentrations [3]. The data from the National Health 
and Nutrition Examination Survey (NHANES) reported the prevalence of serum vitamin B12 
concentrations in the United States population between 1999 to 2002 [53, 54]. Serum vitamin 
B12 concentrations of <148 pmol/L was present in < 1% of children and adolescents. In adults 
aged 20-39 years, concentrations were below this cut-off in ≤3% of individuals. In the elderly 
(70 years and older), ≈ 6% of persons had a vitamin B12 concentration below the cut-off. 
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Furthermore, ≈ 14-16% of adults and >20% of elderly individuals showed evidence of marginal 
vitamin B12 depletion (serum vitamin B12: 148-221 pmol/L) [53, 54]. In the United Kingdom, 
a National Diet and Nutrition Survey (NDNS) was conducted in adults aged between 19 to 64 
years in 2000–2001 [55] and in elderly individuals (≥ 65 years) in 1994–95 [56]. Six percent 
of men (n = 632) and 10% of women (n = 667) had low serum vitamin B12 concentrations, 
defined as <150 pmol/L. In a subgroup of women of reproductive age (19 to 49 years), 11% 
had low serum B12 concentrations <150 pmol/L (n=476). The prevalence of vitamin B12 
deficiency increased substantially in the elderly, where 31% of the elderly had vitamin B12 
levels below 130 pmol/L. In the most recent NDNS survey conducted between 2008-2011, 
serum vitamin B12 was measured in 549 adults [57]. The mean serum vitamin B12 
concentration for men (19-64 years) was 308 pmol/L, of which 0.9% of men had low serum 
B12 concentrations <150 pmol/L. In women aged between 19-64 years, the mean serum 
vitamin B12 concentration was slightly lower than men (298 pmol/L), with 3.3% having low 
vitamin B12 concentrations <150 pmol/L [57]. In Germany, a national survey in 1998 was 
conducted in 1,266 women of childbearing age. Approximately, 14.7% of these women had 
mean serum vitamin B12 concentrations of <148 pmol/L [58]. 
 Few studies have reported vitamin B12 status on a national level in non-Western 
countries [59]. Of these reported studies, vitamin B12 deficiency was prevalent among school-
aged children in Venezuela (11.4% ) [60], children aged 1-6 years in Mexico (7.7%) [61], 
women of reproductive age in Vietnam (11.7%) [62], pregnant women in Venezuela  (61.34%) 
[60] and in the elderly population (>65 years) in New Zealand (12%) [63]. Currently, there are 
no nationally representative surveys for any African or South Asian countries. However, the 
very few surveys which have investigated vitamin B12 deficiency in these countries have been 
based on local or district level data. These surveys have reported a high prevalence of vitamin 
B12 deficiency (<150 pmol/L), among 36% of breastfed and 9% of non-breastfed children 
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(n=2482) in New Delhi [64] and 47% of adults (n=204) [65] in Pune, Maharashtra, India. 
Furthermore, in Kenya a local district survey in Embu (n=512) revealed that 40% of school-
aged children in Kenya had vitamin B12 deficiency [66]. 
Table 3: Worldwide Prevalence of vitamin B12 deficiency (serum/plasma B12 < 148 or 
150 pmol/L) 
Group Number of studies Number of 
participants 
Vitamin B12 
deficiency (%) 
Children (< 1y – 18 
years) 
14 22,331 12.5 
Pregnant women 11 11,381 27.5 
Non-pregnant 
women 
16 18,520 16 
All adults (Under 60 
years) 
18 81.438 6 
Elderly (60+ years) 25 30,449 19 
Data derived from Table 2 available on https://doi.org/10.1016/bs.afnr.2017.11.005 [1] 
1.5.3 Vitamin B12 and metabolic risk in offspring 
Vitamin B12 is a critical micronutrient essential for supporting the increasing metabolic 
demands of the foetus during pregnancy [67]. B12 deficiency in pregnant women is 
increasingly common [68] and has been shown to be associated with major maternal health 
implications, including increased obesity [68], higher body mass index (BMI) [69], insulin 
resistance [67], gestational diabetes, and type 2 diabetes (T2D) in later life [70]. A study in a 
pregnant white non-diabetic population in England, found that for every 1% increase in BMI, 
there was 0.6% decrease in circulating B12 [67]. Furthermore, an animal study in ewes 
demonstrated that a B12, folate and methionine restricted diet around conception, resulted in 
offspring with higher adiposity, blood pressure and insulin resistance which could be accounted 
for altered DNA methylation patterns [71]. 
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Both vitamin B12 and folate are involved in the one-carbon metabolism cycle. In this 
cycle, vitamin B12 is a necessary cofactor for methionine synthase, an enzyme involved in the 
methylation of homocysteine to methionine [72]. DNA methylation is involved in the 
functioning of genes and is an essential epigenetic control mechanism in mammals. This 
methylation is dependent on methyl donors such as vitamin B12 from the diet [73]. Vitamin 
B12 deficiency has the potential to influence methylation patterns in DNA, besides other 
epigenetic modulators such as micro (RNAs), leading to the altered expression of genes [74, 
75]. Consequently, an altered gene expression can possibly mediate impaired foetal growth and 
the programming of non-communicable diseases [13, 74]. 
Vitamin B12 and folate status during pregnancy is associated with the increasing risk 
of low birth weight [68, 76], preterm birth [76], insulin resistance and obesity [67, 69] in the 
offspring. In addition it has been associated with adverse foetal and neonatal outcomes 
including neural tube defects (NTDs) [77-80] and delayed myelination or demyelination [81, 
82]. The mother’s B12 status can be important in determining the later health of the child, as 
shown in the Pune maternal Nutrition Study, conducted in India. In this study mothers with 
high folate concentrations and low vitamin B12 concentrations, led to babies having a higher 
adiposity and insulin resistance at age 6. In the same study, over 60% of pregnant women were 
deficient in vitamin B12 and this was considered to increase the risk of gestational and later 
diabetes in the mothers [69]. Increased longitudinal cohort studies or randomised controlled 
trials are required to understand the mechanisms between vitamin B12 and metabolic 
outcomes, and to potentially offer interventions to improve maternal and offspring health [83]. 
1.5.4 Vitamin B12 and cardiometabolic disease outcomes 
Multiple studies have explored the association between vitamin B12 and metabolic 
disease outcomes, such as obesity, insulin resistance and the development of cardiovascular 
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disease. Results from two recent studies have indicated that vitamin B12 deficiency may be 
associated with obesity during childhood. Pinhas-Hamiel et al., reported that obese children 
and adolescents (n=164) had significantly lower vitamin B12 concentrations in comparison to 
normal-weight children (n=228) [84]. The report from the Canadian Health Measurement 
Survey showed that obese children and adolescents aged 6 to 19 years were more likely to have 
an inadequate vitamin B12 status compared to those with normal weight [85]. In adults, Madan 
et al., (2006) reported that 13% of patients referred to pre-operative bariatric surgery had 
vitamin B12 deficiency [86]. On the other hand, Schweiger et al., (2010) only observed vitamin 
B12 deficiency in 3.4% of patients evaluated in bariatric surgery (n=114) [87]. In addition, in 
a study conducted in post-menopausal women, vitamin B12 concentrations decreased in 
relation to an increase in BMI [88]. A long-term study where vitamin B12 was supplemented 
across a period of 10 years, led to lower levels of weight gain in overweight or obese individuals 
(p < 0.05) [89].   
 There are several mechanisms which may explain the relationship between obesity and 
decreased vitamin B12 status. Vitamin B12 is a major dietary methyl donor, involved in the 
one-carbon cycle of metabolism and a recent genome-wide association (GWA) analysis 
showed that increased DNA methylation is associated with increased BMI in adults [90], 
consequently a  deficiency of vitamin B12 may disrupt DNA methylation and increase non-
communicable disease risk. Vitamin B12 is also a co-enzyme which converts methylmalonyl-
CoA to succinyl-CoA in the one carbon cycle. If this reaction cannot occur, methylmalonyl-
CoA levels elevate, inhibiting the rate-limiting enzyme of fatty acid oxidation (CPT1 – 
carnitine palmitoyl transferase), leading to lipogenesis and insulin resistance [9]. Further to 
this, reduced vitamin B12 concentrations in the obese population is thought to result from 
repetitive short-term restrictive diets and increased vitamin B12 requirements secondary to 
increased growth and body surface area [84, 91]. It has also been hypothesised that low vitamin 
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B12 concentrations in obese individuals are a result of wrong feeding habits, where individuals 
consume a diet low in micronutrient density [92]. Finally, vitamin B12 is involved in the 
production of red blood cells, and vitamin B12 deficiency can result in anaemia, which causes 
fatigue and the lack of motivation to exercise [89]. 
 It is important to screen vitamin B12 deficiency in obese individuals, due to its 
importance in energy metabolism, and relationship with homocysteine and its potential to 
modulate weight gain [92]. More studies are needed to test for the causality of vitamin B12 and 
obesity using genetic markers [93]. Furthermore, many studies have tested for the association 
of vitamin B12 with BMI. However, BMI does not accurately measure adiposity, and a high 
BMI does not necessary indicate that an individual is obese. More studies implementing x-ray 
absorptiometry, magnetic-resonance imaging computed tomography scans and analysing body 
fat % may be important for testing the link between obesity-related traits and vitamin B12 
concentrations [93].  
 A few studies have also reported no deficiency of vitamin B12 in obese individuals [88, 
94-96]. Lower vitamin B12 concentrations were observed in overweight Brazilian adolescents 
compared to normal-weight adolescents, however there was no statistically significant 
difference between the two groups [97]. Likewise, among Thai adults no statistically 
significant difference between overweight and obese individuals compared to normal control 
subjects was detected [98]. In the study by Baltaci et al [7], approximately 37.7% of overweight 
and 40.1% of obese Turkish individuals were deficient in vitamin B12. Despite overweight and 
obese individuals having lower B12 levels in comparison to control non-obese subjects, the 
difference between the groups were not statistically significant. In a Mendelian randomization 
study conducted in a Danish cohort [16], no significant associations were detected between  
genetically determined decreased serum vitamin B12 concentrations and BMI levels, 
indicating that there may not be a causal role of low serum vitamin B12 levels in obesity. 
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Finally, a recent literature review conducted over 19 studies, found no evidence of an inverse 
association between BMI and circulating vitamin B12 [93]. 
 Previous clinical and population-based studies have indicated that vitamin B12 
deficiency is prevalent amongst adults with type 2 diabetes [99-101]. Kaya et al., conducted a 
study in women with polycystic ovary syndrome, and found that obese women with insulin 
resistance had lower vitamin B12 concentrations compared to those without insulin resistance 
[102]. Similarly, in a study conducted in European adolescents, there was an association 
between high adiposity and higher insulin sensitivity with vitamin B12 concentrations. 
Individuals with a higher fat mass index and higher insulin sensitivity (high Homeostatic Model 
Assessment [HOMA] index) had lower plasma vitamin B12 concentrations [103]. 
Furthermore, a recent study conducted in India reported that mean levels of vitamin B12 
decreased with increasing levels of glucose tolerance e.g. individuals with type 2 diabetes had 
the lowest values of vitamin B12, followed by individuals with pre-diabetes and normal 
glucose tolerance, respectively [5]. However, B12 levels of middle aged-women with and 
without metabolic syndrome [104] showed no difference in vitamin B12 levels between those 
with insulin resistance (IR) and those without. It is believed that malabsorption of vitamin B12 
in diabetic patients, is due to individuals taking metformin therapy (an insulin sensitizer used 
for treating type 2 diabetes) [105]. Furthermore, obese individuals with type 2 diabetes are 
likely to suffer from gastroesophageal reflux disease [106], and take proton pump inhibitors, 
which further increased the risk of vitamin B12 deficiency [93]. 
The investigation into the relationship between cardiovascular disease (CVD) and 
vitamin B12 has been limited, and there is still controversy as to whether primary intervention 
with vitamin B12 will lower CVD [107]. Deficiency of vitamin B12 can impair the 
remethylation of homocysteine in the methionine cycle, and result in raised homocysteine 
levels [108]. There is much evidence linking elevated homocysteine concentrations with an 
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increased risk of CVD [109], and homocysteine lowering treatments have led to improvements 
in cardiovascular reactivity and coagulation factors [110]. In adults with metabolic syndrome, 
individuals with low levels of vitamin B12 had higher levels of homocysteine compared to 
healthy subjects [111]. It is thus possible that vitamin B12 deficiency enhances the risk of 
developing cardiovascular disease in individuals who are obese [84]. Alternatively, low levels 
of vitamin B12 may increase the levels of proinflammatory proteins which may induce 
ischaemic stroke [112, 113]. 
A recent literature review conducted over seven studies, found that there was limited 
evidence to show that low vitamin B12 status increased the risk of CVD and diabetes [114]. 
Only one study by Weikert et al. reported that low vitamin B12 status increased the risk of 
cerebral ischaemia [115]. After controlling for homocysteine, the relative risk of cerebral 
ischaemia reduced by approximately 10%, suggesting that the effects of low vitamin B12 are 
partially mediated by homocysteine [115]. In two other studies, higher vitamin B12 
concentrations were associated with an increased risk of mortality, fatal and non-fatal coronary 
events [116, 117]. It is important to note that these discrepancies, may be the result of the study 
population including individuals who were diseased [116] or old [117]. Further to this, both 
studies did not assess whether individuals were taking vitamin B12 supplements or they did 
not exclude individuals with liver disease or malignancy, which is important as raised vitamin 
B12 levels could have been due to a functional deficit [114, 118]. Finally, the review did not 
identify any associations between vitamin B12 and CVD in the remaining four studies [114]. 
Currently, no data supports vitamin B12 supplementation on reducing the risk of CVD. 
In a dose-response meta-analysis of five prospective cohort studies, it was reported that the risk 
of coronary heart disease (CHD) did not change substantially with increasing dietary vitamin 
B12 intake [119]. Of these five studies, three of the studies stated a non-significant positive 
38 
association and two of the studies demonstrated an inverse association between vitamin B12 
supplementation and CHD (only one of the studies was significant) [119].  
1.5.5 Vitamin B12 and Neural tube defects (NTDs) 
Neural tube defects (NTDs), including spina bifida, encephalocele and anencephaly, are 
debilitating birth defects which result from the failure of neural fold closure during embryonic 
development. The causes of NTDs are multifactorial, including folate deficiency, genetic and 
environment factors [120]. The WHO Technical Consultation has concluded that there is 
moderate evidence for the association between low vitamin B12 status and the increased risk 
of developing NTDs [121]. Given that vitamin B12 is a co-factor for methionine synthase 
within the folate cycle. If vitamin B12 supplies are depleted, folate becomes trapped and DNA 
synthesis and methylation reactions are impaired. DNA synthesis is critical for embryonic 
development. Further to this, cell-signalling events which control gene-expression are 
controlled by methylation reactions. As a result, adequate folate and vitamin B12 is needed to 
help prevent NTDs [77]. Many studies have shown associations between maternal vitamin B12 
status and NTD affected pregnancy [77-80]. Low vitamin B12 concentrations have also been 
found in the amniotic fluid of NTD affected pregnancy [122, 123]. Additionally, a population-
based case-control study (89 women with an NTD and 422 unaffected pregnant controls) in 
Canada conducted after the fortification of folic acid in flour, found almost a tripling in the risk 
of NTD, in the presence of low maternal vitamin B12 status (indicated by holoTC)[78]. Future 
studies, using interventions with vitamin B12 supplements or fortification with vitamin B12 is 
needed to confirm the relationship between vitamin B12 and NTDs. 
1.5.6  Vitamin B12 and anaemia 
In countries where vitamin B12 deficiency is common, it is generally assumed that there 
is a greater risk of developing anaemia. However, the overall contribution of vitamin B12 
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deficiency to the global incidence of anaemia may not be significant, except in elderly 
individuals and vegetarians [124]. There are relatively few studies which have assessed the 
impact of haematological measures in response to vitamin B12 supplementation. One study in 
184 premature infants, reported that individuals given monthly vitamin B12 injections (100 
µg) or taking supplements of vitamin B12 and folic acid (100 µg/day), had higher haemoglobin 
concentrations after 10-12 weeks, compared to those only taking folic acid or those taking no 
vitamin B12 injections [125].  In deficient Mexican adult women and pre-schoolers, it was 
found that vitamin B12 supplementation did not affect any haematologic parameters [126, 
127]. Vitamin B12 deficiency is also a major factor leading to megoblastic anaemia, especially 
in those infants breastfed by strict vegetarian mothers [121, 128]. 
1.5.7 Vitamin B12 and Ageing 
Vitamin B12 has been associated with disability in the elderly including the 
development of age-related macular degeneration (AMD) and the risk of frailty [50].  
AMD is the leading cause of severe, irreversible vision loss in older adults [129]. 
During the advanced stages of AMD, individuals are impaired of carrying out basic activities 
such as driving, recognising faces and reading [130]. Several risk factors have been linked to 
AMD, including increasing age, family history, genetics, hypercholesterolemia, hypertension, 
sunlight exposure and lifestyle (smoking and diet) [131, 132]. A few cross-sectional studies 
have found associations between low vitamin B12 status and AMD cases [132, 133]. It has 
been shown that daily supplementation of vitamin B12, B6 and folate over a period of seven 
years can reduce the risk of AMD by 34% in women with  increased risk of vascular disease 
(n=5,204) [134]. However, another study failed to find an association between AMD and 
vitamin B12 status in a sample of 3,828 individuals representative of the non-institutionalized 
US population [135].  
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Frailty is a geriatric condition which is characterized by diminished endurance, 
strength, and reduced physiological function that increases an individual’s risk of mortality and 
impairs an individual from fulfilling an independent lifestyle [136]. Frailty is associated with 
an increased vulnerability to fractures, falls from heights, reduced cognitive function and more 
frequent hospitalisation [137]. The worldwide prevalence of frailty within the geriatric 
population is 13.9% [138], therefore there is an urgent need to eliminate any risk factors 
associated with frailty. Poor vitamin B status has been shown to be associated with an increased 
risk of frailty. Two cross sectional studies have reported that deficiencies of vitamin B12 were 
associated with the length of hospital stay, as observed by serum vitamin B12 concentrations 
and methylmalonic acid (MMA) concentrations [139, 140]. Furthermore, another study 
looking at elderly women (n=326), found that certain genetic variants associated with vitamin 
B12 status (Transcobalamin 2) may contribute to reduced energy metabolism, consequently 
contributing to frailty [141]. In contrast, a recent study by Dokuzlar et al., found that there was 
no association between vitamin B12 levels and frailty in the geriatric population (n=335) [142]. 
Given that there are limited studies, which have assessed the relationship between vitamin B12 
and frailty status, more longitudinal studies are needed to clarify the relationship. 
1.5.8  Vitamin B12 and neurological decline 
Severe vitamin B12 deficiency is associated with subacute combined degeneration of 
the spinal cord, which involves demyelination of the posterior and lateral columns of the spinal 
cord [23]. Symptoms include memory and cognitive impairment, sensory loss, motor 
disturbances, loss of posterior column functions and disturbances in proprioception [143, 144]. 
In advanced stages of vitamin B12 deficiency, cases of psychosis, paranoia and severe 
depression have been observed, which may lead to permanent disability if left untreated [23, 
143, 144]. Studies have shown the rapid reversal of the neurological symptoms of vitamin B12 
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deficiency, after treatment with high-dose of vitamin B12 supplementation; suggesting the 
importance of prompt treatment in reversing neurological manifestations [145].  
1.5.9 Vitamin B12 and cognitive decline 
Elderly individuals are currently assessed on vitamin B12 status during the screening 
process for dementia. Studies investigating the association between vitamin B12 
concentrations and cognitive status have produced inconclusive results [50, 146, 147]. It has 
been shown that elevated MMA concentrations are associated with decreased cognitive decline 
and Alzheimer’s Disease [148]. In addition, low vitamin B12 and folate intakes have shown 
associations with hyperhomocysteinemia, which is associated with cerebrovascular disease, 
cognitive decline and an increased risk of dementia in prospective studies [149]. 
There are limited intervention studies which have investigated the effect of 
supplementation of vitamin B12 and cognitive function. A Cochrane review, analysing two 
studies, found no effect of vitamin B12 supplementation on the cognitive scores of older adults 
[150]. A recent longitudinal study in elderly individuals, found that individuals had a higher 
risk of brain volume loss over a 5-year period, if they had lower vitamin B12 and holoTC levels 
and higher plasma tHcy and MMA levels [151]. More intervention studies are needed to 
determine the modifiable effects of vitamin B12 supplementation on cognition [50].  
1.5.10 Vitamin B12 and Osteoporosis 
There has been growing interest on the effect of low serum vitamin B12 concentrations 
on bone health [152, 153]. Recent studies have found a connection between elevated plasma 
tHcy and an increased risk of bone fractures, but is unknown whether this is related to the 
increased levels of tHcy or to vitamin B12 levels (which are involved in homocysteine 
metabolism) [154].  Results from the third NHANES conducted in the United States, found 
that individuals had significantly lower bone mass density (BMD) and higher osteoporosis rates 
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with each higher quartile of serum MMA (n= 737 men and 813 women) [155]. Given that poor 
bone mineralization has been found in individuals with pernicious anaemia [156], and that the 
content of vitamin B12 within bone cells in culture has shown to affect the functioning of bone 
forming cells (osteoblasts) [157]; it is possible that vitamin B12 deficiency is causally related 
to poor bone health.  
Randomized intervention trials investigating the association of vitamin B12 
supplementation and bone health have yielded mixed results. Two studies conducted in 
osteoporotic risk patients with hyperhomocysteinemia and individuals who had undergone a 
stroke, found positive effects between supplementation of B vitamins on BMD [158, 159]. 
However, no improvement in BMD was observed in a group of healthy older people [160]. 
Further, controlled trials are needed to confirm the impact and mechanisms vitamin B12 
deficiency has on bone mineralization [121]. 
1.5.11 Causes of B12 deficiency  
The most common reason for vitamin B12 deficiency in spite of eating a diet rich in 
animal products is poor absorption. It has been long known that vegans, lacto-ovo vegetarians 
and elderly individuals are at risk of vitamin B12 deficiency. Causes can also relate to having 
inadequate amounts of IF, gastric atrophy, intestinal disease, gastric surgery, bacterial 
overgrowth in the small intestine, alcohol consumption, a tapeworm infection, drug-nutrient 
interactions, as well as some genetic defects [45, 48, 161].  
It is well known that strict vegans are at high risk of vitamin B12 deficiency. At present, 
there are very few studies analysing the association of vitamin B12 deficiency with veganism 
in large populations. In a group of 131 vegan adults from Germany (aged 20-82 years), 
individuals who followed a vegan diet for 7.1 years, had a 1.8 increased rate of deficiency 
compared to those who adhered to a vegan diet for less than 5 years. The study showed that 
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26% of strict vegans who did not take vitamin B12 supplements, had vitamin B12 deficiency 
with a cut-off point of 110 pmol/L  [162]. Furthermore, in another study looking at 25 vegan 
adults from California aged 20 to 60 years, showed that 40% of individuals were vitamin B12 
deficit; based on either low plasma cobalamin (< 150 pmol/L), macrocytosis, or elevated serum 
MMA (>376 nmol/L) [163]. Vegans are therefore recommended to take vitamin B12 fortified 
foods or supplements to meet their recommended daily intake.  
Traditionally, vegans were suggested to be the only group at risk of vitamin B12 
deficiency, but it is now acknowledged that individuals who consume low animal source foods 
are also at risk. Lacto-ovo vegetarians and individuals from less-industrialized (where the 
consumption of meat is rare) have a greater risk of vitamin B12 deficiency compared to 
individuals who consume an omnivorous diet [48]. Evidence shows that meat contains 
comparatively more vitamin B12 (1.3 µg/100 kcal cooked meat) than milk (0.6 µg/100 kcal) 
[48]. In a recent literature review addressing the vitamin B12 deficiency rates amongst 
vegetarians, it was reported that 32% of young adult vegetarians/ lacto-ovo vegetarians had 
vitamin B12 deficiency (MMA >271 nmol/L) [164]. As a result, lacto-ovo vegetarians are 
required to take supplemental vitamin B12 to meet their nutritional needs [50]. 
Vitamin B12 deficiency is also a common condition among the elderly. Elderly 
individuals are frequently malnourished, which enhances the risk of vitamin B12 deficiency. 
Whilst some of these reasons might be the result of underlying ill health, other influences 
include problems with dentition, depression or anxiety, mobility difficulties (e.g. difficulties 
with food preparation) and the use of medications which may interfere with appetite or 
absorption of vitamin B12 [165]. Atrophic gastritis is also a common condition observed in the 
elderly, which results in the inflammation of the stomach mucous membrane. In atrophic 
gastritis, there is a reduction or absence in gastric acid secretion which is needed to release 
vitamin B12 from proteins in food. However, elderly individuals still retain the ability to absorb 
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vitamin B12 in synthetic form (as it is not protein bound), due to sufficient intrinsic factor being 
secreted [48].   
Pernicious anaemia is the final stage of an auto-immune gastritis (Type A atrophic 
gastritis). In autoimmune gastritis, parietal cells of the corpus and fundus of the stomach are 
destroyed. These parietal cells are responsible for producing hydrochloric acid and intrinsic 
factor, which is required for the uptake of vitamin B12 [166]. As there is no therapy at present 
for auto-immune gastritis, patients are required to take vitamin B12 injections, or large doses 
of vitamin B12 to prevent the development of megaloblastic anaemia and future neurological 
complications [50]. 
Vitamin B12 uptake in the ileum can be reduced by the overgrowth of bacteria or 
parasites. Intestinal bacteria may have the potential to compete for vitamin B12, convert the 
vitamin B12 into inactive analogs or impair the absorption of vitamin B12 [48]. At present, 
Helicobacter pylori infection is one of the most common gastric infections worldwide. H. 
pylori infection is characterized by gastritis, gastric and duodenal ulcers, achlorhydria and 
gastric atrophy. Numerous studies have suggested that there may be a causal relationship 
between H. pylori and food-bound vitamin B12 malabsorption [167]. Furthermore, diseases of 
the ileum such as Crohn’s Disease, chronic bowel inflammatory disease and gastrointestinal 
surgery may induce vitamin B12 malabsorption [45].  
Vitamin B12 malabsorption is also linked to genetic disorders which regulate the uptake 
and metabolism of vitamin B12. Vitamin B12 is a cofactor for methionine synthase (MS) and 
methylmalonyl CoA mutase (MCM). In order to function as a co-factor, the structure of vitamin 
B12 must be modified [168]. Obstructions in the intracellular processing of vitamin B12 into 
its co-factor forms; methylcobalamin (MeCbl) for (MS) and adenosylcobalamin (AdoCbl) for 
MCM or changes in the functional activity of MS or MCM can result in inborn errors of vitamin 
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B12 utilisation. The genetically inherited blocks can be detrimental for new-borns and children 
[168]. A number of inborn errors of intracellular vitamin B12 metabolism, designated cblA-
cblG, have been determined by biochemical analysis of radioactive metabolites and B12 
(complementation analysis). Methylmalonic acidemia (cblA, cblB, cblD variant 2), 
hyperhomocysteinemia (cblD variant 1, cblE, cblG) or combined methylmalonic acidemia and 
hyperhomocysteinemia (cblC, classic cblD, cblF) have so far been acknowledged as inborn 
errors [169]. These disorders and the genes involved in intracellular B12 metabolism are listed 
in Table 4. Further to this, vitamin B12 levels in the general population are underpinned by 
molecular mechanisms which are responsible for the absorption, distribution, metabolism and 
elimination of vitamin B12 [170]. The genetics of vitamin B12 status and genetic variation in 
different ethnicities within individuals without inborn errors of metabolism will be discussed 
in detail in chapter 2. 
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Table 4: Inborn Errors of Cobalamin Transport and Metabolism  
Disorder Gene Location Phenotype 
(Inborn errors) 
Function 
Intrinsic factor 
deficiency 
GIF 11q13 Intrinsic factor 
deficiency 
Encodes a glycoprotein 
secreted by parietal cells of 
the gastric mucosa. The gene 
encodes the protein that is 
required for adequate 
absorption of vitamin B12.  
Imerslund–
Gräsbeck syndrome 
(Megaloblastic 
anaemia 1) 
AMN 14q32 Intestinal 
absorption of 
dietary cobalamin 
is impaired (Partial 
loss of IF binding 
affinity to 
cobalamin or the 
cubam receptor 
complex) 
Involved in the transfer of the 
cubilin-vitamin B12 complex 
into the intestinal cell 
CUBN 10p12.1 It encodes the intestinal 
receptor Cubilin, which is 
expressed in the renal 
proximal tubule and intestinal 
mucosa. Cubilin recognizes 
the vitaminB12-intrinsic 
factor complex, and binds to 
another protein called 
Amnionless to facilitate the 
entry of vitamin B12 into the 
intestinal cells 
Transcobalamin 
deficiency 
(Transcobalamin II 
deficiency) 
TCN2 22q11.2 Decreased 
intestinal 
absorption of B12, 
uncorrected by 
intrinsic factor. 
It encodes a transport protein 
called transcobalamin 2 (TC), 
which binds to vitamin B12 
within the enterocyte. The 
TC-B12 complex enters the 
portal circulation and makes 
vitamin B12 available for 
cellular uptake in target 
tissues 
Haptocorrin 
deficiency  
(Transcobalamin I 
deficiency) 
TCN1 11q11–q12 Affects multiple 
specific granule 
proteins, and 
results in low 
serum B12 levels 
It encodes a glycoprotein 
called Transcobalamin 1, also 
known as haptocorrin (HC), 
which binds to vitamin B12. It 
shields dietary vitamin B12 
from the acidic environment 
of the stomach.  
Transcobalamin 
receptor deficiency 
CD320 19p13.2 Loss of a glutamate 
residue in the 
extracellular 
It encodes the membrane 
receptor transcobalamin 
receptor (TCblR), which binds 
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domain of the 
receptor. Decreased 
receptor‐mediated 
uptake of TC‐B12 
in vitro. 
to the transcobalamin-vitamin 
B12  complex, and mediates 
the uptake of vitamin B12 into 
cells 
cblA MMAA 4q31.1–q31.2 Adenosyl-
vitaminB12 
deficiency in cells 
MMAA encodes a protein that 
may be involved in the 
translocation of vitamin B12 
into the mitochondria. In 
addition, MMAA could play 
an important role in the 
protection and reactivation of 
Methylmalonyl-coA mutase 
(MCM) in vitro. 
cblB MMAB 12q24 Adenosyl-
vitaminB12 
deficiency in cells 
Adenosylates cobalamin in an 
ATP-dependent manner 
cblC MMACHC 1p23.2 The inability to 
convert cynano-
vitaminB12 into 
biological forms 
The MMACHC gene encodes 
a chaperone protein 
MMAACHC (cblC protein) 
which binds to vitamin B12 in 
the cytoplasm and appears to 
catalyse the reductive 
decyanation of 
cyanocobalamin into 
cob(II)alamin 
cblD MMADHC 2q23.2 Improper targeting 
of vitamin B12 to 
cognate enzymes 
This gene leads to the 
Branching of vitamin B12 
within the cell to either the 
cytosol or the mitochondrion 
CblE MTRR 5p15.3-p15.2 Inactive methionine 
synthase 
This gene is responsible for 
the reductive methylation of 
vitamin B12 to generate 
methylcobalamin from 
cob(II)alamin   
CblF LMBRD1 6q13 Accumulation of 
vitamin B12 within 
lysosome 
Potentially helps in the 
transport of vitamin B12 out 
of the lysosome 
CblG MTR 1q43 Homocysteine 
accumulation 
Transfers a methyl group from 
methyltetrahydrofolate to 
homocysteine to produce 
methionine 
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CblJ ABCD4 14q24.3 Accumulation of 
cobalamin within 
lysosome 
Transports vitamin B12 from 
lysosomes to the cytosol 
Methylmalonyl 
CoA mutase 
deficiency 
MUT 6p21 Methylmalonic acid 
accumulation 
The enzyme converts 
methylmalonylCoA and 
succinylCoA, reversibly.  
Data derived from Table 1 available on https://doi.org/10.1016/bs.afnr.2017.11.005  [1] and 
from Table 3 available on https://doi.org/10.1186/s12263-018-0591-9 
 
Currently there is concern that the mandatory fortification of folic acid to cereals and grains, 
may in fact conceal the macrocytic anaemia associated with vitamin B12 deficiency, 
consequently eliminating an important diagnostic tool [171]. The combination of high folate 
and low serum vitamin B12 is associated with higher concentrations of methylmalonic acid 
and homocysteine, contributing to hematologic and neurologic disturbances. The National 
Health and Nutrition Examination Survey (NHANES) collected on older adults during 1999-
2002 showed that high folate intakes were related to impaired mental functioning and cognitive 
decline among individuals with a low vitamin B12 status [172]. Considering these findings, 
there has been interest as to whether vitamin B12 fortification in flour should be implemented. 
However, as of yet there is not enough data evaluating the bioavailability of the vitamin from 
fortified flour in specific population groups (such as the elderly with food-bound vitamin B12 
malabsorption and others with gastric atrophy) to make a firm decision [121]. 
1.5.12 Drug-nutrient interactions 
There are some drugs which are thought to interfere with the absorption or metabolism 
of vitamin B12 [50]. These include H2-receptor antagonists, proton pump inhibitors and 
metformin. Cimetidine is a H2-receptor antagonist which is used to treat peptic ulcers and 
alleviate heartburn. Cimetidine inhibits the secretion of gastric acid and pepsin and has been 
reported to inhibit IF secretion [173, 174]. A >1000 mg/day dose may in fact lead to 
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malabsorption of protein-bound vitamin B12 by peptic ulcer patients (n=9 male) and normal 
subjects (n=4 male) [175], however this malabsorption was shown to be reversible upon 
discontinuation of cimetidine in another study [174] .  
Proton pump inhibitors (PPIs) such as omeprazole and lansoprazole are widely 
prescribed to treat gastroesophageal reflux disease. It has been suggested that prolonged use of 
PPIs may influence vitamin B12 status, by inhibiting gastric acid secretion. The effect of 
omeprazole on vitamin B12 absorption is dose-related, with intakes of 20 mg/day reducing 
food-bound vitamin B12 absorption by 70%, whilst 40 mg/day reducing absorption by 90% 
[176]. At present the current literature on the association between PPI usage and vitamin B12 
status is mainly based on case-reports or retrospective observational studies, which have 
produced relatively inconsistent findings [177].  
Metformin therapy is used as the first line of therapy for individuals with type 2 diabetes 
mellitus. Studies have shown that Metformin induces vitamin B12 malabsorption and impaired 
intrinsic factor secretion in the ileum [178-181]. The mechanism of metformin-related vitamin 
B12 deficiency is still under debate. Metformin delays glucose absorption in the upper small 
intestine affecting the motility of the small bowel, which stimulates bacterial overgrowth and 
consequential vitamin B12 deficiency [178, 179]. Metformin has also been shown to enhance 
competitive inhibition or inactivation of vitamin B12 absorption, leading to alterations in 
intrinsic factor (IF) levels and interactions with the cubulin endocytic receptor. Additionally, 
Metformin inhibits the calcium dependent absorption of the vitamin B12-IF complex at the 
terminal ileum [181], as a result increasing calcium intake may improve the uptake of vitamin 
B12 in metformin users [180]. 
1.6 Assessment of Vitamin B12 status  
Traditionally, measuring serum cobalamin remains the preferred choice for determining 
vitamin B12 deficiency. However, using serum vitamin B12 concentrations alone does not 
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confirm the uncertainties of underlying functional and biochemical deficiencies. Nowadays 
other methods such as measuring plasma methylmalonic acid, serum holotranscobalamin and 
plasma homocysteine are also used [23]. 
1.6.1 Vitamin B12 and Holotranscobalamin 
The measurement of serum vitamin B12 levels is the most widely used assay to screen 
vitamin B12 deficiency. However this method is rarely used alone, as it is known to have a 
poor sensitivity and specificity in detecting vitamin B12 deficiency [182]. Serum B12 assays 
measures both serum holohaptocorrin (HoloHC) and serum holotranscobalamin (holoTC). 
HoloHC, represent 70-90% of vitamin B12, but is biologically inert as no cellular receptors 
exist, except on the liver. On the other hand, HoloTC contains biologically active vitamin B12, 
which can be taken up by cells, and represents 10-30% of circulating vitamin B12 [183]. Given 
that the majority of vitamin B12 is bound to HC, results would mask the true deficiency or 
would falsely infer vitamin deficiency [23]. Vitamin B12 is usually measured using an 
automated method and a competitive-binding immune chemiluminescence, a low cost test [23]. 
Depending on the technique used to measure vitamin B12, vitamin B12 deficiency is usually 
considered when the plasma vitamin B12 concentration is less than 200 pg/mL. However, there 
is no gold standard value to represent subclinical deficiency of vitamin B12 (Table 5) [184]. 
Currently, the TC bound to plasma vitamin B12, is more relevant for assessing the 
functional vitamin B12 status. HoloTC reflects the absorptive capacity of vitamin B12, and any 
deficiency of TC has been previously associated with neurological and haematological 
complications [182]. HoloTC is usually measured by immunoassay, and cut-off values for low 
HoloTC depend on the specific laboratory guidelines [23].  
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Table 5: Biomarkers of vitamin B12 status 
Biomarker (Unit) Assay Type Tentative 
reference 
intervala* 
Tentative 
cut-off value 
for vitamin 
B12 
deficiencyb* 
Tentative cut-
off value for 
repletion of 
vitamin B12* 
 
Plasma B12 
(pmol/L) 
Competitive-binding immune 
chemiluminescence method/ 
protein binding assay 
200-600 <148 >221 
Holotranscobalamin 
(pmol/L)  
Immunological 40-100 <35 >40 
Homocysteine 
(μmol/l) 
Immunological, Liquid 
chromatography– mass 
spectrometry or gas 
chromatography mass 
spectrometry 
8-15 >15 <8 
Methylmalonic acid 
(μmol/l) 
Liquid chromatography– mass 
spectrometry or gas 
chromatography mass 
spectrometry 
0.04-0.37 >0.37 <0.27 
aThe Tentative reference intervals cover approximately 95% of B12 replete individuals. bThe 
tentative cut-off value for vitamin B12 deficiency includes both clinical and subclinical 
deficiency.*The values indicated in this table are based on previously cited literature. Data 
derived from Table 1 available on https://doi.org/10.1038/nrdp.2017.40 [2] 
1.6.2 Homocysteine and Methylmalonic acid 
Homocysteine (Hcy) and methylmalonic acid (MMA) can be used as sensitive biomarkers 
to detect an underlying vitamin B12 deficiency, even when no apparent sign of clinical vitamin 
B12 deficiency or low serum vitamin B12 levels are present [182]. There are two B12-
dependent enzymatic reactions which use MMA and Hcy as substrates. Vitamin B12 in 
combination with folic acid is required to convert Hcy to methionine, and vitamin B12 is used 
to convert MMA to succinyl-CoA [185]. As a result, MMA is a more sensitive indicator of 
vitamin B12 deficiency compared to Hcy. These two biomarkers can be confounded by both 
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environmental and physiological conditions [161]. Renal failure, heart transplantation, thyroid 
dysfunction, certain medications, genetic variation in the methylenetetrahydrofolate reductase 
(MTHFR) gene and high folate and vitamin B6 deficiency can contribute to elevated Hcy 
concentrations. Furthermore, MMA is elevated in renal impairment and rare inborn errors 
affecting methylmalonate-CoA mutase activity [50, 186]. 
Elevated Hcy and MMA concentrations, have been found to be 99.8% sensitive for 
diagnosing vitamin B12 deficiency [187]. Both Hcy and MMA are usually measured using 
Liquid chromatography– mass spectrometry or gas chromatography mass spectrometry [188]. 
According to Carmel (2006), an inadequate vitamin B12 status is described as serum vitamin 
B12 < 148 pmol/L, or 148–258 pmol/L and MMA > 0.30μmol/L, or tHcy > 13 nmol/L 
(females) and >15 nmol/L (males) [189]. However, it should be noted that the reference range 
depends on the individual techniques used to measure Hcy and MMA; as the published 
estimates for the specificity and sensitivity for diagnosing vitamin B12 deficiency varies 
extensively (Table 5)[184]. 
1.7 Treatment of vitamin B12 deficiency 
1.7.1  Parenteral treatment 
In the United Kingdom and other western countries worldwide, most patients with 
vitamin B12 deficiency are given intramuscular injections of vitamin B12. Intramuscular 
vitamin B12 exists in two forms: cyanocobalamin or hydroxocobalamin. Hydroxocobalamin is 
generally used as the first line of treatment, as it is retained in the body for a longer period of 
time and it can be administered at intervals of up to three months [190]. Approximately 10% 
(100 µg) of injected hydroxocobalamin is retained in the body after administration of 1000 µg 
[22]. 
The standard treatment for patients without neurological symptoms is three injections 
of intramuscular hydroxocobalamin (1000 µg) three times a week, for a duration of two weeks. 
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On the other hand, for patients with neurological involvement, injections are given 
intramuscularly (1000 µg) on alternative days for three weeks or until clear improvement is 
shown. Individuals with pernicious anaemia are given lifelong treatment. Individuals with 
severe anaemia and cardiac symptoms are usually treated with transfusion and diuretic agents 
[22, 23, 191].  
Hydroxocobalamin is usually well-tolerated, with serious adverse reactions being rare. 
However, injections can cause significant amount of pain in thin patients and can be dangerous 
in anticoagulated patients [190]. Side effects which are rarely observed for hydroxocobalamin 
include: chills, fever, hot flushes, itching, nausea, dizziness, skin rash and anaphylaxis [23].  
1.7.2 Oral treatment 
When vitamin B12 deficiency is related to an individual’s diet, a dose of 50-150 µg 
cyanocobalamin is given between meals [23]. Oral therapy is considered during mild or 
subclinical vitamin B12 deficiency and when there are no concerns of compliance or 
abnormalities associated with absorption [192].  
Previous case control studies have suggested that the oral administration of vitamin 
B12, is equally safe and effective at eliminating vitamin B12 deficiency [193, 194]. Vitamin 
B12 taken in the oral route, can be absorbed both actively and passively. In passive absorption, 
the vitamin B12 is absorbed without binding to IF. Approximately 0.5-4% of radioactively 
labelled oral vitamin B12 can be absorbed by passive diffusion in both healthy and patients 
with pernacious anemia [190, 195].  On the other hand, in active absorption, vitamin B12 binds 
to IF in the terminal ileum [190].  
It has been noted that patients with IF deficiency can  still adequately absorb vitamin 
B12, provided that they are given high doses of vitamin B12 (1000 µg daily) [190]. A cochrane 
review of two randomised controlled trials comparing oral with intramuscular administration 
54 
in 108 participants, found that high oral doses (1000 µg and 2000 µg daily)  are as effective as 
intramuscular injections in responding to neurological and haemotological symptoms [190]. 
However, due to the limited data available to present the support of oral therapy in individuals 
with neurological dysfunction, parenteral vitamin B12 is still the prefered method of treatment.  
At present, oral vitamin B12 is widely prescribed in Canada and Sweden [190]. 
However, high doses of oral vitamin B12 are unavailable for prescription under the NHS in the 
United Kingdom. Given that intramuscular injections require patients to visit a health facility 
or have a health care visitor to administer an injection, using oral vitamin B12 instead, could 
potentially save NHS resources and the time of medical staff [190]. 
1.8 Vitamin B12 Toxicity 
High serum vitamin B12 is defined as a value above 950 pg/ml; this refers to the upper 
limit of biological normality [196]. At present, few studies have looked at the toxic effects 
associated with a high serum vitamin B12 concentration. One study observed that when vitamin 
B12 was administered at 2 mg (2,000 μg) daily by mouth or 1 mg monthly by intramuscular 
(IM) injection to treat pernicious anaemia, no toxic effects were identified [197]. It is known 
that only a certain percentage of vitamin B12 can be absorbed by the body, and any ingested 
amounts which exceed the absorption capacity of vitamin B12 intrinsic factor receptors are 
excreted through the urine or faeces. This could partly explain the low toxicity [38]. On the 
other hand, other studies have noted that high doses of vitamin B12 supplements were 
associated with a greater risk of CVD in individuals with diabetic nephropathy [198] and a 
greater risk of autism spectrum disorder in the offspring of pregnant women [199].  
 It is possible that an increase in plasma vitamin B12 could be a result of a functional 
deficit. The destruction of hepatocytes in chronic hepatitis, can stimulate the binding of vitamin 
B12 to haptocorrin (HC) in the plasma, to form holohatocorrin (holoHC- inactive form of 
vitamin B12) leading to a decline of vitamin B12 attaching to holotranscobalamin (holoTC) II 
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(active form of vitamin B12). As a result, there is an increase in vitamin B12 in the plasma, as 
vitamin B12 cannot be delivered to the cells [200]. Furthermore, elevated vitamin B12 
concentrations could be due to the leakage of vitamin B12 from damaged liver tissue into the 
plasma [196]. As a result, high vitamin B12 levels are not always beneficial and could underlie 
a number of underlying pathologies [196]. 
1.9 Nutrigenetics approach 
Nutrigenetics is a branch of science that investigates the effect of genetic variants in 
response to dietary manipulation. The ultimate goal of nutrigenetics is to investigate the 
molecular and physiological basis of genetic variants associated with health and disease, and 
how these genotype-phenotype associations can be modified by dietary intake [201]. The field 
of nutrigenetics is rapidly evolving, with the hope that one day in the future nutritionists will 
be able to provide personalised dietary recommendations to patients to delay or prevent the 
onset of disease [202].  
1.9.1  Genetic factors and ethnic variation 
Vitamin B12 absorption and metabolism involves complex biological pathways 
containing multiple steps. Genetic variants may alter vitamin B12 tissue status by affecting the 
proteins involved in vitamin B12 absorption, cellular uptake and intracellular metabolism 
[143]. In a study using monozygotic and dizygotic twins, the heritability of B12 levels was 
estimated to be 59%, indicating that the magnitude of genetic influence on vitamin B12 levels 
are considerable [203]. At present, genetic studies of vitamin B12 status suggest that it is a 
multifactorial trait (also called complex trait), where several single nucleotide polymorphisms 
(SNPs) in multiple genes interact with the environment to cause the altered B12 status [204]. 
The genetics of vitamin B12 status and the genetic variation in different ethnicities are 
discussed in detail in chapter 2. 
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A review article from Surendran et al., (2018) which is found in chapter 2 of this thesis, 
identified 59 vitamin B12-related gene polymorphisms associated with vitamin B12 status, 
from the following populations: African American, Brazilian, Canadian, Chinese, Danish, 
English, European ancestry, Icelandic, Indian, Italian, Latino, Northern Irish, Portuguese and 
residents of the USA [14]. The most compelling evidence has been accumulated for the 
fucosyltransferase 2 (FUT2) SNP (rs602662), for which homozygosity of the minor G allele 
has been associated with lower vitamin B12 status. Variants in other B12 metabolic genes, 
including methylmalonyl CoA mutase (MUT), cubulin (CUBN) and transcobalamin-I 
(TCN1) have been reported in European populations [205]. Furthermore, an additional four 
loci, membrane-spanning 4-domains (MS4A3), citrate lyase beta like 
(CLYBL), fucosyltransferase 6 (FUT6) and 5q32 were constricted to the Chinese population 
[206]. It has been suggested that ethnic-specific associations are involved in the genetic 
determination of vitamin B12 concentrations. However, despite recent success in genetic 
studies, most of the identified genes that could explain variation in vitamin B12 concentrations 
were from Caucasian populations. As a result, further research utilizing larger sample sizes of 
non-Caucasian populations is necessary in order to better understand these ethnic-specific 
associations [14]. 
Genes alone are not responsible for explaining the variation in vitamin B12 
concentrations, as lifestyle factors e.g. dietary factors, also influence vitamin B12 
concentrations. Therefore, this is investigated by identifying gene-diet interactions 
(Nutrigenetics). In my thesis, I aimed to investigate the interaction between dietary factors 
(modifiable factor) and genetic markers (non-modifiable factors) on vitamin B12 
concentrations and metabolic disease trait outcomes. 
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1.9.2 Rational for studying gene-diet interactions 
Many SNPs have been shown to be associated with vitamin B12 status and these SNPs 
only represent a fraction of the heritability of vitamin B12 status [14]. It is well known that 
environmental factors, such as diet, can modulate the effects of genes on metabolic traits [12]. 
However, it is unknown whether dietary factors can interact with genes to impact vitamin B12 
status; hence the interaction between genetic and dietary factors must be considered. Findings 
from gene-diet interactions will contribute to identifying the interactions of genes and diet in 
the development of vitamin B12 deficiency.  Therefore, this knowledge is essential for the 
primary prevention of vitamin B12 deficiency, and for developing effective dietary strategies 
for the prevention of vitamin B12 deficiency and its related metabolic outcomes.  
1.9.3 Importance of studying gene-diet interactions in different genetic groups 
 It has been established that genetic studies looking at vitamin B12 status in healthy 
adults, especially large-scale ones, have been unable to capture the level of diversity which 
exists worldwide, as they are mainly based on individuals of European ancestry [14]. The 
under-representation of diverse ethnic groups hampers our full understanding of the genetic 
architecture of vitamin B12 levels [207]. Furthermore, the limited genetic data on non-
Caucasian populations in relation to genetic susceptibility to vitamin B12 deficiency, can also 
impede our ability to translate genetic research into clinical care, and will exacerbate health 
inequalities across the current public health policy [207]. Given that vitamin B12 status can 
also be determined by environmental factors, it is also important to explore gene-diet 
interactions in different ethnic groups, so that it will be eventually possible to personalise diet 
according to each ethnic sub-group.  It is important to note that, different ethnic groups respond 
differently to specific dietary interventions [12]. Therefore, using estimates of genetic risk for 
vitamin B12 deficiency from European-based studies in non-Europeans may result in an 
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inaccurate assessment of risk of vitamin B12 deficiency and could result in an inappropriate 
environmental intervention (dietary or physical activity) in under-studied populations.  
1.9.4 Study designs and their role in identifying gene-diet interactions 
Multiple lines of evidence suggest that SNPs may modify gene expression and 
consequently influence metabolic disease outcomes. Besides, it is well known that interactions 
may exist between genes and dietary factors to influence metabolic outcomes [12]. Several 
genes are involved in vitamin B12 metabolism [14] and variants in these genes may modify 
cardio-metabolic disease outcomes [16, 17]. Beyond the independent gene effects, no studies 
have evaluated interactions between vitamin B12 gene polymorphisms and macronutrient 
intake on cardiometabolic disease outcomes. A more detailed understanding of gene- diet 
interactions is needed to generate information required to develop strategies for diet 
modification to reduce the incidence of cardiometabolic disease related traits in individuals 
with specific variants related to vitamin B12 absorption and metabolism. The following section 
describes the potential study designs which can be employed for gene-diet interactions. 
The most commonly used study design is the cross-sectional design. A cross-sectional 
design is a study design, where disease related-outcomes and exposures in study participants 
are measured at a single point in time [208]. One of the limitations of a cross-sectional study 
design is that it is a one-time measurement of exposure and outcome, thus it is difficult to derive 
causal relationships between risk factors and a disease. Another limitation is that these studies 
are prone to confounding. Thus, it is important, that confounding factors are adjusted during 
statistical analysis (within the regression model) [208]. 
A case-control study determines whether an exposure is associated with an outcome of 
interest (e.g. disease). In simple terms, a case-control design, is a study which compares a group 
of individuals who have a disease or an outcome of interest (cases), with patients who are free 
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from a disease/outcome at a given point of time [209]. The study design is very similar to a 
cross-sectional study design, and both studies share many strengths. The main strengths of 
observational studies are that they can be used to generate a hypothesis, or they may be the 
only study design which is feasible or ethically viable to be carried out. Furthermore, 
observational studies are quick, easy and relatively inexpensive. They have the potential for 
large numbers of samples to be collected [210]. Under a nutrigenetics perspective, 
observational studies (cross sectional and case control) can impose substantial limitations. 
Firstly, phenotypes can vary across different time periods. For example, when testing gene-diet 
interactions, TAG concentrations vary upon the time of collection [211], thus only collecting 
fasting blood samples may be a limitation. Further to this, observational studies lack 
replication, making it difficult to conclude whether the findings are due to chance. 
Observational studies rely on FFQs, which are self-reported by participants and this can 
introduce bias. Ultimately, cross-sectional studies are beneficial as they are able to identify 
genetic variants which may be associated with diseases, and these variants are less likely to be 
affected by confounding variables [212].  
The next study design is a randomized clinical trial (RCT). RCTs are part of an 
experimental study design, where volunteers are randomly assigned to receive an experimental 
treatment (intervention) or a control treatment (where they receive the current standard 
treatment: this could be no treatment, a placebo or the best existing treatment currently 
available) [213]. As a result, any observed changes in the outcome e.g. vitamin B12 levels, is 
a result of the intervention treatment. The main advantages of an experimental trial are that 
both participants and trialists are unaware of whether the participant is receiving the treatment 
or control diet, until the study is completed. Although randomised control trials are powerful 
tools, studies are often limited by the sample size. It is difficult to have large sample sizes as it 
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is not cost effective, furthermore participants may drop out or have poor compliance with the 
treatment [214].  
Alternatively, another type of experimental study is the ‘cross over’ study design. In a 
cross over study design, half of the study samples are randomly assigned to a control diet for a 
certain period of time, they then undergo a wash out period, and they then switch to the 
experimental dietary intervention. The other half of the study sample, start off the experimental 
dietary intervention, undergo a wash out period, and then switch to the control diet [215]. In 
this type of study, the groups exchange their respective arms at a specific point of the 
experiment. The advantages of following cross-over studies are that they verify the findings of 
the first phase of the study, by reproducing it in the second phase, consequently reinforcing the 
conclusion of the study. Furthermore, intervention studies minimize the effect of confounding 
factors. However, one of the main concerns of dietary intervention studies is the need for a 
washout period between studies and that the trials often have a small sample size, which may 
reduce the power of detecting gene-diet interaction effect sizes [212, 216]. 
The postprandial study design (sequential meal design) is a type of experimental design. In 
this protocol two test meals are given to participants at different time intervals. The purpose of 
the following test design is to determine how chronic dietary fat or cereal/non-digestible 
carbohydrate supplements manipulate the lipaemic response. Secondly, this test design is used 
to determine the acute impact of specific fatty acids on the first meal on the postprandial 
lipaemic response of the second meal. As a result, looking at the changes in biochemical 
variables during the postprandial state highlights the importance of using the postprandial 
design in investigating gene-diet interactions [217]. An overview of the different study designs 
employed in gene-diet interactions is shown in Table 6. 
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Table 6: Types of studies used to perform gene-diet interactions 
Type of 
Study 
design 
Overview Strengths Disadvantages 
Cross-
sectional 
Disease related-outcomes and 
exposures in study participants 
are measured at a single point in 
time. 
• Can be used to generate a hypothesis. 
• Quick and Easy  
• Relatively inexpensive. 
• Potential for a large sample to be collected  
• Provides estimates of prevalence of all 
factors measured 
• It is not possible to say whether the exposure 
or the outcome is the cause, and which is the 
effect. 
• Results are prone to confounding, so it 
important that confounding factors are 
adjusted during statistical analysis (within the 
regression model)  
• Phenotypes can vary across different time 
periods, thus only collecting fasting blood 
samples may be a limitation. 
• Using an FFQ, measures the current diet in a 
group of individuals. The current diet may be 
altered by the presence of a disease. 
• The reliance of FFQs, which are self-reported 
by participants, can introduce Bias. 
Case-
control 
A study which compares a group 
of individuals who have a disease 
or an outcome of interest (cases), 
with patients who are free from a 
disease/outcome at a given point 
of time  
• Can be used to generate a hypothesis. 
• Can study several exposure factors 
simultaneously 
• Quick 
• Easy  
• Phenotypes can vary across different time 
periods, thus only collecting fasting blood 
samples may be a limitation. 
• Selection bias 
• Not useful for rare exposures 
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•  Relatively inexpensive. 
• Potential for a large sample to be collected  
• The reliance of food frequency 
questionnaires, which are self-reported by 
participants, can introduce Bias. 
• Incidence rate cannot be computed 
Randomize
d clinical 
trials 
Volunteers are randomly 
assigned to receive an 
experimental treatment 
(intervention) or a control 
treatment 
• In blinded study designs, both participants 
and trialists are unaware of whether the 
participant is receiving the treatment or 
control diet, until the study is completed. 
However, often in nutrition studies it is 
difficult to blind interventions. 
• Ability to detect causal relationships 
• Studies are usually limited by sample size. 
• It is not cost effective to have a large sample 
size. 
• Participants may have poor compliance with 
the treatment.  
Cross-over  Half of the study samples are 
randomly assigned to a control 
diet for a certain period of time, 
they then undergo a wash out 
period, and they then switch to 
the experimental dietary 
intervention. The other half of the 
study sample, start off the 
experimental dietary 
intervention, undergo a wash out 
period, and then switch to the 
control die 
• Verification of the findings of the first 
phase of the study can be conducted, by 
reproducing it in the second phase, 
consequently reinforcing the conclusion of 
the study. 
• This study has minimal effect from 
confounding factors 
• The small sample size, which may reduce the 
power for detecting gene-diet interaction 
effect sizes. 
Postprandia
l 
In this protocol two test meals 
are given to participants at 
different time intervals. The 
purpose of the following test 
design is to determine how 
chronic dietary fat or cereal/non-
• The frequency of blood sampling, with on 
average 10–13 blood samples taken during 
each postprandial assessment 
• Determination of the postprandial response is 
complex 
•  Lack of standardisation of methodologies, 
test meal size and composition, between 
different studies and research groups  
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digestible carbohydrate 
supplements manipulate the 
lipaemic response. Secondly, this 
test design is used to determine 
the acute impact of specific fatty 
acids on the first meal on the 
postprandial lipaemic response 
of the second meal. 
• Small subject numbers 
 
 
64 
1.9.5 From Nutrigenetics to Personalised nutrition  
It is becoming increasingly evident that genes and nutrients interact and influence an 
individual’s risk of developing metabolic disease related traits [11]. Approximately over 1000 
genes have been shown to be associated with human diseases, [218]; however, many of these 
genes will not increase the risk of developing a disease without exposure to certain dietary 
compounds [219]. Given that 80% of chronic diseases can be prevented by lifestyle and dietary 
modifications [220], it is important that dietary prevention strategies and dietary guidelines are 
revised. It is now possible to individualise diets using dietary, phenotype and genotypic data 
[221]. Greater attention is now being placed in switching dietary interventions from being 
population-based to being ‘personalised’ according to an individual’s genotype. The concept 
of personalised nutrition is continually changing as research is developing in the field. Grimaldi 
et al, describes it as an approach that ‘uses information on individual characteristics to develop 
targeted nutritional advice, products, or services’ [222]. The importance of personalised 
nutrition was shown in a retrospective study, which found that participants who were truly 
matched to a diet based on their genotype, had a twofold to threefold greater reduction in body 
weight  during a 12-month period, compared to individuals falsely matched to a diet [223].  
 At present, personalised nutrition is in its infancy. The success of personalised dietary 
advice relies on its ability to drive dietary change and attract consumer interest [221]. Although 
nutrient-gene interactions are a promising field of research, the molecular and 
pathophysiological mechanisms underlying these interactions is unclear. It is important that 
functional studies are carried out to clarify the biological significance and potential clinical 
applications of gene-diet interactions [12]. Furthermore, it has been shown that gut microbiota 
could interact with gene-diet interactions, to modify the risk of developing metabolic diseases 
[224]. As a result, future studies should profile individuals for metabolites, so that personalised 
dietary advice can be based on an individual’s metabotype [12]. It is essential that before 
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personalised nutrition is introduced; larger, well-powered studies should be conducted in a 
range of ethnic groups. Furthermore, other modifiable factors (e.g. physical activity), which 
could interact with genetic factors should be taken into account. 
1.10 Conclusions 
The findings from these studies indicate that diet modifications, which attempts to 
optimize vitamin B12 concentrations and other lipid traits, must consider genetic factors. Gene-
diet interaction studies are important for clarifying the relationship between nutrients, genetic 
variants and vitamin B12 status. Although nutrigenetics research is developing and garnering 
public health interest, consistent challenges have emerged surrounding the nature of 
nutrigenetics research. Several unregulated websites offering tests and dietary advice are 
available, with limited scientific evidence [225]. It is believed that there are no defined 
standards of how to conduct nutrigenetics studies. Additionally, the majority of nutrigenetics 
studies, have been published as secondary analyses to studies, the purpose of which was not to 
study gene-diet interactions [226]. Future studies will require an appropriate study design and 
a well-powered sample size. Furthermore, certain genetic variants may contribute to 
interindividual variability during postprandial states [211]; therefore, gene-diet interactions 
studies must examine both fasting and postprandial states.  
 In summary, there is a need to increase the number of nutrigenetics studies to establish 
the link between SNPs, dietary factors and health outcomes. It is also important to identify how 
gene-diet interactions influence vitamin B12 metabolic and lipid metabolism pathways at the 
molecular level, in order to determine the mechanism of action. Once this has been determined 
and validated in various ethnic groups, personalised dietary advice can be enforced to prevent 
diet-related diseases.  
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1.11 Thesis aims and outlines of the thesis 
 Based on the hypothesis that SNPs would influence serum vitamin B12 concentrations that 
may be modulated by lifestyle factors across different ethnic groups, the aims of this thesis are 
outlined below and is visually represented in Figure 3 (This diagram is a generic diagram that is 
modified throughout the thesis, depending on the study nature): 
1. To examine the association of selected common SNPs associated with vitamin B12 
concentrations and SNPs associated with metabolic traits with vitamin B12 concentrations and 
metabolic outcomes in different ethnic groups. 
2. To examine the interaction between these SNPs and lifestyle factors [dietary (fat, carbohydrate, 
and protein as total energy %) and physical activity levels] on vitamin B12 concentrations and 
metabolic outcomes using various study designs. 
 
Figure 3: The aims of this thesis 
The diagram shows four possible associations, and four possible interactions. One-sided arrows 
with unbroken lines represent genetic associations and one-sided arrows with broken lines 
67 
represent interactions between a lifestyle factor and SNPs on serum vitamin B12/ metabolic traits.  
The first aim was to test for the associations between the B12-related SNPs and vitamin B12 status 
and metabolic disease related traits. Next, the association between the metabolic-related SNPs 
and vitamin B12 concentrations and metabolic disease-related traits was tested. The second aim 
was to test whether these genetic associations were modified by lifestyle factors (macronutrient 
intake and physical activity levels). 
 
The hypothesis and aims of each chapter are outlined below and is summarized in Table 7: 
Chapter 2: Based on the candidate gene and GWA studies, associations between genetic loci in 
several genes involved in vitamin B12 metabolism have been identified. The aim of this literature 
review was to establish a reliable list of genetic variations that will allow us to predict the vitamin 
B12 status of an individual by knowing their genotype in these genetic variations. This review 
identified the genetic determinants of circulating vitamin B12 levels by focusing on new findings 
from GWA and candidate gene association studies, as well as results from Mendelian 
randomization analyses conducted so far for vitamin B12 pathway genes. The review also 
discussed the role of the genes involved in B12 status and reported the genetic variants specific to 
particular ethnic groups. 
Chapter 3: Cardiovascular disease (CVD) has remained the leading cause of mortality in Brazil 
since the late 1960s and may be influenced by abnormal concentrations of vitamin B12, 
homocysteine, folic acid and lipids in our body. To date, common variants in genes of the one-
carbon metabolism pathway have been reported to influence the concentrations of vitamin B12, 
folic acid, homocysteine and lipids. However, the interaction between SNPs involved in the one-
carbon metabolism pathway and macronutrient intake on cardiovascular risk factors in the 
Brazilian population has not yet been investigated. Hence, the present study investigated whether 
the association of ten SNPs involved in the one-carbon metabolism pathway with vitamin B12, 
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folic acid, homocysteine and lipid levels, and examined the interaction of these SNPs with lifestyle 
factors (dietary factors and physical activity) in adolescents (n=119) with cardiovascular risk. 
Chapter 4: Observational studies in South Asian populations have suggested an association 
between vitamin B12 status and metabolic traits; however, the findings have been inconclusive. 
Given that there are no gene-diet interaction studies, to date, in the Sri Lankan population, I used 
a genetic approach to explore the relationship between metabolic traits and vitamin B12 status in 
a South Asian Sri Lankan population and investigated whether these relationships were modified 
by lifestyle factors (dietary factors and physical activity) in 109 Sinhalese adults (61 men and 48 
women aged 25-50 years).   
Chapter 5: Low vitamin B12 concentrations have been associated with major clinical outcomes, 
including adiposity, in Indian populations. The Fat mass and obesity associated gene (FTO) is an 
established obesity-susceptibility locus; however, it remains unknown whether it influences 
vitamin B12 status. Hence, I investigated the association of two previously studied FTO 
polymorphisms (rs2388405 and rs8050136)  with vitamin B12 concentrations and metabolic 
disease-related outcomes and examined whether these associations were modified by dietary 
factors and physical activity  in an Asian Indian population (300 Type 2 Diabetic cases, 300 pre-
diabetics and 300 normal glucose-tolerant (NGT)). 
Chapter 6: Adverse effects of maternal vitamin B12 deficiency have been linked to major clinical 
outcomes, including increased body mass index and gestational diabetes, however, less is known 
about vitamin B12 nutrition in non-pregnant women. The aim of this study was to use a gene-
based approach to explore the relationship between metabolic traits and vitamin B12 status in a 
cohort of 117 Minangkabau women (25-60 years) in Padang, West Sumatra, Indonesia, and 
investigated whether these relationships were modified by lifestyle factors (dietary factors and 
physical activity). 
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Chapter 7: Low vitamin B12 status has been shown to be a risk factor for several cardiometabolic 
traits such as obesity, diabetes and cardiovascular disease (CVD). Animal models have shown that 
the modification of dietary fat intake can affect vitamin B12 status. Hence, we investigated 
whether vitamin B12- and metabolic disease-related genetic variants modify vitamin B12 
concentrations and cardiometabolic traits in response to replacement of saturated fatty acids (SFA) 
with monounsaturated (MUFA) or n-6 polyunsaturated (PUFA) fatty acids. A retrospective 
analysis was conducted on 119 participants in the Dietary Intervention and VAScular function 
(DIVAS) study.  
Chapter 8: This chapter focuses on the discussion, which is based on the findings from all the 
studies, and the future prospects of this PhD work.  
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Table 7: Summary of the SNPs that were examined in each chapter 
 
Chapters Population Study 
design 
B12-related SNPs   analysed Metabolic disease 
SNPs analysed 
Journal name and status of  
publication 
Chapter 2: An 
update on 
vitamin B12-
related gene 
polymorphisms 
and B12 status. 
 
Multi-ethnic Literature 
review 
• 59 B12-related SNPs 
from 19 genes were 
analysed. 
• Not applicable Genes & Nutrition (Published, 
DOI number:  10.1186/s12263-
018-0591-9) 
 
 
Chapter 3: The 
Influence of 
One-carbon 
Metabolism 
Gene 
Polymorphisms 
and Gene–
environment 
Interactions on 
Homocysteine, 
Vitamin B12, 
Folate and 
Lipids in a 
Brazilian 
Adolescent 
Population 
Brazilian  Cross-
sectional 
study  
• Fucosyltransferase 
[FUT2]- rs602662 
• Transcobalamin 2 
[TCN2]- rs1801198 
• 5-methyltetrahydrofolate-
homocysteine 
methyltransferase or 
methionine synthase 
[MTR]- rs1805087a 
•  5-
methyltetrahydrofolate-
homocysteine 
methyltransferase 
reductase or methionine 
synthase reductase 
[MTRR]- rs1801394a 
• Betaine-homocysteine S-
methyltransferase 
• Catechol-o-
methyl 
transferase 
[COMT]-
rs4680 and 
rs4633 
Journal of Diabetology 
(Published, DOI number: 
10.4103/jod.jod_37_18) 
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[BHMT]-rs3797546 and 
rs492842b 
• methylenetetrahydrofolate 
reductase [MTHFR]- 
rs1801131c 
• methylenetetrahydrofolate 
reductase [MTHFR]-
rs1801133d 
Chapter 4: A 
genetic 
approach to 
examine the 
relationship 
between vitamin 
B12 status and 
metabolic traits 
in a South Asian 
population 
Sri Lankan Cross-
sectional 
study 
• MTHFR- rs1801133 
• Carbamoyl-phosphate 
synthase 1 [CPS1]- 
rs1047891 
•  Cubulin [CUBN]- 
rs1801222 
•  CD320 molecule 
[CD320]- rs2336573 
•  TCN2- rs1131603 
•  Citrate lyase beta like 
[CLYBL]- rs41281112 
•  FUT2- rs602662 
•  Transcobalamin 1 
[TCN1]- rs34324219 
• Fucosyltransferase 6 
[FUT6]- rs778805 
•  Methylmalonyl-CoA 
mutase [MUT]- 
rs1141321) 
• Fat mass and 
obesity-
associated 
[FTO]- 
rs9939609 and 
rs8050136 
•  Melanocortin 
4 Receptor 
[MC4R]- 
rs17782313 
and rs2229616 
•  Transcription 
factor 7-like 2 
[TCF7L2]- 
rs12255372 
and rs7903146 
•  Potassium 
voltage-gated 
channel 
subfamily J 
member 11 
[KCNJ11]- 
rs5219 
International Journal of 
Diabetes in Developing 
Countries (Published, DOI 
number: 
https://doi.org/10.1007/s13410-
019-00749-8) 
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• Calpain 10 
[CAPN10]- 
rs3792267, 
rs2975760 and 
rs5030952 
Chapter 5: 
Evidence for the 
association 
between FTO 
gene variants 
and vitamin B12 
concentrations 
in an Asian 
Indian 
population 
Indian Case-
Control  
• Not applicable • FTO-
rs9939609 and 
rs2388405 
Genes & Nutrition (Published, 
DOI number: 
https://doi.org/10.1186/s12263-
019-0649-3) 
Chapter 6: A 
nutrigenetic 
approach for 
investigating the 
relationship 
between vitamin 
B12 status and 
metabolic traits 
in Indonesian 
women 
Indonesian Cross-
sectional 
study 
• MTHFR- rs1801133 
•  CPS1- rs1047891 
• CUBN- rs1801222 
•  CD320- rs2336573 
•  TCN2- rs1131603 
•  FUT2- rs602662 
• TCN1- rs34324219 
•  FUT6- rs778805 
• MUT- rs1141321 
• FTO- 
rs9939609 and 
rs8050136 
• MC4R- 
rs17782313 
and rs2229616 
• TCF7L2- 
rs12255372 
and rs7903146 
• KCNJ11- 
rs5219 
• CAPN10- 
rs3792267 and 
rs5030952 
Journal of Diabetes & 
Metabolic Disorders 
(Published, DOI number: 
https://doi.org/10.1007/s40200-
019-00424-z) 
Chapter 7: 
DIVAS A 
genetic 
British Dietary 
intervention 
study  
• FUT2- rs602662, 
rs492602 and rs16982241 
• TCF7L2- 
rs12255372 
and rs7903146 
Lipids in Health and Disease 
(Under review) 
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approach to 
investigate the 
relationship 
between vitamin 
B12 status and 
cardiometabolic 
traits in response 
to changes in 
dietary fat 
composition in 
adults with 
moderate 
cardiovascular 
disease risk   
•  MC4R- 
rs17782313 
and rs2229616 
•  FTO- 
rs9939609 and 
rs8050136. 
 
aSNPs which have shown associations with folate 
b SNPs which have shown associations with homocysteine 
cSNPs which have shown associations with folate and homocysteine 
d SNPs which have shown associations with vitamin B12, folate and homocysteine 
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Chapter 2  
An update on vitamin B12-related gene polymorphisms and B12 
status 
For this literature review, I extracted and interpreted genetic variants related to vitamin B12 
status. I conducted a literature search and identified 10,534 articles from the PubMed database. 
Following this, 10,482 articles were excluded according to the established exclusion criteria. 
In addition, the reference lists of identified publications were hand searched to identify any 
further studies. Further exclusions were applied and as a result, only 23 articles were selected 
for analysis. I was also responsible for contacting corresponding authors to provide any 
additional information where needed. I wrote the manuscript and revised the manuscript based 
on comments from the co-authors. I was also involved in drafting the responses to the 
comments from the reviewers.  
 
Published (The published version of the paper is attached as an appendix at the end of 
the thesis) 
Surendran, S., Adaikalakoteswari, A., Saravanan, P., Shatwaan, I. A., Lovegrove, J. 
A. and Vimaleswaran, K. S. (2018) An update on vitamin B12-related gene polymorphisms 
and B12 status. Genes & Nutrition, 13 (1). pp. 1555-8932. ISSN 1865-3499 
doi: https://doi.org/10.1186/s12263-018-0591-9 
 
2.1 Abstract 
Background: Vitamin B12 is an essential micronutrient in humans needed for health 
maintenance. Deficiency of vitamin B12 has been linked to dietary, environmental and genetic 
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factors. Evidence for the genetic basis of vitamin B12 status is poorly understood. However, 
advancements in genomic techniques have increased the knowledge-base of the genetics of 
vitamin B12 status. Based on the candidate gene and genome wide association (GWA) studies, 
associations between genetic loci in several genes involved in vitamin B12 metabolism have 
been identified.  
Objective: The objective of this literature review was to identify and discuss reports of 
associations between single nucleotide polymorphisms (SNPs) in vitamin B12 pathway genes, 
and their influence on the circulating levels of vitamin B12.  
Methods: Relevant articles were obtained through a literature search on PubMed through to 
May 2017. An article was included if it examined an association of a SNP with serum or plasma 
vitamin B12 concentration. Beta coefficients and odds ratios were used to describe the strength 
of an association, and a P< 0.05 was considered as statistically significant. Two reviewers 
independently evaluated the eligibility for the inclusion criteria and extracted the data.  
Results: From twenty-three studies which fulfilled the selection criteria, sixteen studies 
identified SNPs that showed statistically significant associations with vitamin B12 
concentrations. Fifty-nine vitamin B12-related gene polymorphisms associated with vitamin 
B12 status were identified in total, from the following populations: African American, 
Brazilian, Canadian, Chinese, Danish, English, European ancestry, Icelandic, Indian, Italian, 
Latino, Northern Irish, Portuguese and residents of the United States.  
Conclusion: Overall, the data analysed suggests that ethnic-specific associations are involved 
in the genetic determination of vitamin B12 concentrations. However, despite recent success 
in genetic studies, the majority of identified genes that could explain variation in vitamin B12 
concentrations were from Caucasian populations. Further research utilizing larger sample sizes 
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of non-Caucasian populations is necessary in order to better understand these ethnic-specific 
associations.  
 
2.2 Introduction 
Vitamin B12, also known as cobalamin (Cbl), is an essential water-soluble micronutrient 
required to be ingested by humans to maintain health. The nutritional deficiency of vitamin 
B12 has been linked to many complications including an increased risk of macrocytic anaemia, 
neuropsychiatric symptoms [227], cardiovascular diseases [228],  and the onset of different 
forms of cancer [229, 230]. To maintain adequate vitamin B12 status, individuals must ingest 
sufficient dietary vitamin B12 and retain the ability to absorb vitamin B12. The absorption, 
transport and cellular uptake of vitamin B12 is dependent upon the co-ordinated action of the 
binding proteins: haptocorrin (HC), intrinsic factor (IF), transcobalamin II (TC) and other 
specific cell receptors. After vitamin B12 binds to HC in the stomach and IF in the duodenum, 
it binds to TC within the enterocyte and is then released into the blood stream. The vitamin 
B12-TC complex then binds to the transcobalamin receptor (TC-R) and is taken up by cells via 
endocytosis  [231]. 
Genetic variants may alter vitamin B12 tissue status by affecting the proteins involved 
in vitamin B12 absorption, cellular uptake and intracellular metabolism [143]. In a study using 
monozygotic and dizygotic twins, the heritability of B12 levels was estimated to be 59%, 
indicating that the magnitude of genetic influence on vitamin B12 levels are considerable [203]. 
At present, genetic studies of vitamin B12 status suggest that it is a multifactorial trait, where 
several single nucleotide polymorphisms (SNPs) in multiple genes interact with the 
environment to cause the altered B12 status [204]. Most of the SNPs related to vitamin B12 
status have been examined using a candidate gene approach [204]. However, it is now possible 
to use an unbiased genome-wide association (GWA) study to associate DNA sequence 
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variations across the human genome with the risk factors of developing a disease [232]. Despite 
a number of informative genome-wide association studies and candidate gene analyses, the 
complex relationship between an individual’s genotype and their vitamin B12 status remains 
poorly understood. This article is the first literature review  to discuss the results of genetic 
studies associated with vitamin B12 status in healthy individuals. Understanding the possible 
underlying genetic factors of vitamin B12 metabolism will lead to an increased understanding 
of the biological mechanisms underlying vitamin B12 status.  
2.3 Materials and Methods 
2.3.1 Study identification 
In order to identify published articles, literature searches were completed using the 
PubMed database (https://www.ncbi.nlm.nih.gov/pubmed/), from the earliest date of indexing 
until May 2017. The following keywords were used to identify articles from PubMed: ‘vitamin 
B12 and genetics’ (n=2,792), ‘vitamin B12 and gene polymorphisms’ (n=447), ‘genetic 
variants of vitamin B12’ (n=115), ‘genetic variants of cobalamin’ (n=95), ‘genetics of 
cobalamin’ (n=2,574), ‘genetics of vitamin B12’(n= 2,721)’,‘vitamin B12 and genes (n=932) 
and ‘cobalamin and genes’ (n=858). In addition, reference lists of identified publications were 
hand searched to identify other studies potentially eligible for inclusion. 
No limits on geographical location were placed in the literature search, and only articles 
written in English were selected. After inclusion and exclusion criteria were applied, a 
comprehensive list of relevant articles was included in this review. 
2.3.2 Study selection 
The abstracts of  all articles with relevant titles were reviewed first and were further 
assessed if they reported original data on testing for an association of a SNP with plasma or 
serum vitamin B12 concentrations. Articles were excluded if: 1) they included non-human 
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subjects 2) they were limited to a subset of the population (e.g. pregnant women / carrying a 
disease) and 3) the sample size of the population was less than 10. 
Based on the search criteria and keywords used, 10,534 articles were identified from 
the PubMed database. Following this, 10,482 articles were excluded according to the 
established exclusion criteria, and 52 articles were then considered as potentially relevant for 
the review. The full text of the 52 articles was read, which resulted in the exclusion of a further 
29 articles. As a result, only 23 articles were selected for analysis (Figure 4). A P< 0.05 was 
considered as statistically significant. 
 
Figure 4: Flow diagram of studies identified in the literature search for the identification 
of genetic variants associated with vitamin B12 concentrations 
2.3.3 Data extraction: 
The studies were identified by a single investigator (SS) and the following data were 
double-extracted independently by two reviewers (VKS and IAS): first author, publication 
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year, location or ethnicity of participants, sample size, mean age, study design, SNP position, 
name and rs ID, genotype and allele distribution by vitamin B12 status. For the outcome data, 
the beta coefficients of vitamin B12 concentrations per risk allele, odds ratios (ORs) with their 
corresponding 95% confidence intervals (95% CIs) were extracted. Any discrepancies over 
extracted data were settled through discussion between the two independent reviewers (VKS 
and IAS). Finally, corresponding authors were contacted to provide any additional information 
where needed.  
2.4  Results of Database search: Genes associated with vitamin B12 status 
The following section reviews studies of genetic variants which have been associated 
with vitamin B12 status. These variants have been grouped as: a) co-factors or regulators 
essential for the transport of vitamin B12 (b) membrane transporters actively facilitating 
membrane crossing (c) involved in the catalysis of enzymatic reactions in the one carbon cycle  
(d) involved in cell cycle regulation, (e) mitochondrial proteins and (f) other genes (Figure 5 
and 6. A summary of GWA and candidate gene association studies that have been reported to 
be associated with circulating plasma or serum B12 concentrations are presented in Table 8 
and Table 9. The location and function of the most frequently studied genes associated with 
vitamin B12 concentrations are summarized in Table 10.
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Figure 5: Diagram representing the genes associated with vitamin B12 status 
The diagram shows the proteins involved in the metabolism of vitamin B12 from dietary intake 
to reaching the circulatory system. Genes identified to harbour variants regulating serum 
levels of B12 are surrounded by dashed lines. B12: vitamin B12; CUBN: cubilin (intrinsic 
factor-cobalamin receptor); FUT2: fucosyl-transferase 2; FUT6: fucosyl-transferase 6; HC: 
Haptocorrin (TCN1); H. pylori: Helicobacter pylori; IF: Intrinsic factor; PON1: serum 
paraoxonase/arylesterase 1; R-A-P: Receptor-Associated-Protein; TCII: Transcobalamin II 
(TCN2); TCII-R: Transcobalamin II receptor (CD320). 
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Figure 6: Diagram representing the genes associated with vitamin B12 status 
The diagram shows the proteins involved in the metabolism of vitamin B12 from the 
extracellular space to being internalised within the cell. Genes identified to harbour variants 
regulating serum levels of B12 are surrounded by dashed lines. Ado-B12: Adenosyl-
cobalamin; ABDC4: ATP-binding cassette, sub-family D (ALD), member 4; CD320: CD320 
Molecule; CLYBL: Citrate Lyase Beta Like; DNMT2: DNA methyltransferase 2 gene; LMBD1: 
LMBR1 domain containing 1; LMBRD1: LMBR1 Domain Containing 1; MMAA: 
Methylmalonic Aciduria (Cobalamin Deficiency) CblA Type; MMAB: Methylmalonic Aciduria 
(Cobalamin Deficiency) CblB Type; MMACHC: Methylmalonic aciduria and homocystinuria, 
cblC type; MMADHC:Methylmalonic Aciduria (Cobalamin Deficiency) CblD Type, With 
Homocystinuria; MS4A3: Membrane-Spanning 4-Domains, Subfamily A, Member 3 
(Hematopoietic Cell-Specific); MTHFR: 5-methyl-tetrahydrafolate reductase; MTR:5-
Methyltetrahydrofolate-Homocysteine Methyltransferase; MTRR: 5-Methyltetrahydrofolate-
Homocysteine Methyltransferase Reductase; MUT: Methylmalonyl CoA Mutase; PRELID2: 
PRELI Domain Containing 2; THF: Tetrahydrofolate; 5,10-Methyl THF: 5,10-Methyl-
tetrahydrofolate 
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Table 8: Genome-wide association studies showing the association of SNPs with vitamin B12 concentrations  
Chromosom
e location 
Gene name (Gene 
symbol) 
Reference 
SNP 
Cluster ID 
Sample size & 
Ethnicity 
Age 
(years) 
Minor 
allele + 
Minor 
allele 
frequency 
Effect size  P-value References 
1p34.1 Methylmalonic aciduria 
and homocystinuria type C 
protein 
(MMACHC) 
rs1227266
9 
Icelandic sample: 
n = 37283  
  
63 ± 24 
 
A = 0.002 Effect: A  allele  
Other: G allele  
 
β  = 0.51 pmol/L 
 
 
3.00 x 
10−9 
Grarup et al., 
2013 [12] [205] 
[205]  
1q42.2 Intergenic rs583228 Initial sample:  
n = 1999 
Chinese Han men 
 
 
 
 
38 ± 11 
 
 
T = 0.220 Effect: T allele 
Other: C allele 
 
β = Not available 
 
 
7.68 x 10-6 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
 n = 1496  
Chinese men 
 
37± 11 Effect: T allele 
Other: C allele 
 
β = Not available 
>0.05 
Combined total: 
n = 3495 
 Effect: T allele 
Other: C allele 
 
β = 25.50 pg/ml 
SE = 7.19 
3.92 x 
10−4 
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2q34 Carbamoyl-Phosphate 
Synthase 1 
(CPS1) 
rs1047891 Icelandic sample: 
n = 37283  
                       
                                                      
63 ± 24 A = 0.372 Effect: C allele  
Other: A allele  
 
β = 0.04 pmol/L 
7.60 x 
10−6 
 
 
 
 
Grarup et al., 
2013 [12] 
Danish Inter99 
population: 
 n = 5481 
 
 
46 ± 8 
 
 
Effect: C allele  
Other: A allele  
 
β = 0.10 pmol/L 
 
5.50 x 10-4 
 
Danish - Health 
2006: 
 n  = 2812       
49 ± 13 Effect: C allele  
Other: A allele  
 
β = 0.03 pmol/L 
 
>0.05 
 
Combined total: 
 n  = 45574 
 Effect: C allele  
Other: A allele  
 
β = Not available 
 
3.00 x 10-8 
4q31.21 Methylmalonic aciduria 
(cobalamin deficiency) 
cblA type 
(MMAA) 
rs2270655 Parents of PMNS 
cohort*: 
n  = 1001 
Indian 
 
 
36 ± 5 
 
 
 
 
 
C = 0.157# Effect allele: C 
 
β = -0.07 pmol/L 
>0.05 Nongmaithem et 
al., 2017 [22] 
[233] [233]  
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
Effect allele: C 
 
β  = 0.00 pmol/L 
 
>0.05 
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PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: C 
 
β = -0.09 pmol/L 
 
>0.05 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: C 
 
β = -0.20 pmol/L 
 
2.00 x 10-2 
4q31.21 Methylmalonic aciduria 
(cobalamin deficiency) 
cblA type 
(MMAA) 
rs2270655 Icelandic sample: 
 n  = 37283  
 
 
 
 
                                                                                       
63 ± 24 C = 0.059 Effect: G allele  
Other: C allele  
 
β = 0.07 pmol/L 
 
 
 
 
3.50 x 
10−5 
 
 
Grarup et al., 
2013 [12] [205] 
[205]  
Danish Inter99 
population: 
 n  = 5481 
 
 
46 ± 8 
 
 
Effect: G allele  
Other: C allele  
 
β  = 0.30 pmol/L 
 
2.80 x 
10−7 
 
Danish - Health 
2006: 
 n  = 2812       
  
49 ± 13 Effect: G allele  
Other: C allele  
 
β = 0.25 pmol/L 
 
5.80 x 
10−8 
 
Combined total: 
 n  = 45576 
 Effect: G allele  
Other: C allele  
 
β = Not available 
2.20 x 10-
13 
4q31.21 Methylmalonic aciduria 
(cobalamin deficiency) 
cblA type 
(MMAA) 
 
 
 
rs1146994
96 
 
 
 
 
 
 
 
 
 
Icelandic sample: 
 n  = 25960 
63 ± 24 
 
 
 
 
 
 
 
T = 
0.046** 
Effect: T 
 Other: C 
 
β = -0.07 pmol/L 
 
 7.60 x 10-
6 
Grarup et al., 
2013 [12] 
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5q32 Intergenic rs1051555
2 
Initial sample:  
 n  = 1999 
Chinese Han men 
 
 
 
38 ± 11 
 
 
C = 0.162 Effect: C allele 
Other: T allele 
 
β = Not available 
 
 
8.52 x 10-7 
 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
  n  = 1496  
Chinese men 
37 ± 11 Effect: C allele 
Other: T allele 
 
β = Not available 
 
5.15 x 10-3 
Combined total: 
 n  = 3495 
 Effect: C allele 
Other: T allele 
 
β = 43.93 pg/ml 
SE = 7.98 
3.94 x 
10−8 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
chr6:4950
8102 
Icelandic sample: 
 n  = 25960 
  
63 ± 24 
 
Not 
available 
Effect: C allele  
Other: G allele  
 
β = 0.07 pmol/L 
 
 
1.60 x 10-
18 
Grarup et al., 
2013 [12] 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs1141321  
(rs947355
8) 
Icelandic sample: 
 n  = 37283  
 
 
 
                                                                                       
63 ± 24 T = 0.373 Effect: C allele  
Other: T allele  
β = 0.06 pmol/L 
 
 
 
1.40 x 
10−16 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population:
 n  = 5481 
46 ± 8 
 
Effect: C allele  
Other: T allele  
β = 0.12 pmol/L 
 
 
1.40 x 
10−5 
 
Danish- Health 
2006: 
 n  = 2812       
49 ± 13 Effect: C allele  
Other: T allele  
 
β = 0.11 pmol/L 
1.40 x 
10−7 
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Combined total: 
 n  = 45574 
 Effect: C allele  
Other: T allele  
 
β = Not available 
3.60 x 
10−26 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs1141321  
(rs947355
8) 
Initial sample: 
 n  = 1999   
Chinese Han men 
38 ± 11 T = 0.237 Effect: T allele  
Other: C allele 
 
β= -30.34  pg/ml 
SE = 8.91 
5.51 x 
10−4 
Lin et al., 2012 
[19] [206] [206]  
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs1141321  
(rs947355
8) 
NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6 
 
 
T = 0.350 Effect: T allele  
Other: C allele  
 
β = −0.03 pg/ml 
SE = 0.01 
 
4.27 x 10-2 
 
 
 
Hazra et al., 
2009 [20] 
[234][234] 
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 
 
 
Effect: T allele  
Other: C allele  
 
β = −0.03 pg/ml 
SE = 0.01 
 
1.87 x 10-2 
 
SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: T allele  
Other: C allele  
 
β = −0.07 pg/ml 
SE = 0.01 
 
3.96 x 10-7 
 
Combined total:  
 n  = 4763 
 Effect: T allele  
Other: C allele  
 
β = −0.04 pg/ml 
SE = 0.01 
 4.05 x 10-
8 
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6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs9473555 Icelandic sample: 
 n  = 25960  
  
63 ± 24 
 
C = 0.402 Effect: C allele 
 Other: G allele  
 
β = -0.06 pmol/L 
 
 
5.40 x 10-
17 
Grarup et al., 
2013 [12] 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs9473555 Initial sample: 
 n = 1999   
Chinese Han men 
38 ± 11 C = 0.238 Effect: C allele  
Other: G allele 
 
β  = -31.00  pg/ml 
SE = 8.860 
4.06 x 10-4 Lin et al., 2012 
[19] 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs9473555 NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6 
 
 
C = 0.350 Effect: C allele  
Other: G allele  
 
β= −0.03 pg/ml 
SE = 0.01 
 
 
 
 
4.27 x 10-2 
 
 
 
Hazra et al., 
2009 [20] 
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 Effect: C allele  
Other: G allele  
 
β= −0.03 pg/ml 
SE = 0.01 
 
2.26 x 10-2 
 
SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: C allele  
Other: G allele  
 
β= −0.07 pg/ml 
SE = 0.01 
 
3.71 x 10-7 
 
Combined total:  
 n  = 4763 
 Effect: C allele  
Other: G allele  
 
β= −0.04 pg/ml 
4.91 x 10-8 
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SE = 0.01 
 
6q15 Nearest gene: 
Sperm Acrosome 
Associated 1 
(SPACA1) 
Chr6_8879
2234 
Icelandic sample: 
 n  = 37283  
  
63 ± 24 
 
G = 0.006 Effect: G allele  
Other: A allele  
 
β = 0.26 pmol/L 
 
 
2.80 x 10-7 Grarup et al., 
2013 [12] [205] 
[205]  
7q21.3 Paraoxonase 1 
 (PON1) 
rs3917577 n  = 3114  
Canadian (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
G = 0.020 Effect: A allele  
Other: G allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 0.67 (95% CI: 
0.54, 0.81) pmol/L 
 
7.20 x 10-5 Zinck et al., 
2015 [18]   
8q21.13 Nearest gene: 
Zinc Finger and BTB 
Domain Containing 10 
(ZBTB10) 
 
rs6251506
6 
Icelandic sample: 
 n  = 37283  
  
63 ± 24 
 
G = 0.025 Effect: G allele  
Other: A allele  
 
β = 0.12 pmol/L 
 
5.40 x 10-7 Grarup et al., 
2013 [12] 
9p21.1 NONE 
(Intergenic) 
rs1237746
2 
Initial sample:  
 n  = 1999 
Chinese Han men 
 
38 ± 11 
 
 
T = 0.366 Effect: T allele 
Other: C allele 
 
β = Not available 
 
3.34 x 10-7 
 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
  n  = 1496  
Chinese men 
37 ± 11 Effect: T allele 
Other: C allele 
 
β = Not available 
 
>0.05 
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Combined total: 
 n  = 3495 
 Effect: T allele 
Other: C allele 
 
β = 28.53 pg/ml 
SE = 5.99 
2.02 x 
10−6 
10p12.31 
 
Cubulin 
(CUBN) 
rs1801222 n  = 3114  
Canadian (85% 
Caucasian, 15% 
non-Caucasian)  
20 – 79 
(range) 
A = 0.100 Effect: G allele 
 Other: A allele  
 
Vitamin B12 
deficiency (< 148 
pmol/L): 
OR: 1.61 (95% CI: 
1.24, 2.09) pmol/L 
 
3.00 x 10–
4 
Zinck et al., 
2015 [18]   
10p12.31 
 
Cubulin 
(CUBN) 
rs1801222 n  = 3114 
Canadian (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
A = 0.100 Effect: G allele  
Other: A allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
 OR: 1.39 (95% CI: 
1.23, 1.58)  pmol/L 
 
2.00 x 10–
7 
Zinck et al., 
2015 [18]    
10p12.31 Cubulin    
( CUBN) 
rs1801222 Icelandic sample: 
 n = 37283  
 
 
                                                                                       
63 ± 24 A = 0.407 Effect: G allele  
Other: A allele  
 
β = 0.10 pmol/L 
1.10 x 
10−52 
 
 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population: 
 n  = 5481 
46 ± 8 
 
 
Effect: G allele  
Other: A allele  
 
β  = 0.14 pmol/L 
 
7.60 x 
10−8 
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Danish - Health 
2006: 
 n  = 2812       
 
49 ± 13 Effect: G allele  
Other: A allele  
 
β = 0.17 pmol/L 
 
2.90 x 
10−18 
 
Combined total: 
 n = 45576 
 Effect: G allele  
Other: A allele  
 
β = Not available 
 
3.30 x 10-
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10p12.31 Cubulin    
( CUBN) 
rs1801222 NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6 
 
 
A = 0.280 Effect: A allele  
Other: G allele  
 
β = −0.05 pg/ml 
SE = 0.01 
9.04 x 10-5 
 
 
Hazra et al., 
2009 [20]   
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 
 
 
Effect: A allele  
Other: G allele  
 
β = −0.04 pg/ml 
SE = 0.02 
6.32 x 10-3 
 
SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: A allele  
Other: G allele  
 
β = −0.05 pg/ml 
SE = 0.02 
3.56 x 10-4 
 
Combined total:  
 n  = 4,763 
 Effect: A allele  
Other: G allele  
 
β = −0.05 pg/ml 
SE = 0.01 
 
2.87 x 10-9 
 
91 
10p12.31 
 
Cubulin 
(CUBN) 
rs4748353 n  = 3114  
Canadian (85% 
Caucasian, 15% 
non-Caucasian)  
20 – 79 
(range) 
C = 0.000 Effect: C allele  
Other:  T allele  
 
Vitamin B12 
deficiency (< 148 
pmol/L): 
OR: 2.14 (95% CI: 
1.36, 3.37) pmol/L 
 
 
8.00 x 10–
4 
Zinck et al., 
2015 [18]     
10p12.31 
 
Cubulin 
(CUBN) 
rs1125436
3 
n  = 3114  
Canadian (85% 
Caucasian, 15% 
non-Caucasian) 
20  – 79 
(range) 
G = 0.010 Effect: A allele 
Other: G allele 
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 0.81 (95% CI: 
0.70, 0.93) pmol/L 
 
3.00 x 10-3 Zinck et al., 
2015 [18]    
10p12.31 
 
Cubulin 
(CUBN) 
rs1125436
3 
GWAS Meta-
analysis: 
 
InCHIANTI 
study: 
  n  = 1175  
Italian  
  
SardiNIA study: 
  n  = 1115  
Italian  
  
BLSA study¶: 
  n  = 640  
Residents from 
the USA 
 
 
 
 
 
InCHIA
NTI: 
68  ± 16 
 
SardiNI
A: 
45 ± 18 
 
BLSAg: 
68 ± 16 
 
 
G = 0.300 Effect: A allele  
Other: G allele 
 
β = -39.16 pg/ml 
SE = 9.18 
 
7.24 x 10-8 
 
 
Tanaka et al., 
2009 [21]   
Replication study: 47 ± 13 Effect: A allele  >0.05 
92 
Progetto 
Nutrizione study:  
n  = 687  
Italian 
 
 
 
  
Other: G allele 
 
β = 3.62 pg/ml 
SE = 10.94 
 
Combined meta-
analysis (GWAS 
Meta-analysis + 
Replication 
study): 
 n  = 3613 
 Effect: A allele  
Other: G allele 
 
β = -21.49 pg/ml 
SE = 7.03 
 1.11 × 
10−6 
 
10p12.31 
 
Cubulin 
(CUBN) 
rs1224389
5 
Initial sample: 
 n  = 1999   
Chinese Han men 
38 ± 11 A = 0.243 Effect: A allele  
Other: G allele 
 
β  = 23.49  pg/ml 
SE = 9.06 
 
7.11 x 10-3 Lin et al., 2012 
[19] 
10p12.31 
 
Cubulin 
(CUBN) 
rs1278084
5 
Parents of PMNS 
cohort*: 
n  = 1001 
Indian 
 
 
36 ± 5 
 
 
 
 
 
G = 0.415# Effect allele: G 
 
β = 0.09   pmol/L 
 
 
 
 
 
 
 >0.05 
 
 
 
Nongmaithem et 
al., 2017 [22] 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
Effect allele: G 
 
β = 0.09 pmol/L 
 
>0.05 
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PMNS children*: 
n  = 690 
Indian 
 
 
 
11 ± 1 
 
Effect allele: G 
 
β = 0.08 pmol/L 
 
>0.05 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: G 
 
β = 0.03 pmol/L 
>0.05 
10p13 DNA methyltransferase 
gene 
(DNMT2) / TRNA 
Aspartic Acid 
Methyltransferase 1 
(TRDMT1) 
rs2295809 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
T = 0.240 Effect: A allele  
Other: T allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 0.82 (95% CI: 
0.73, 0.92) pmol/L 
 
1.00 x 10-3 Zinck et al., 
2015 [18]     
10p13 DNA methyltransferase 
gene 
(DNMT2) / TRNA 
Aspartic Acid 
Methyltransferase 1 
(TRDMT1) 
rs5607712
2 
Icelandic sample: 
 n  = 25960 
 
 
 
 
63 ± 24 
 
A = 0.335 Effect: A allele  
Other: C allele  
 
β = 0.09 pmol/L 
 
 
 
 
 
4.80 x 
10−21 
Grarup et al., 
2013 [12] 
94 
11q12.1 Intergenic 
 
Nearest gene: 
Transcobalamin 1 (TCN1) 
rs1174560
53 
Icelandic sample: 
 n  = 25960 
 
 
63 ± 24 
 
A = 0.024 Effect: G allele  
Other: A allele  
 
β = 0.16 pmol/L 
 
 
 
 
 
1.90 x 
10−9 
Grarup et al., 
2013 [12] 
11q12.1 Membrane Spanning 4-
Domains A3 
(MS4A3) 
rs2298585   Icelandic sample: 
 n  = 25960 
 
  
63 ± 24 
 
T = 0.001 Effect: T allele  
Other: C allele 
 
β = 0.21  pmol/L 
 
 
 
 
 
>0.05 Grarup et al., 
2013 [12] [205] 
[205]  
11q12.1 Membrane Spanning 4-
Domains A3 
(MS4A3) 
rs2298585   Initial sample:  
 n  = 1999 
Chinese Han men 
 
 
 
 
38 ± 11  
 
 
T = 0.120 Effect: T allele 
Other: C allele 
 
β = Not available 
 
1.71 x 10-
10 
 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
  n  = 1496  
Chinese men 
37 ± 11 Effect: T allele 
Other: C allele 
 
β = Not available 
 
1.58 x 10-6 
 
Combined total: 
 n  = 3495 
 Effect: T allele 
Other: C allele 
 
β = 71.80 pg/ml 
SE = 9.04 
2.64 x 
10−15 
 
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
G = 0.216# Effect allele: G 
 
β = -0.07 pmol/L 
 
>0.05 Nongmaithem et 
al., 2017 [22] 
95 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1  Effect allele: G 
 
β = -0.10 pmol/L 
 
>0.05 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: G 
 
β = -0.16 pmol/L 
 
2.00 x 10-2 
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
G = 0.080 Effect: A allele 
Other: G allele 
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 1.38 (95% CI: 
1.21, 1.57) pmol/L 
 
1.40 x 10–
6 
Zinck et al., 
2015 [18]    
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 Icelandic sample: 
 n  = 25960 
 
  
63 ± 24 
 
G = 0.296 Effect: G allele  
Other: A allele  
 
β = -0.12  pmol/L  
 
 
 
 
 
2.30 x 
10−48 
Grarup et al., 
2013 [12] 
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 Initial sample: 
 n  = 1999   
Chinese Han men 
8 ± 11 G = 0.189 Effect: G allele 
 Other: A allele 
 
β= -30.39  pg/ml 
SE = 9.66 
1.78 x 10-3 Lin et al., 2012 
[19] 
96 
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6  
 
 
G = 0.270 Effect: G allele  
Other: A allele  
 
β = −0.05 pg/ml 
SE = 0.01 
 
1.27 x 10-3 
 
 
Hazra et al., 
2009 [20] 
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 
 
 
Effect: G allele  
Other: A allele  
 
β = −0.06 pg/ml 
SE = 0.02 
 
6.69 x 10-5 
 
SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: G allele  
Other: A allele  
 
β = −0.06 pg/ml 
SE = 0.02 
 
1.64 x 10-4 
 
Combined total:  
 n  = 4763 
 Effect: G allele  
Other: A allele  
 
β = −0.05 pg/ml 
SE = 0.01 
 
2.25 ×10-
10 
97 
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 GWAS Meta-
analysis: 
 
InCHIANTI 
study: 
  n  = 1175  
Italian  
  
SardiNIA study: 
  n  = 1115  
Italian  
  
BLSA study¶: 
  n  = 640  
Residents from 
the USA 
 
 
 
 
 
InCHIA
NTI: 
68 ± 16 
 
SardiNI
A: 
45 ± 18  
 
BLSAg: 
68 ± 16 
 
 
G = 0.330 Effect: A allele  
Other: G allele 
 
β = 36.76 pg/ml 
SE = 10.35 
 8.33 x 10-
7 
 
Tanaka et al., 
2009 [21]   
Replication study: 
Progetto 
Nutrizione study:  
n = 687  
Italian  
47 ± 14 Effect: A allele  
Other: G allele 
 
β = 12.83 pg/ml 
SE = 13.24 
 
>0.05 
Combined meta-
analysis (GWAS 
Meta-analysis + 
Replication 
study): 
 n  = 3613 
 Effect: A allele  
Other: G allele 
 
β = 27.62 pg/ml 
SE = 8.15 
 
1.51 x 10-6 
 
11q12.1 Transcobalamin 1 
(TCN1) 
rs3432421
9 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
A = 
0.041†† 
Effect allele: A 
 
β = -0.30 pmol/L 
 
2.00 x 10-2 
 
Nongmaithem et 
al., 2017 [22] 
PMNS children*: 
n  = 690  
11 ± 1 
 
Effect allele: A 
 
>0.05 
98 
Indian 
 
 
 
β = -0.14 pmol/L 
 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: A 
 
β = -0.65 pmol/L 
 
9.50 x 10-7 
11q12.1 Transcobalamin 1 
(TCN1) 
rs3432421
9 
Icelandic sample: 
 n  = 37283  
 
 
                                                                                       
63 ± 24 A = 0.119 Effect: C allele  
Other: A allele  
 
β = 0.21 pmol/L 
 
 
 
8.80 x 
10−71 
 
 
 
 
Grarup et al., 
2013 [12] 
Danish Inter99 
population: 
 n  = 5481 
46 ± 8 
 
 
Effect: C allele  
Other: A allele  
 
β = 0.40 pmol/L 
3.20 x 
10−23 
 
Danish - Health 
2006: 
 n  = 2812       
49 ± 13 Effect: C allele  
Other: A allele  
 
β = 0.30 pmol/L 
 
3.50 x 
10−24 
 
Combined total: 
 n  = 45576 
 Effect: C allele  
Other: A allele  
 
β = Not available 
 
1.10 x 10-
111 
11q12.1 Transcobalamin 1 
(TCN1) 
rs3452891
2 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
T = 
0.006†† 
Effect allele: T 
 
β = -0.79 pmol/L 
 
1.00 x 10-2 Nongmaithem et 
al., 2017 [22] 
99 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: T 
 
β = 0.38 pmol/L 
 
>0.05 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: T 
 
β = -0.47 pmol/L 
 
3.00 x 10-2 
11q12.1 Transcobalamin 1 
(TCN1) 
rs3452891
2 
Icelandic sample: 
 n  = 25960 
63 ± 24  
 
T = 0.036 Effect: T allele 
 Other: C allele  
 
β = 0.17 pmol/L 
 
 
 
 
 
2.10 x 
10−15 
Grarup et al., 
2013 [12] 
13q32.3 Citrate Lyase Beta Like 
(CLYBL) 
 
 
rs4128111
2 
 Initial sample:  
 n  = 1999 
Chinese Han men 
 
 
 
 
38  ± 11 
 
 
T = 0.044 Effect: T allele 
Other: C allele 
 
β = Not available 
 
1.09 x 10-8 
 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
  n  = 1496  
Chinese men 
37 ± 11 Effect: T allele 
Other: C allele 
 
β = Not available 
 
7.41 x 10-3 
Combined total: 
 n  = 3495 
 Effect: T allele 
Other: C allele 
 
β = −83.60 pg/ml 
SE = 13.62 
9.23 x 
10−10 
 
13q32.3 Citrate Lyase Beta Like 
(CLYBL) 
 
 
rs4128111
2 
Icelandic sample: 
 n  = 37283  
 
 
 
 
                                                                                       
63 ± 24 T = 0.052 Effect: C allele  
Other: T allele  
 
β = 0.17 pmol/L 
 
 
 
9.60 x 10-
27 
 
 
 
Grarup et al., 
2013  [12] 
100 
Danish Inter99 
population: 
 n  = 5481 
 
 
46 ± 8 
 
 
Effect: C allele  
Other: T allele  
 
β = 0.24 pmol/L 
 
1.30 x 10-3 
 
Danish - Health 
2006: 
 n  = 2812       
49 ± 13 Effect: C allele  
Other: T allele  
 
β = 0.29 pmol/L 
 
2.50 x 
10−7 
 
Combined total: 
 n  = 45576 
 Effect: C allele  
Other: T allele  
 
β = Not available 
 
8.90 x 10-
35 
14q24.3 ATP Binding Cassette 
Subfamily D Member 4 
(ABCD4) 
rs3742801 Icelandic sample: 
 n  = 37283  
 
 
 
 
63 ± 24 T = 0.294 Effect: T allele  
Other: C allele  
 
β = 0.05 pmol/L 
 
 
 
5.30 x 
10−8 
 
 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population: 
 n  = 5481 
46 ± 8 
 
 
Effect: T allele  
Other: C allele  
 
β = 0.09 pmol/L 
 
7.60 x 
10−4 
 
Danish - Health 
2006: 
 n  = 2812       
 
49 ± 13 Effect: T allele  
Other: C allele  
 
β = 0.08 pmol/L 
 
4.50 x 
10−5 
 
Combined total: 
 n  = 45571 
 Effect: T allele  
Other: C allele  
 
β = Not available 
1.70 x 
10−13 
101 
14q24.3 ATP Binding Cassette 
Subfamily D Member 4 
(ABCD4) 
rs4619337 Icelandic sample: 
 n  = 25960  
 
  
63 ± 24 
 
C = 
0.292‡‡ 
Effect: C allele  
Other: T allele  
 
β = 0.05 pmol/L 
 
 
 
 
 
3.40 x 10-8 Grarup et al., 
2013 [12] 
19p13.2 Actin Like 9 
(ACTL9) 
rs2340550  Initial sample:  
 n  = 1999 
Chinese Han men 
 
 
 
38  ± 11 
 
 
A = 0.134 Effect: A allele 
Other: G allele 
 
β = Not available  
 
9.34 x 10-7 
 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
  n  = 1496  
Chinese men 
37 ± 11 Effect: A allele 
Other: G allele 
 
β = Not available  
 
>0.05 
Combined total: 
 n  = 3495 
 Effect: A allele 
Other: G allele 
 
β = 23.39 pg/ml 
SE = 8.56 
6.32 x 10-3 
19p13.2 CD320 molecule 
(CD320) / Transcobalamin 
II Receptor (TcblR) 
rs2336573 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
T = 0.010 Effect: C allele 
Other: T allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 0.62 (95% CI: 
0.45, 0.86)  pmol/L 
 
3.0 x 10-3 Zinck et al., 
2015 [18]    
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19p13.2 CD320 molecule 
(CD320) / Transcobalamin 
II Receptor (TcblR) 
rs2336573 Icelandic sample: 
 n  = 37283  
 
 
 
 
                                                                                       
63 ± 24 T = 0.031 Effect: T allele  
Other: C allele  
 
β  = 0.32 pmol/L 
 
 
 
1.10 x 10-
51 
 
 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population: 
 n  = 5481 
 
 
46 ± 8 
 
 
Effect: T allele  
Other: C allele  
 
β  = 0.22 pmol/L 
 
5.70 x 10-3 
 
Danish - Health 
2006: 
 n  = 2812       
 
49 ± 13 Effect: T allele  
Other: C allele  
 
β  = 0.31 pmol/L 
 
1.70 x 
10−8 
 
Combined total: 
 n  = 45575 
 Effect: T allele  
Other: C allele  
 
β = Not available 
 
8.40 x 
10−59 
19p13.2 CD320 molecule 
(CD320) / Transcobalamin 
II Receptor  
(TcblR) 
rs8109720 Icelandic sample: 
 n  = 25960 
  
63 ± 24 
 
Not 
available 
Effect: G allele 
 Other: A allele  
 
β = 0.32 pmol/L 
 
 
 
 
 
5.80 x 10-
52 
Grarup et al., 
2013 [12] 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs281379 Parents of PMNS 
cohort*: 
n  = 1001 
Indian 
 
 
36 ± 5 
 
 
 
 
 
A = 0.222# Effect allele: A 
 
β = 0.20 pmol/L 
 
 
 
4.60 x 10-4 
 
 
 
 
 
Nongmaithem et 
al., 2017 [22] 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
Effect allele: A 
β = 0.05  pmol/L 
 
>0.05 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: A 
 
β = 0.24  pmol/L 
 
4.50 x 10-4 
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PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: A 
β = 0.13 pmol/L 
 
>0.05 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs492602 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
A = 0.210  Effect: G allele 
 Other: A allele  
 
Vitamin B12 
deficiency (< 148 
pmol/L): 
OR: 0.60 (95% CI: 
0.54, 0.70) pmol/L 
 
2.00 x 10–
4 
Zinck et al., 
2015 [18]   
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs492602 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
A = 0.210 Effect: G allele 
 Other: A allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 0.71 (95% CI: 
0.65, 0.81) pmol/L 
 
9.00 x 10–
8 
Zinck et al., 
2015 [18]    
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs492602 NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6  
 
 
G = 0.440 Effect: G allele 
Other: A allele  
 
β = 0.09 pg/ml 
SE = 0.01 
 
 
5.39 x 10-
11 
 
 
Hazra et al., 
2009 [20] 
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 
 
 
Effect: G allele 
Other: A allele  
 
β = 0.04 pg/ml 
SE = 0.02 
5.89 x 10-3 
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SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: G allele 
Other: A allele  
 
β = 0.05 pg/ml 
SE = 0.01 
 
2.36 x 10-4 
 
Combined total:  
 n  = 4763 
 Effect: G allele 
Other: A allele  
 
β = 0.06 pg/ml 
SE = 0.01 
 
1.30 x 10-
14 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs492602 NHS-CGEMS‡: 
n  = 1637 
Caucasian women 
 
 
 
59 
(Mean) 
 
 
G = 0.490 Effect: A allele 
Other: G allele  
 
β = -0.08 pg/ml 
SE = 0.01 
 
2.68 x 10-
10 
 
Hazra et al., 
2008 [29]   
Replication: 
n  = 1059 
Caucasian women 
 
63 
(Mean) 
 
Effect: A allele 
 Other: G allele  
 
β = -0.10 pg/ml 
SE = 0.02 
 
5.60 x 10-9 
 
Combined  meta-
analysis: 
n  = 2696 
 Effect: A allele 
Other: G allele  
 
β = -0.09 pg/ml 
SE = 0.01 
 
5.36 x 10-
17 
105 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs516316 Icelandic sample: 
 n  = 25960 
 
  
63 ± 24 
 
C = 
0.469‡‡ 
Effect: C allele  
Other: G allele 
β = 0.17  pmol/L 
 
 
 
 
 
3.60 x 
10−103 
Grarup et al., 
2013 [12] 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs601338 Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
A = 0.230# Effect: A 
Other: G 
 
β = 0.05 pmol/L 
 
>0.05 Nongmaithem et 
al., 2017 [22] 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect: A 
Other: G 
 
β = 0.25 pmol/L 
 
3.8 x 10-5 
 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
 
Effect: A 
Other: G 
 
β = 0.18 pmol/L 
 
4.30 x 10-3 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs601338 n  = 25960 
Icelandic  
63 ± 24 
 
G = 0.384 Effect: G allele  
Other: A allele  
 
β = -0.16  pmol/L 
 
 
2.40 x 
10−95 
Grarup et al., 
2013 [12] 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs601338 NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6 
 
A = 0.450 Effect: A allele 
Other: G allele  
 
β = 0.09 pg/ml 
SE = 0.01 
 
 
 
4.25 x 10-
11 
 
 
Hazra et al., 
2009 [20] 
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 
 
 
Effect: A allele 
Other: G allele  
 
2.63 x 10-3 
 
106 
β = 0.05 pg/ml 
SE = 0.01 
 
SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: A allele 
Other: G allele  
 
β = 0.05 pg/ml 
SE = 0.01 
 
4.02 x 10-4 
 
Combined total:  
 n  = 4763 
 Effect: A allele 
Other: G allele  
 
β = 0.06 pg/ml 
SE = 0.01 
 
6.92 × 10-
15 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs601338 NHS-CGEMS‡: 
n  = 1658 
Caucasian women 
 
59 
(Mean) 
 
 
G = 0.490 Effect: G allele 
Other: A allele  
 
β = -0.08 pg/ml 
SE = 0.01 
 
4.11 x 10-
10 
Hazra et al., 
2008 [29]   
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
A = 0.233# Effect allele: A 
 
β = 0.10 pmol/L 
 
>0.05 Nongmaithem et 
al., 2017 [22] 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: A 
 
β = 0.25 pmol/L 
 
1.90 x 10-5 
 
PS children†: 
n  = 534  
5 ± 0 
 
Effect allele: A 
 
1.40 x 10-3 
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Indian 
 
 
β = 0.20 pmol/L 
 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 n  = 3114 
Canadian (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
G = 0.230 Effect: A allele 
 Other: G allele  
 
Vitamin B12 
deficiency (< 148 
pmol/L): 
OR: 0.61 (95% CI: 
0.47, 0.80)  pmol/L 
 
3.00 x 10–
4 
Zinck et al., 
2015 [18]   
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 n  = 3114 
Canadian (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
G = 0.230 Effect: A allele  
Other: G allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
 OR: 0.74 (95% CI: 
0.66, 0.84) pmol/L 
 
1.20 x 10–
6 
Zinck et al., 
2015 [18]    
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 Icelandic sample: 
 n  = 37283  
 
 
 
 
 
 
63 ± 24 G = 0.404 Effect: A allele  
Other: G allele  
 
β = 0.16 pmol/L 
 
 
4.10 x 
10−96 
 
 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population: 
 n  = 5481 
 
 
46 ± 8 
 
 
Effect: A allele  
Other: G allele  
 
β  = 0.19 pmol/L 
 
3.50 x 
10−13 
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Danish - Health 
2006: 
 n  = 2812       
49 ± 13 Effect: A allele  
Other: G allele  
 
β = 0.23 pmol/L 
 
1.90 x 10-
34 
 
Combined total  
 n  = 45568  
                                                                                       
 Effect: A allele  
Other: G allele  
 
β = Not available 
2.40 x 
10−139 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 NHS-CGEMS‡: 
 n  = 1658  
Caucasian women 
 
 
 
 
 
 
59 ± 6 
 
G = 0.440 Effect: G allele  
Other: A allele  
 
β = - 0.08 pg/ml 
SE = 0.01 
 
 
 
 
 
3.09 x 10-
10 
 
Hazra et al., 
2009 [20] 
SHARe§: 
 n  = 1647  
Caucasian women 
59 ± 10 
 
 
Effect: G allele  
Other: A allele  
 
β = -0.05 pg/ml 
SE = 0.02 
 
3.80 x 10-4 
 
SHARe§: 
 n  = 1458  
Caucasian men 
59 ± 10 Effect: G allele  
Other: A allele  
 
β = - 0.05 pg/ml 
SE = 0.01 
 
2.80 x 10-4 
 
Combined total:  
 n  = 4763 
 Effect: G allele  
Other: A allele  
 
β = - 0.07 pg/ml 
SE = 0.01 
 
1.83 x 10-
15 
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19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 
 
GWAS Meta-
analysis: 
 
InCHIANTI 
study: 
  n  = 1175  
Italian  
  
SardiNIA study: 
  n  = 1115  
Italian  
  
BLSA study¶: 
  n  = 640  
Residents from 
the USA 
 
 
 
 
 
InCHIA
NTI: 
68 ± 16 
 
SardiNI
A: 
45 ± 18 
 
BLSAg: 
68 ± 16  
 
 
G = 0.470 Effect: A allele  
Other: G allele 
 
β = 44.20 pg/ml 
SE = 8.26 
 2.43 x 10-
12 
 
Tanaka et al., 
2009 [21]     
Replication study: 
Progetto 
Nutrizione study:  
N = 687  
Italian  
47 ± 13 Effect: A allele  
Other: G allele 
 
β = 58.65 pg/ml 
SE = 10.43 
2.19 x 10-
10 
 
Combined meta-
analysis (GWAS 
Meta-analysis + 
Replication 
study): 
 n  = 3613 
 Effect: A allele  
Other: G allele 
 
β = 49.77 pg/ml 
SE = 6.47 
 
2.83 x 10-
20 
 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs602662 NHS-CGEMS‡: 
n  = 1658 
Caucasian women 
 
 
 
59 
(Mean) 
 
 
G = 0.490 Effect: G allele  
Other: A allele  
 
β = -0.08 pg/ml 
SE = 0.01 
 
 
 
6.54 x 10-
10 
 
Hazra et al., 
2008 [29]   
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Replication: 
n  = 1056 
Caucasian women 
 
63 
(Mean) 
 
 Effect: G allele  
Other: A allele  
 
β = -0.08 pg/ml 
SE = 0.02 
 
1.13 x 10-6 
 
Combined meta-
analysis: 
n  = 2714 
  Effect: G allele  
Other: A allele  
 
β = -0.08 pg/ml 
SE = 0.01 
 
3.52 x 10-
15 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs838133 Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
T = 0.205# Effect allele: A 
 
β = 0.05 pmol/L 
 
>0.05 Nongmaithem et 
al., 2017 [22] 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: A 
 
β = 0.27 pmol/L 
 
2.00 x 10-4 
 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: A 
 
β = 0.06 pmol/L 
 
>0.05 
19q13.33 Fucosyl transferase 2 gene 
(FUT2) 
rs1047781 Initial sample:  
 n  = 1999 
Chinese Han men 
 
 
 
 
38  ± 11 
 
 
T = 0.459 Effect: T allele 
Other: A allele 
 
β = Not available 
 
4.63 x 10-
17 
 
 
Lin et al., 2012 
[19] 
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Replication 
sample: 
  n  = 1496  
Chinese men 
 
37 ± 11 Effect: T allele 
Other: A allele 
 
β = Not available 
 
 
6.79 x 10-
22 
 
Combined total: 
 n  = 3495 
 Effect: T allele 
Other: A allele 
 
β = 70.21 pg/ml 
SE = 5.53 
3.62 x 
10−36 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs708686 Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
T = 0.335# Effect: T allele  
 
β = 0.13 pmol/L 
 
1.0 x 10-2 
 
Nongmaithem et 
al., 2017 [22] 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect: T allele  
 
β = 0.22 pmol/L 
 
2.20 x 10-4 
 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect: T allele  
 
β = 0.23 pmol/L 
 
2.70 x 10-4 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs708686 N = 25960 
Icelandic  
63 ± 24  
 
T = 
0.301‡‡ 
 
 
 
Effect: T allele  
Other: C allele 
 
β = 0.05 pmol/L 
 
2.90 x 
10−9 
Grarup et al., 
2013 [12] 
112 
19p13.3 Fucosyltransferase 6 / 
Fucosyltransferase 3 
(FUT6/FUT3) 
rs3760775  Parents of PMNS 
cohort*: 
n  = 1001 
Indian 
 
 
36 ± 5  
 
 
 
 
A = 0.188# Effect allele: A 
 
β  = 0.24 pmol/L 
 
 
 
 
 
6.00 x 10-6 
 
 
Nongmaithem et 
al., 2017 [22] 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
Effect allele: A 
 
β  = 0.24 pmol/L 
 
9.90 x 10-5 
 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: A 
 
β  = 0.31 pmol/L 
 
2.90 x 10-6 
 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: A 
 
β  = 0.24 pmol/L 
 
2.10 x 10-4 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs3760776 Parents of PMNS 
cohort*: 
n  = 1001 
Indian 
 
 
36 ± 5  
 
 
 
 
T = 0.161# Effect allele: T 
 
β  = 0.10 pmol/L 
 
 
>0.05 
 
Nongmaithem et 
al., 2017 [22] 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
Effect allele: T 
 
β = 0.23 pmol/L 
 
4.40 x 10-4 
 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: T 
 
β = 0.30 pmol/L 
 
 3.30 x 10-
6 
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PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
 
Effect allele: T 
 
β = 0.18 pmol/L 
 
6.50 x 10-3 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs3760776 n  = 25960 
Icelandic  
63 ± 24 
 
A = 0.071 Effect: A allele  
Other: G allele  
 
β = 0.07 pmol/L 
 
 
 
 
 
4.40 x 
10−6 
Grarup et al., 
2013 [12] 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs3760776 Initial sample:  
 n  = 1999 
Chinese Han men 
 
 
 
 
38  ± 11 
 
 
A = 0.212 Effect: A allele 
Other: G allele 
 
β = Not available 
 
 
4.23 x 10-
10 
 
 
Lin et al., 2012 
[19] 
Replication 
sample: 
  n  = 1496  
Chinese men 
37 ± 11 Effect: A allele 
Other: G allele 
 
β = Not available 
 
1.98 x 10-4 
 
Combined total: 
 n  = 3495 
 Effect: A allele 
Other: G allele 
 
β = 49.78 pg/ml 
SE = 6.82 
3.68 x 
10−13 
 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs7788053 Icelandic sample: 
 n  = 37283  
 
 
 
 
                                                                                       
63 ± 24 A = 0.254 Effect: A allele  
Other: G allele  
 
β = 0.05  pmol/L 
 
 
 
2.10 x 
10−7 
 
 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population: 
 n  = 5481 
 
 
46 ± 8 
 
 
Effect: A allele  
Other: G allele  
 
β = 0.05 pmol/L 
 
>0.05 
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Danish - Health 
2006: 
 n  = 2812       
49 ± 13 Effect: A allele  
Other: G allele  
 
β = 0.07 pmol/L 
 
7.20 x 10-4 
Combined total: 
 n  = 45575 
 Effect: A allele  
Other: G allele  
 
β = Not available 
 
1.70 x 10-
10 
19p13.3 Fucosyltransferase 6  
(FUT6) 
rs7806069
8 
Parents of PMNS 
cohort*: 
n  = 1001 
Indian 
 
 
36 ± 5  
 
 
 
 
A = 
0.130†† 
Effect allele: A 
 
β  = 0.21 pmol/L 
 
 
 
 
 
 
2.90 x 10-4 
 
 
 
 
Nongmaithem et 
al., 2017 [22] 
Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
Effect allele: A 
 
β  = 0.20 pmol/L 
 
3.70 x 10-3 
 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect allele: A 
 
β  = 0.27 pmol/L 
 
1.20 x 10-4 
 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect allele: A 
 
β  = 0.19 pmol/L 
 
8.20 x 10-3 
21q22.3 Cystathionine beta 
synthase 
(CBS) 
rs2124459 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
C = 0.180 Effect: T allele  
Other: C allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 0.82 (95% CI: 
0.73, 0.93) pmol/L 
 
2.00 x 10-3 Zinck et al., 
2015 [18]     
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22q12.2 Transcobalamin 2 
(TCN2) 
rs757874 n  = 3114  
Canadian  (85% 
Caucasian, 15% 
non-Caucasian) 
20 – 79 
(range) 
T = 0.080 Effect: G allele 
 Other: T allele  
 
Vitamin B-12 below 
adequate (< 220 
pmol/L): 
OR: 1.42 (95% CI: 
1.11, 1.72) pmol/L 
 
3.30 x 10–
4 
Zinck et al., 
2015 [18]     
22q12.2 Transcobalamin 2 
(TCN2) 
rs1131603 Adults: 
n  = 724  
Indian 
 
38 ± 11 
 
C = 0.023# Effect: C allele 
 
β = 0.43 pmol/L 
 
4.00 x 10-2 Nongmaithem et 
al., 2017 [22] 
PMNS children*: 
n  = 690  
Indian 
 
 
 
11 ± 1 
 
Effect: C allele 
 
β = 0.05 pmol/L 
 
>0.05 
PS children†: 
n  = 534  
Indian 
 
 
5 ± 0 
 
Effect: C allele 
 
β = 0.44 pmol/L 
 
5.00 x 10-2 
22q12.2 Transcobalamin 2 
(TCN2) 
rs1131603 Icelandic sample: 
 n  = 37283  
 
 
 
 
                                                                                       
63 ± 24 C = 0.055 Effect: C allele  
Other: T allele  
 
β = 0.19 pmol/L 
 
 
 
4.30 x 
10−28 
 
 
 
 
Grarup et al., 
2013  [12] 
Danish Inter99 
population: 
n = 5481
 
 
 
 
46 ± 8 
 
Effect: C allele  
Other: T allele  
β = 0.33 pmol/L 
 
1.80 x 
10−9 
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All studies have a cross-sectional study design. 
SNP, Single Nucleotide Polymorphism 
* Pune Maternal Nutrition Study (PMNS) 
† Parthenon Study (PS) 
‡ Nurses’ Health Study (NHS) NCI-Cancer Genetic Markers of Susceptibility (CGEMS) project 
§ Framingham-SNP-Health Association Resource (SHARe) 
¶ Baltimore Longitudinal Study of Aging (BLSA) 
#Data refers to the HapMap-GIH population, with data collected from Gujarati Indians from Houston, Texas 
**Data refers to European populations collected from: Utah Residents (CEPH) with Northern and Western European Ancestry, Toscani in Italia, 
Finnish in Finland, British in England and Scotland and Iberian Population in Spain 
††Data refers to South Asian populations collected from: Gujarati Indian from Houston, Texas, Punjabi from Lahore, Pakistan, Bengali from 
Bangladesh, Sri Lankan Tamil from the UK and Indian Telugu from the UK 
‡Data refers to the HapMap-CEU population, with data collected from Utah Residents (CEPH) with Northern and Western European Ancestry
Danish - Health 
2006: 
 n  = 2812       
49 ± 13 Effect: C allele  
Other: T allele  
 
β = 0.33 pmol/L 
 
5.30 x 
10−17 
 
Combined total: 
 n  =  45575 
 Effect: C allele  
Other: T allele  
 
β = Not available 
4.90 x 
10−49 
22q12.2 Transcobalamin 2 
(TCN2) 
rs5753231 Icelandic sample: 
 n  = 25960 
 
 
63 ± 24 
 
T = 0.210 Effect: C allele 
 Other: T allele  
 
β = 0.06 pmol/L 
 
 
 
 
 
7.50 x 
10−10 
Grarup et al., 
2013 [12] 
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Table 9: Candidate gene association studies examining the association of SNPs with vitamin B12 concentrations 
Chromos
ome 
location 
Gene name  
(Gene symbol) 
Reference 
SNP Cluster 
ID 
Sample size & 
Ethnicity 
Study design Age 
(years) 
Minor allele 
frequency 
Effect size  P-value References 
1p34.1 Methylmalonic 
aciduria and 
homocystinuria type 
C protein 
(MMACHC) 
rs10789465 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 C = 0.469† Not available 1.00 x 10-3 Andrew et al., 
2013 [13] 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801131 n  = 988 
French women 
Cross-
sectional  
40 – 65 
(range)  
C =  0.290 Not available >0.05 
 
De Batlle et al., 
2016 [79] 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
Rs1801131 
 
n  = 6784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
C =  0.340 Not available >0.05 
 
Thuesen et al., 
2010 [57] 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
Rs1801131 
 
n  = 220 
Brazilian 
Cross-
sectional  
1 – 8  
(range) 
C = 0.240 Not available >0.05 
 
Aléssio et al., 
2004 [78] 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 n  = 988 
French women 
Cross-
sectional  
40 – 65 
(range) 
T =  0.360 Not available >0.05 
 
De Batlle et al., 
2016 [79] 
 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 n  = 731   
English (White 
Caucasian) 
Cross-
sectional  
85 T = 0.330 β = 5.00 x 10-5 
pmol/L‡ 
>0.05 
 
Mendonca et al., 
2016 [28] 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 Elderly individuals:  
n  = 262  
Brazilian 
 
Cross-
sectional  
60 – 91 
 (range) 
 
 
T = 0.370 Not available 
 
 
 
>0.05 
 
Barnabe et al., 
2015 [77] 
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Children: 
n  = 106  
Brazilian 
 
0.5 – 6 
(range) 
T = 0.290 Not available 
 
>0.05 
 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 n  = 6784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
T =  0.290 Effect allele: Not 
available 
Other allele: Not 
available 
 
Low serum 
vitamin B12: 
OR: 1·78 (95% 
CI: 
1.25, 2.54) 
pmol/L 
3.00 x 10-3 Thuesen et al., 
2010 [57] 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 n  = 153  
Spanish 
 
 
Cross-
sectional  
13 – 19 
(range)  
T = 0.380 Not available 
 
 
>0.05 Al-Tahan et al., 
2008 [81] 
 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 
 
n  = 10601 
Norwegian 
Cross-
sectional  
56 T = 0.280 Not available >0.05 Hustad et al., 
2007 [80] 
 
1p36.3 Methylenetetrahydro
folate Reductase 
(MTHFR) 
rs1801133 n  = 220 
Brazilian 
Cross-
sectional  
1 – 8 
(range) 
T = 0.320 Not available >0.05 Aléssio et al., 
2004 [78] 
 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs1805087 n  = 731   
English (White 
Caucasian) 
Cross-
sectional  
85 G = 0.180 β = 4.00 x 10-3 
pmol/L‡  
>0.05 Mendonca et 
al.,2016 [28] 
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1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs1805087 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.161† Not available >0.05 Andrew et al., 
2013 [13] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs1805087 n  = 6784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
G = 0.200 Not available >0.05 
 
Thuesen et al., 
2010 [57] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs2275568 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 A = 0.460† Not available >0.05 Andrew et al., 
2013 [13] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs2789352 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 T = 0.381† Not available >0.05 Andrew et al., 
2013 [13] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs3768142 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.384† Not available >0.05 Andrew et al., 
2013 [13] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs10733118 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 T = 0.381† Not available >0.05 Andrew et al., 
2013 [13] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs10925257 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.155† Not available >0.05 Andrew et al., 
2013 [13] 
120 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs11800413 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.431† Not available >0.05 Andrew et al., 
2013 [13] 
1q43 5-
Methyltetrahydrofol
ate-Homocysteine 
methyltransferase 
(MTR) 
rs12060264 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 A = 0.438† Not available >0.05 Andrew et al., 
2013 [13] 
2q23.2 Methylmalonic 
Aciduria and 
Homocystinuria,Cbl
D Type 
(MMADHC) 
rs7580915 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.228† Not available >0.05 Andrew et al., 
2013 [13] 
4p14 Replication Factor C 
Subunit 1 
(RFC1) 
rs1051266 Elderly individuals:  
n  = 262  
Brazilian 
 
Cross-
sectional  
60 – 91 
 (range) 
 
 
A = 0.430 Not available 
 
 
 
>0.05 Barnabe et al., 
2015 [77] 
 
 
Children: 
n  = 106  
Brazilian 
 
 
 
1– 6 
(range) 
A/G = 0.500 Not available 
 
>0.05 
4q31.21 Methylmalonic 
aciduria (cobalamin 
deficiency) cblA 
type 
(MMAA) 
rs4835011 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.080† Not available >0.05 Andrew et al., 
2013 [13] 
4q31.21 Methylmalonic 
aciduria (cobalamin 
deficiency) cblA 
type 
(MMAA) 
rs4835012 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G = 0.178† 
 
Not available 3.00 x 10-2 
 
Andrew et al., 
2013 [13] 
121 
4q31.21 Methylmalonic 
aciduria (cobalamin 
deficiency) cblA 
type 
(MMAA) 
rs4835014 
 
n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 T = 0.031† 
 
Not available >0.05 Andrew et al., 
2013 [13] 
4q31.21 Methylmalonic 
aciduria (cobalamin 
deficiency) cblA 
type 
(MMAA) 
rs11728906 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 G =  0.235† Not available >0.05 Andrew et al., 
2013 [13] 
5q14.1 Betaine-
homocysteine S-
methyltransferase 
(BHMT) 
rs3733890 
 
n  = 6784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
A = 0.290 
 
Not available >0.05 Thuesen et al., 
2010 [57] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs10380 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.156† 
 
Not available >0.05 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs162031 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T =  0.205† Not available >0.05 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs162036 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 G = 0.186† 
 
Not available 4.00 x 10-2 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs162040 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 C = 0.124† Not available >0.05 Andrew et al., 
2013 [13] 
122 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs162048 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 G =  0.164† Not available 5.00 x 10-2 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs326120 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 G = 0.155† Not available >0.05 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs1532268 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 A = 0.308† 
 
Not available 1.00 x 10-2 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs1801394 n  = 6784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
A =  0.430 Not available >0.05 Thuesen et al., 
2010 [57] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs1801394 
 
n  = 220 
Brazilian 
Cross-
sectional  
1 – 8 
(range) 
A = 0.490 Not available >0.05 
 
Aléssio  et al., 
2004 [78] 
 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs2966952 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.167† 
 
Not available >0.05 Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs3776455 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 G = 0.389† Not available  2.00 x 10-3  Andrew et al., 
2013 [13] 
5p15.31 Methionine synthase 
reductase 
(MTRR) 
rs6555501 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 C = 0.473† 
 
Not available >0.05 Andrew et al., 
2013 [13] 
123 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs6458687 n  = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.372† Not available >0.05 Andrew et al., 
2013 [13] 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs6458690 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 G = 0.363† Not available 2.00 x 10-4 Andrew et al., 
2013 [13] 
6p12.3 Methylmalonyl-CoA 
Mutase 
(MUT) 
rs9381784 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.363† 
 
Not available 3.00 x 10-2 
 
Andrew et al., 
2013 [13] 
6q13 LMBR1 Domain 
Containing 1 
(LMBRD1) 
rs991974 
 
n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.044† Not available >0.05 Andrew et al., 
2013 [13] 
6q13 LMBR1 Domain 
Containing 1 
(LMBRD1) 
rs1457498 
 
n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.084† Not available >0.05 Andrew et al., 
2013 [13] 
6q13 LMBR1 Domain 
Containing 1 
(LMBRD1) 
rs3778241 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 T = 0.398† Not available >0.05 Andrew et al., 
2013 [13] 
6q13 LMBR1 Domain 
Containing 1 
(LMBRD1) 
rs3799105 
 
n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 C = 0.384† Not available >0.05 Andrew et al., 
2013 [13] 
6q13 LMBR1 Domain 
Containing 1 
(LMBRD1) 
rs6455338 
 
n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 C = 0.387† Not available >0.05 Andrew et al., 
2013 [13] 
124 
6q13 LMBR1 Domain 
Containing 1 
(LMBRD1) 
rs9294851 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study) 
48 ± 13 T =  0.384† Not available >0.05 Andrew et al., 
2013 [13] 
11q12.1 Transcobalamin 1 
(TCN1) 
rs526934 
 
n = 731   
English (White 
Caucasian) 
Cross-
sectional  
85 G =  0.270 β = 4.00 x 10-3  
pmol/L‡ 
>0.05 Mendonca et al., 
2016 [28] 
 
12q24.11  Methylmalonic 
aciduria (Cobalamin 
deficiency) cblB 
type 
(MMAB) 
rs2287182 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 A = 0.128† 
 
Not available >0.05 Andrew et al., 
2013 [13] 
12q24.11 Methylmalonic 
aciduria (Cobalamin 
deficiency) cblB 
type  
(MMAB) 
rs3759387 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 A = 0.235† 
 
Not available >0.05 Andrew et al., 
2013 [13] 
12q24.11 Methylmalonic 
aciduria (Cobalamin 
deficiency) cblB 
type  
(MMAB) 
rs7134594 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 C =  0.487† Not available >0.05 Andrew et al., 
2013 [13] 
12q24.11 Methylmalonic 
aciduria (Cobalamin 
deficiency) cblB 
type  
(MMAB) 
rs7957619 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 A =  0.110 † Not available >0.05 Andrew et al., 
2013 [13] 
12q24.11 Methylmalonic 
aciduria (Cobalamin 
deficiency) cblB 
type  
(MMAB) 
rs12314392 n = 262  
Caucasian women 
of North European 
descent 
Cross-
sectional 
(Twin Study)  
48 ± 13 G = 0.433 † Not available >0.05 Andrew et al., 
2013 [13] 
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19p13.2 
 
 
 
 
 
  
CD320 molecule 
(CD320) / 
Transcobalamin II 
Receptor (TcblR) 
rs2336573 n = 591 
Caucasian women 
 
 
Cross-
sectional  
77 ± 7 
 
 
A = 0.050 Not available  >0.05 Kurnat-Thoma et 
al., 2015 [59] 
n = 198 
African American 
women 
 
75 ± 6 A = 0.330 Not available 4.0 x 10-2 
n = 797 
Combined total 
 
 
 
 
 
 
 
 
 
 Not available 2.0 x 10-2 
 
 
 
 
 
19q13.33 Fucosyl transferase 
2 gene 
(FUT2) 
rs492602 n = 731   
English (White 
Caucasian) 
Cross-
sectional  
85 A = 0.450 β = 0.05  pmol/L‡ <0.001 Mendonca et al., 
2016 [28] 
 
 
19q13.33 Fucosyl transferase 
2 gene 
(FUT2) 
rs602662 Vegetarian: 
n = 553 
North Indian  
Cross-
sectional  
50 (41 – 
59) 
 
Median 
(interqua
rtile 
range) 
A = 0.310 Effect: A allele 
Other: G allele 
 
β = 0.12 pmol/L 
5.0 x 10-3 Tanwar et al., 
2013 [27] 
Non-Vegetarian: 
n = 593 
North Indian  
Cross-
sectional  
47 (37 – 
55) 
 
Median 
(interqua
Effect: A allele 
Other: G allele 
 
β = 0.12 pmol/L 
4.0 x 10-3 
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rtile 
range) 
Combined total: 
n = 1146 
North Indian  
Cross-
sectional  
49 (40 – 
57) 
 
Median 
(interqua
rtile 
range) 
Effect: A allele 
Other: G allele 
 
β = 0.12 pmol/L 
4.0 x 10-5 
22q12.2 Transcobalamin 2 
(TCN2) 
rs1801198 NORCAP cohort*: 
n = 2411 
Norwegian  
 
Serum holoTC 
could be analysed 
in only 2379 
individuals 
Cross-
sectional  
50 – 64 
(range)   
G = 0.440 Effect: C allele 
Other: G allele 
 
Total holo-TC: 
β = 0.02 pmol/L‡ 
 
 
>0.05‡ 
 
 
Riedel et al.,2011 
[55] 
Effect: C allele 
Other: G allele 
 
Plasma Cbl: 
β = 0.03 pmol/L‡ 
>0.05‡ 
22q12.2 Transcobalamin 2 
(TCN2) 
rs1801198 n = 122 
Portuguese 
Cross-
sectional  
46 ± 13 
 
G = 0.480 Not available Vitamin 
B12: 
>0.05 
Holo-TC: 
<0.05 
Castro et al., 2010 
[52]   
22q12.2 Transcobalamin 2 
(TCN2) 
rs1801198 n = 554 
Participants of 
Latino ancestry 
residing in USA 
Cross-
sectional  
69 ± 6 G = 0.350 Not available Vitamin 
B12: 
>0.05 
 
Garrod et al., 
2010 [56] 
127 
Total holo 
TC: 
>0.05 
 
22q12.2 Transcobalamin 2 
(TCN2) 
rs1801198 n = 613 
Northern Irish Men 
(Caucasian) 
Cross-
sectional  
30 – 49 
(range) 
G = 0.450 Not available 1.00 x 10-2 Stanislawska-
Sachadyn et 
al.,2010 [54] 
22q12.2 Transcobalamin 2 
(TCN2) 
rs1801198 n = 6,784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
G =  0.440 Not available >0.05 Thuesen et al., 
2010 [57] 
22q12.2 Transcobalamin 2 
(TCN2) 
rs1801198 n = 207 
Brazilian 
Cross-
sectional  
1 – 8 
(range) 
G = 0.360 Not available >0.05 Alessio et al., 
2007 [58] 
22q12.2 Transcobalamin 2 
(TCN2) 
rs4820888 
 
n = 591 
Caucasian women 
 
 
Cross-
sectional  
77 ± 7 
 
 
G = 0.430 Not available >0.05 Kurnat-Thoma et 
al., 2015 [59] 
n = 198 
African American 
women 
 
75 ± 6 G = 0.450 Not available  >0.05 
n = 797 
Combined total 
 
 
  Not available 2.0 x 10-2 
22q12.2 Transcobalamin 2 
(TCN2) 
rs9606756 NORCAP cohort*: 
n = 2411 
Norwegian  
 
Serum holoTC 
could be analysed 
in only 2379 
individuals 
Cross-
sectional  
50 – 64 
(range) 
G = 0.120 Effect: A allele 
Other: G allele 
 
Total holo-TC: 
β = -0.21 pmol/L‡ 
 
 
<0.001‡ 
 
 
 
Riedel et al.,2011 
[55] 
Effect: A allele >0.05‡ 
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All studies have a cross sectional design 
SNP, Single Nucleotide Polymorphism 
*NORwegian Colorectal CAncer Prevention (NORCCAP) cohort 
†Data refers to HapMap European population, with data collected from Utah Residents (CEPH) with Northern and Western European Ancestry 
‡The specific data available is not published elsewhere and was obtained by contacting the corresponding author
Other: G 
allelePlasma Cbl: 
β = -0.02 pmol/L‡ 
22q12.2 Transcobalamin 2 
(TCN2) 
rs9606756 n = 6784 
Danish 
Cross-
sectional  
30 – 60 
(range)  
G =  0.120 Not available >0.05 Thuesen et al., 
2010 [57] 
1p36.3 
 
 
 
19q13.33 
 
Methylenetetrahydro
folate Reductase 
(MTHFR) 
+ 
Fucosyl transferase 
2 gene 
(FUT2) 
rs180133 
rs180131 
rs492602 
n = 988 
Brazilian 
Cross-
sectional  
5 ± 3 rs180133 
T = 0.320 
rs180131 
C = 0.220 
rs492602 
G = 0.390 
 
β for GRS= −0·11 
pmol/L 
 <0·001 Cobayashi et al., 
2015 [105] 
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Table 10: A summary of the most frequently studied genes associated with vitamin B12 concentrations 
Vitamin B12-
related 
proteins 
Gene name Location Function 
Co-factors or 
regulators of 
co-factors 
essential for the 
transport of 
vitamin B12 
 
Methylmalonic aciduria 
and homocystinuria, cblC 
type (MMACHC) 
1p34.1 The MMACHC gene encodes a chaperone protein MMAACHC (cblC protein) which binds to 
vitamin B12 in the cytoplasm and appears to catalyse the reductive decyanation of 
cyanocobalamin into cob(II)alamin [235].  
Transcobalamin 1 
(TCN1) 
11q12.1 It encodes a glycoprotein called Transcobalamin 1, also known as haptocorrin (HC), which binds 
to vitamin B12. It shields dietary vitamin B12 from the acidic environment of the stomach [236].  
Fucosyltransferase 2 
(FUT2) 
19q13.33 It encodes the enzyme fucosyltransferase 2 (FUT2), which is involved in the synthesis of antigens 
of the Lewis blood group [231]. These antigens mediate the attachment of gastric pathogens to the 
gastric mucosa, which can affect the absorption of vitamin B12 [109].  
Fucosyltransferase 6 
(FUT6) 
19p13.3 It encodes the enzyme fucosyltransferase 6 (FUT6), which is involved in forming Lewis associated 
antigens. These antigens attach gastric pathogens to the gastric mucosa. It has been shown that 
these gastric pathogens can reduce the absorption of vitamin B12 in the gut [43,44]. 
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Transcobalamin 2 
(TCN2) 
22q12.2 It encodes a transport protein called transcobalamin 2 (TC), which binds to vitamin B12 within 
the enterocyte. The TC-B12 complex enters the portal circulation [59] 
[237][237][237][237][237][237][237][237][237][237][237][237][237][237][237][237][237][237
][237][237][237][237][237][237][236][236][236][236][236][236][236][236][236][236][236][23
6][236][236]and makes vitamin B12 available for cellular uptake in target tissues [238].  
Membrane 
transporters 
that actively 
facilitates 
membrane 
crossing 
Cubilin (CUBN) 10p13 It encodes the intestinal receptor Cubilin, which is expressed in the renal proximal tubule and 
intestinal mucosa [239]. Cubilin recognizes the vitaminB12-intrinsic factor complex, and binds to 
another protein called Amnionless to facilitate the entry of vitamin B12 into the intestinal cells 
[240].  
ATP Binding Cassette 
Subfamily D Member 4 
(ABCD4) 
14q24.3 ABCD4 codes for an ABC transporter. It has been postulated that ABCD4 is involved in 
intracellular cobalamin processing [241], and is involved in transporting vitamin B12 from 
lysosomes to the cytosol. In the cytosol, vitamin B12 can be converted into methylcobalamin 
(MeCbl) and adenosylcobalamin (AdoCbl) [241].  
CD320 Molecule 
(CD320) 
19p13.2 It encodes the membrane receptor transcobalamin receptor (TCblR), which binds to the 
transcobalamin-vitamin B12  complex, and mediates the uptake of vitamin B12 into cells [[242].  
Proteins 
involved in the 
catalysis of 
enzymatic 
Methylenetetrahydrofola
te reductase (MTHFR) 
1p36 MTHFR codes for a critical enzyme involved in homocysteine remethylation. MTHFR catalyses 
the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in an irreversible 
reaction [[243].  
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reactions in the 
one carbon 
cycle 
 Methionine synthase 
reductase (MTRR) 
5p15.31 This gene is responsible for maintaining adequate levels of activated vitamin B12 
(methylcob(III)alamin), which maintains the enzyme methionine synthase in its active state [83].  
Proteins 
involved in cell 
cycle 
regulation 
Membrane Spanning 4-
Domains A3 (MS4A3) 
 11q12.1 
  
MS4A3 encodes a protein involved as a hematopoietic cell cycle regulator [244]. MS4A3 gene may 
have a role in the cell-cycle regulation in the GI tract, thus affecting the renewal of intestinal and 
gastric epithelial cells, and absorption of vitamin B12 [206, 244].  
Mitochondrial 
protein 
Methylmalonic aciduria 
(cobalamin deficiency) 
cb1A type (MMAA) 
4q31 MMAA encodes a protein that may be involved in the translocation of vitamin B12 into the 
mitochondria [245]. In addition, MMAA could play an important role in the protection and 
reactivation of Methylmalonyl-coA mutase (MCM) in vitro [246].  
Methylmalonyl-CoA 
Mutase (MUT) 
 6p12.3   It encodes a Mitochondrial enzyme methylmalonyl-CoA mutase (MUT), which catalyses the 
isomerization of methylmalonyl-CoA to succinyl-CoA. This isomerization requires vitamin B12 
as a cofactor in the form of 5-prime-deoxyadenosylcobalamin (AdoCbl) [168]. 
Citrate Lyase Beta Like 
(CLYBL) 
 13q32.3  It encodes a human mitochondrial enzyme, which is co-expressed with other co-enzymes in the 
mitochondrial B12 pathway [247].    
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2.4.1 Co-factors or regulators of co-factors essential for the transport of vitamin 
B12  
2.4.1.1 Methylmalonic aciduria and homocystinuria, cblC type (MMACHC) 
The Methylmalonic aciduria and homocystinuria, cblC type (MMACHC) gene is 
located in the chromosome region 1p34.1 [248]. The MMACHC gene encodes a chaperone 
protein MMACHC (cblC protein) which binds to vitamin B12 in the cytoplasm and appears to 
catalyse the reductive decyanation of cyanocobalamin into cob(II)alamin [235].  
Among the common variations,  SNP rs12272669 has been associated with vitamin 
B12 status, where ‘A’ allele carriers had higher vitamin B12 concentrations compared with ‘G’ 
allele carriers (P=3.00 x 10−9, β=0.51 pmol/L) in 37,283 Icelandic individuals [205]. 
Furthermore, SNP rs10789465 was associated with vitamin B12 concentrations (P=1.00 x 10-
3) in a candidate gene association study comprising 262 Caucasian women of North European 
descent [170]. Currently, it is unknown how these variants affect the regulation of the 
MMACHC gene. 
2.4.1.2  Transcobalamin 1 (TCN1)  
The Transcobalamin 1 (TCN1) gene is located on chromosome 11, and codes for the 
vitamin B12 binding protein, Transcobalamin I (TCI; also called haptocorrin (HC) or R binder)  
[249-251]. TCI is involved in facilitating the entry of vitamin B12 into the cells, via receptor-
mediated endocytosis [252]. Six studies have reported associations between variants within the 
TCN1 gene and circulating vitamin B12 concentrations [205, 206, 233, 234, 253, 254]. 
Nongmaithem et al. [233] investigated the association between several nucleotide 
variations within the TCN1 gene and vitamin B12 levels in a GWA study comprising 534 
healthy children from Mysore, India. Carriers of the ‘G’ allele of the rs526934 variant were 
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found to have lower circulating vitamin B12 concentrations (β=-0.16 pmol/L, P=0.02) 
compared to ‘A’ allele carriers [233]. This finding was in accordance with the studies 
conducted in Chinese, Icelandic, Italian and individuals residing in the US (predominantly non-
Hispanic white) [205, 206, 234, 254]. Furthermore, additional variants of the TCN1 gene 
(rs34528912 and rs34324219) were observed to be associated with vitamin B12 status (P < 
0.05) in individuals of Icelandic, Indian and Danish  backgrounds [205, 233].  
Although no functional data are available to confirm the functional effect of these SNPs 
on vitamin B12 concentrations, the results from these studies suggest that the SNPs may have 
important physiological consequences for the role of the TCN1 protein in relation to vitamin 
B12 levels. 
2.4.1.3  Fucosyltransferase 2 (FUT2)  
The fucosyltransferase 2 (FUT2 gene), also known as the Se gene (secretor), is located 
on chromosome 19. The FUT2 gene codes for a secretor enzyme α(1,2) fucosyltransferase 
which fucosylates oligosaccharides producing H type 1 and 2 antigens. H antigens are 
precursors of ABO and Lewis b histo-blood group antigens that are expressed on mucosal 
surfaces [231]. Recent studies have shown suggestive associations between variants of FUT2 
with diabetes and body mass index [16, 255-257]. 
For the FUT2 gene, seven SNPs including: rs281379, rs492602, rs516316, rs601338, 
rs602662, rs838133 and rs1047781 were previously reported to be associated with vitamin B12 
levels [205, 206, 233, 234, 253, 254, 258-260]. To identify loci associated with plasma vitamin 
B12, a meta-analysis of three genome wide association scans (n=4763) was carried out in a 
Caucasian population residing in the US [234]. The SNP rs601338, also known as 428 G/A 
nonsecretor variant allele (W143X variant), was significantly associated with plasma vitamin 
B12 levels (P=6.92 x 10-15), with the  allele ‘A’ being positively associated with plasma vitamin 
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B12 levels (β=0.06 pg/ml) [234]. This finding was further confirmed in another study looking 
at 37,283 Icelandic adults (P=2.40 x 10−95, β=0.162 pmol/L) [205], as well as in two Indian 
populations of children (β= 0.18 pmol/L – 0.25 pmol/L) [233]. Notably, the minor allele 
frequency (MAF) of rs601338 varies widely between ethnicities, contributing to genetic 
heterogeneity in FUT2-B12 associations. In  previous reports by Grarup et al. [205] and Hazra 
et al. [260], the frequency of the minor allele ‘G’ for the associated SNP (rs601338) was 
between 38.4% and 49.0%, for Icelandic and Caucasian populations from the US, respectively. 
In contrast, the allele ‘A’ was found to be the minor allele in the Indian population 
(MAF=23.0%) [233]. The presence of the ‘A’ allele is associated with higher vitamin B12 
concentrations, compared to ‘G’ allele carriers. This indicates that in the Indian population, a 
greater number of individuals carry the ‘G’ allele and hence could partly explain why they are 
expected to have a lower vitamin B12 status [258]. The FUT2 rs601338 variant is less common 
in East Asians than Europeans [MAF= 3.5%; HapMap HCB (Han Chinese in Beijing, China) 
and MAF= 1.2%; HapMap JPT (Japanese in Tokyo, Japan)], and may explain why the locus 
has not been identified in Chinese individuals in previous studies [206].  Another common non-
synonymous SNP rs1047781 (A385T) has been shown to be a potential functional variant 
associated with vitamin B12 status and a major FUT2 secretor defining SNP in East Asians, 
and has also been reported to reduce the expression of Fucosyltransferases [261, 262]. Lin et 
al. found that the ‘T’ allele of the SNP rs1047781 was significantly associated with higher 
vitamin B12 concentrations in 3,495 Chinese men (P=3.62 x 10−36, β = 70.21 pg/ml) [206]. 
This genetic marker is present only in East-Asians; hence, it could not be replicated in a study 
conducted in Icelandic individuals [205].  
To date, three studies have shown an association between the SNP rs492602 and 
vitamin B12 concentrations [234, 253, 260]. The SNP rs492602 is in complete linkage 
disequilibrium (LD) with FUT2 W143X (rs601338) (r2= 1), as shown in the Nurses’ Health 
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Study [260]. Hazra et al. [234] found that the ‘A’ allele of the SNP rs492602 variant was 
associated with lower vitamin B12 concentrations (β= -0.06 pg/ml, P= 1.30 × 10-14) amongst 
4,763 Caucasians  from the US, this finding was similarly observed in a GWA study (2,696 
women) by the same authors (β= -0.09 pg/ml, P= 5.36 ×10-17) [260]. In a subsequent study in 
3,114 Canadian adults, the ‘G’ allele was shown to be associated with a lower risk (P=2.0 x 
10–4, Odds Ratio: 0.60, 95% CI 0.54-0.70) of vitamin B12 deficiency (< 148 pmol/L) [253]. 
Finally, the most commonly studied variant of the FUT2 gene is the SNP rs602662. 
This SNP was also reported to be in LD with the SNPs rs601338 (r2 = 0.76) and rs516316 (r2 
= 0.83) in Caucasian populations from the US and Iceland [205, 260]. Zinck, et al. [253], 
reported that ‘A’ allele carriers of the rs602662 variant were at a lower risk of vitamin B12 
deficiency (< 148 pmol/L) (OR: 0.61, 95% CI 0.47-0.80, P=3.0 x 10–4) in a population of 3,114 
Canadian adults [253]. Similarly,  a higher vitamin B12 status was observed in carriers of the 
‘A' allele in four different studies looking at Caucasians (β= 0.04-43.27  pmol/L) [205, 234, 
254, 260] and Indians (β= 0.10-0.25 pmol/L) [233, 258]. Furthermore, additional variants of 
the FUT2 gene were observed to be associated with vitamin B12 levels (P < 0.05) in the 
following SNPs: rs1047781, rs516316, rs838133 and rs281379 [205, 206, 233]. 
It has been proposed that host genetic variation in the FUT2 gene may alter the 
composition of the gut microbiome. Individuals, who are nonsecretors (homozygous for the 
non-functional FUT2 phenotype), lack terminal fucose residues on mucin glycans [263, 264]. 
As a result, the gut microbial community of individuals with FUT2 deficiency may reduce in 
composition and diversity, as microbes cannot adhere or utilize host-derived glycans [264, 
265]. Variations in the FUT2 gene can potentially alter the susceptibility to Helicobacter Pylori 
(H. pylori) infection, and its related gastric-induced vitamin B12 malabsorption [266-271]. 
Gastric pathogens such as H. pylori, attach to α1,2-fucosylated glycan’s on epithelial cells, or 
structures masked by fucosylation with the help of these H antigens in individuals with the 
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secretor status [266-271]. Infections with H. pylori in the human intestine, have been reported 
to interfere with the release of intrinsic factor needed for vitamin B12 absorption [271]. 
Interestingly, a study in Northern Portugal found that the SNP rs602662 ‘A’ allele has been 
linked to a non-secretor status (null H antigens), and this may decrease the risk of bacterial 
infection from pathogens such as H. pylori, and explains why subjects who carry ‘A’ allele 
have a high vitamin B12 status [272]. Alternatively, independent of H. pylori-mediated 
gastritis, individuals who carried FUT2 secretor variants who were also heterozygous for a GIF 
(a fucosylated glycoprotein needed for vitamin B12 absorption) mutation, had lower vitamin 
B12 concentrations [273].  
2.4.1.4  Fucosyltransferase 6 (FUT6)  
The fucosyltransferase 6 (FUT6) gene is located on chromosome 19, and encodes a 
Golgi stack membrane protein; involved in the formation of Sialyl-Lewis X, an E-selectin 
ligand [206]. These Lewis associated antigens are associated with H. pylori adherence to the 
gastric and duodenal mucosa [274, 275]. Overgrowth of H. pylori has been linked to vitamin 
B12 deficiency, as gastric bacteria reduces the secretion of IF which is needed to form the 
vitamin B12-IF complex [206, 271].  
In light of the potential physiological link between the FUT6 gene and vitamin B12 
deficiency, three studies investigated the relationship between variants in the FUT6 gene and 
vitamin B12 status. Lin et al. first observed [206] that the ‘A’ allele of the rs3760776 variant 
was associated with higher vitamin B12 levels (β=49.78 pg/ml, P=3.68 × 10-13) in a sample of 
3,495 men of Chinese Han and Chinese descent [206]. Similarly, homozygous ‘A’ allele 
carriers of Icelandic (β=0.068 pmol/L, P=4.4×10−6) [205] and Indian (β=0.18-0.30 pmol/L) 
[233] populations had high serum vitamin B12 concentrations. Interestingly, this gene variant 
may have the potential to serve as a genetic marker for Type 2 diabetes [257].  
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Furthermore, additional variants of the FUT6 gene (rs708686 [205, 233], rs78060698 
[233], rs3760775 [233] and rs7788053 [205]) were observed to be associated with a higher 
vitamin B12 status in individuals of the Indian, Icelandic  and Danish populations (P < 0.05). 
Bioinformatic analysis has shown that the FUT3, FUT5 and FUT6 genes form a cluster on 
chromosome 19p13.3 [276]. Interestingly, the SNPs: rs3760775, rs10409772, rs12019136, 
rs78060698, rs17855739, rs79744308, rs7250982, rs8111600 from this cluster were in LD with 
the FUT6 SNP rs3760775 (r2 = 0.57 – 0.84) in South Asian populations. Available data has 
shown differences in the LD structure between South Asian populations and individuals of East 
Asian and European origin [233]. The variation of LD patterns across ethnicities could account 
for the heterogeneity of vitamin B12 concentrations [277].  
Nongmaithem et al. [233] noted that alternative allelic states of the SNP rs78060698 
variant, may influence the binding affinity of HNF4α (a key regulator of FUT6 expression) to 
the FUT6 protein. FUT6 is responsible for synthesizing α(1,3) fucosylated glycans, which act 
as a biological interface for the host-microbial interaction [278]. It is plausible that the SNP 
rs78060698 maintains the structure of glycans, which in turn control intestinal host-microbial 
interactions leading to altered concentrations of vitamin B12 [233, 279].  Another hypothesis, 
is that genetic variants may disrupt the formation of fucosyltransferases which mediate the 
glycosylation of B12 binding proteins and their receptors, thus influencing vitamin B12 
concentrations [233].  
2.4.1.5  Transcobalamin 2 (TCN2)  
The TCN2 gene  also known as transcobalamin 2 is located on chromosome 22. This 
gene has the function of making a vitamin B12  binding protein called transcobalamin II (TC) 
found in human serum [280].  Data suggests that TCN2 genetic variants are associated with 
Alzheimer’s disease and clinical manifestations of autoimmune gastritis in individuals with 
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low vitamin B12 status [281, 282]. TC is involved with absorption and transporting vitamin 
B12 into the cell. Only 10-20% of vitamin B12 is attached to TC, the remainder is attached to 
holo-haptocorrin (transcobalamin 1) [253, 283, 284]. Five studies have reported associations 
between variants within the TCN2 gene and vitamin B12 levels [205, 233, 253, 283, 285].     
The most commonly reported TCN2 polymorphism in Caucasian populations is the 
SNP rs1801198, where the C to G substitution at nucleotide 776 (TCN2 776C>G) results in an 
amino acid exchange of proline to arginine at codon 259 (P259R). In a candidate gene 
association study of 613 Irish men, a significant association was observed between the SNP 
rs1801198   and serum vitamin B12 levels (P=0.01). Individuals with the homozygous wildtype 
‘CC’ genotype had lower vitamin B12 levels (mean: 243.5 pmol/L) compared to those with 
‘GG’ genotype (mean: 279.7 pmol/L) [285]. In contrast, it was observed that Holo-
transcobalamin (Holo-TC) concentrations were significantly associated with the SNP 
rs1801198, in a population of 122 individuals from Portugal, where the G allele carriers 
(median 54.2 pmol/L) had lower Holo-TC levels compared to the C variant (P < 0.05; median 
66.3 pmol/L) [283]. Four other studies reported no significant associations between the SNP 
rs1801198 and vitamin B12 concentrations in Caucasian populations (P>0.05) [286-289]. It 
was found that the minor allele frequency (G allele) of the SNP rs1801198 ranged between 
35% to 48% in  Brazilian (36%) [289], Latino (35%) [287], Nordic (44%) [286, 288], Northern 
Irish (45%) [285] and Portuguese (48%) [283] individuals. Additional variants of the TCN2 
gene (rs757874, rs4820888, rs1131603 and rs5753231) were associated with vitamin B12 
status (P<0.05) in individuals of Indian, Canadian,  US, African American, and Scandinavian 
background [205, 233, 237, 253, 286]. 
It has been suggested that the 776GG homozygous variant encodes a protein with a 
lower binding affinity to vitamin B12 in comparison to the wildtype ‘C’ allele [287]. 
Additionally, other studies have indicated that variations in the TC protein reduce the binding 
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of vitamin B12 to TC or prevent the TC-R from recognising the vitamin B12-TC complex 
[231].  
2.4.2 Genes that code for membrane transporters that actively facilitate 
membrane crossing 
2.4.2.1 Cubulin (CUBN)  
 Cubulin (CUBN) also known as the intestinal intrinsic factor receptor or intrinsic factor-
cobalamin (IF-B12) receptor is located on chromosome 10. CUBN is expressed on the intestinal  
and kidney epithelial cells and is involved with the uptake of the intrinsic factor-vitamin B12 
(vitaminB12-IF) complex  [234, 290, 291]. CUBN polymorphisms have been associated with 
maternal neural tube defects risk, megaloblastic anaemia, coronary heart disease and gastric 
cancer in individuals with low vitamin B12 status [292-296].  
Studies of the association between vitamin B12 status and the variants within CUBN 
have yielded conflicting results. Hazra et al. [234] was first to report an association between 
the ‘G’ allele of the rs1801222 (Ser253Phe) variant and higher vitamin B12 status (β= 0.05 
pg/ml, P=2.87×10-9) in 4,763 individuals from the US population [234]. This association was 
confirmed in another study looking at 45,571 Icelandic and Danish individuals (β = 0.10 - 0.17 
pmol/L; P=3.3 x10-75) [205]. In contrast, a study in 3,114 Canadian individuals (85% Caucasian 
and 15% Non-Caucasian) showed that the ‘G’ allele of the rs1801222 variant was associated 
with a higher risk of vitamin B12 deficiency (OR: 1.61 pmol/L, 95% CI 1.24-2.09, P=3.0 x 10–
4)[253]. Genotypic frequency of the risk conferring minor allele ‘A’ was compared between 
three different studies (Canadian, Nordic and individuals of European ancestry living in the 
USA). It was found that Canadian individuals carried the lowest frequency of the risk allele 
‘A’, at 10% [253]. On the other hand, Hazra et al. [234]  and Grarup et al. [205], observed that 
the minor allele frequency ‘A’ was 28.0% and 40.7% in Caucasian individuals residing in the 
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USA and Nordic populations, respectively. Interestingly, several other genetic variants 
within CUBN (rs4748353, rs11254363 and rs12243895) were found to be either positively or 
negatively associated with vitamin B12 levels in residents from China, [206] Canada [253], 
USA and Italy [254]. 
To date several hypotheses have attempted to explain how CUBN variants are involved 
with lower vitamin B12 concentrations. One hypothesis is that CUBN is co-expressed with the 
protein amnionless (AMN, Chromosome 14) forming the cubam complex [240]. Cubilin has 
additionally been suggested to function together with megalin (LRP2, chromosome 2) [297], 
thus any polymorphisms in either AMN or LRP2 genes can affect B12 absorption leading to 
B12 malabsorption and deficiency. Another hypothesis is that polymorphisms affecting 
CUBN, decreases the transport and the absorption of vitamin B12 in the ileum [234]. 
Functional studies on rs11254363, rs1801222, rs12243895 and rs4748353 are required to 
explain how these variants affect the regulation of the CUBN gene. 
2.4.2.2  ATP-binding cassette Subfamily D Member 4 (ABCD4)  
The ATP-binding cassette Subfamily D Member 4 (ABCD4) gene is located on 
chromosome 14. This gene codes for the ABCD4 protein, which is a membrane transporter 
involved in transporting vitamin B12 out of lysosomes [298]. It has been shown that 
polymorphisms of the ABCD4 gene affect the functioning of the ABCD4 protein and the 
intracellular processing of vitamin B12 [241]. 
There has been only one study to date investigating the association between vitamin 
B12 status and ABCD4 variants. Grarup et al. [205] examined 45,571 Nordic adults and 25,960 
Icelandic adults in a GWA study [205], where the ‘T’ allele of the rs3742801 and ‘C’ allele of 
the rs4619337 variants were associated with higher vitamin B12 levels (β=0.045-0.093 pmol/L, 
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P=5.3×10−8 ; β=0.05,  P= 3.4 × 10-8, respectively), suggesting an impact of this gene on vitamin 
B12 status.  
Previous research has shown that the protein LMBD1 (which is responsible for the 
lysosomal export of vitamin B12), interacts with the ABCD4 protein. The mechanisms of 
interaction between LMBD1 and ABCD4 remain unclear, but it is believed that polymorphisms 
in human LMBRD1 gene and ABCD4 can prevent translocation of the vitamin B12 from the 
lysosome to the cytoplasm [241, 299].  
2.4.2.3  CD320 molecule (CD320)  
The CD320 gene also known as the ‘CD320 molecule’ gene is located on chromosome 
19. This gene codes for the transcobalamin receptor (TCblR), which binds and engulfs holoTC 
by endocytosis [300]. At present, two SNPs: rs2336573 and rs8109720 have shown association 
with vitamin B12 levels [205, 237, 253]. 
The most commonly studied variant of the CD320 gene is the rs2336573 variant, a 
missense polymorphism that results in an amino acid change from glycine to arginine, at the 
codon position 220. Zinck et al. found that the ‘C’ allele of the rs2336573 variant was 
associated with a lower risk (OR: 0.62, 95% CI 0.45-0.86, P=0.003) of vitamin B12 below 
adequate (< 220 pmol/L) among 3114 Canadian adults [253]. In contrast, an earlier study 
looking at a population of 45,571 adults from Iceland and Denmark found that the ‘T’ allele 
was associated with higher B12 levels (β = 0.22 - 0.32 pmol/L; P=8.4×10−59) [205]. A previous 
study has shown that this polymorphism is associated with the maternal risk of developing 
neural tube defects [292]. Cell culture models have shown that SNPs in the CD320 receptor 
can lead to a reduction in vitamin B12 uptake [300]. 
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2.4.3 Involved in the catalysis of enzymatic reactions in the one carbon cycle 
2.4.3.1  Methylenetetrahydrofolate reductase (MTHFR) 
The methylenetetrahydrofolate reductase (MTHFR) gene is located on chromosome 1 
[301] and  codes for a critical enzyme involved in homocysteine remethylation. MTHFR 
catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in an 
irreversible reaction [243]. The two most well-known MTHFR gene polymorphisms are the 
C677T (rs1801133) and A1298C (rs1801131) variants. Both variants have been associated 
with reduced enzyme activity and an altered distribution of intracellular folate [302, 303]. 
 The majority of candidate gene association studies have shown no association (P>0.05)  
with  MTHFR gene polymorphisms (rs1801131 and rs1801133) and vitamin B12 
concentrations in Brazilian [304, 305], North European [259], French [306], Norwegian [307] 
and Spanish [308] populations. However, Thuesen, et al. reported that ‘T’ allele carriers of the 
C677T genotype variant were associated with an increased prevalence of low serum vitamin 
B12 (OR 1·78; 95% CI 1·25, 2·54; P=0·003) in a population of 6,784 Danish adults [288]. 
There are no explanations to date, which have linked the biological mechanism of TT 
homozygosity and B12 deficiency. It could be postulated that the C677T polymorphism is 
associated with a decrease in intestinal absorption of vitamin B12 [309]. 
2.4.3.2  Methioninesynthase reductase (MTRR) 
The MTRR gene, also known as the ‘methionine synthase reductase’ gene is located on 
chromosome 5. This gene is responsible for maintaining adequate levels of activated vitamin 
B12 (methylcob(III)alamin), which maintains the enzyme methionine synthase in its active 
state [310]. Currently four SNPs: rs162036, rs162048, rs1532268 and rs3776455 have shown 
associations with vitamin B12 levels in healthy individuals [170]. 
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 The  first SNP MTRR rs162036 (Lys350Arg) is a missense polymorphism [311], 
which was found to be associated with vitamin B12 levels (P=4.00 x 10-2) in 262 women of 
North European descent (No effect size available) [170]. The same authors also identified a 
significant association (P < 0.05) between the SNPs rs162048, rs1532268 and rs3776455 with 
vitamin B12 levels. This study provides the first evidence that MTRR polymorphisms 
(rs162036, rs162048, rs1532268 and rs3776455) significantly influence the circulating vitamin 
B12 concentrations. 
2.4.4 Involved in cell cycle regulation 
2.4.4.1  Membrane Spanning 4-Domains A3 (MS4A3)  
 The Membrane Spanning 4-Domains A3 (MS4A3) gene is located on chromosome 11, and 
codes for the MS4A3 protein (also called HTm4). It has been suggested from limited studies 
that the MS4A3 protein may play a role in cell cycle regulation of hematopoietic cell 
development by inhibiting the G1/S cell cycle transition [244]. The only studied variant within 
this gene in relation to vitamin B12 concentrations is rs2298585, which was investigated in 
3,495 men, all of Chinese origin. In this study [206], the ‘T’ allele of the rs2298585 variant 
was associated with higher serum vitamin B12 concentrations (β=71.80 pg/ml, P=2.64 x 10-15) 
[206]. Another study investigated this SNP in 37,283 Icelandic individuals, but found no 
statistical significance (β=0.214 pmol/L, P=0.075) [205]. 
It has been  suggested that polymorphisms of the MS4A3 gene may affect the cell-cycle 
regulation in the GI tract, thus affecting the renewal of intestinal and gastric epithelial cells 
leading to vitamin B12 malabsorption [312] . However, data from animal studies have 
demonstrated that MS4A3 is restricted to differentiating cells in the central nervous system and 
hematopoietic cells [313].  
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2.4.5 Mitochondrial protein 
2.4.5.1  Methylmalonic aciduria (cobalamin deficiency) cb1A type (MMAA) 
The MMAA gene, also known as the ‘methylmalonic aciduria (cobalamin deficiency) cb1A 
type’, is located on chromosome 4q31.1-2 [314]. MMAA encodes a protein (MMAA) that may 
be involved in the translocation of vitamin B12 into the mitochondria [245]. In addition, 
MMAA could play an important role in the protection and reactivation of methylmalonyl-coA 
mutase (MCM) in vitro [246]. Three studies have reported associations between variants within 
the MMAA gene and vitamin B12 concentrations [170, 205, 233]. 
 Andrew et al. was first to report that the SNP rs4835012 was significantly associated 
with vitamin B12 concentrations (P= 3.00 x 10-2) in 262 Caucasian women of North European 
descent (no effect size available) [170]. More recently in a GWA study looking at 534 Indian 
children, the ‘C’ allele of the SNP rs2270655 was significantly associated with lower vitamin 
B12 concentrations (β = -0.20 pmol/L, P= 2.00 x 10-2) [233]. This association was confirmed 
in another study looking at 45,576 Danish and Icelandic adults (β = -0.07 - -0.30, P=2.20 x 10-
13) [205]. While these SNPs might be involved with determination of vitamin B12 
concentrations, their precise biochemical role is unknown.  
2.4.5.2  Methylmalonyl-CoA mutase (MUT) 
 The MUT gene also known as the methylmalonyl-CoA mutase is located on 
chromosome 6. The MUT gene provides instructions for the formation of methylmalonyl-CoA 
mutase (MUT), which is a mitochondrial enzyme. MUT acts as a catalyst which isomerizes 
methylmalonyl-CoA to succinyl-CoA [315]. MUT requires 5-prime-deoxyadenosylcobalamin 
(AdoCbl), which is a form of B12 that works with MUT to form succinyl-CoA. Succinyl-CoA 
participates in the TCA cycle (tricarboxylic cycle) to yield energy [316]. The MUT gene is 
involved in homocysteine metabolism, and it is dependent on vitamin B12 for its function 
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[317]. Four studies have reported associations between variants within the MUT gene 
(chr6:49508102, rs1141321, rs9473555, rs6458690 and rs9381784) and vitamin B12 status 
[170, 205, 206, 234]. 
In a meta-analysis of data from 4,763 Caucasian individuals from the US, participants 
homozygous for the rs9473558 (now merged into rs1141321) ‘T’ allele (β = −0.04 pg/ml ,P= 
4.05 x 10-8) and MUT rs9473555 ‘C’ allele ( β = −0.04 pg/ml, P= 4.91 x 10-8)  were inversely 
associated with plasma vitamin B12 levels [234]. These findings were confirmed in other 
studies involving Icelandic (β= -0.061 pmol/L; β=-0.062 pmol/L, respectively) [205] and 
Chinese populations (β= -30.34 pg/ml; β= -31.0 pg/ml, respectively) [206].  
2.4.5.3  Citrate lyase beta like (CLYBL)  
The citrate lyase beta like (CLYBL) gene is located at chromosome 13 and codes for a 
human mitochondrial protein. The functions of CLYBL include metal ion binding, carbon-
carbon lyase activity and citrate (pro-3s)-lyase activity [206]. Approximately 5% of humans 
have a stop codon polymorphism in CLYBL which is associated with low levels of plasma 
vitamin B12, but the mechanistic link of this to vitamin B12 is currently unknown [318]. 
The association between the CLYBL variant rs41281112 and vitamin B12 levels has 
been studied in two different populations. Lin et al. [206] found that the ‘T’ allele was 
associated with lower serum vitamin B12 levels among 3,495 men of Chinese Han and Chinese 
descent (β=-83.60 pg/ml, P= 9.23×10-10) [206]. Similarly, Grarup et al. [205] found that the 
‘T’ allele of  the SNP rs41281112 variant was associated with lower serum vitamin B12 levels 
(β=-0.29- -0.17 pmol/L, P=8.9 x 10-35)  in 45,571 adults,  all of Icelandic and Danish origin 
[205].  
At present, molecular functioning studies have elucidated that the polymorphism 
rs41281112 (G<A)  changes the amino acid from Arginine to a stop codon resulting in a loss 
146 
of protein expression [318]. As a result, Lin et al. [206] proposed that the rs41281112 variant 
interferes with the binding of CLYBL protein to metal ions, potentially leading to a lower uptake 
of vitamin B12 [206].  
2.4.6 Other genes 
Our review also identified that SNPs in actin like 9 (ACTL9,rs2340550) [206], serum 
paraoxonase/arylesterase 1 (PON1, rs391757)[253], cystathionine beta synthase (CBS, 
rs2124459)[253], carbamoyl-phosphate synthase 1 (CPS1, rs1047891) [205] and DNA 
methyltransferase gene/ tRNA aspartic acid methyltransferase 1  (DNMT2/TRDMT1, 
rs56077122[205] and rs2295809[253])  genes were associated with vitamin B12 status in 
Canadian, Chinese, Danish and Icelandic populations. The SNPs in the intergenic regions 
[rs583228, rs10515552, rs12377462 [206], rs117456053, rs62515066 and Chr6:88792234 
[205] were found to be associated with vitamin B12 status, however, plausible underlying 
biological mechanism as to why these SNPs were associated with vitamin B12 concentrations 
have not been identified.  
2.4.7 Ethnic-specific genetic differences in B12 deficiency 
 In the past, vitamin B12 deficiency within populations in the Indian subcontinent, Mexico, 
Central and South America and certain regions of Africa was solely attributed to dietary 
habits/low consumption of meat [3]. We now know that genetic factors also influence vitamin 
status in individuals [319]. Indian populations have a high prevalence of vitamin B12 
deficiency, typically attributed to the high number of vegetarians present in the population. 
However, non-vegetarians in India have been observed to have lower vitamin B12 
concentrations compared to Caucasian populations [258, 320]. In addition, a recent systematic 
review showed that B12 deficiency is common during pregnancy in other populations where 
vegetarianism is rare [68]. Poor dietary intake, low bioavailable B12 in meat products (i.e., 
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food processing and reheating of food) as well as a possible underlying genetic predisposition 
to vitamin B12 status could be the reasons for such observation in non-vegetarian populations 
[9, 321].  
 Although several studies have explored the association of SNPs with vitamin B12 status, 
only a limited number of genetic loci have been reported to support the presence of ethnic 
differences in vitamin B12 status in non-European populations [206, 233]. We can assume four 
genetic mechanisms which possibly account for these differences: 1) difference in effect allele 
frequencies 2) genetic heterogeneity across different ethnic groups 3) variance in LD structure, 
and 4) gene-gene and gene-environment interactions [322]. A key example of ethnic specificity 
has been demonstrated in the FUT2 gene, whereby different mutations leading to nonsecretor 
status have been identified (the secretor status of FUT2 gene is associated with a low vitamin 
B12 status) [323]. The 428G→A polymorphism (rs601338) is characteristic for the nonsecretor 
allele in Europeans and appears in about 20% of the Caucasian population [324]. In South-East 
and East-Asians populations, the SNP rs601338 is rare and the more common FUT2 missense 
mutation rs1047781 is associated with nonsecretor status [325].  
Genetic variants associated with circulating vitamin B12 have been studied in the 
following populations: African American (n=1) [237], Brazilian (n=4) [289, 304, 305, 326],  
Canadian (n=1) [253], Caucasian (n=4) [234, 237, 259, 260], Chinese (n=1)[206],  Danish 
(n=2) [205, 288], European ancestry (n=1) [170], French (n=1) [306], Icelandic (n=1) [205], 
Indian (n=2) [233, 258], Italian ancestry and residents of the USA (n=1) [254], Latino (n=2) 
[287, 308], Northern Irish (n=1) [285], Norwegian (n=2) [286, 307] and Portuguese (n=1) 
[283]. To date, the majority of genetic association studies of vitamin B12 status have been 
performed in Caucasian populations, and a few have reported associations in high-risk 
populations such as Mexico and India [258, 327]. More studies exploring a wider range of 
ethnicities with large sample sizes may help to identify novel SNPs that may be associated with 
148 
vitamin B12 status. Studying the genetic structure of chromosomal regions that are associated 
with variability in vitamin B12 levels in different populations, can help us understand the 
evolutionary aspects of B12 associations and their relationship with environmental exposures. 
It is important that before any diet-related recommendations based on genotypes are given at 
the population level, associations between the SNPs and various health outcomes need to be 
confirmed [222]. 
2.5 Conclusion 
In summary, our review has identified significant associations of vitamin B12 status 
with 59 B12-related SNPs from 19 genes. Among these genes; five were co-factors or 
regulators for the transport of vitamin B12 (FUT2, FUT6, MMACHC, TCN1 and TCN2); three 
were membrane transporters actively facilitating the membrane crossing of vitamin B12 
(ABCD4, CUBN and CD320); three were involved in the catalysis of enzymatic reactions in 
the one carbon cycle (CBS, MTHFR and MTRR); one was involved in cell cycle regulation 
(MS4A3); three were mitochondrial proteins (CLYBL, MMAA and MUT) and lastly four genes 
had an unknown function (ACTL9, CPS1, DNMT2/TRDMT1 and PON1). Our review 
highlights the complex nature of the B12 genetics where several genes/ SNPs from various 
parts of B12 metabolic pathway contribute to the susceptibility to vitamin B12 deficiency. 
Identification of gene variants involved in this metabolic pathway using large scale genetic 
association studies in diverse ethnic populations would contribute to our understanding of the 
pathophysiology of B12 deficiency and help in discovering biomarkers of vitamin B12-related 
chronic diseases.  
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Chapter 3  
The influence of one-carbon metabolism gene polymorphisms and 
gene-environment interactions on homocysteine, vitamin B12, 
folate and lipids in a Brazilian adolescent population 
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3.1 Abstract: 
Background: Several single nucleotide polymorphisms (SNPs) have been associated with the 
metabolism of vitamin B12, folic acid, homocysteine and lipids. However, the interaction 
between SNPs involved in the one-carbon metabolism pathway and macronutrient intake on 
cardiovascular risk factors in the Brazilian population has not yet been investigated. Hence, 
this study investigated the association of ten SNPs involved in the one-carbon metabolism 
pathway with vitamin B12, folic acid, homocysteine and lipid levels, and examined the 
interaction of these SNPs with lifestyle factors (dietary and physical activity levels) in 
adolescents with cardiovascular risk.  
Methods: A total of 113 adolescents (10-19 years old), from a public school in the city of 
Goiânia, Goiás, Brazil underwent anthropometric, biochemical, food consumption evaluations 
and genetic tests.  
Results: After adjusting for potential confounders, SNPs rs4633 (catechol-O-
methyltransferase, COMT), rs602662 (fucosyltransferase 2, FUT2) and rs1801394 (5-
methyltetrahydrofolate-homocysteine methyltransferase reductase, MTRR) showed significant 
associations with folic acid (P=0.042), vitamin B12 (P=0.009) and oxidized-low density 
lipoprotein (ox-LDL) (P=0.041) concentrations, respectively. The COMT SNP rs4680 showed 
a significant interaction with carbohydrate intake on ox-LDL concentrations (Pinteraction=0.005). 
In addition, the FUT2 SNP rs602662, showed a significant interaction with protein intake on 
homocysteine concentrations (Pinteraction=0.007). However, after correction for multiple testing, 
none of these associations and interactions were statistically significant. 
Conclusion: For the first time, we provide evidence for the interactions between COMT SNP 
rs4680 and carbohydrate intake on ox-LDL levels and the FUT2 SNP rs602662 and protein 
intake on homocysteine concentrations, respectively. However, given that our findings did not 
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reach Bonferroni significance, replication of our results in a larger sample size is required to 
confirm our findings. 
3.2 Introduction: 
Cardiovascular disease (CVD) has remained the leading cause of mortality in Brazil since 
the latter part of the 1960s [328, 329]. Although effective tobacco control policies and access 
to improved healthcare have led to drastic improvements in cardiovascular health, an upward 
trend in unhealthy eating habits and physical inactivity has been observed in the Brazilian 
population [329]. Smoking, obesity, hypertension, hyperlipidaemia, and insulin resistance have 
long been recognized as major risk factors for CVDs [330]; however the aetiology of CVD is 
not yet fully understood [331]. There has recently been renewed interest in the relationship 
between elevated homocysteine levels and the development of CVD [24].  
Epidemiological studies have shown that hyperhomocysteinaemia is a well-known 
independent  risk factor for atherosclerotic vascular disease and hypercoagulability states [24]. 
It is known to mediate adverse effects on vascular endothelium and smooth muscle cells [332]. 
In addition, hyperhomocysteinaemia reduces high-density lipoprotein (HDL) synthesis [333] 
and enhances the synthesis of lipoprotein A [334]. Some studies have indicated that up to 25% 
of coronary events may be attributed to the increase in homocysteine levels [335], which have 
been shown to inversely correlate with B-complex vitamins, such as folate and vitamin B12. 
Although B vitamins have a role in reducing blood homocysteine concentrations, the effect of 
these vitamins on cardiovascular function remain unclear [4]. A few studies have indicated that 
high folate and vitamin B12 status are associated with a reduced risk of coronary heart disease 
[336, 337]. Therefore, maintaining the concentrations of homocysteine, vitamin B12, folate 
and lipids within the body is of grave importance.   
The one carbon metabolism pathway is a network of biochemical reactions involved in the 
transfer of single-carbon units (CH3 or methyl group), controlled by different enzymes and 
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nutritional cofactors [338]. Cells require one-carbon units for nucleotide synthesis and 
methylation reactions. Currently, common variants in genes of the one-carbon metabolism 
pathway have been reported to influence concentrations of homocysteine, folate, vitamin B12 
and lipids [234]. A few studies have examined whether the association between genetic variants 
involved in the one-carbon metabolism pathway and homocysteine concentrations are modified 
by lifestyle factors such as diet [339, 340]. However, no studies, to date, have examined the 
interaction between one-carbon metabolism-related genes and lifestyle factors on vitamin B12, 
folate and lipid concentrations. Hence, seven genes involved in the one carbon metabolism 
were selected for our study [betaine-homocysteine S-methyltransferase (BHMT), catechol-o-
methyl transferase (COMT), fucosyltransferase 2 (FUT2), methylenetetrahydrofolate reductase 
(MTHFR), 5-methyltetrahydrofolate-homocysteine methyltransferase or methionine synthase 
(MTR), 5-methyltetrahydrofolate-homocysteine methyltransferase reductase or methionine 
synthase reductase (MTRR) and transcobalamin 2 (TCN2)].   
In this study, the aim was to examine whether 10 SNPs involved in the one-carbon 
metabolism pathway are associated with vitamin B12, homocysteine, folic acid and lipid-
related outcomes, and whether dietary intake and physical activity levels have a modifying 
effect on these associations. Interaction and association analyses were carried out in 113 
adolescents with cardiovascular risk factors from the city of Goiânia, Goiás, Brazil.   
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3.3 Materials and methods 
3.3.1 Study Participants  
This cross-sectional study was conducted in a public school in the city of Goiânia, Goiás, 
Brazil, between March to May 2014. A total of 454 students were initially enrolled into the 
study, and 201 students were found to be eligible for participation. After screening through 
lifestyle, socioeconomic and clinical history, only 113 adolescents (aged 10-19 years) were 
selected to answer a food frequency record and provided a blood sample for biochemical and 
DNA analysis. Full details of the methodology have been explained previously [341]. Table 
11 shows the characteristics of the study participants.  
Table 11: The characteristics of study participants stratified by sex 
 All (N=113) Boys (N=47) Girls (N=66) P value* 
Age (yrs) 
 
13.87 ± 2.37 13.32 ± 2.35 14.26 ± 2.32 0.037 
Height (m) 
 
1.62 ± 0.11 1.63 ± 0.14 1.61 ± 0.08 0.205 
Weight (kg) 
 
63.53 ± 17.59 66.36 ± 20.13 61.51 ± 15.37 0.169 
BMI (kg/m2) 
 
24.01 ± 4.92 24.33 ± 5.07 23.79 ± 4.84 0.567 
Vitamin B12 (pg/ml) 
 
519.80 ± 232.15 534.62 ± 252.96 509.24 ± 217.50 0.569 
Homocysteine (μmol/l) 
 
7.04 ± 2.99 7.90 ± 2.91 6.42 ± 2.92 0.009 
Folic acid (ng/ml) 
 
11.02 ± 3.27 10.78 ± 3.62 11.20 ± 3.01 0.519 
Triacylglycerol (mg/dl) 94.05 ± 54.16 99.00 ± 59.00 90.53 ± 50.61 
 
0.415 
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Abbreviations: BMI Body mass index  
Data presented as Mean ± SD 
*P values are showing the differences in mean values between Boys and Girls.  
P values were calculated by using Independent t test 
 
Participants were selected on the basis that they were overweight/ obese and/or were 
previously diagnosed with dyslipidaemia, but not with CVD [341]. The presence of 
dyslipidaemia was identified by the use of specific medications or when the interviewees 
reported having hypercholesterolemia or hypertriglyceridemia, previously diagnosed by a 
physician. Individuals were not included in the study if they were previously diagnosed with 
CVD, they used lipid-lowering drugs and they were supplemented with folic acid, cobalamin 
and/or pyridoxine and/or nutritional treatment.  
Total Cholesterol (mg/dl) 155.42 ± 26.34 150.47 ± 24.51 158.95 ± 27.20 0.091 
HDL (mg/dl) 46.29 ± 11.79 
 
43.60 ± 11.47 
 
48.21 ± 11.72 
 
0.040 
LDL (mg/dl) 90.28 ± 21.00 
 
87.04 ± 18.19 92.59 ± 22.64 0.167 
VLDL (mg/dl) 18.85 ± 10.82 19.83 ± 11.75 18.15 ± 10.15 
 
0.419 
Oxidized-LDL (U/L) 6.42 ± 13.69 5.92 ± 11.47 6.77 ± 15.12 0.749 
Total energy (Kcal/day) 2521.63 ± 
585.84 
3010.08 ± 594.92 2173.79 ± 213.40 <0.0001 
Carbohydrate intake (energy 
%) 
47.70 ± 20.59 40.86 ± 19.56 52.56 ± 20.05 0.003 
Fat intake (energy %) 25.36 ± 13.22 22.84 ± 11.58 27.16 ± 14.09 0.087 
Protein intake (energy %) 16.99 ± 8.38 14.56 ± 6.94 18.72 ± 8.92 0.006 
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The present study was approved by the Federal University of Goiás (addendum in protocol 
number 422.329, 07/10/2013). Written informed consent was obtained from students whose 
age was above 18 years, and for those whose age was less than 18 years consent was obtained 
from their parents or guardians. Participants were allowed to leave the study at will and opt out 
from any of the procedures. All clinical investigations were conducted according to the 
principles expressed in the Declaration of Helsinki.  
3.3.2 Anthropometric and biochemical measurements  
Details of anthropometric measurements have been described previously [341]. In brief, 
at baseline, all participants were measured for weight, height, and waist circumference (WC) 
using standard study protocols [341]. The Body Mass Index (BMI) was estimated as weight (in 
kg) divided by the square of body height (m). BMI was classified according to the WHO (2007) 
classification for BMI/age according to sex [342]. Individuals below the 15th percentile were 
considered below normal weight, those between the 15th and 85th percentiles were classified 
as normal-weight, those who fit between the 85th and 97th percentiles were classified as 
overweight, and those above the 97th percentile were considered obese. 
For the determination of biochemical parameters, blood samples (12 ml) were collected by 
peripheral venous puncture in the morning, after a 12 hour fast. The blood samples were used 
to measure homocysteine, vitamin B12, folic acid, lipid profile [including oxidized-low density 
lipoprotein (ox-LDL)] concentrations, and for DNA extraction. Vitamin B12 and homocysteine 
concentrations were analysed using a chemiluminescence method. HDL-cholesterol (HDL-C) 
was determined after precipitation of the LDL and very-low-density lipoprotein (VLDL) 
fractions. The Friedewald formula was applied to obtain the measurement of LDL and VLDL 
cholesterol [343]. Plasma ox-LDL levels were measured using commercially available 
sandwich enzyme-linked immunosorbent assay (Mercodia AB, Uppsala, Sweden) [344]. 
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3.3.3 Assessment of Dietary intake and physical activity 
Study participants undertook a food consumption record, where all foods and beverages 
consumed over two days were reported in a diary. Prior to completing the record, participants 
were given oral and written instructions to help them record all the food and beverages that 
they had consumed e.g. place of consumption and preparation method. This method was used 
to collect participant’s usual food intake, highlighting household measures and portion sizes. 
After completion of the record, a trained member of research staff reviewed the record with the 
respondent. All information provided by the participants was double-checked for accuracy. 
Energy and nutrient intake from the recorded data was calculated based on the Avanutri ® 
software (Avanutri Informática Ltda, Rio de Janeiro, Brazil), with emphasis on lipids, B12 and 
folic acid. Wherever appropriate, nutrient intake values were adjusted to energy by the nutrient 
(energy-adjusted) residual method [345].  
The Global Physical Activity Questionnaire (GPAQ), short form was used to assess 
physical activity. Individuals were divided into physically active and inactive individuals. 
3.3.4 SNP Selection and Genotyping 
Ten common SNPs involved in the one carbon metabolism pathway were selected based 
on the published reports [254, 340, 346-349]: rs1801133 (677C>T) and rs1801131 (1298A>C) 
of MTHFR; rs1805087 (2756A>G) of MTR; rs1801394 (66A>G) of MTRR; rs1801198 
(776G>C) of TCN2; rs4680 (158G>A) and rs4633 of  COMT; rs3797546 and rs492842 of 
BHMT; and rs602662 of FUT2. The MTHFR rs1801133 and MTHFR rs1801131 SNPs [1-4] 
are essential variants known to influence circulating homocysteine. Whilst variations in the 
BHMT gene may contribute to hyperhomocysteinemia [5], it is unknown whether the SNPs 
rs3797546 and rs492842 alter homocysteine levels. Previous studies indicate that the SNPs 
MTR rs1805087, MTRR rs1801394 [14], MTHFR rs1801133 and MTHFR rs1801131 [1-4] are 
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associated with folate concentrations. Furthermore, genome-wide significant associations with 
serum B12 have been reported for the SNPs TCN2 rs1801198 [6] and FUT2 rs602662 [4, 7]. 
The most commonly studied, MTHFR SNP rs1801133 has shown associations with total 
cholesterol, HDL-C, and LDL-C [8, 9]. The COMT gene is known to be involved in 
cardiovascular, endocrine and sympathetic pathways [350-352]. The COMT rs4680 SNP is an 
extensively studied polymorphism, which has shown associations with triacylglycerol (TAG) 
[10, 11], total cholesterol, and LDL-C levels [12].  Currently, no studies have examined the 
association between COMT rs4633 with incident CVD or metabolic traits. 
DNA was then extracted from peripheral leukocytes in the blood, using a commercial kit 
(Roche TM Diagnostics GmbH, Mannheim, Germany) following the manufactures guidelines 
accordingly. The purity and concentration of the DNA samples were assessed using a 
Nanodrop ® ND-1000 spectrophotometer (Thermo Scientific, Wilmington, N.C., USA). The 
10 SNPs involved in the one carbon metabolism were genotyped by using real-time polymerase 
chain reaction using the QuantStudio TM OpenArray TaqMan TM platform (Life 
Technologies, Foster City, Calif., USA) with personalised cards for 12K Flex system 
QuantStudio ® (Life Technologies) with validated TaqMan Assay. The frequency of each SNP 
in this study sample was in agreement with the Hardy-Weinberg equilibrium (P>0.05) (Table 
12).  
Table 12: Genotype distribution of SNPs involved in the one carbon-metabolism pathway 
Gene 
symbol 
SNP  
rs 
number 
Major 
allele/ 
Minor 
allele 
Common 
homozygotes 
(%) 
Heterozygotes 
(%) 
Rare 
homozygotes 
(%) 
Minor 
allele 
frequency 
HWE 
P 
value 
MTHFR  
 
rs1801131 A/C 
 
56 (49.9) 43 (38.1) 13 (11.5) 0.31 0.29 
MTHFR  
 
rs1801133 C/T 55 (48.7) 41 (36.3) 12 (10.6) 0.30 0.31 
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Abbreviations: HWE, Hardy Weinberg Equilibrium; MTHFR, methylene tetrahydrofolate 
reductase; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; MTRR, 5-
methyltetrahydrofolate-homocysteine methyltransferase reductase;TCN2, transcobalamin 2; 
COMT, catechol-O-methyltransferase; BHMT, betaine-homocysteine methyltransferase; 
FUT2, fucosyltransferase 2 
 
3.3.5 Statistical Analysis 
Statistical analyses were carried out using the SPSS software (version 22; SPSS Inc., 
Chicago, IL, USA). Data distribution was verified by the Shapiro-Wilk test. Individuals with 
BMI of ≥ 25 kg/m2 were categorised as obese and those with a BMI of < 25 kg/m2 were 
classified as non-obese. Descriptive statistics for continuous variables are shown as means and 
standard deviation (SD). The mean differences between continuous variables and the genotypes 
were analysed by the independent sample t test. 
Linear regression was used to examine the association of the SNPs involved in the one 
carbon metabolism pathway with vitamin B12, folic acid, homocysteine and lipid 
concentrations (TAG, HDL-cholesterol, LDL-cholesterol, and ox-LDL). The interaction 
between the SNPs and dietary factors on determining vitamin B12, folic acid, homocysteine 
MTR  
 
rs1805087 A/G 77 (68.1) 32 (28.3) 2 (1.8) 0.16 0.52 
MTRR  
 
rs1801394 A/G 45 (39.8) 49 (43.4) 16 (14.2) 0.37 0.66 
TCN2  
 
rs1801198 G/C 60 (53.1) 33 (29.2) 10 (8.8) 0.26 0.10 
COMT  
 
rs4680 G/A 35 (31) 48 (42.5) 24 (21.2) 0.45 0.33 
COMT  
 
rs4633 C/T 44 (38.9) 51 (45.1) 16 (14.2) 0.37 0.84 
BHMT  rs3797546 T/C 67 (59.3) 27 (23.9) 7 (6.2) 0.20 0.08 
BHMT  rs492842 T/C 35 (31) 43 (38.1) 27 (23.9) 0.46 0.07 
 
FUT2  rs602662 G/A 34 (30.1) 52 (46.0) 24 (21.2) 0.45 0.62 
160 
and lipid concentrations were determined by including the interaction term (SNP*diet) in the 
general linear regression models. Models were adjusted for age, sex, BMI and total energy 
intake, wherever appropriate. The dominant model was applied only for those SNPs which had 
a frequency of rare homozygotes less than ≤19%. Correction for multiple testing was applied 
using Bonferroni correction [adjusted P value for association was <0.00071 (10 SNPs * 7 
outcomes (B12, folic acid, homocysteine, TAG, HDL-C, LDL-C, and ox-LDL concentrations) 
=70 tests)] and for interaction <0.00018 (10 SNPs * 7 outcomes (B12, folic acid, homocysteine, 
TAG, HDL-C, LDL-cholesterol, and ox-LDL concentrations)* 4 lifestyle factors= 280 tests). 
All data are expressed as mean ± SD. 
3.3.6 Power calculation 
Given that there were no previously reported effect sizes, we were unable to perform a 
power calculation. However, based on the effect sizes that were observed for the associations, 
we performed a retrospective power calculation using the QUANTO software, Version 1.2.4 
(May 2009). Power calculations were carried out in the form of least detectable effects based 
on the assumption of significance levels and powers of 5 and 80%, respectively. At 80% power, 
the minimum detectable effects ranged from beta 7.5 U/L (ox-LDL) for a SNP with MAF of 
15% to beta 8.5 U/L for a SNP with MAF 50% for a sample size of 113 individuals.  
3.4 Results 
3.4.1 Characteristics of the participants  
The clinical characteristics of the studied population are shown in Table 11. The sample 
consisted of 47 boys and 66 girls. The mean age ± SD of the student group was 13.32 ± 2.35 
years for boys and 14.26 ± 2.32 years for girls. When the metabolite means were categorized 
by sex, plasma homocysteine and HDL concentrations were found to show significant 
differences between boys and girls (P=0.009, P=0.040, respectively). In the study population, 
dietary intake of carbohydrate (energy %) and protein intake (energy %) was higher in girls 
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than boys (P=0.003, P=0.006 respectively), while there was no significant difference observed 
(P=0.087) in dietary intake of fat (energy %) between girls and boys (Table 11).  
3.4.2 Association between SNPs and vitamin B12, folic acid, homocysteine and lipid 
traits 
When analysing associations between 10 SNPs involved in genes related to the one-carbon 
metabolism cycle and biochemical indexes, we found that COMT rs4633 was significantly 
associated with folic acid (Passociation=0.042). Folic acid was significantly lower in CC common 
homozygous individuals (10.25 ± 2.99 ng/ml) than in pooled TT and CC individuals (11.67 ± 
3.29 ng/ml) (Passociation=0.042) (Table 13). Furthermore, homozygosity for the G allele at the 
FUT2 rs602662 SNP was significantly associated with lower vitamin B12 concentrations 
compared with the wild-type group where vitamin B12 concentrations was 24.27% lower in 
GG individuals than in AA individuals (Passociation=0.009) (Table 13). In addition to these 
findings, the minor allele (G) of the MTRR rs1801394 SNP, was significantly associated with 
elevated ox-LDL levels (Passociation=0.041) (Table 13). After Bonferroni correction, none of the 
results were considered statistically significant (P>0.00071).
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Table 13: Association between SNPs involved in the one-carbon metabolism pathway and vitamin B12, homocysteine, folic acid and 
lipid traits 
SNPs MAF Vitamin B12 
(pg/ml) 
Homocysteine 
(μmol/l) 
Folic acid 
(ng/ml) 
High-density 
lipoprotein 
cholesterol 
(mmol/l) 
Low-density 
lipoprotein  
cholesterol 
(mmol/l) 
 
Triglycerides 
(mmol/l) 
Oxidized-low 
density 
lipoprotein 
cholesterol 
(U/L) 
MTHFR gene 
(rs1801131) 
0.31        
AA  524.23 ± 223.49 6.90 ± 2.96 11.26 ± 3.34 47.18 ± 12.84 87.55 ± 21.54 95.05 ± 62.54 7.90 ± 18.65 
A/C  520.21 ± 241.74 7.19 ± 3.07 10.87 ± 3.20 45.68 ± 10.60 92.54 ± 20.21 92.73 ± 45.32 5.07 ± 5.67 
Dominant model  
(AA vs AC+ CC) 
P value 
  
0.916 
 
0.895 
 
0.682 
 
0.708 
 
0.180 
 
0.739 
 
0.209 
MTHFR gene 
(rs1801133) 
0.30        
CC  562.36 ± 238.63 6.80 ± 3.00 11.51 ± 3.18 46.04 ± 10.33 90.67 ± 22.87 86.33 ± 46.07 4.28 ± 5.21 
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C/T  491.42 ± 224.74 7.37 ± 3.00 10.75 ± 3.37 46.25 ± 13.14 89.08 ± 19.51 100.26 ± 61.36 8.95 ± 19.12 
Dominant model  
(CC vs CT+ TT) 
P value 
  
0.058 
 
0.100 
 
 
0.158 
 
0.468 
 
0.519 
 
0.300 
 
0.106 
MTR gene 
(rs1805087) 
0.16        
AA  523.97 ± 221.74 7.22 ± 3.29 11.03 ± 3.31 46.64 ± 12.73 89.42 ± 20.73 92.83 ± 58.11 6.70 ± 14.34 
A/G  518.59 ± 518.59 6.77 ± 2.21 11.08 ± 3.27 45.82 ± 9.78 91.71 ± 22.29 95.44 ± 46.26 6.01 ± 12.72 
Dominant model  
(AA vs AG+ GG) 
P value 
  
0.815 
 
0.301 
 
0.919 
 
0.886 
 
0.517 
 
0.893 
 
0.836 
 
MTRR gene 
(rs1801394) 
0.37        
AA  560.53 ± 249.40 6.61 ± 2.58 10.96 ± 3.42 46.29 ± 9.67 90.78 ± 23.02 93.98 ± 62.30 3.13 ± 3.81 
A/G  494.11 ± 218.14 7.35 ± 3.27 11.14 ± 3.20 46.38 ± 13.09 89.60 ± 19.91 93.28 ± 48.75 8.95 ± 17.46 
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Dominant model  
(AA vs AG + GG) 
P value 
  
0.265 
 
0.394 
 
0.508 
 
0.827 
 
0.814 
 
0.958 
 
0.041 
TCN2 gene 
(rs1801198) 
0.26        
GG  523.88 ± 221.89 6.99 ± 2.60 11.34 ± 3.26 46.93 ± 12.74 90.70 ± 22.25 91.88 ± 50.19 5.99 ± 13.23 
G/C  530.67 ± 263.13 6.94 ± 3.16 10.67 ± 3.14 44.95 ± 9.83 90.09 ± 19.48 98.53 ± 61.99 7.82 ± 15.69 
Dominant model  
(GG vs GC + CC) 
P value 
  
0.982 
 
0.751 
 
0.231 
 
0.213 
 
0.776 
 
0.463 
 
0.497 
COMT gene (rs4680) 0.45        
GG  495.54 ± 234.10 6.98 ± 3.20 10.02 ± 2.81 44.00 ± 10.67 86.71 ± 20.17 102.14 ± 65.53 5.14 ± 6.30 
GA  546.98 ± 249.81 6.88 ± 2.32 11.56 ± 3.24 45.58 ± 11.29 87.71 ± 22.27 95.27 ± 57.18 7.07 ± 17.47 
AA  515.50 ± 181.22 7.08 ± 3.94 11.59 ± 3.61 49.21 ± 13.83 96.83 ± 17.83 81.13 ± 27.52 7.20 ± 14.86 
Additive model P 
value 
 0.825 0.843 0.094 0.258 0.186 0.376 0.658 
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COMT gene (rs4633) 0.37        
CC  511.77 ± 248.82 6.98 ± 3.28 10.25 ± 2.99 45.05 ± 10.87 87.91 ± 19.92 99.84 ± 61.18 4.99 ± 6.00 
C/T  532.07 ± 221.84 7.00 ± 2.77 11.67 ± 3.29 47.25 ± 12.36 90.99 ± 21.46 89.36 ± 49.63 7.54 ± 17.11 
Dominant model  
(CC vs CT + TT) 
P value 
  
0.907 
 
0.740 
 
0.042 
 
0.524 
 
0.337 
 
0.364 
 
0.146 
BHMT gene 
(rs3797546) 
0.20        
TT  536.31 ± 233.97 7.04 ± 3.18 11.51 ± 3.33 46.21 ± 11.33 89.57 ± 21.17 94.55 ± 56.16 6.68 ± 15.25 
T/C  523.41 ± 224.50 6.53 ± 2.03 10.54 ± 2.90 46.59 ± 12.48 92.18 ± 21.76 99.29 ± 54.96 6.74 ± 12.72 
Dominant model 
(TT vs TC + CC) 
P value 
 0.971 0.151 0.231 0.461 0.495 0.811 0.791 
BHMT gene 
(rs492842) 
0.46        
TT  554.89 ± 254.53 6.65 ± 2.66 11.92 ± 3.21 47.57 ± 11.81 85.91 ± 24.16 90.83 ± 43.39 6.47 ± 12.79 
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TC  492.35 ± 196.18 7.64 ± 3.30 10.14± 3.16 45.77 ± 10.46 93.84 ± 17.92 97.05 ± 55.94 8.74 ± 18.36 
CC  469.70 ± 201.74 6.91 ± 3.14 11.27 ± 3.35 44.26 ± 11.06 89.37 ± 21.64 99.07 ± 68.56 3.34 ± 4.95 
Additive model P 
value 
 0.293 0.602 0.095 0.872 0.179 0.915 0.220 
FUT2 gene 
(rs602662) 
0.45        
GG  471.41 ± 193.77 6.93 ± 3.35 11.47 ± 3.31 44.68 ± 10.01 84.50 ± 20.31 90.12 ± 54.27 8.21 ± 13.26 
GA  494.73 ± 220.75 7.18 ± 2.46 10.69 ± 3.19 47.21 ± 13.38 90.52 ± 20.81 93.40 ± 54.93 4.99 ± 13.69 
AA  622.50 ± 268.60 6.84 ± 3.64 11.15 ± 3.40 46.29 ± 10.37 97.79 ± 21.98 104.17 ± 56.13 7.42 ± 15.24 
Additive model P 
value 
 0.009 0.677 0.620 
 
0.622 0.063 0.664 0.374 
Values are given as mean ± SD. P values for differences between genotypes were obtained using linear regression model adjusted for age, sex and 
BMI. Adjusted P value after correction for multiple testing was 0.00071. 
Abbreviations: MAF, minor allele frequency;MTHFR, methylene tetrahydrofolate reductase; MTR, 5-methyltetrahydrofolate-homocysteine 
methyltransferase; MTRR, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase;TCN2, transcobalamin 2; COMT, catechol-O-
methyltransferase; BHMT, betaine-homocysteine methyltransferase; FUT2, fucosyltransferase 2; SNPs, Single-nucleotide polymorphisms; SD, 
Standard deviation 
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3.4.3 Interaction between SNPs and B12, folic acid, homocysteine  
An interaction was observed between the BHMT SNP rs492842 and dietary fat intake on 
vitamin B12 levels (P=0.034). In addition, further interactions were found between the FUT2 
SNP rs602662 with dietary protein intake (P= 0.007) and carbohydrate intake (P= 0.031) on 
homocysteine concentrations (Table 14). We found that rare AA homozygotes of the FUT2 
SNP rs602662 had higher homocysteine levels (Mean ± SE: 8.038 ± 0.896 μmol/l) compared 
to the GG allele carriers (Mean ± SE: 5.857 ± 1.039 μmol/l) among those in the highest tertile 
of protein intake (Mean ± SE: 148.618± 5.777 g/day); however,  the difference in the means of 
homocysteine concentrations between the genotype groups in the highest tertile of protein 
intake was not statistically significant (P=0.227), which could be because of the small sample 
size.  
Table 14: Interaction between SNPs and dietary factors on vitamin B12, homocysteine 
and Folic acid traits 
P values for the interaction between SNPs and dietary factors on vitamin B12 
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.685 0.095 0.074 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.429 0.067 0.115 
Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.368 0.539 0.206 
Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.733 0.070 0.743 
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Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.789 0.109 0.631 
Interaction between SNP 
rs4680* fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.662 0.265 0.559 
Interaction between SNP 
rs4633* fat energy intake  
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.455 0.490 0.799 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.353 0.979 0.281 
Interaction between SNP 
rs492842* fat energy 
intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.034 0.678 0.331 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.087 0.144 0.533 
P values for the interaction between SNPs and dietary factors on homocysteine 
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.806 0.803 0.625 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.975 0.621 0.433 
Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.123 0.922 0.389 
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Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.252 0.645 0.456 
Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.869 0.212 0.341 
Interaction between SNP 
rs4680* fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.062 0.189 0.054 
Interaction between SNP 
rs4633* fat energy intake 
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.596 0.359 0.133 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.713 0.614 0.209 
Interaction between SNP 
rs492842* fat energy 
intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.232 0.227 0.606 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.334 0.007 0.031 
P values for the interaction between SNPs and dietary factors on folic acid 
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.378 0.642 0.774 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.595 0.587 0.722 
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Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.834 0.887 0.498 
Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.641 0.826 0.327 
Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.845 0.759 0.547 
Interaction between SNP 
rs4680* fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.610 0.495 0.228 
Interaction between SNP 
rs4633* fat energy intake 
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.721 0.248 0.050 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.188 0.394 0.754 
Interaction between SNP 
rs492842* fat energy 
intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.084 0.971 0.447 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.521 0.775 0.115 
 
P values were obtained by using a general linear model adjusted for age, sex and BMI. 
Abbreviations: SNPs, Single-nucleotide polymorphisms; BMI, Body mass index 
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3.4.4 Interaction between SNPs and dietary factors on lipid concentrations 
Interactions were observed between the COMT SNPs (rs4680 and rs4633) and dietary 
carbohydrate intake on HDL-C concentrations (P=0.011 and P=0.036, respectively). 
Furthermore, an interaction was found between the COMT SNP (rs4680) and dietary 
carbohydrate intake on ox-LDL concentrations (P=0.005) (Table 15). However, none of the 
interactions between the SNPs and dietary intake on lipid outcomes reached statistical 
significance after correction for multiple testing.   
Table 15: Interaction between SNPs and dietary factors on lipid traits 
Interaction between SNPs and dietary factors on HDL-C  
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.964 0.402 0.899 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.393 0.471 0.994 
Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.651 0.298 0.499 
Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.896 0.712 0.676 
Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.414 0.822 0.649 
Interaction between SNP 
rs4680* fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.898 0.536 0.011 
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Interaction between SNP 
rs4633* fat energy intake 
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.846 0.620 0.036 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.274 0.162 0.555 
Interaction between SNP 
rs492842 fat energy intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.604 0.960 0.513 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.650 0.123 0.813 
Interaction between SNPs and dietary factors on LDL-C  
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.529 0.467 0.798 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.640 0.656 0.737 
Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.456 0.933 0.876 
Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.487 0.384 0.222 
Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.127 0.664 0.250 
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Interaction between SNP 
rs4680* fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.509 0.709 0.299 
Interaction between SNP 
rs4633* fat energy intake 
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.743 0.915 0.067 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.594 
 
0.097 0.306 
Interaction between SNP 
rs492842* fat energy 
intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.380 0.392 0.402 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.399 0.462 0.610 
Interaction between SNPs and dietary factors on Triglycerides  
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.970 0.792 0.504 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.938 0.798 0.266 
Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.648 0.362 0.245 
Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.176 0.285                      0.857 
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Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.490 0.719 0.317 
Interaction between SNP 
rs4680*  fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.290 0.408 0.923 
Interaction between SNP 
rs4633* fat energy intake 
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.185 0.220 0.770 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.127 0.741 0.457 
Interaction between SNP 
rs492842* fat energy 
intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.237 0.216 0.989 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.360 0.082 0.817 
Interaction between SNPs and dietary factors on LDL-ox 
Interaction between SNP * 
rs1801131 fat energy 
intake 
Interaction between SNP 
rs1801131* protein energy 
intake 
Interaction between SNP 
rs1801131* carbohydrate 
energy intake 
0.161 0.962 0.582 
Interaction between SNP 
rs1801133* fat energy 
intake 
Interaction between SNP 
rs1801133* protein energy 
intake 
Interaction between SNP 
rs1801133* carbohydrate 
energy intake 
0.399 0.972 0.908 
Interaction between SNP 
rs1805087* fat energy 
intake 
Interaction between SNP 
rs1805087* protein energy 
intake 
Interaction between SNP 
rs1805087* carbohydrate 
energy intake 
0.493 0.126 0.784 
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Interaction between SNP 
rs1801394* fat energy 
intake 
Interaction between SNP 
rs1801394* protein energy 
intake 
Interaction between SNP 
rs1801394* carbohydrate 
energy intake 
0.235 0.781 0.672 
Interaction between SNP 
rs1801198* fat energy 
intake 
Interaction between SNP 
rs1801198* protein energy 
intake 
Interaction between SNP 
rs1801198* carbohydrate 
energy intake 
0.832 0.100 0.489 
Interaction between SNP 
rs4680* fat energy intake 
Interaction between SNP 
rs4680* protein energy 
intake 
Interaction between SNP 
rs4680* carbohydrate 
energy intake 
0.353 0.348 0.005 
Interaction between SNP 
rs4633* fat energy intake 
Interaction between SNP 
rs4633* protein energy 
intake 
Interaction between SNP 
rs4633* carbohydrate 
energy intake 
0.217 0.372 0.984 
Interaction between SNP 
rs3797546* fat energy 
intake 
Interaction between SNP 
rs3797546* protein energy 
intake 
Interaction between SNP 
rs3797546* carbohydrate 
energy intake 
0.846 0.227 0.270 
Interaction between SNP 
rs492842* fat energy 
intake 
Interaction between SNP 
rs492842* protein energy 
intake 
Interaction between SNP 
rs492842* carbohydrate 
energy intake 
0.624 0.466 0.690 
Interaction between SNP 
rs602662* fat energy 
intake 
Interaction between SNP 
rs602662* protein energy 
intake 
Interaction between SNP  
rs602662* carbohydrate 
energy intake 
0.743 0.298 0.112 
 
P values were obtained by using a general linear model adjusted for age, sex and BMI. 
Abbreviations: SNPs, Single-nucleotide polymorphisms; BMI, Body mass index 
 
3.4.5 Gene-physical activity interactions on vitamin B12, folic acid, homocysteine and 
lipid profile 
In addition to the genetic component of metabolic traits and markers of one-carbon 
metabolites, physical inactivity could be an important contributor that could interact with an 
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individual’s genetic predisposition.  Our results showed that the MTHFR SNP rs1801131 
showed a significant interaction with physical activity on folic acid concentrations 
(Pinteraction=0.034). Folate plays a critical role in the methylation pathway  and is involved in the 
methylation of DNA, creatine and acetylcholine, all of which are important for physical 
activity. It is important to note that physical activity levels may interact with folate metabolism 
by increasing intestinal folate absorption or stimulating the methionine synthase enzyme due 
to an increased metabolic demand and the associated possible increase in turnover of 
methylated molecules required for exercise [353]. In addition, the three SNPs individually: 
MTHFR SNP rs1801133, BHMT rs492842 and FUT2 rs602662 all showed a significant 
interaction with physical activity on triglyceride concentrations (Pinteraction=0.030, 0.004 and 
0.014, respectively). Finally, the BHMT SNP rs3797546 showed an interaction with physical 
activity on ox-LDL levels. However, these interactions were not statistically significant after 
correction for multiple testing (Pinteraction >0.00018) (Table 16). To date all the gene-physical 
activity interactions observed in this study are novel, thus we are unable to compare our 
findings with previous literature. It important that in the future, replications of these findings 
are made preferably in an independent larger cohort with adequate statistical power utilising 
more direct measures of physical activity, in order to confirm or refute our findings. 
Table 16: P values for the interaction between SNPs and physical activity levels on 
vitamin B12, homocysteine, folic acid and lipid traits 
Gene rs 
number 
Model B12 Homocysteine Folic 
acid 
HDL LDL Triglycerides LDL-
ox 
MTHFR  rs1801131 Dominant 0.758 0.640 0.034 0.570 0.764 0.139 0.496 
MTHFR rs1801133 Dominant 0.589 0.810 0.404 0.446 0.541 0.030 0.760 
MTR rs1805087 Dominant 0.607 0.560 0.940 0.440 0.890 0.345 0.134 
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P values were obtained by using a general linear model adjusted for age, sex and BMI. 
Abbreviations: SNPs, Single-nucleotide polymorphisms; BMI, Body mass index 
 
3.4.6 Discussion 
To our knowledge, this is the first genetic epidemiological study to investigate the 
interactions between SNPs involved in the one-carbon metabolism pathway and 
environmental/lifestyle factors on vitamin B12, folic acid, homocysteine and lipid levels 
(HDL-C, LDL, TAG and ox-LDL) in the Brazilian adolescent population. Our study provides 
evidence for novel interactions between SNP rs4680 (COMT gene) and carbohydrate intake on 
ox-LDL levels and the SNP rs602662 (FUT2 gene) and protein intake on homocysteine 
concentrations in Brazilian adolescents. Given that ox-LDL and hyperhomocysteinaemia are 
well-known independent risk factors for atherosclerotic vascular disease [24, 354], our findings 
have significant public health implications. 
Genes involved in one carbon metabolism are of particular interest because of their role 
in CVDs [355]. From the 10 SNPs which were investigated in this study, association of the 
SNP rs4633 at the COMT gene with folic acid concentrations (P=0.042), the SNP rs602662 at 
MTRR rs1801394 Dominant 0.106 0.325 0.238 0.956 0.915 0.701 0.563 
TCN2  rs1801198 Dominant 0.414 0.321 0.941 0.517 0.726 0.186 0.887 
COMT  rs4680 Additive  0.543 0.058 0.783 0.537 0.663 0.113 0.681 
COMT  rs4633 Dominant 0.221 0.253 0.993 0.828 0.400 0.056 0.597 
BHMT  rs3797546 Dominant 0.146 0.274 0.255 0.811 0.250 0.209 0.050 
BHMT rs492842 Additive  0.947 0.281 0.423 0.513 0.483 0.004 0.677 
FUT2  rs602662 Additive  0.613 0.100 0.458 0.147 0.724 0.014 0.491 
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the FUT2 gene with vitamin B12 levels (P=0.009) and finally the SNP rs1801394 at the MTRR 
gene with ox-LDL concentrations (P=0.041) were observed. Even though the findings were 
not significant after Bonferroni correction, the association between the FUT2 SNP rs602662 
and vitamin B12 concentrations is in accordance with previous studies [205, 233, 234, 253, 
254, 258, 260]. Since the current sample size is relatively small, further studies utilizing a larger 
sample size is required to confirm the observed associations. 
To date, only one study has shown a gene-diet interaction on ox-LDL concentrations in 
a population from the Attica region in Greece [356]. In this study, there was an interaction of 
the MTHFR SNP rs1801133 with the Mediterranean diet on ox-LDL concentrations. A high 
adherence to the Mediterranean diet was found to be associated with decreased ox-LDL 
concentrations in T allele carriers of SNP rs1801133 [356]. Further to this, many studies have 
reported that MTHFR variants (C677T and A1298C) are linked to higher homocysteine levels, 
when folate consumption is low [357, 358]. In the present study, we identified significant gene-
diet interactions between SNP rs4680 at the COMT gene and carbohydrate intake on ox-LDL 
concentrations and the SNP rs602662 at the FUT2 gene and protein intake on homocysteine 
concentrations. However, further stratification of participants based on their consumption of 
low, medium and high dietary carbohydrate/protein did not show a statistically significant 
association between the SNP and the outcome in any of the tertiles, which could account for 
the small sample size. This is the first study to provide evidence for gene-diet interactions at 
the COMT and FUT2 gene loci, on ox-LDL and homocysteine concentrations, respectively, 
and hence, we do not have any previous studies to compare our findings. 
Total carbohydrate intake has increased considerably in Brazil in the last few decades 
[359]. Data from two population-based surveys conducted in women over 35 years of age from 
Rio de Janeiro, reported that the carbohydrate intake has increased from 352g (95% CI 325 to 
382) in 1995 to 437 g (95% CI 415 to 458) in 2005 [359]. Interestingly, our study in this 
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Brazilian adolescent population has identified an interaction between COMT SNP rs4680 and 
carbohydrate intake on ox-LDL concentrations. Despite our study being the first to report this 
gene-diet interaction, previous studies have shown that carbohydrate restricted diets can 
promote weight loss and is associated with reduced cardiovascular disease risk [360]. However, 
the exact mechanism by which the COMT SNP rs4680 interacts with dietary carbohydrate to 
influence ox-LDL concentrations is unknown and requires further studies to understand the 
mechanism contributing to this association. Furthermore, in our study we observed an 
interaction of the FUT2 SNP rs1805087 with protein consumption on homocysteine levels. 
However, we have no previous studies to confirm and validate this novel finding. The findings 
in this paper suggest that that the inheritance of ox-LDL and homocysteine levels are complex, 
where several genes/polymorphisms are likely to contribute to the alteration of ox-LDL or 
homocysteine levels through gene-gene and gene-diet interactions. More in depth research 
implementing animal studies, nutrigenomics and metabolomics are needed to clarify the effects 
of SNPs and carbohydrate on ox-LDL concentrations, and protein on homocysteine 
concentrations, respectively.  
One of the main limitations of our study is the small sample size. Given that there are no 
previously reported effect sizes for the FUT2 and COMT SNP-diet interactions on blood 
homocysteine and ox-LDL concentrations, we were unable to calculate the statistical power of 
our study. Our retrospective power calculation showed that the minimum detectable effects for 
ox-LDL levels ranged from beta 7.5 U/L (ox-LDL) for a SNP with MAF of 15% to beta 8.5 
U/L for a SNP with MAF 50%. Hence, if the actual effect sizes were lower than this, our study 
would be underpowered. However, our study did find significant associations and gene-diet 
interactions despite the small sample size; but the findings requires a replication given that the 
significant P values did not reach the Bonferroni corrected P value. Another limitation is that 
our study was cross-sectional, and therefore we were unable to examine the causal relationship 
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between the SNP-diet interactions on blood homocysteine and ox-LDL concentrations. 
Therefore, randomized controlled trials with prospective genotyping are required to explore 
the causality using genetic markers. Given that our study relied on a usual food record, we 
cannot negate the possibility of misreporting and measurement error. A further limitation of 
the current study is the lack of a control group, as only individuals with cardiovascular risk 
factors were included. On the other hand, the main strength of our study is that we examined 
the effect of ten SNPs on vitamin B12, folic acid, homocysteine concentrations and lipid traits 
during adolescence, a critical period where lifestyle habits are usually followed through to 
adulthood. By studying this population, we were able to identify different genotypes of interest, 
which could be further investigated to improve the understanding of the role of these 
micronutrients in relation to the prevention of hyperhomocysteiemia and increased ox-LDL 
concentrations. Additionally, little is known about gene-diet interactions which influence ox-
LDL concentrations; thus, our study adds to the limited body of research. 
3.4.7 Conclusion 
Our study shows an interaction between COMT SNP rs4680 and carbohydrate intake on 
ox-LDL levels among adolescents with cardiovascular risk factors. Furthermore, a borderline 
interaction was observed between FUT2 SNP rs602662 and protein intake on homocysteine 
concentrations. After correction for multiple testing, none of the SNP-environment interactions 
on homocysteine, folate, B12 or lipid concentrations were detected. Hence, our findings 
warrant confirmation in larger, well characterized and well powered prospective studies/ 
randomized controlled trials, before any public health recommendations and personalised 
nutrition advice can be developed for the adolescent Brazilian population. 
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Chapter 4  
A genetic approach to examine the relationship between vitamin 
B12 status and metabolic traits in a South Asian population 
I was the lead co-ordinator for this study. I was responsible for writing up the documents 
required to gain ethical approval to conduct the study both in the University of Colombo, Sri 
Lanka and the University of Reading, UK. I was involved in recruiting participants for the 
study and organizing the locations of the study visits. I spent three months in 2017 in Colombo, 
Sri Lanka to conduct this study. I was primarily involved in data collection, which involved 
collecting anthropometric measurements, conducting food frequency questionnaires and 
physical activity questionnaires. I was also involved in transporting the blood samples to LGC 
genomics for genetic analysis in the United Kingdom. 
For this study, I developed an analysis plan before I undertook the statistical analysis. I 
screened and validated the dataset to perform statistical analysis. I performed the entire 
statistical analysis using the SPSS software; I undertook a literature review as part of the 
introduction to the study and wrote the manuscript. I revised the manuscript based on the 
comments from all the co-authors before the manuscript was submitted to the International 
Journal of Diabetes in Developing Countries. I was also involved in drafting the responses to 
the comments from the reviewers. 
Published (The Published paper is attached as an appendix at the end of the thesis) 
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Surendran S, Alsulami S1, Lankeshwara R, Jayawardena R, Wetthasinghe K Sarkar S, Ellahi 
B, Lovegrove JA, Anthony DJ, Vimaleswaran KS (2019). A genetic approach to examine the 
relationship between vitamin B12 status and metabolic traits in a South Asian population. 
International Journal of Diabetes in Developing Countries (Published). 
4.1 Abstract   
Background: Observational studies in South Asian populations have suggested an association 
between vitamin B12 status and metabolic traits; however, the findings have been inconclusive. 
Hence, the aim of the present study was to use a genetic approach to explore the relationship 
between metabolic traits and vitamin B12 status in a Sri Lankan population and to investigate 
whether these relationships were modified by dietary intake.   
Methods: A total of 109 Sinhalese adults (61 men and 48 women aged 25-50 years), from 
Colombo city underwent anthropometric, biochemical, dietary intake analysis and genetic 
tests. Genetic risk scores (GRS) based on 10 metabolic single nucleotide polymorphisms 
(SNPs) (metabolic-GRS) and 10 vitamin B12 SNPs (B12-GRS) were constructed.  
Results: The B12-GRS was significantly associated with serum vitamin B12 (P=0.008), but 
not with metabolic traits (P>0.05); whereas, the metabolic-GRS had no effect on metabolic 
traits (P>0.05) and vitamin B12 concentrations (P>0.05). An interaction was observed between 
B12-GRS and protein energy intake (%) on waist circumference (P=0.002). Interactions were 
also seen between the metabolic-GRS and carbohydrate energy intake (%) on waist to hip ratio 
(P=0.015).  
Conclusion: Our findings suggest that a genetically lowered vitamin B12 concentration may 
have an impact on central obesity in the presence of a dietary influence; however, our study 
failed to provide evidence for an impact of metabolic-GRS on lowering B12 concentrations. 
Given that our study has a small sample size, further large studies are required to confirm our 
findings.  
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4.2  Introduction 
In recent years, the incidence of obesity in Sri Lanka has increased markedly [361]. The 
prevalence of being overweight or obese in Sri Lankan adults is 34.4% (25.2% and 9.2%, in 
2005 and 2006 respectively), with an upward trend being observed [361, 362]. Obesity 
increases the risk for certain health conditions, such as insulin resistance, diabetes mellitus and 
hypertension [363]. South Asians have been observed to exhibit increased visceral fat and waist 
circumference (WC), hyperinsulinemia and insulin resistance; this has been termed the ‘South 
Asian phenotype’ [364]. Despite a known genetic contribution, the increase in obesity has been 
largely associated with changes in lifestyle habits [365, 366]. It is imperative that modifiable 
risk factors for obesity and associated metabolic problems are identified, especially if they can 
be easily addressed. 
Vitamin B12 is a micronutrient that has been identified as a modifiable risk factor 
associated with the progression of metabolic disorders. In humans, vitamin B12 acts as an 
essential co-enzyme involved in DNA synthesis and cellular energy production [161].  
Subclinical deficiency of vitamin B12 has been linked to higher levels of homocysteine; this 
may have important consequences in the progression of chronic diseases, by inducing oxidative 
stress and inflammation [367]. Vitamin B12 deficiency has also been linked to many other 
complications including an increased risk of obesity [7, 84, 85], diabetes [67, 69, 70] and 
cardiovascular disease [115]. Currently, one study has investigated the effect of genetically 
instrumented vitamin B12 concentrations on body mass index (BMI) in individuals with 
European ancestry; however, there were no associations between the vitamin B12 genetic risk 
score (GRS) and BMI [16].  
Genetic studies have implicated several gene loci in the predisposition to vitamin B12 
deficiency, but no study has yet been carried out in the Sri Lankan population [14].  The 
mechanisms by which obesity and its comorbidities are related to vitamin B12 deficiency are 
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poorly understood.  Hence, we conducted a gene-based approach to explore the relationship 
between metabolic traits and vitamin B12 status in a Sinhalese cohort and investigated whether 
these relationships were modified by dietary intake in the Genetics of Obesity and Diabetes 
(GOOD) study. 
4.3 Methodology 
4.3.1 Study Participants  
 The Genetics of Obesity and Diabetes (GOOD) study is a cross-sectional study that was 
conducted in the city of Colombo, Sri Lanka, between April to August 2017. Healthy adults 
between the ages of 25-50 years were enrolled into the study. Exclusion criteria were: having 
a previous history of type 2 diabetes, cardiovascular disease or hypertension, having a BMI of 
more than 40 kg/m2 or being classed morbidly obese by a physician, being blood related to 
other participants in the study, having any communicable disease, being pregnant or lactating, 
taking dietary or vitamin supplements and taking medications that affect lipid metabolism or 
hypertension (Figure 7).  
The study was conducted in accordance with the principles of the Declaration of 
Helsinki and was approved by the Ethical Review Committee of the University of Colombo 
(EC-17-107) and the University of Reading Research Ethics Committee (17/25). All 
participants provided informed written consent before participating. 
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Figure 7: Flowchart of the subject recruitment process 
  
4.3.2 Anthropometric Measures  
 Body weight was measured to the nearest 100 grams using an electronic scale (Seca 
815, Seca GmbH. Co. kg, Germany) and height was measured to the nearest millimeter using 
a stadiometer (Seca 217, Seca GmbH. Co. kg, Germany). The BMI calculation was based on 
the body weight (kg) divided by the square of body height (m). Waist circumference and hip 
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circumference was measured using a metal tape (Lufkin W606PM®, Parsippany, NJ, USA). 
Body fat percentage was estimated using a hand-held bio-electrical impedance analysis 
technique (Omron Body Fat Monitor BF306, Omron, Milton Keynes, United Kingdom).  
4.3.3 Biochemical Analysis  
 Blood samples (10 ml) were collected by a trained phlebotomist in the morning, after a 
12 hour overnight fast. Fasting serum insulin and vitamin B12 levels were determined using 
the chemiluminescent microparticle immunoassay method on an Architect i1000 analyser 
(Abbott Laboratories, IL, USA). Fasting plasma glucose concentrations were measured using 
the glucose hexokinase method using the Beckman Coulter AU5800 analyser (Beckman 
Coulter®, California, United States). Glycated haemoglobin (HbA1c) was estimated by high-
performance liquid chromatography using the BioRad D10 HPLC analyser (Biorad, Hercules, 
CA, USA).  
4.3.4 Dietary intake analysis  
Dietary intakes were assessed using a previously validated and published [368] interviewer 
administered food frequency questionnaire (FFQ) containing 85 food items. In brief, 
participants were asked to estimate the usual frequency (number of times per day, week or 
month/never) and the portion sizes of various food items. The recorded data was analysed with 
the NutriSurvey 2007 database (EBISpro, Germany) to estimate energy as well as macro- and 
micronutrient consumption[345].  
  “The Global Physical Activity Questionnaire” (GPAQ), developed by the World Health 
Organization (WHO) was used to measure physical activity [369]. Individuals were classified 
as vigorously active, when they both exercised and engaged in demanding work activities, and 
moderately active, when the participants either exercised or carried out heavy physical work. 
The remaining study participants were classified into the sedentary group. 
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4.3.5 SNP selection and Genotyping  
We selected 10 metabolic disease-related SNPs (associated with obesity and diabetes): Fat 
mass and obesity-associated [FTO]- rs9939609 and rs8050136, Melanocortin 4 Receptor 
[MC4R]- rs17782313 and rs2229616, Transcription factor 7-like 2 [TCF7L2]- rs12255372 and 
rs7903146, Potassium voltage-gated channel subfamily J member 11 [KCNJ11]- rs5219, 
Calpain 10 [CAPN10]- rs3792267, rs2975760 and rs5030952) for our analysis based on 
previously published candidate gene association and genome-wide association (GWA) studies 
for metabolic disease-related traits [370-378].  
The 10 vitamin B12-related SNPs (Methylenetetrahydrofolate reductase [MTHFR]- 
rs1801133, Carbamoyl-phosphate synthase 1 [CPS1]- rs1047891, Cubulin [CUBN]- 
rs1801222, CD320 molecule [CD320]- rs2336573, Transcobalamin 2 [TCN2]- rs1131603, 
Citrate lyase beta like [CLYBL]- rs41281112, Fucosyltransferase 2 [FUT2]- rs602662, 
Transcobalamin 1 [TCN1]- rs34324219, Fucosyltransferase 6 [FUT6]- rs778805 and 
Methylmalonyl-CoA mutase [MUT]- rs1141321) were chosen on the basis of the recent review 
article  by Surendran et al. [14].  
Blood samples for the measurement of DNA were transported in dry ice to the UK. Genomic 
DNA was extracted from a 5 ml whole blood sample from each participant and genotyping was 
performed at LGC Genomics (http://www.lgcgroup.com/services/genotyping), which employs 
the competitive allele-specific PCR-KASP® assay. 
  The Hardy-Weinberg equilibrium (HWE) P values were computed for the following 20 
SNPs. The SNPs FUT2 rs602662 and CAP10 rs3792267 deviated from HWE; however, these 
SNPs were not excluded from analysis. The FUT2 SNP rs602662 previously departed from 
HWE in a GWA study conducted in India; the authors ruled out that the deviation was not due 
to a genotyping error and still used this SNP for analysis in their study [233]. In addition, the 
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KASPTM genotyping technology used in our study has been independently assessed to be over 
99.8% accurate. Validation of the KASPTM genotyping was conducted at LGC genomics, 
where the genotyping results were assessed by two project managers separately to confirm that 
the data was accurate, and this ruled out genotyping artefacts as possible reasons for deviation 
from HWE. The reasons for deviation from HWE could be due to population or racial grouping 
substructure (Sub-grouping), non-random mating, linkage disequilibrium (incomplete mixing 
of different ancestral population) or chance findings [379]. 
4.3.6 Statistical Analysis 
The SPSS statistical package (version 22; SPSS Inc., Chicago, IL, USA) was used for the 
statistical analysis. Allele frequencies were estimated by gene counting (Table 17). The 
normality of variable distribution was verified by the Shapiro-Wilk test, and data not normally 
distributed were log transformed prior to analysis. We performed an independent t-test to 
compare the means of the quantitative variables between men and women. Comparison of the 
means between the two groups was analysed by the Chi Square test for categorical outcomes.
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Table 17: Genotype distribution of vitamin B12 related SNPs and metabolic disease-related SNPs 
Gene rs number Major 
allele 
Minor 
allele 
Common 
Homozygotes  
(%) 
Heterozygotes 
(%) 
Rare 
Homozygotes  
(%) 
Minor 
allele 
frequency 
HWE P 
value 
 
MTHFR rs1801133 C T 89 (81.7) 19 (17.4) 1 (0.9) 0.100 0.990 
CPS1 rs1047891 C A 56 (51.9) 44 (40.7) 8 (7.4) 0.278 0.873 
CUBN rs1801222 C T 78 (72.2) 29 (26.9) 1 (0.9) 0.144 0.338 
CD320 rs2336573 C T 99 (90.8) 10 (9.2) 0 (0) 0.046 0.616 
TCN2 rs1131603 T C 107 (98.2) 2 (1.8) 0 (0) 0.009 0.923 
CLYBL rs41281112 C T 105 (96.3) 4 (3.7) 0 (0) 0.018 0.845 
FUT2 rs602662 G A 60 (55.6) 30 (27.8) 18 (16.7) 0.306 0.000 
TCN1 rs34324219 C A 107 (98.2) 2 (1.8) 0 (0) 0.009 0.923 
FUT6 rs778805 C T 29 (26.6) 53 (48.6) 27 (24.8) 0.491 0.776 
MUT rs1141321 G A 28 (25.7) 60 (55.0) 21 (19.3) 0.470 0.271 
CAPN10 rs3792267 G A 79 (72.5) 24 (22.0) 6 (5.5) 0.165 0.035 
192 
CAPN10 rs2975760 T C 66 (60.6) 38 (34.9) 5 (4.6) 0.220 0.874 
CAPN10 rs5030952 C T 101 (92.7) 8 (7.3) 0 (0) 0.037 0.691 
KCNJ11 rs5219 C T 49 (45.0) 45 (41.3) 15 (13.8) 0.344 0.373 
TCF7L2 rs12255372 G T 57 (52.3) 45 (41.3) 7 (6.4) 0.271 0.633 
TCF7L2 rs7903146 C T 45 (41.3) 54 (49.5) 10 (9.2) 0.340 0.274 
FTO rs9939609 T A 48 (44.0) 47 (43.1) 14 (12.8) 0.344 0.641 
MCR rs17782313 T C 48 (44.0) 50 (45.9) 11 (10.1) 0.330 0.700 
FTO rs8050136 C A 48 (44.0) 47 (43.1) 14 (12.8) 0.340 0.641 
MC4R rs2229616 G A 99 (91.7) 9 (8.3) 0 (0) 0.042 0.651 
 
MAF; minor allele frequency, HWE; Hardy Weinberg Equilibrium, X2; Chi-Squared value
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A schematic representation of the study design is presented in figure 8. The 
unweighted, risk-allele GRS method was calculated for each participant as the sum of risk 
allele counts across each SNP, which predicted vitamin B12 status or metabolic disease risk. 
The B12-GRS was generated from the SNPs in the genes MTHFR, CPS1, CUBN, CD320, 
TCN2, CLYBL, FUT2, TCN1, FUT6, MUT, which have been shown to be associated with 
vitamin B12 concentrations. Furthermore, another unweighted GRS was created using allele 
markers previously reported to be associated with metabolic disease traits. The metabolic-GRS 
was generated from the SNPs in the genes CAP10, KCNJ11, TCF7L2, FTO and MC4R. A value 
of 0,1 or 2 was assigned to each SNP, which denotes the number of risk alleles on that SNP. 
These values were then calculated by adding the number of risk alleles across each SNP. The 
average number of risk alleles per person for the B12-GRS was 8.69 (SD = 1.70), which ranged 
from 5 to 15. The sample was stratified, by the median, into a “low genetic risk group,” for 
those with a GRS ≤ 9 risk alleles (n = 79), and into a “high genetic risk group,” for those with 
a GRS ≥ 10 risk alleles (n = 30). For the metabolic-GRS, the average number of risk alleles per 
person was 7.00 (SD = 2.28), which ranged from 1 to 13. The sample was stratified, into a “low 
genetic risk group,” for those with a GRS ≤ 8 risk alleles (n = 88), and into a “high genetic risk 
group,” for those with a GRS ≥ 9 risk alleles (n = 21). Linear regression was used to examine 
the association of the two GRS scores with the biochemical and anthropometric outcomes 
(glucose, insulin, HbAC1, vitamin B12, body fat %, BMI, WC and WHR). The interaction 
between the two GRS scores and dietary factors on biochemical and anthropometric outcomes 
was determined by including interaction terms (GRS*diet) in the regression model. Models 
were adjusted for age, sex, BMI, and total energy intake, wherever appropriate.  
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Figure 8: Diagram representing the study design 
The diagram shows four possible associations, and four possible interactions. One-sided 
arrows with unbroken lines represent genetic associations and one-sided arrows with broken 
lines represent interactions between a lifestyle factor and GRS on serum vitamin B12/ 
metabolic traits.  We tested the association between the metabolic-GRS and vitamin B12 
concentrations and metabolic disease-related traits. We then tested the associations between 
the B12 –GRS and vitamin B12 status and metabolic disease related traits. Lastly, we tested 
whether these genetic associations were modified by lifestyle factors (macronutrient intake and 
physical activity levels).  
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Correction for multiple testing was applied using Bonferroni correction [adjustment P value 
for association analysis was <0.00313 [2 GRS * 8 biochemical and anthropometric outcomes 
(Fasting blood glucose, fasting insulin, glycated haemoglobin, vitamin B12, Fat %, BMI, WC 
and WHR)=16 test)] and for interaction < 0.00078 [2 GRS * 8 biochemical and anthropometric 
* 4  lifestyle factors (dietary carbohydrate energy %, dietary protein energy %, dietary fat 
energy % and physical activity levels))= 64]. Given that there are no studies on GRS and no 
previously reported effect sizes for the South Asians, we were unable to perform a power 
calculation.  
 
4.4 Results  
4.4.1 Characteristics of the participants  
In this study, 109 participants (mean age, 38.34 ± 6.92 years; BMI, 24.58 ± 4.12 kg/m2) were 
included. Table 18 illustrates the main characteristics of the study participants stratified 
according to sex. No significant difference between men and women were observed in the 
levels of fasting glucose, insulin, HbAC1 and plasma vitamin B12 (P>0.05).  
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Table 18: Anthropometric and biochemical characteristics of men and women participants (n=109, Men 61: women 48) 
 Total (n=109) Men (n=61) Women (n=48) P value* 
     
Age (yrs) 38.24 ± 6.92 37.34 ± 6.97 39.38 ± 6.77 0.129 
Height (cm) 164.97 ± 9.15 170.95 ± 6.18 157.36 ± 6.16 <0.0001 
Weight (kg) 67.07 ± 13.05 71.76 ± 11.81 61.11 ± 12.17 <0.0001 
BMI (kg/m2) 24.58 ± 4.12 24.51 ± 3.52 24.68 ± 4.80 0.844 
Waist circumference (cm) 83.73 ± 17.97 89.83 ± 14.04 75.99 ± 19.52 <0.0001 
Hip circumference (cm) 91.16 ± 17.78 92.27 ± 13.83 89.75 ± 21.87 0.488 
WHR 0.92 ± 0.11 0.98 ± 0.08 0.85 ± 0.11 <0.0001 
Fat (%) 27.25 ± 7.37 23.52 ± 5.12 32.00 ± 7.08 <0.0001 
Obesity cases** 40.37% 37.70% 43.75% 0.523 
Fasting Blood Glucose (mg/dL) 85.64  ± 12.64 87.41 ± 15.41 83.40 ± 7.40 0.100 
Fasting Blood Insulin (pmol/L) 68.55 ± 49.97 71.77 ± 59.12 64.46 ± 35.28 0.451 
Fasting Blood HbA1C (mmol/mol) 35.62  ± 5.91 35.20 ± 5.99 36.16 ± 5.84 0.402 
Fasting Blood B12 (pmol/L) 380.65  ± 132.83 389.80 ±  
135.00 
369.02 ± 130.52 
0.420 
Physical Activity Levels  
(Low %/ moderate %/ high %) 
72.5/ 19.3/ 8.3 
 
70.5/19.7/9.8 75.0/18.8/6.3 
0.777 
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Total energy (kcal/d) 2097.92  ± 456.01 2173.68 ± 
427.82 
2001.65 ± 
476.72 0.050 
Protein (energy %) 11.29 ± 2.31 11.25 ± 2.41 11.33 ± 2.20 0.853 
Fat (energy %) 21.87 ± 5.31 21.64 ± 5.22 22.16 ± 5.45 0.613 
Carbohydrate (energy %) 69.62 ± 8.80 69.89 ± 10.29 69.28 ± 6.52 0.721 
Dietary fibre (g) 16.78  ± 8.18 17.24 ± 8.46 16.20 ± 7.85 0.513 
Polyunsaturated fatty acids  (g) 3.32  ± 1.69 3.36 ± 1.66 3.27 ± 1.75 0.779 
 
Abbreviations: BMI Body mass index; SD indicates standard deviations; WHR, waist to hip ratio 
Data presented as Mean ± SD 
* P < 0.05, statistically significant differences in mean values between men/women, unadjusted 
**Obesity cases refers to the percentage of individuals with a BMI of over 25. 
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4.4.2 Association between B12-GRS and Obesity GRS with biochemical and 
anthropometric measurements 
A significant association between B12-GRS and serum vitamin B12 was observed (P = 0.008) 
(Table 19 and Figure 9); However, this finding was not significant after correction for 
multiple testing. No associations between the B12-GRS and metabolic traits (P > 0.05) were 
observed (Table 19). Furthermore, no associations between the metabolic-GRS and vitamin 
B12 or metabolic traits (P>0.05) were observed (Table 20). 
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Table 19: Association between the B12-GRS with obesity traits, biochemical traits and anthropometric measurements 
Values are given as mean ± standard deviation.  
P values for differences between ≤9 and ≥10 risk alleles were obtained using linear regression model adjusted for age, sex and BMI. 
† P values were obtained by using a general linear model adjusted for age and sex 
Abbreviations: HbAC1 glycated haemoglobin; BMI body mass index; WC waist circumference; WHR waist to hip ratio 
SNPs Log Glucose 
(mg/dL) 
Log Insulin 
(pmol/L) 
Log HbA1C 
(mmol/mol) 
Vitamin B12 
(pmol/L) 
Fat 
(%) 
Log BMI Log WC WHR 
≤ 9 risk alleles 1.931 ± 0.046 1.773 ± 0.261 1.545 ± 0.070 402.101 ± 129.265 27.098 ± 7.757 1.388 ± 0.074  1.912 ± 0.123 0.921 ± 0.116 
≥ 10 risk  
alleles 
1.923 ± 0.068 1.722 ± 0.201 1.549 ± 0.068 324.167 ± 127.344 27.651 ± 6.331 1.377 ± 0.065 1.900 ± 0.131 0.919 ± 0.111 
P value 0.782 0.553 0.652 0.008 0.576 0.515 † 0.785 0.525 
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Table 20: Association between the metabolic-GRS and obesity traits, biochemical traits and anthropometric measurements 
Values are given as mean ± standard deviation. 
 P values for differences between ≤8 and ≥9 risk alleles were obtained using linear regression model adjusted for age, sex and BMI. 
† P values were obtained by using a general linear model adjusted for age and sex 
Abbreviations: HbAC1 glycated haemoglobin; BMI body mass index; WC waist circumference; WHR waist to hip ratio 
SNPs Log Glucose 
(mg/dL) 
Log Insulin 
(pmol/L) 
Log HbA1C 
(mmol/mol) 
Vitamin B12 
(pmol/L) 
Fat 
(%) 
Log BMI WC WHR 
≤  8 risk 
alleles 
1.929 ± 0.056 1.760 ± 0.243 1.545 ± 0.070 382.227 ± 139.729 26.651 ± 7.375 1.384 ± 0.072 1.912 ± 0.123  0.928 ± 0.119 
≥ 9 risk 
alleles 
1.930 ± 0.035 1.753 ± 0.267 1.551 ± 0.070 374.048 ± 101.471 29.761 ± 6.949 1.387 ± 0.069 1.893 ± 0.136  0.887 ± 0.087 
P value  0.550 0.777 0.772 0.962 0.247 0.732 † 0.722 0.796 
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Figure 9: Association between the B12-GRS and serum vitamin B12 levels 
Vitamin B12 decreasing alleles ranged from 5 to 15. Individuals with ≤9 or ≥10 alleles were 
grouped to obtain a reasonable number of individuals in each group. Error bars indicate 
Standard error.
4.4.3 Interaction between the B12-GRS and dietary factors on biochemical and 
anthropometric measurements 
An interaction was found between the B12-GRS and protein energy (%) on log transformed 
WC (P=0.002). However, further stratification of participants based on their consumption of 
low, medium and high dietary protein (energy %) did not show statistically significant 
associations between the GRS and the outcome in any of the tertiles, which could account for 
the small sample size (Table 21).  
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Table 21: Interaction between the B12-GRS and lifestyle factors on anthropometric measurements 
Interaction between the GRS and lifestyle factors on Log waist circumference (cm) 
Interaction between B12-GRS * fat 
energy %  
Interaction between B12-GRS * protein 
energy % 
Interaction between B12-GRS * 
carbohydrate energy % 
Interaction between B12-GRS * 
Physical activity levels 
0.002 ± 0.004  
(0.727) 
0.037 ± 0.011 
(0.002) 
-0.003 ± 0.003  
(0.344) 
 
-0.051 + 0.037 
(0.173) 
Interaction between metabolic-GRS 
* fat energy %  
Interaction between metabolic-GRS * 
protein energy % 
Interaction between metabolic-GRS * 
carbohydrate energy % 
Interaction between metabolic-GRS 
* Physical activity levels 
-0.007 ± 0.006  
(0.212) 
-0.024 ± 0.009 
(0.011) 
0.007 ± 0.003  
(0.031) 
0.020 ± 0.044 
(0.654) 
Interaction between the GRS and dietary factors on waist to hip ratio 
Interaction between B12-GRS * fat 
energy %  
Interaction between B12-GRS * protein 
energy % 
Interaction between B12-GRS * 
carbohydrate energy % 
Interaction between-B12 GRS * 
Physical activity levels 
0.002 ± 0.004 
(0.660) 
0.013 ± 0.010 
(0.196) 
-0.003 ± 0.002  
(0.241) 
0.018 ± 0.032 
(0.584) 
Interaction between metabolic-GRS 
* fat energy %  
Interaction between metabolic-GRS * 
protein energy % 
Interaction between metabolic-GRS * 
carbohydrate energy % 
Interaction between metabolic-GRS 
* Physical activity levels 
-0.009 ± 0.005 
(0.079) 
-0.012 ± 0.008 
(0.158) 
0.007 ± 0.003 
(0.015) 
0.038 ± 0.039 
(0.323) 
Interaction between the GRS and lifestyle factors on Log BMI 
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Values are beta coefficients ± standard errors. P values are inserted in brackets 
P values were obtained by using a general linear model adjusted for age, sex and BMI  
† P values were obtained by using a general linear model adjusted for age and sex 
Interaction between B12-GRS * fat 
energy %  
Interaction between B12-GRS * protein 
energy % 
Interaction between B12-GRS * 
carbohydrate energy % 
Interaction between B12-GRS * 
Physical activity levels 
-0.002 ± 0.003 
(0.539†) 
0.009 ± 0.008 
(0.259†) 
-0.001 ± 0.002 
(0.762†) 
0.015 ± 0.023 
(0.513†) 
Interaction between metabolic-GRS 
* fat energy %  
Interaction between metabolic-GRS * 
protein energy % 
Interaction between metabolic-GRS * 
carbohydrate energy % 
Interaction between metabolic-GRS 
* Physical activity levels 
-0.004 ± 0.004 
(0.245†) 
-0.004 ± 0.006 
(0.480†) 
0.002 ± 0.002 
(0.322†) 
-0.005 ± 0.028 
(0.851†) 
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4.4.4 Interaction between the metabolic-GRS and dietary factors on biochemical and 
anthropometric measurements 
We observed a significant interaction between the metabolic-GRS and carbohydrate energy 
intake (%) on waist to hip ratio (Pinteraction = 0.015) (Figure 10 and Table 21). Individuals who 
carried 8 or less risk alleles for metabolic disease had 7.47 % lower WHR measurements (cm) 
in the highest tertile of carbohydrate energy intake (%) (Mean ± S.D: 78.00 ± 7.90%) compared 
to those with 9 or more risk alleles (P= 0.035) (Table 21). 
 
Figure 10: Interaction between the metabolic-GRS and carbohydrate energy intake (%) 
on waist-to-hip ratio (cm) (Pinteraction = 0.015).  
Among those who consumed a high carbohydrate diet, individuals who carried 9 or more risk 
alleles had significantly higher levels of waist-to-hip ratios compared to individuals carrying 
8 or less risk alleles (P = 0.035). Error bars indicate Standard error. 
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 Interactions were also seen between the metabolic-GRS and carbohydrate energy (%) 
on log fasting insulin concentrations (P=0.011) and log WC (P=0.031), and the metabolic-GRS 
and protein energy (%) on log fasting insulin levels and (P= 0.032) and log WC (P=0.011) 
(Table 21 and Table 22). 
Table 22: Interaction between the B12-GRS and metabolic-GRS and lifestyle factors on 
biochemical outcomes 
Interaction between the GRS and lifestyle factors on Log glucose (mg/dL) 
Interaction between 
B12-GRS * fat 
energy %  
Interaction between 
B12-GRS * protein 
energy % 
Interaction between 
B12-GRS * 
carbohydrate energy % 
Interaction between the 
B12-GRS * Physical 
activity levels 
0.002 ± 0.002 
(0.416) 
-0.004 ± 0.005 
(0.437) 
-0.000 ± 0.001 
(0.866) 
0.035 ± 0.016 
(0.053) 
Interaction between 
metabolic-GRS * fat 
energy %  
Interaction between 
metabolic-GRS * 
protein energy % 
Interaction between 
metabolic-GRS * 
carbohydrate energy % 
Interaction between 
metabolic-GRS * 
Physical activity levels 
0.001 ± 0.003 
(0.609) 
0.004 ± 0.004 
(0.295) 
-0.002 ± 0.002 
(0.258) 
-0.013 ± 0.020 
(0.518) 
Interaction between the GRS and lifestyle factors on Log insulin (pmol/L) 
Interaction between 
B12-GRS * fat 
energy %  
Interaction between 
B12-GRS * protein 
energy % 
Interaction between 
B12-GRS * 
carbohydrate energy % 
Interaction between B12-
GRS * Physical activity 
levels 
-0.005 ± 0.008 
(0.545) 
-0.009 ± 0.022 
(0.681) 
0.003 ± 0.005 
(0.591) 
-0.035 ± 0.067 
(0.600) 
Interaction between 
metabolic-GRS * fat 
energy %  
Interaction between 
metabolic-GRS * 
protein energy % 
Interaction between 
metabolic-GRS * 
carbohydrate energy % 
Interaction between 
metabolic-GRS * 
Physical activity levels 
0.018 ± 0.010 0.037 ± 0.017 -0.016 ± 0.006 -0.076 ± 0.080 
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(0.076) (0.032) (0.011) (0.345) 
Interaction between the GRS and lifestyle factors on Log HbA1C (pmol/L) 
Interaction between 
B12-GRS * fat 
energy %  
Interaction between 
B12-GRS * protein 
energy % 
Interaction between 
B12-GRS * 
carbohydrate energy % 
Interaction between B12-
GRS * Physical activity 
levels 
-0.000 ± 0.003 
(0.954) 
-0.007 ± 0.007 
(0.299) 
0.001 ± 0.002 
(0.711) 
0.019 ± 0.022 
(0.387) 
Interaction between 
metabolic-GRS * fat 
energy %  
Interaction between 
metabolic-GRS * 
protein energy % 
Interaction between 
metabolic-GRS * 
carbohydrate energy % 
Interaction between 
metabolic-GRS * 
Physical activity levels 
0.001 ± 0.003 
(0.802) 
0.001 ± 0.006 
(0.810) 
-0.001 ± 0.002 
(0.543) 
-0.041 ± 0.026 
(0.116) 
Interaction between the GRS and lifestyle factors on vitamin B12 (pmol/L) 
Interaction between 
B12-GRS * fat 
energy %  
Interaction between 
B12-GRS * protein 
energy % 
Interaction between 
B12-GRS * 
carbohydrate energy % 
Interaction between B12-
GRS * Physical activity 
levels 
-2.377 ± 5.093 
(0.642) 
13.481 ± 13.969 
(0.337) 
-0.722 ± 3.337 
(0.829) 
-46.714 ± 43.442 
(0.285) 
Interaction between 
metabolic-GRS * fat 
energy %  
Interaction between 
metabolic-GRS * 
protein energy % 
Interaction between 
metabolic-GRS * 
carbohydrate energy % 
Interaction between 
metabolic-GRS * 
Physical activity levels 
-6.189 ± 6.856 
(0.369) 
7.017 ± 11.531 
(0.544) 
-0.806 ± 4.181 
(0.848) 
36.492 ± 53.889 
(0.500) 
Interaction between the GRS and lifestyle factors on body fat (%) 
Interaction between 
B12-GRS * fat 
energy %  
Interaction between 
B12-GRS * protein 
energy % 
Interaction between 
B12-GRS * 
carbohydrate energy % 
Interaction between the 
B12-GRS * Physical 
activity levels 
0.031 ± 0.124 -0.326 ± 0.342 0.049 ± 0.082 -0.548 ± 1.068 
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(0.804) (0.343) (0.550) (0.609) 
Interaction between 
metabolic-GRS * fat 
energy %  
Interaction between 
metabolic-GRS * 
protein energy % 
Interaction between 
metabolic-GRS * 
carbohydrate energy % 
Interaction between 
metabolic-GRS * 
Physical activity levels 
0.084 ± 0.160 
(0.601) 
0.060 ± 0.273 
(0.826) 
-0.037 ± 0.099 
(0.709) 
0.637 ± 1.270 
(0.617) 
 
Values are beta coefficients ± standard errors. P values were inserted in brackets 
P values were obtained by using a general linear model adjusted for age, sex and BMI  
Abbreviations: HbAC1 glycated haemoglobin; BMI body mass index 
 
4.4.5 Interaction between the B12-GRS and physical activity on biochemical and 
anthropometric measurements 
No statistically significant interactions were observed between the two GRSs (vitamin B12 
and metabolic) and physical activity on biochemical and anthropometric measurements (Table 
21 and Table 22). After correction for multiple testing, none of these gene-diet and gene-
physical activity interactions remained statistically significant. 
4.5 Discussion: 
To our knowledge, this is the first study to use a genetic approach to explore the relationship 
between metabolic traits and vitamin B12 status in a South Asian population. Our study 
confirmed the strength of the association between B12-GRS and B12 concentrations and 
demonstrated the impact of genetically instrumented B12 concentrations on waist 
circumference, an indicator of central obesity, through the influence of dietary protein intake. 
Furthermore, our study has also showed a significant effect of metabolic-GRS on waist to hip 
ratio through the influence of high carbohydrate intake. Given that the total daily intake of 
208 
protein is low and carbohydrate is high in Sri Lankan adults [380], our findings, if replicated 
in future studies, might carry significant public health implications in terms of revising the 
food-based dietary guidelines which could prevent central obesity and the associated CVD-
related outcomes. 
In this study, we constructed a GRS consisting of ten vitamin B12 decreasing SNPs in 
genes involved in vitamin B12 metabolism [14]. The B12-GRS was associated with vitamin 
B12 levels, suggesting that it would be an ideal instrument for vitamin B12 status. Given the 
lack of association between the B12-GRS and metabolic disease traits in our study, we were 
unable to provide evidence for linear decreases in vitamin B12 concentrations having 
substantive effects on metabolic disease traits. However, we found a significant interaction 
between the B12-GRS and protein energy (%) on log WC. Interestingly, individuals who 
carried 9 or less alleles had lower WC when consuming a high protein diet compared to those 
consuming a low protein diet. Although no statistically significant differences in WC were 
observed between the alleles of the B12-GRS, the impact of the B12-GRS on WC was observed 
only under the influence of a high protein diet. Further investigations are required to confirm 
this finding to determine the clinical significance and potential applications as part of weight 
management interventions. 
At present, carbohydrates constitute the majority of the energy intake among South Asian 
countries such as Sri Lanka (~71.2%) [380]; in contrast, the consumption of carbohydrates is 
lower in Western countries (~45 %) [381]. Furthermore, high carbohydrate intake has been 
associated with an increased risk of diabetes in a South Indian population [382], and an increase 
in WC among pre-menopausal (20-45 years) Sri Lankan women [383]. In the present study, 
we found a significant interaction between the metabolic-GRS and carbohydrate energy 
percentage on waist-to-hip ratio, where the individuals carrying more than 9 risk alleles had a 
higher waist-to-hip ratio among those in the highest tertile of carbohydrate energy percentage. 
209 
There are no previous reports of the risk variants used in our GRS, but Goni et al [384] found 
that carbohydrates (total and complex) interacted with a GRS of 16 obesity/lipid metabolism 
polymorphisms to modify the effect on body fat mass in 711 individuals of Caucasian ancestry. 
In our study, we only observed interactions of the metabolic-GRS on WC and waist-to-hip 
ratio, which suggests that effects are likely to be on central obesity as opposed to common 
obesity. 
South Asians have a higher risk of developing obesity related non-communicable diseases 
relative to white Caucasians despite lower BMI levels; this has been termed the ‘South Asian 
phenotype’. The distinctive features of this phenotype include a higher WC, abdominal 
adiposity combined with insulin resistance, and a greater predisposition to diabetes [364]. The 
role of vitamin B12 in promoting this adverse phenotype has been suggested by Yajnik et al., 
who demonstrated that offspring born to mothers with a low vitamin B12  and high folate status 
had a greater risk of developing insulin resistance during childhood [69]. According to Yajnik 
et al., vitamin B12 deficiency prevents the generation of tetrahydrofolate from 5-
methyltetrahydrofolate in the one-carbon metabolism cycle; as a result, homocysteine levels 
accumulate leading to altered lean tissue deposition and reduced protein synthesis [69]. 
Furthermore, vitamin B12 is involved in the conversion of methylmalonyl-CoA to succinyl-
CoA by the enzyme methylmalonyl-CoA mutase (adenosyl-B12 as a cofactor). Subsequently, 
vitamin B12 deficiency results in elevated methylmalonyl-CoA, inhibiting the mitochondrial 
enzyme carnitine palmitoyltransferase, which may promote lipogenesis and insulin resistance 
[69, 385].   
No studies to date, have investigated interactions between the two GRSs and physical 
activity on metabolic traits and B12 concentrations in Asian Sri Lankans. Although, 60% of 
Sri Lankan adults are reported to be highly physically active [386], no significant interactions 
were found between the two GRSs and physical activity on metabolic traits, which could be 
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due to a small sample size and measurement bias associated with self-reported physical activity 
questionnaire. The strengths of our study include the use of a validated food frequency 
questionnaire [368] to measure macronutrient intake, the comprehensive measurements of 
lifestyle factors, and the use of GRSs which increased the statistical power of our study [387]. 
Nevertheless, some limitations need to be acknowledged. The first limitation concerns the 
relatively small sample size of the study; however, we were still able to identify significant 
gene-diet interactions. Furthermore, we used Bonferroni correction to correct for multiple 
testing and this can often lead to larger power, specifically where studies have a small sample 
size and a small number of disease-associated markers. This is also true for when studies have 
a large allele frequency difference due to a small sample size [388].  Secondly, information 
about the type of oil used for frying, the estimation of different dietary fat components 
(monounsaturated or saturated fatty acids) and vitamin B12 intake was not collected. This 
could have limited our in-depth analysis of interactions of specific macronutrients and vitamins 
with the two GRSs. Furthermore, the study was limited to Sinhalese adults in Colombo, and 
the conclusions may not be applicable to other ethnic groups in Sri Lanka. Finally, none of the 
genetic associations or gene-lifestyle interactions were statistically significant after correction 
for multiple testing; however, given that this is the first study using a genetic approach to 
establish a relationship between vitamin B12 status and metabolic disease outcomes in South 
Asians, we have taken into consideration of the significant findings; hence, further large studies 
are required to replicate our findings. 
4.6  Conclusion 
In summary, our study suggests that a genetically lowered vitamin B12 concentration may 
have an impact on central obesity in the presence of a dietary influence; however, our study 
failed to show an impact of the metabolic-GRS on lowering B12 concentrations through a 
dietary influence. Our study also showed a significant effect of the metabolic-GRS on waist to 
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hip ratio, another indicator of central obesity, through the influence of a high carbohydrate 
intake. However, after correction for multiple testing, none of these findings were statistically 
significant. Hence, further replication studies are highly warranted on large samples to confirm 
or refute our findings. 
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Chapter 5  
Evidence for the association between FTO gene variants and 
vitamin B12 concentrations in an Asian Indian population  
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5.1 Abstract 
Background: Low vitamin B12 concentrations have been associated with major clinical 
outcomes, including adiposity, in Indian populations. The Fat mass and obesity associated gene 
(FTO) is an established obesity-susceptibility locus; however, it remains unknown whether it 
influences vitamin B12 status. Hence, we investigated the association of two previously studied 
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FTO polymorphisms with vitamin B12 concentrations and metabolic disease-related outcomes 
and examined whether these associations were modified by dietary factors and physical 
activity. 
Methods: A total of 176 individuals with type 2 diabetes, 152 with pre-diabetes and 220 
normal glucose-tolerant individuals were randomly selected from the Chennai Urban Rural 
Epidemiology Study. Anthropometric, clinical and biochemical investigations, which included 
body mass index (BMI), waist circumference, vitamin B12, homocysteine and folic acid were 
measured. A validated food frequency questionnaire was used for dietary assessment and self-
reported physical activity measures were collected. An unweighted genetic risk score (GRS) 
was calculated for two FTO single nucleotide polymorphisms (rs8050136 and rs2388405) by 
summation of the number of risk alleles for obesity. Interaction analyses were performed by 
including the interaction terms in the regression model. 
Results: The GRS was significantly associated with increased BMI (P=0.009) and risk of 
obesity (P=0.023). Individuals carrying more than one risk allele for the GRS had 13.13% 
lower vitamin B12 concentrations, compared to individuals carrying zero risk alleles 
(P=0.018). No associations between the GRS and folic acid and homocysteine concentrations 
were observed. Furthermore, no statistically significant GRS-diet or GRS-physical activity 
interactions with vitamin B12, folic acid, homocysteine or metabolic-disease outcomes were 
observed. 
Conclusion: The study shows for the first time that a genetic risk score using two FTO SNP’s 
is associated with lower vitamin B12 concentrations; however, we did not identify any 
evidence for the influence of lifestyle factors on this association. Further replication studies in 
larger cohorts are warranted to investigate the association between the GRS and vitamin B12 
concentrations. 
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5.2 Introduction 
Obesity and its related comorbidities are leading causes of mortality and morbidity worldwide 
[389]. It is estimated that >12% of the Indian population is either overweight or obese [390]. 
Epidemiological studies have documented that the increased accessibility of low-cost, high-
calorie and nutrient-poor foods, were among the major driving forces for the epidemic of 
obesity [391-393]. This has led to a substantial increase in the prevalence of obesity-associated 
metabolic problems, such as type 2 diabetes mellitus (T2DM), dyslipidaemia and hypertension 
in India [394]. Furthermore, several studies have also demonstrated that obesity is associated 
with substantial nutrient deficiencies, including vitamin B12 [6, 395, 396]. 
 Vitamin B12 deficiency is a major public health problem in India and a recent cross-
sectional study conducted in 630 healthy adults in a South Indian population, reported that 35% 
of adults were vitamin B12 deficient [397]. An adequate vitamin B12 concentration is essential 
for growth, development and health. In addition, it is essential for DNA synthesis, 
haematological development and maintenance of the myelin nerve sheaths [398-400]. The 
primary causes of vitamin B12 deficiency are age, consumption of vegetarian diets and the 
inability to absorb vitamin B12 from food (via genetic defects or disease) [14, 190]. To date, 
several studies have indicated that vitamin B12 status may be influenced by excess body weight 
[7, 401]. However a pooled analysis of 19 studies found no evidence for an inverse relationship 
between vitamin B12 and BMI levels and reported that the majority of observational studies 
had a high risk of bias and heterogeneity [93]. In the light of these findings, using a genetic 
approach to explain the genetic mechanisms for obesity and its link with vitamin B12 
concentrations could be a better option, in terms of reducing any influence from unmeasured 
confounding factors.  
Genome-wide association studies have identified several genetic variants related to 
obesity and type 2 diabetes risk [402, 403].To date, the Fat mass and obesity associated (FTO) 
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gene has been identified as the strongest common genetic predictor of obesity [11]. Individuals, 
who are homozygous for FTO risk alleles, are on average, at 1.67-fold increased odds of obesity 
and three kg heavier in comparison to individuals without any risk alleles [404]. While several 
studies have reported the association between the FTO gene on measures of body weight and 
composition, various dietary parameters and physical activity levels have also been shown to 
contribute [405-407]. Recently, a cross-sectional study in an Indian population showed that 
physical activity and dietary intake may modify the association between the FTO gene variants 
and obesity-related traits [408].We used FTO gene variants as instruments to establish the 
relationship between obesity and B12 status and tested whether this relationship was modified 
by lifestyle factors. The two main objectives of this study were firstly to determine whether the 
FTO single nucleotide polymorphisms (SNPs), rs8050136 and rs2388405, were associated 
with obesity traits, vitamin B12, folic acid, and homocysteine and secondly whether these 
associations were modified by diet and physical activity levels in Asian Indians. 
5.3 Methodology 
5.3.1 Study population 
 A total of 900 unrelated study subjects were randomly recruited from the Chennai 
Urban Rural Epidemiology Study (CURES) follow-up study, which is an epidemiological 
study conducted on a representative population of Chennai, (formerly Madras) in southern 
India. The methodology of the study is published elsewhere [409, 410] and is briefly outlined 
here (Figure 11). In Phase 1 of CURES, 26,001 (aged ≥20 years) individuals were recruited 
based on a systematic random sampling technique. In the baseline survey, of the 26,001 
individuals screened, all the individuals with diabetes (Phase 2, n = 1,382) and 1 in every 
10 individuals (Phase 3, n = 2,207) underwent further detailed investigations, and these 
constituted the cohort for the follow-up study (n = 3,589).  From these 3,589 individuals, 
900 individuals, 300 normal glucose-tolerant (NGT), 300 prediabetic and 300 T2DM 
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individuals were randomly selected for this study. Only 548 individuals had samples 
available for genetic analysis (220 NGT, 152 prediabetic and 176 T2DM individuals). 
Individuals were excluded from participation if they were known cases of type I diabetes, had 
diabetes secondary to other causes, e.g., chronic pancreatitis, if they were 80 years of age or 
were taking vitamin B12 supplements. Table 23 shows the characteristics of the study 
participants.  
 
 
Figure 11: Flow diagram describing the selection of study participants 
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Table 23: Baseline characteristics of the CURES study participants: Comparison of non-obese and obese individuals 
Characteristics n 
Non-Obese 
individuals 
n Obese individuals P value * 
Age (yrs) 320 52.2 ± 13.0 579 48.8 ± 10.8 <0.001 
BMI (kg/m2) 320 21.9 ± 2.0 579 29.4 ± 4.0 <0.001 
WC (cm) 320 80.5 ± 8.3  578 93.1 ± 9.7 <0.001 
Hip (cm) 320 88.5 ± 6.2 578 102.6 ± 9.5 <0.001 
WHR 320 0.91 ± 0.09 578 0.91 ± 0.09 0.991 
Fasting plasma glucose (mg/dl) 299 118 ± 55 553 116 ± 42 0.618 
Fasting serum insulin (μIU/ml) 320 8.1 ± 6.1 579 9.9 ± 6.3  <0.001 
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Glycated Haemoglobin (%) 320 6.5 ± 1.8 579 6.6 ± 1.6 0.414 
Vitamin B12 levels (pg/mL) 320 425 ± 263 579 412 ± 273 0.495 
Homocysteine  
320 14.0 ± 8.9 579 13.6 ± 9.0 0.511 
(μmol/L) 
Folic  
320 8.73 ± 5.71 579 8.29 ± 5.79 0.276 
(ng/ml) 
Total energy intake (kcal) 194 2526 ± 791 335 2600 ± 753 0.280 
 Protein energy % 194 11.4 ± 1.1 335 11.4 ± 1.1 0.889 
220 
Carbohydrate energy % 194 63.6 ± 6.3 335 64.8 ± 5.8 0.033 
Fat Energy %  194 24.1 ± 4.5 335 23.7 ± 4.7 0.400 
Total Fibre (g) 194 31.1 ± 10.3 335 32.2 ± 11.1 0.227 
Physical Activity Level 186 
Low (78.0%) 
280 
Low (83.2%) 
0.009a 
Medium (20.4%) Medium (15.0%) 
High (1.6%) High (1.8%) 
 
Data shown are represented as means ± SD 
P values were calculated by using the Independent t test 
* P values for the differences in the means/proportions between non-obese and obese individuals 
aP values were calculated by using the Chi Squared test 
Abbreviations: CURES Chennai Urban Rural Epidemiological Study; BMI Body mass index; WC waist circumference; WHR waist to hip ratio 
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The Madras Diabetes Research Foundation Institutional Ethics Committee granted the 
ethical approval and informed consent was obtained from the study participants. All clinical 
investigations were conducted according to the principles expressed in the Declaration of 
Helsinki (ICH GCP). 
5.3.2 Phenotype measurements 
Anthropometric measurements including weight, height and waist circumference were 
measured using standardized techniques. The body mass index (BMI) was calculated using 
the formula, weight (kg)/height (m2) and obesity was classified as BMI ≥ 25 according to 
WHO Asia Pacific Guidelines for Asians (The Asia Pacific perspective 2000). Fasting 
plasma glucose (glucose oxidase–peroxidase method), was measured using Hitachi-912 
Autoanalyzer (Hitachi, Mannheim, Germany). Glycated haemoglobin (HbA1c) was estimated 
by high-performance liquid chromatography using a Variant™ machine (Bio-Rad, Hercules, 
CA, USA).  Serum insulin, serum vitamin B12 and folic acid concentration was estimated using 
the electrochemiluminescence using a Roche e601Cobas immunoassay analyser (Roche 
Diagnostics, Indianapolis, Indiana, USA). The intra- and inter-assay coefficients of variation 
for vitamin B12 assay were 0.95% and 4.08%. Serum homocysteine was measured using 
enzymatic assay using the Beckman Coulter AU2700 (Fullerton, CA, USA) Biochemistry 
analyser. 
5.3.3 Dietary assessments and physical activity: 
Dietary intakes were assessed using a previously validated and published [35] 
interviewer administered semi-quantitative food frequency questionnaire (FFQ) containing 222 
food items to estimate food intake over the past year. The length of the interview ranged from 
20 and 30 min during which participants were asked to recall their usual portion size and usual 
frequency (number of times per day, week, month or year/never) of foods listed within the FFQ 
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over the year. Common household measures such as household cups, bowls, ladles, spoons (for 
the cooked foods like vegetables), wedges, circles of different diameter and visual atlas of 
different sizes of fruits (small, medium, large) were shown to assist the individuals in 
estimating portions. A detailed description of the development of FFQ and the data on 
reproducibility and validity had been published previously [411]. The recorded data was 
analysed with the EpiNu® software to estimate energy as well as macronutrient and dietary 
fibre intake. 
A validated self-report questionnaire was used to measure physical activity 
questionnaire [412]. Based on exercise, leisure time activities and job-related activities 
respondents were categorized into three groups indicating activity level (vigorously active, 
moderately active and sedentary). Individuals were graded as vigorously active if they did 
leisure time exercise and had physically demanding work, whereas individuals who either 
exercised or had physically demanding work were categorized as moderately active. All others 
were categorized as sedentary. 
5.3.4 SNP selection and genotyping 
Genetic variants within the FTO gene have shown consistent and strong associations with 
obesity [11]. Evidence suggests that the FTO gene confers an increased risk of obesity by 
approximately 1.20-fold, and a corresponding increase in BMI by 0.39 kg/m2 per minor allele 
[413]. The BMI-increasing allele in the FTO gene is less prevalent in Asian (~ 30%) and 
African populations (~ 12%), than in European ancestry populations (~ 42%). However, the 
effect of the risk alleles on BMI variance is somewhat similar in the Asian (0.2%), African 
(0.1%) and European populations (0.3%) [413-415]. 
Of particular interest are intronic SNPs, which may harbour ‘intronic enhancers’ that 
may exert functional effects and contain potential transcriptional factor binding sites. 
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Furthermore, some of these intronic variants have been shown to increase disease risk or 
modulate the genotype-phenotype relationship [416]. The SNP rs8050136 of the FTO gene has 
shown consistent and strong associations with obesity and type 2 diabetes [11, 417]. 
Additionally, the SNP rs2388405 was previously selected for analysis in a case-control study 
conducted in a Chinese population, due to its possibility of being an ‘intronic enhancer’ [418] 
and also in a study in a Han Chinese population [419] and a Caucasian population [420]. Hence, 
we selected these two intronic SNPs of the FTO gene with a known minor allele frequency 
(MAF) >15% in the South Asian population: rs8050136 (intron 1, MAF = 29%; HapMap South 
Asian population) and rs2388405 (intron 4, MAF = 40%; HapMap South Asian population).  
The standard Phenol-chloroform method was used to extract DNA from whole blood 
[421]. The SNPs rs8050136 and rs2388405 were genotyped by polymerase chain reaction on 
a GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Foster City, CA) using the 
primers “F: 5ˈTTT GTT TTG GCT TTC TGC AGT CT3ˈ, R: CAA AAA CCA CAG GCT 
CAG A3ˈ and F: 5ˈTCT GTG GGA ATC TCC GCT TTC AGT, R: 5ˈGAG CCC TTG CGC 
ATT GCC AG3ˈ respectively. The PCR products were digested with MluCI (rs8050136) and 
ScaI (rs2388405) restriction enzymes (New England Biolabs, Inc., Beverly, MA) and the 
digested products were resolved by a 3 % agarose gel electrophoresis. Based on the analysis of 
200 blind duplicates (20 %), there was 100% concordance in the genotyping. Furthermore, a 
few variants were confirmed by direct sequencing with an ABI 310 genetic analyser (Foster 
City, CA).  
5.3.5 Statistical analysis: 
The SPSS statistical package (version 22; SPSS Inc., Chicago, IL, USA) was used for 
the statistical analysis. Allele frequencies were estimated by gene counting. The Chi-square 
test was used to compare the proportions of genotypes or alleles. The genotypic frequencies 
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in all participants showed no significant departure from the Hardy Weinberg Equilibrium 
(HWE) (P > 0.05) for the FTO rs8050136 (MAF: 0.13 and HWE: P=0.749) and rs2388405 
(MAF: 0.09 and HWE: P=0.259) SNPs. 
 Generalised obesity was defined according to the World Health Organization Asia 
Pacific Guidelines for Asians as non-obese (BMI < 25 kg/m2 ) and obese (BMI ≥ 25 kg/m2 ) 
[422].We performed an independent t-test to compare the means of the quantitative variables 
between individuals with normal-glucose tolerance (NGT) vs pre-diabetes and NGT vs T2D). 
Comparison of the proportion of individuals engaging in different types of physical activity 
levels (vigorously active, moderately active and sedentary) between NGT individuals vs pre-
diabetes and NGT individual’s vs T2D was analysed by the Chi Square test.  
 The unweighted, risk-allele GRS method was calculated for each participant by 
summation of the number of risk alleles for obesity. The GRS was generated from the SNPs 
rs8050136 and rs2388405 of the FTO gene. A value of 0, 1 or 2 was assigned to each SNP, 
which denotes the number of risk alleles for obesity on that SNP. These values were then 
calculated by adding the number of risk alleles across each SNP. The risk allele score was then 
divided into individuals carrying 0 risk allele vs more than 1 risk alleles. Association analyses 
between the GRS and continuous and categorical variables were carried out by linear and 
logistic regression models, respectively. Linear and logistic regression models were also used 
for interaction analyses between GRS and dietary factors (continuous variables) / physical 
activity (categorical variable) on continuous and categorical outcomes respectively, where the 
interaction terms were included into the models and were adjusted for age, BMI, sex, T2D, 
T2D medication and total energy intake when appropriate.  
 Correction for multiple testing was applied using Bonferroni correction [adjustment P 
value for association analysis was <0.0083 [1 GRS * 6 biochemical and metabolic traits 
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(vitamin B12, Homocysteine, folic acid, obesity, BMI, waist circumference) = 6 tests)] and for 
interaction <0.0017 [1 GRS* 6 biochemical and metabolic traits * 5  lifestyle factors (dietary 
carbohydrate energy %, dietary protein energy %, dietary fat energy %, dietary fiber intake (g) 
and physical activity levels)= 30 tests]. Given that there are no studies on GRS and no 
previously reported effect sizes for the South Asians, we were unable to perform a power 
calculation for the present study. 
5.4 Results 
5.4.1 Characteristics of the participants  
Based on the clinical and biochemical characteristics of the individuals from the CURES 
study as illustrated in Table 23, individuals with obesity (n=579) had higher fasting plasma 
insulin (<0.001) compared to non-obese individuals (n=320). We also observed that obese 
individuals consumed higher quantities of dietary carbohydrate (energy %) than non-obese 
individuals (P=0.033). Additionally, a significant difference in physical activity levels between 
non-obese individuals and obese individuals was observed (P=0.009). The baseline 
characteristics which compares individuals with NGT, pre-diabetes and T2D is shown in Table 
24.  
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Table 24: Baseline characteristics of the CURES study participants: Comparison of NGT, Pre-diabetics and T2D individuals 
Characteristic n 
Participants with 
normal glucose 
tolerance (NGT) 
n Pre-diabetics P value * n 
Participants with 
type 2 diabetes 
(T2D) 
P value ** 
Age (yrs) 300 48.2 ± 11.9 300 48.4 ± 11.7 0.849 300 53.6 ± 11.0 <0.001 
BMI (kg/m2) 300 25.8 ± 5.0 300 27.4 ± 5.2 <0.001 299 26.9 ± 4.6 0.010 
WC (cm) 300 85.9 ± 11.4 300 89.6 ± 11.1 <0.001 298 90.3 ± 10.1 <0.001 
Hip (cm) 300 96.4 ± 11.0 300 98.7 ± 11.6 0.015 298 97.6 ± 9.6  0.174 
WHR 300 0.89 ± 0.09 300 0.91 ± 0.09 0.022 298 0.93 ± 0.08 <0.001 
Fasting plasma glucose 
(mg/dl) 
274 90 ± 6 283 103 ± 18 <0.001 296 154 ± 61 <0.001 
Fasting serum insulin 
(μIU/ml) 
300 8.3 ± 5.6  300 8.1  ± ± 5.6 0.757 300 11.3 ± 6.9 <0.001 
Glycated Haemoglobin 
(%) 
300 5.7 ± 0.6 300 5.9 ± 0.6 <0.001 300 8.1 ± 2.0 <0.001 
Vitamin B12 levels 
(pg/mL) 
300 450 ± 332 300 409 ± 246 0.086 300 389 ± 211 0.008 
Homocysteine  300 13.1 ± 6.1 300 13.3 ± 7.4 0.650 300  14.9 ± 11.7 0.020 
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(μmol/L) 300 
300 
13.1 ± 6.1 
10.16 ± 6.35 
300 
300 
13.3 ± 7.4 
7.99 ± 6.17  
0.650 
<0.001 
300 
300 
 14.9 ± 11.7 
7.17 ± 4.11 
0.020 
<0.001 Folic  
(ng/ml) 300 
248 
10.16 ± 6.35 
2581 ± 750 
300 
124 
7.99 ± 6.17  
2588 ± 807 
<0.001 
0.932 
300 
157 
7.17 ± 4.11 
2548 ± 767 
<0.001 
0.675 Total energy intake (kcal) 
 Protein energy % 248 11.3 ± 1.2 124 11.3 ± 1.1 0.912 157 11.4 ± 1.1  0.328 
Carbohydrate energy % 248 64.1 ± 6.5 124 64.8 ± 5.5 0.284 157 64.4 ± 5.5  0.657 
Fat Energy %  248 24.0 ± 4.8 124 23.5 ± 4.4 0.299 157 23.9 ± 4.5 0.879 
Total Fibre (g) 248 31.9 ± 10.7 124 31.1 ± 10.8 0.510 157 32.2 ± 11.0 0.832 
Physical Activity Level 228 Low (77.6%) 105 Low (82.9%) 0.230 133 Low (85.7%) 0.143a 
  
Medium (21.1%) 
 
Medium (14.3%) 
  
Medium (12.3%) 
 
High (1.3%) High (2.9%) High (1.5%) 
  
Data shown are represented as means ± SD 
P values were calculated by using the Independent t test 
*P values for the differences in the means/ proportions between NGT and pre-diabetic individuals 
** P values for the differences in the means/ proportions between NGT and T2D individuals 
aP values were calculated by using the Chi Squared test 
Abbreviations: CURES Chennai Urban Rural Epidemiological Study; BMI Body mass index; WC waist circumference; WHR waist to hip ratio 
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5.4.2 Association between GRS and obesity-related phenotypes 
We were able to identify an association between GRS and BMI (P=0.009). Individuals who 
carried more than one risk allele had higher BMI levels (Mean ± SE: 27.55 ± 4.98) compared 
to individuals with zero risk alleles (Mean ± SE: 26.43 ± 5.03) (Table 25 and Figure 12). 
 
Figure 12: Association between the GRS and BMI 
Obesity risk increasing alleles ranged from 0 to 3. The white bars indicate individuals with 0 
risk alleles and the black bars indicate individuals carrying ≥1 alleles. Individuals who carried 
1 or more risk alleles had significantly higher BMI compared to individuals carrying 0 risk 
alleles (P = 0.009)]. Error bars indicate Standard error.
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Table 25: Association between the FTO-GRS with vitamin B12, folic acid, homocysteine and obesity traits   
Risk alleles 
in all 
participants 
n 
Vitamin 
B12 
(pg/mL) 
n 
Homocysteine 
(μmol/L) 
n 
Folic acid 
(ng/ml) 
n 
BMI 
(kg/m2) 
n WC (cm) n 
Odds Ratio 
(95% CI) of 
Obesity 
0 380 
410 ± 
202 
390 13.2 ± 7.7 390 8.89 ± 5.92 390 26.4 ± 5.0 390 
87.6 ± 
11.1 
194 
1.63 (1.07-
2.49) 
≥1 154 
356 ± 
189 
157 14.8 ± 8.9 157 7.89 ± 5.48 157 27.6 ± 5.0 156 
90.0 ± 
11.6 
353 
P valuea 0.018 0.077 0.147 0.009† 0.747 *0.023 
Risk alleles 
in NGT 
individuals 
n 
Vitamin 
B12 
(pg/mL) 
n 
Homocysteine 
(μmol/L) 
n 
Folic acid 
(ng/ml) 
n 
BMI 
(kg/m2) 
n WC (cm) n 
Odds Ratio 
(95% CI) of 
Obesity 
0 151 
416 ± 
199 
157 12.5 ± 5.7 157 
10.45 ± 
6.42 
157 25.7 ± 5.0 157 
85.0 ± 
11.2 
157 
1.71 (0.92 -
3.21) 
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≥1 61 
327 ± 
167 
63 13.9 ± 5.9 63 8.99 ± 6.02 63 27.2 ± 5.4 63 
88.5 ± 
12.6 
63 
P valueb 0.004 0.102 0.143 0.054†† 0.694 0.092** 
Values are given as mean ± standard deviation. 
aP values for differences between 0 and 1 risk alleles were obtained using linear regression model adjusted age, BMI, Type 2 diabetes status, 
Type 2 diabetes medication and sex  
† P values were obtained by using a general linear model adjusted for age, Type 2 diabetes status, Type 2 diabetes medication and sex 
* P values were adjusted for age, sex and Type 2 diabetes status using binary logistic regression 
bP values for differences between 0 and 1 risk alleles were obtained using linear regression model adjusted age, BMI and sex  
†† P values were obtained by using a general linear model adjusted for age and sex 
** P values were adjusted for age and sex using binary logistic regression 
 
Abbreviations: BMI body mass index; WC waist circumference; WHR waist to hip ratio; NGT normal glucose tolerant 
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There was a significant association between the GRS and obesity (Passociation=0.023), 
where individuals carrying more than one risk allele had 1.6 times increased risk of obesity 
compared to those carrying zero risk alleles (Table 25). However, after Bonferroni correction, 
none of these associations remained statistically significant. Moreover, no statistically 
significant associations were observed between GRS and waist circumference (P=0.747) 
(Table 25). 
 
5.4.3 Association between the GRS and vitamin B12, homocysteine and folic acid 
levels 
We found that the GRS was significantly associated with vitamin B12 concentrations 
(P=0.018) (Table 25 and Figure 13), and individuals carrying more than one risk allele had 
13.1% lower vitamin B12 concentrations (Mean ± SE: 355 ± 189 pg/mL), compared to 
individuals carrying zero risk alleles (Mean ± SE: 410 ± 202 pg/mL). However, this finding 
was not significant after correction for multiple testing. 
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Figure 13: Association between the GRS and serum vitamin B12 concentrations 
Obesity risk increasing alleles ranged from 0 to 3. The white bars indicate individuals with 0 
risk alleles and the black bars indicate individuals carrying ≥1 alleles. Individuals who carried 
1 or more risk alleles had significantly lower B12 concentrations compared to individuals 
carrying 0 risk alleles (P = 0.018)]. Error bars indicate Standard error. 
 
There were no statistically significant associations between GRS and homocysteine or 
folic acid concentrations (Table 25). 
5.4.4 Interaction between the GRS and lifestyle factors on vitamin B12, folic acid, 
homocysteine and obesity traits 
None of the lifestyle factors (dietary intake (carbohydrate, protein, fat, fibre) or physical 
activity) significantly interacted with the GRS on biochemical and anthropometric 
measurements after correction for multiple testing (Tables 26 and 27).  
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Table 26: Interaction between the FTO-GRS and lifestyle factors on vitamin B12, folic acid, homocysteine and obesity traits   
  
BMI (kg/m2) WC (cm) 
Vitamin 
B12(pg/mL) 
Homocysteine 
(μmol/L) 
Folic acid (ng/ml) 
Interaction between the GRS and 
carbohydrate energy (%) 
-0.08 ± 0.09 0.02 ± 0.11 1.40 ± 3.55 -0.03 ± 0.13 0.01 ± 0.10 
P value †0.387 0.882 0.694 0.830 0.952 
Interaction between the GRS and 
Fat energy (%) 
0.23 ± 0.12 0.18 ±0.15 0.98 ± 4.87 -0.07 ± 0.18 0.09 ± 0.14 
P value †0.052 0.225 0.841 0.709 0.539 
Interaction between the GRS and 
Protein energy (%) 
0.37 ± 0.50 0.77 ± 0.59 6.10 ± 19.95 0.03 ± 0.75 0.20 ± 0.58 
P value †0.451 0.196 0.760 0.968 0.728 
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Interaction between the GRS and 
Fibre (g) 
0.08 ± 0.05 0.14 ± 1.49 1.68 ± 1.90 -0.01 ± 0.07 0.04 ± 0.05 
P value †0.081 0.925 0.376 0.898 0.503 
Interaction between the GRS and 
physical activity levels 
1.14 ± 1.16 -0.14 ± 1.46 23.02 ± 51.29 0.99 ± 1.93 0.46 ± 1.51 
P value †0.327 0.924 0.654 0.609 0.760 
 
Values are beta coefficients ± standard errors.  
P values were obtained by using a general linear model adjusted for age, BMI, Type 2 diabetes status, Type 2 diabetes medication and sex 
† P values were obtained by using a general linear model adjusted for age, Type 2 diabetes status, Type 2 diabetes medication and sex 
Abbreviations: BMI body mass index; WC waist circumference; WHR waist to hip ratio 
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Table 27: Interaction between the FTO-GRS and lifestyle factors on obesity  
 
Interaction between the GRS and dietary factors on Obesity Interaction between the 
GRS and physical activity 
levels on Obesity 
GRS * Fat energy % 
GRS * carbohydrate 
energy % 
GRS * protein energy % GRS * fibre (g) 
Odds Ratio (95% 
CI) 
1.096 (0.980-1.227) 0.962 (0.889-1.040) 1.113 (0.729-1.762) 1.034 (0.984-1.086) 1.026 (0.263-4.003) 
P Value 0.109 0.326 0.578 0.182 0.970 
Values are beta coefficients ± standard errors.  
 P values were obtained by using binary logistic regression adjusted for age, T2D, Type 2 diabetes medication and sex
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5.4.5 Discussion 
Both obesity and vitamin B12 deficiency, are modifiable risk factors for several chronic 
diseases. Moreover, both risk factors have been shown previously to be associated with one 
another. This is the first study to use a genetic approach to establish a relationship between 
obesity and vitamin B12 levels in an Asian Indian population. Our study confirmed the strength 
of the association between the GRS generated from the two FTO SNPs and BMI and 
demonstrated the impact of genetically instrumented BMI on serum B12 concentrations. These 
results suggest that increases in BMI could potentially contribute to the adverse health effects 
associated with vitamin B12 deficiency. Given that low vitamin B12 concentrations in Asian 
Indians are common [397, 423], our study highlights the importance of considering obesity as 
a risk factor for vitamin B12 deficiency with implications on the possible targeting of relevant 
obesity prevention strategies. 
 Variants of the FTO gene are known to be the strongest genetic predictor of obesity to 
date [424, 425]. It has been suggested that risk variants at the FTO locus trigger the 
overexpression of ghrelin mRNA, leading to higher levels of the hunger hormone, ghrelin, to 
be secreted [426], which in turn makes individuals over consume energy-dense foods [427, 
428]. In general, the two selected intronic SNPs rs2388405 and rs8050136 could potentially be 
relevant as intronic enhancers, as they may enhance the expression of the FTO gene [416]. In 
support of this, in a previous study conducted in a South Indian population (CURES), the FTO 
SNP, rs8050136, was associated with an increased risk of obesity [371]. Given the strong role 
of the FTO locus in obesity [11, 371], FTO was considered as a suitable candidate to establish 
the genetic link between obesity-related traits and vitamin B12 concentrations. 
Reduced vitamin B12 concentrations in the obese population are thought to result from 
a nutrient-poor diet, increased nutrient requirements in relation to an increased body size and 
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the physiological effects of obesity on nutrient absorption/metabolism [84, 85]. Additionally, 
obesity is a well-known risk factor for T2DM [429] and gastroesophageal reflux disease 
(GERD) [430]. As a result, obese individuals are more likely to take metformin and proton 
pump inhibitors (PPIs), which have been shown to reduce serum B12 levels by inhibiting the 
absorption of the vitamin [93, 431]. In our study, we found a significant association between 
FTO GRS and vitamin B12 concentrations in South Asian adults. Several studies in India, have 
reported significant associations between vitamin B12 status and obesity related traits [4-7]. A 
study conducted in North India, reported that there was a negative correlation between waist 
circumference and reduced levels of vitamin B12 [4]. A study looking at 2,403 school-going 
adolescents (11–17 years) from Haryana, India reported that more than half (51.2%) of obese 
adolescents were vitamin B12 deficient [6]. Furthermore, recent findings from the CURES (n 
= 1500 individuals) demonstrated that the prevalence of vitamin B12 deficiency significantly 
increased in those with abdominal obesity and the mean levels of vitamin B12 significantly 
decreased with increasing degrees of glucose tolerance [5]. However, in this study, we were 
unable to identify a similar trend when considering the GRS, which could be due to the smaller 
sample size of our study (data not shown). However, our data confirms the association between 
vitamin B12 concentrations and obesity and suggests that individuals genetically predisposed 
to obesity are at a higher risk of vitamin B12 deficiency. 
Current literature suggests that the genetic profile of an individual can shape the 
microbiome of the host, and indeed an altered gut flora has been associated with vitamin B12 
deficiency [14, 264]. In a study in rodents, it was found that the type of dietary lipids (lard or 
fish oil) influenced the structure of the microbiome as there was an interaction between gut 
microbiota and saturated lipids in promoting white adipose tissue inflammation [432]. 
Chakraborty et al postulated that a higher concentration of inflammatory cytokines could 
impair vitamin B12 absorption or biosynthesis [6]. Another study reported that low vitamin 
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B12 status induced excess triacylglycerol biosynthesis and secretion of pro-inflammatory 
cytokines [433]. Whether the FTO genotypes influence the association between obesity and 
vitamin B12 concentrations by modulating the gut microbiota composition and inducing 
metabolic inflammation requires further investigation utilizing faecal samples.  
The main strength of this  study was the use of a validated food frequency questionnaire 
[372], which has shown high reproducibility and validity for total carbohydrates and dietary 
fibre, and the use of a GRS. Moreover, the sampling was representative of the overall 
population of Chennai. Nevertheless, some limitations need to be acknowledged. Although the 
majority of Indian adults are physically inactive and consume a diet high in carbohydrates [382, 
405], no significant interactions were found between the GRS and lifestyle factors on vitamin 
B12 and metabolic disease outcomes in our study, which could be attributed to the small sample 
size. The GRS only used two variants from the FTO gene, and we cannot fully exclude that 
other variants of the FTO gene may also be important.  Another limitation was the use of a 
cross-sectional design to investigate genetic effects at a single point in time and hence no cause 
effect inferences can be drawn, for which a longitudinal analysis design over a specific time 
period would be needed. 
5.5 Conclusion 
In summary, our study suggests that genetic variations at the FTO locus appear to 
influence serum vitamin B12 concentrations. However, we were unable to show an impact of 
the GRS on lowering B12 concentrations through a dietary influence. Longitudinal studies 
could help to establish the effect of genetic influences on vitamin B12 concentration.  
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Chapter 6  
A nutrigenetic approach for investigating the relationship between 
vitamin B12 status and metabolic traits in Indonesian women 
For this study, I developed an analysis plan before I undertook the statistical analysis. I 
screened and validated the dataset to perform statistical analysis. I performed the entire 
statistical analysis using the SPSS software; I undertook a literature review as part of the 
introduction to the study and wrote the manuscript. I revised the manuscript based on the 
comments from all the co-authors before the manuscript was submitted to the journal.  
Published (The published version of the paper is attached as an appendix at the end of 
the thesis) 
Surendran S, Aji AS, Ariyasra U, Sari SR, Malik SG, Tasrif N, Yani FF, Lovegrove JA,Sudji 
IR, Lipoeto NI, Vimaleswaran KS  (2019). A nutrigenetic approach for investigating the 
relationship between vitamin B12 status and metabolic traits in Indonesian women. Journal of 
Diabetes & Metabolic Disorders (Published). 
6.1 Abstract 
Purpose: Adverse effects of maternal vitamin B12 deficiency have been linked to major 
clinical outcomes, including increased body mass index and gestational diabetes, however, less 
is known about vitamin B12 nutrition in non-pregnant women. Hence, the aim of the present 
study was to explore the relationships between metabolic traits and vitamin B12 status in a 
cohort of healthy Indonesian women and to investigate whether these relationships were 
modified by dietary intake using a genetic approach.   
Methods: A total of 117 Minangkabau women (aged 25-60 years), from the city of Padang, 
West Sumatra underwent anthropometric, biochemical, dietary intake analysis and genetic 
241 
tests. Genetic risk scores (GRS) based on nine vitamin B12 associated single nucleotide 
polymorphisms (SNPs) (B12-GRS) and nine metabolic SNPs (metabolic-GRS) were 
constructed.  
Results: The B12-GRS and metabolic-GRS had no effect on vitamin B12 (P>0.160) and 
metabolic traits (P>0.085). However, an interaction was observed between the B12-GRS and 
dietary fibre intake (g) on glycated haemoglobin (HbA1C) levels (P interaction=0.042), where 
among those who consumed a low fibre diet (4.90 ± 1.00 g/day), individuals carrying ≥9 risk 
alleles for vitamin B12 deficiency had significantly higher HbA1C levels (P=0.025) compared 
to those carrying ≤8 risk alleles.  
Conclusion: Our study showed a significant impact of the B12-GRS on HbA1C concentrations 
through the influence of a dietary factor, however, our study failed to provide evidence for an 
impact of metabolic-GRS on lowering B12 concentrations. Further replication studies utilizing 
larger sample sizes are needed to confirm our findings.  
 
6.2 Introduction 
Vitamin B12 adequacy plays a critical role in a multitude of physiological processes, including 
DNA synthesis, haematological development and neurological function [2, 50]. Moreover, 
vitamin B12 is now known to play a much more profound and wide-ranging role in maternal 
health as well as foetal development [70, 434]. Low maternal plasma concentrations of vitamin 
B12 have shown negative correlations with body mass index (BMI) levels in healthy women 
[401] and have been associated with pregnancy complications such as gestational diabetes 
mellitus [70], recurrent pregnancy loss [435], higher BMI [69] and neural tube defects [436]. 
Notably, the harmful effects of maternal malnutrition are not just confined to pregnancy 
complications and birth defects. Findings from the Pune Maternal Nutrition Study (PMNS) in 
India have shown that low maternal vitamin B12 increases the risk of insulin resistance and 
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relative adiposity in 6- to 7-y-old children, with the highest levels of insulin resistance 
occurring when mothers had a combination of a high folate and low vitamin B12 status [69].  
 Suboptimal vitamin B12 status is common in many parts of the world [59]. Published 
data on vitamin B12 status of any life-stage group in Indonesian women is lacking with the 
exception of an earlier report in 2017 showing that the prevalence of a vitamin B12 deficient 
diet was 34.5% in 606 Indonesian pregnant women (14-49 years) [437]. The Minangkabau 
culture in Indonesia is of particular interest, as it is the world’s largest matrilineal system of 
kinship, where women hold greater power in both family and society [438]. Food supply is 
centred around women and compelling evidence suggests that adequate nutrition protects 
against metabolic disorders related to obesity [439], as a result understanding the dietary 
patterns of women in relation to their genetic susceptibility is of great importance.  
Although vitamin B12 deficiency is associated with a wide range of chronic diseases 
and conditions, including obesity, and with increasing severity of metabolic dysfunction, such 
as insulin dysregulation [4-7], the relationship between low vitamin B12 status and obesity 
related traits has remained inconsistent [93]. It is possible that certain genotypes might jointly  
contribute to obesity and vitamin B12 deficiency [93] and the implementation of a genetic 
approach to establish the relationship between vitamin B12 and obesity could be a more 
desirable option over observational studies, as results are less prone to confounding factors. 
While genetic studies have implicated several gene loci in the predisposition to vitamin B12 
deficiency, no study has yet been carried out in the Indonesian  population [14]. Hence, for the 
first time we used a genetic approach to explore the relationship between metabolic traits and 
vitamin B12 status and investigated whether these relationships were modified by lifestyle 
factors in a cohort of Minangkabau women in Padang. Identifying the impact of vitamin B12 
status on metabolic traits will help us to reduce the burden of metabolic diseases through 
implementation of policies for screening of vitamin B12 deficiency. 
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6.3 Methodology 
6.3.1 Study participants 
The Minangkabau Indonesia Study on Nutrition and Genetics (MINANG) study is a cross-
sectional pilot study that was conducted in the city of Padang, West Sumatra, Indonesia, from 
December 2017 to January 2018. This study was conducted as part of the ongoing GeNuIne 
(Gene-Nutrient Interactions) Collaboration, the main objective of which is to investigate the 
effect of gene-nutrient interactions (nutrigenetics) on metabolic disease outcomes using 
population based studies from various ethnic groups [12]. The study was conducted in 
accordance with the principles of the Declaration of Helsinki and was approved by the Ethical 
Review Committee of the Medical Faculty, Andalas Univesity (No.311/KEP/FK/2017). All 
participants provided written informed consent before participating. Participants were allowed 
to leave the study at will and opt out from any of the procedures. One hundred and thirty-three 
women were recruited from community health centers in two sub districts in Padang City to 
represent both urban (50% Padang Timur) and rural areas of Padang (50% Kuranji) population. 
Inclusion criteria were healthy women (between 25-60 years old) with Minangkabau ethnicity. 
Among the 133 eligible adults, 10 adults were excluded from the study. Exclusion criteria 
included the following: having a previous history of type 2 diabetes, cardiovascular disease or 
hypertension (n=6), having a BMI of more than 40 kg/m2 or being classified as morbidly obese 
by a physician (n=0), being blood related to other participants in the study (n=0), having any 
communicable disease (n=4), being pregnant or lactating (n=0) and taking dietary or vitamin 
supplements (n=0). Among the 123 remaining adults, 5 volunteers did not undergo blood 
sample collection and were excluded from the study and one participant did not undertake the 
validated semi-quantitative food frequency questionnaire (FFQ) [440]. The final sample 
consisted of 117 women who completed an FFQ and underwent blood sample collection for 
biochemical and genetic analysis (Figure 14).  
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Figure 14: Flow chart of the subject recruitment process 
6.3.2 Anthropometric Measures  
 Body weight was measured to the nearest 100 g using an electronic scale (Seca 803, 
Seca GmbH. Co. kg, Hamburg, Germany) and height was measured to the nearest mm using a 
stadiometer (OneMed Medicom stature meter, YF.05.05.V.A.1022, Indonesia). The BMI was 
estimated as weight (kg) divided by the height (m) squared. BMI was classified according to 
the Asia-Pacific classification for BMI/age according to sex [441].The waist (cm) 
circumference was measured in a standing position with the feet positioned close together. The 
waist circumference (WC) was measured using a metal tape (Medline-OneMed Medicom, 
Jakarta, Indonesia) midway between the lower border of the rib cage and the iliac crest, at the 
end of gentle expiration. Body fat percentage was measured using the Tanita MC780 multi 
frequency segmental body composition analyser. 
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6.3.3 Biochemical measures 
For the determination of biochemical parameters, blood samples (5 ml) were collected by 
a trained phlebotomist in the morning, after a 12 hour fast. The blood samples were used to 
measure vitamin B12, glucose, insulin and glycated hemoglobin (HbA1c). All biochemical 
samples were assayed using the xMark Microplate Spectrophotometer (Bio-Rad Laboratories 
Inc, Hercules, California, USA). Serum concentrations of vitamin B12, glucose, insulin and 
HbA1c were assessed using enzyme-linked immunosorbent assay (ELISA) kits from Bioassay 
Technology Laboratory (Shanghai, China). 
6.3.4 Assessment of dietary intake and physical activity 
Data collection was completed by a qualified nutritionist in the home or in an integrated 
health service post. Dietary intakes were assessed using a previously validated and published 
semi-quantitative food frequency questionnaire (SQ-FFQ) containing 223 food items [440]. In 
brief, participants were asked to estimate the usual frequency (number of times per day, week 
or month) and the portion sizes of various food items.  Portion size photographs of all relevant 
foods (including some prepared dishes) were used by participants while completing the SQ-
FFQ, to aid the estimation of portion size intake [442]. All information provided by the 
participants was double-checked for accuracy. The recorded data was analyzed with the 
Indonesian Food Database and Nutrisurvey (EBISpro, Germany) to estimate energy as well as 
macro- and micronutrient consumption. Wherever appropriate, nutrient intake values were 
adjusted to energy by the nutrient (energy-adjusted) residual method [345].  
  “The Global Physical Activity Questionnaire” (GPAQ), developed by the World Health 
Organization (WHO) was used to measure physical activity [369]. Total time in moderate-to-
vigorous physical activity was calculated according to the WHO STEPwise method and was 
expressed as metabolic equivalent minutes per day (METmins/day). Furthermore, participants 
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were classified as “active” if they accumulated ≥600 METmins/week or “inactive” if they did 
<600 METmins/week. Sedentary behaviour (SB, mins/day) was determined from the last 
question of the GPAQ, based on how long the participants spent sitting while working, in a 
vehicle, watching television, or lying down, except sleeping [369]  
6.3.5 SNP selection and genotyping 
We selected nine vitamin B12-related SNPs (Methylenetetrahydrofolate reductase 
[MTHFR]- rs1801133, Carbamoyl-phosphate synthase 1 [CPS1]- rs1047891, Cubulin 
[CUBN]- rs1801222, CD320 molecule [CD320]- rs2336573, Transcobalamin 2 [TCN2]- 
rs1131603, Fucosyltransferase 2 [FUT2]- rs602662, Transcobalamin 1 [TCN1]- rs34324219, 
Fucosyltransferase 6 [FUT6]- rs778805 and Methylmalonyl-CoA mutase [MUT]- rs1141321) 
based on the recent review article by Surendran et al. [14].  
The nine metabolic disease-related SNPs were selected for our analysis based on 
previously published candidate gene association and genome-wide association (GWA) studies 
for metabolic disease-related traits [370-378]: Fat mass and obesity-associated [FTO]- 
rs9939609 and rs8050136, Melanocortin 4 Receptor [MC4R]- rs17782313 and rs2229616, 
Transcription factor 7-like 2 [TCF7L2]- rs12255372 and rs7903146, Potassium voltage-gated 
channel subfamily J member 11 [KCNJ11]- rs5219, Calpain 10 [CAPN10]- rs3792267 and 
rs5030952) 
Genomic DNA was isolated from peripheral blood leukocytes using the PureLink 
Genomic DNA Mini Kit (Invitrogen, Carlsbad, USA) with spin column methods. The DNA 
concentration was determined using a NanoDrop spectrophotometer. Genotyping was 
performed at LGC Genomics (http://www.lgcgroup.com/services/genotyping), which employs 
the competitive allele-specific PCR-KASP® assay. 
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6.3.6 Statistical analysis 
The SPSS statistical package (version 22; SPSS Inc., Chicago, IL, USA) was used for 
the statistical analysis. Results from the descriptive analyses are presented as means and 
standard deviations (SD) for continuous variables and as percentages for categorical variables. 
Generalized obesity was defined according to the Asia-Pacific classification of BMI  for Asians 
as non-obese (BMI < 23 kg/m2) and obese (BMI ≥ 23 kg/m2) [441]. We performed an 
independent t-test to compare the means of the quantitative variables between non-obese 
individuals vs obese individuals. Comparison of the proportion of individuals engaging in 
different types of physical activity levels (vigorously active, moderately active and sedentary) 
between non-obese vs obese individuals was analyzed by the Chi Square test. The normality 
of variable distribution was verified by the Shapiro-Wilk test; WC, body fat percentage, 
glucose, insulin, HbAC1 and vitamin B12 levels were not normally distributed in our study 
population; therefore, the data were natural log-transformed prior to analysis.  
Allele frequencies were estimated by gene counting. The Chi-square test was used to 
compare the proportions of genotypes or alleles. Fifteen of the SNPs were in Hardy Weinberg 
Equilibrium (HWE) (P > 0.05) (Table 28). HWE was not calculated for the SNPs TCN2 
rs1131603 and TCN1 rs34324219 as no minor alleles were present. The SNP FUT2 rs602662 
deviated from HWE; however, this SNP was not excluded from analysis. The KASPTM 
genotyping technology used in this study, has been independently assessed to be over 99.8% 
accurate [443]. Validation of the KASPTM genotyping was conducted at LGC genomics and 
the quality of the genotyping results were independently assessed and confirmed by the project 
manager. This ruled out genotyping artefacts as possible reasons for deviation from HWE. 
Hence, it is possible that the SNP FUT2 rs602662 could have deviated from HWE due to 
population or racial grouping substructure (Sub-grouping), non-random mating, linkage 
disequilibrium (incomplete mixing of different ancestral population) or chance findings [379]. 
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Interestingly, the SNP FUT2 rs602662 deviated from HWE within the Sri Lankan 
(GOOD) population and  in a GWA study conducted in India; the authors ruled out that the 
deviation was not due to a genotyping error and still used this SNP for analysis in their study 
[233]. It is possible, that FUT2 rs602662 does not reach HWE in South / South East Asian 
populations. An alternative reason could be that the HWE is not reached in this population, due 
to the small sample size and the possibility of interbreeding (especially as consanguineous 
marriages are common in these populations). 
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Table 28: Genotype distribution of vitamin B12 related SNPs and metabolic disease-related SNPs 
 
Gene rs number Major 
allele 
Minor 
allele 
Common 
Homozygotes  (%) 
Heterozygotes 
(%) 
Rare 
Homozygotes  (%) 
Minor 
allele 
frequency 
HWE 
P 
value 
MTHFR rs1801133 C T 92 (79.30) 24 (20.70) 0 (0.00) 0.10 0.214 
CPS1 rs1047891 C A 48 (41.00) 56 (47.90) 13 (11.10) 0.35 0.579 
CUBN rs1801222 C T 84 (74.30) 27 (23.90) 2 (1.80) 0.14 0.920 
CD320 rs2336573 C T 86 (74.10) 29 (25.00) 1 (0.90) 0.13 0.390 
TCN2 rs1131603 T C 117 (100) 0 (0.00) 0 (0.00) 0 N/A 
FUT2 rs602662 G A 111 (94.90) 4 (3.40) 2 (1.70) 0.03 0.000 
TCN1 rs34324219 C A 117 (100) 0 (0.00) 0 (0.00) 0 N/A 
FUT6 rs778805 T C 33 (28.20) 61 (52.10) 23 (19.70) 0.46 0.586 
MUT rs1141321 G A 67 (59.30) 40 (35.40) 6 (5.30) 0.23 0.993 
CAP10 rs3792267 G A 108 (91.50) 9 (7.60) 1 (0.80) 0.05 0.123 
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CAP10 rs5030952 C T 77 (66.40) 31 (26.70) 8 (6.90) 0.20 0.063 
KCNJ11 rs5219 C T 55 (47.00) 47 (40.20) 15 (12.80) 0.33 0.329 
TCF7L2 rs12255372 G T 97 (82.90) 20 (17.10) 0 (0.00) 0.09 0.312 
TCF7L2 rs7903146 C T 95 (81.90) 21 (18.10) 0 (0.00) 0.09 0.284 
FTO rs9939609 T A 70 (60.30) 39 (33.60) 7 (6.00) 0.23 0.618 
MC4R rs17782313 T C 89 (76.10) 26 (22.20) 2 (1.70) 0.13 0.929 
FTO rs8050136 C A 69 (60.00) 39 (33.90) 7 (6.10) 0.23 0.638 
MC4R rs2229616 G A 116 (99.10) 1 (0.90) 0 (0.00) 0.00 0.963 
 
MAF; minor allele frequency, HWE; Hardy Weinberg Equilibrium, X2; Chi-Squared value  
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 A schematic representation of the study design is presented in Figure 15. The 
unweighted, risk-allele GRS method was calculated for each participant as the sum of risk 
allele counts across each SNP which predicted vitamin B12 status. The B12-GRS was 
generated from the vitamin B12-related SNPs in the MTHFR, CPS1, CUBN, CD320, TCN2, 
FUT2, TCN1, FUT6, MUT genes. Furthermore, another unweighted GRS was created using 
allele markers previously reported to be associated with metabolic disease traits. The 
Metabolic-GRS was generated from the SNPs in the CAP10, KCNJ11, TCF7L2, FTO and 
MC4R genes. A value of 0, 1 or 2 was assigned to each SNP, which denotes the number of risk 
alleles on that SNP. These values were then calculated by adding the number of risk alleles 
across each SNP. The average number of risk alleles per person for the B12-GRS was 8.18 
(SD = 1.36), which ranged from 5 to 12. The sample was stratified, by the median, into a “low 
genetic risk group,” for those with a GRS ≤ 8 risk alleles (n = 73), and into a “high genetic risk 
group,” for those with a GRS ≥ 9 risk alleles (n = 44). For the metabolic-GRS, the average 
number of risk alleles per person was 4.66 (SD = 1.76), which ranged from 2 to 9. The sample 
was stratified, by the median, into a “low genetic risk group,” for those with a GRS ≤ 4 risk 
alleles (n = 61), and into a “high genetic risk group,” for those with a GRS ≥ 5 risk alleles 
(n = 56). Linear regression was used to examine the association of the two GRS scores with 
the biochemical and anthropometric outcomes (vitamin B12, glucose, insulin, HbA1c, BMI, 
WC and body fat percentage). The interaction between the two GRS scores and dietary factors 
on biochemical and anthropometric outcomes was determined by including interaction term 
(GRS*lifestyle factor) in the regression model. Models were adjusted for age, BMI, and total 
energy intake, wherever appropriate. Correction for multiple testing was applied using 
Bonferroni correction [2 GRS * 7 biochemical and anthropometric measurements (vitamin 
B12, glucose, insulin, HbA1c, BMI, WC, body fat percentage) * 5 lifestyle factors (dietary 
carbohydrate (energy %), dietary protein (energy %), dietary fat (energy %), dietary fibre (g) 
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and physical activity levels) = 70 tests; 0.05/70 = 0.000714; P<0.000714]. All data are 
expressed as mean ± SD. Given that there are no studies on GRS in relation to B12 status and 
metabolic outcomes and no previously reported effect sizes for the South-East Asians, we were 
unable to perform a power calculation. 
 
Figure 15: Diagram representing the study design.  
Four possible associations and four possible interactions were examined. One-sided arrows 
with unbroken lines represent genetic associations and one-sided arrows with broken lines 
represent interactions between a GRS and a lifestyle factor on serum vitamin B12/ metabolic 
traits.  The association of the metabolic-GRS with vitamin B12 and metabolic disease-related 
traits and the association of B12–GRS with vitamin B12 and metabolic disease related traits 
were tested. Lastly, the impact of lifestyle factors (macronutrient intakes and physical activity 
levels) on these genetic associations was investigated.  
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6.4 Results  
6.4.1 Characteristics of the participants  
In this study, 117 women (mean age, 40.40 ± 10.20 years; BMI, 25.10 ± 4.20 kg/m2) were 
included. Table 29 illustrates the main characteristics of the study participants.
Table 29: Anthropometric and biochemical characteristics of women participants 
  
All women Non-obese* Obese** 
P value*** 
(N=117) (N=32) (N=85) 
Age (yrs) 40.40 ± 10.20 35.70 ± 11.30 42.10 ± 9.20 0.006 
Height (cm) 152.90 ± 5.20 154.90 ± 4.70 152.20 ± 5.20 0.012 
BMI (kg/m2) 25.10 ± 4.20 20.10 ± 2.10 27.00 ± 3.10 <0.001 
WC (cm) 83.10 ± 12.50 72.80 ± 13.30 87.00 ± 9.70 <0.001 
Body fat (%) 35.70 ± 7.00  27.00 ± 5.20 39.00 ± 4.30 <0.001 
Fasting serum Glucose 
(mg/dl) 
92.20 ± 20.20 85.70 ± 9.00 94.70 ± 22.70 0.033 
Fasting serum Insulin 
(mIU/L) 
32959  ± 26327 30372 ± 26179 33933 ± 26470 0.517 
HbA1C (ng/ml) 662 ± 624 638 ± 606 672 ± 633 0.794 
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Fasting vitamin B12 
(pg/mL) 
591 ± 579 426 ± 137 433 ± 193 0.795 
Physical Activity Levels 
Sedentary (39.30%) Sedentary (46.90%) Sedentary (36.50%) 
0.490a Moderate (49.60%) Moderate (40.60%) Moderate (52.90 %) 
Vigorous (11.10%) Vigorous (12.50 %) Vigorous (10.60 %) 
Total energy (kcal/d) 1774 ± 609 1849 ± 585 1746 ± 619 0.416 
Protein (g) 76.90 ± 36.50 80.50 ± 29.00 75.50 ± 39.00 0.514 
Fat (g) 59.00 ± 33.10 67.30 ± 27.70 55.80 ± 34.60 0.096 
Carbohydrate (g) 233 ± 71 230 ± 70 235 ± 72 0.714 
Dietary fibre (g) 8.80 ± 4.50 9.70 ± 4.80 8.50 ± 4.40  0.222 
Saturated Fat (g) 20.90 ± 11.10 23.70 ± 11.10 19.80 ± 10.90 0.085 
MUFA (g) 8.20 ± 4.50 9.80 ± 5.20 7.50 ± 4.20 0.015 
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PUFA (g) 6.30 ± 3.50 6.80 ± 3.20 6.10 ± 3.60 0.332 
 
Data shown are represented as means ± SD 
P values were calculated by using the Independent t test 
*Non-Obese individuals refers to the percentage of individuals with a BMI of under 23 according to 
the Asia-Pacific classification of BMI. 
**Obesity cases refers to the percentage of individuals with a BMI of equal to or over 23 according to 
the Asia-Pacific classification of BMI. 
***P values for the differences in the means/ proportions between non-obese and obese individuals 
aP values were calculated by using the Chi Squared test 
Abbreviations: BMI Body mass index; WC Waist circumference; MUFA Monounsaturated fatty acids; 
PUFA Polyunsaturated fatty acids. 
 
6.4.2 Association between B12-GRS and metabolic-GRS with biochemical and 
anthropometric measurements 
 After correction for multiple testing, none of the associations of the B12-GRS with vitamin 
B12 and metabolic traits (P> 0.160) were statistically significant (Table 30). Furthermore, no 
associations between the metabolic-GRS and vitamin B12 or metabolic traits (P>0.085) were 
observed (Table 31). 
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Table 30: Association of the B12-GRS with obesity traits, biochemical traits and anthropometric measurements 
GRS BMI (kg/m2) WC (cm) 
 
Body Fat (%) 
Fasting serum 
glucose (mg/dl) 
Fasting serum 
insulin (mIU/L) HbAC1 (ng/ml) 
Vitamin B12 
(pg/ml) 
 
≤ 8 risk 
alleles 
24.90 ± 4.10 82.10 ± 13.20 
 
 
35.40 ± 7.10 89.90 ± 9.30 31331 ± 24636 625 ± 579 452 ± 187 
 
 
≥ 9 risk  
alleles 
25.50 ± 4.30 84.60 ± 11.00 
 
 
 
36.30 ± 6.90 96.10 ± 30.60 35659 ± 29008 726 ± 693 392 ± 156 
P value 0.468† 0.456* 
 
 
 
0.898* 0.193* 0.328* 0.444* 0.160* 
Values are given as mean ± standard deviation.  
P values for differences between ≤8 and ≥9 risk alleles were obtained using linear regression model adjusted for age, sex and BMI. 
† P values were obtained by using a general linear model adjusted for age and sex 
*P values were based on the log transformed values 
Abbreviations: BMI body mass index; WC waist circumference; HbAC1 glycated haemoglobin 
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Table 31: Association of the metabolic-GRS with obesity traits and biochemical and anthropometric measurements 
GRS BMI (kg/m2) WC (cm) 
 
 
Body Fat (%) Fasting serum 
glucose (mg/dl) 
Fasting serum insulin 
(mIU/L) 
Glycated 
Haemoglobin 
(ng/ml) 
Vitamin 
B12 
(pg/ml) 
 
≤ 4 risk alleles 24.50 ±4.10 82.30 ± 14.40 
 
35.00 ± 6.80 95.00 ± 26.00 33764 ± 27805 670 ± 651 436 ± 174 
 
≥ 5 risk  alleles 25.80 ± 4.20 83.90 ± 10.20 
 
36.50 ± 7.20 89.20 ± 10.30 32082 ± 24837 654 ± 598 426 ± 184 
P value 0.085† 0.570* 
 
 
 
0.383* 0.361* 0.785* 0.653* 0.778* 
Values are given as mean ± standard deviation  
P values for differences between ≤4 and ≥5 risk alleles were obtained using linear regression model adjusted for age, sex and BMI. 
† P values were obtained by using a general linear model adjusted for age and sex 
*P values were based on the log transformed values 
Abbreviations: BMI body mass index; WC waist circumference; HbAC1 glycated haemoglobin
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6.4.3 Interaction between the B12-GRS and dietary factors on biochemical and 
anthropometric measurements 
We observed an interaction between the B12-GRS and dietary fibre intake (g) on log 
transformed HbA1C (Pinteraction= 0.042) (Figure 16 and Table 32). Individuals who carried 9 
or more risk alleles for vitamin B12 deficiency had 8.10 % higher HbAC1 concentrations 
(ng/ml) in the lowest tertile of fibre intake (g) (Mean ± S.D: 4.90 ± 1.00 g) compared to those 
with 8 or less risk alleles for vitamin B12 deficiency.  
Table 32: Interaction between the B12-GRS and metabolic-GRS and lifestyle factors on 
biochemical outcomes and anthropometric measurements 
Interaction between the GRS * lifestyle factors on BMI 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
0.933†  0.685†  0.993†  0.155†  0.682† 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
Physical 
activity levels 
 0.422†  0.230†  0.110†  0.273† 0.757† 
Interaction between the GRS * lifestyle factors on Log waist circumference (cm) 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
 0.444  0.875  0.395  0.547  0.706 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
Physical 
activity levels 
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 0.812  0.072  0.032  0.648  0.796 
Interaction between the GRS * lifestyle factors on Log Body fat (%) 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
0.275  0.064  0.034  0.697   0.419 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
Physical 
activity levels 
 0.775  0.844 0.568  0.423  0.253 
Interaction between the GRS * lifestyle factors on Log fasting serum glucose (mg/dl) 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
 0.347  0.260  0.368  0.380  0.315 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
Physical 
activity levels 
 0.634  0.771  0.929  0.537  0.056 
Interaction between the GRS * lifestyle factors on Log fasting serum insulin (mIU/L) 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
 0.757  0.341  0.073  0.215  0.629 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
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Physical 
activity levels 
 0.108  0.104  0.890 0.947  0.723 
Interaction between the GRS * lifestyle factors on Log HbAC1 (ng/ml) 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
 0.175  0.091  0.150  0.042  0.475 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
Physical 
activity levels 
 0.298  0.166  0.155  0.851  0.969 
Interaction between the GRS * lifestyle factors on Log Vitamin B12 (pg/ml) 
B12-GRS * fat 
energy %  
B12-GRS * 
carbohydrate 
energy % 
B12-GRS * 
protein energy % 
B12-GRS * 
fibre (g) 
B12-GRS * 
Physical 
activity levels 
 0.772  0.936  0.270  0.157  0.078 
metabolic-GRS * 
fat energy %  
metabolic-GRS * 
carbohydrate 
energy % 
metabolic-GRS * 
protein energy % 
metabolic-
GRS * fibre 
(g) 
metabolic-
GRS * 
Physical 
activity levels 
 0.983  0.682  0.298  0.171 0.242 
     
P values were obtained by using a general linear model adjusted for age, sex, and BMI 
† P values were obtained by using a general linear model adjusted for age and sex  
Abbreviations: BMI body mass index 
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Figure 16: Interaction between the B12-GRS and dietary fibre intake (g) on log HbAC1 
(ng/ml) (Pinteraction = 0.042) 
Among those who consumed a low fibre diet, individuals who carried 9 or more risk alleles 
had significantly higher levels of log HbAC1 compared to individuals carrying 8 or less risk 
alleles (P = 0.025). Error bars indicate Standard error. 
 
Interactions were also seen between the B12-GRS and protein (energy %) on log 
transformed body fat percentage (P = 0.034). However, further stratification of participants 
based on their consumption of low-, medium- and high-dietary protein (energy %) did not show 
a statistically significant association between the GRS and the outcomes in any of the tertiles. 
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6.4.4 Interaction between the metabolic-GRS and dietary factors on biochemical and 
anthropometric measurements 
An interaction was found between the metabolic-GRS and protein (energy %) on log 
transformed WC (P=0.032) (Table 32 and Figure 17). Individuals who carried 5 or more risk 
alleles for metabolic disease had 2.15% lower WC measurements (cm) in the lowest tertile of 
protein energy intake (%) (Mean ± S.D: 1.91 ± 0.06 %) compared to those with 4 or less risk 
alleles (P= 0.027) (Figure 17).  
 
Figure 17: Interaction between the metabolic-GRS and protein energy (%) on log waist 
circumference (Pinteraction = 0.032) 
Among those who consumed a low protein diet, individuals who carried 5 or more risk alleles 
had significantly lower waist circumference measurements compared to individuals carrying 
4 or less risk alleles (P = 0.027). Error bars indicate Standard error.
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6.4.5 Interaction between the B12-GRS and physical activity on biochemical and 
anthropometric measurements 
No statistically significant interactions were observed between the two GRSs (vitamin 
B12 and metabolic traits) and physical activity on biochemical and anthropometric 
measurements (P>0.056) (Table 32).  
After correction for multiple testing (Bonferroni corrected <0.000714), none of these GRS-
lifestyle interactions were considered statistically significant. 
6.5 Discussion 
To our knowledge, this is the first study to use a nutrigenetic approach to explore the 
relationship between vitamin B12 status and metabolic traits in Indonesian women. Our study 
demonstrated the impact of genetically instrumented B12 concentrations on HbA1C levels, a 
marker of glycaemic control [444], through the influence of dietary fibre intake. Given that 
previous studies have shown that the consumption of dietary fibre is inadequate in Indonesian 
adults [445-447], our findings, if replicated in future studies, may have significant public health 
implications in terms of encouraging a consumer education campaign targeted around 
increasing fibre intake, in order to reduce HbA1C levels, which may be associated with 
improved glycaemic control.  
 In the present study, we constructed a GRS consisting of nine vitamin B12 decreasing 
SNPs in genes involved in vitamin B12 metabolism [14]. Our study showed that individuals 
carrying less than 8 risk alleles for vitamin B12 deficiency had higher vitamin B12 
concentrations, compared to those carrying more than 9 risk alleles. However, there was no 
statistically significant difference between individuals carrying 8 or less risk alleles vs 9 or 
more risk alleles for the B12-GRS, which could be attributed to the small sample size. 
Furthermore, we were unable to identify any association between the B12-GRS and metabolic 
disease traits in our study, implying that linear decreases in vitamin B12 may not have a role 
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in the development of metabolic disease traits. Our finding goes in line with a Mendelian 
Randomization study investigating the effect of genetically instrumented vitamin B12 
concentrations on BMI, where there was no evidence to suggest the causal role of decreased 
serum vitamin B12 levels in obesity [16]. 
Interestingly, in our study, we found a significant interaction between the B12-GRS 
and dietary fibre intake (g) on log HbA1C levels, where, among those who consumed a low 
fibre diet (Mean ± S.D: 13.60 ± 4.30), individuals carrying more than 9 risk alleles had 
significantly higher HbAC1 levels compared to those carrying 8 or less risk alleles. The average 
fibre intake in Indonesia is 10.5 g/day [448], which is lower compared to the mean fibre intake 
in the UK ( ~18g/day) and USA (~16g/day) [373]. In comparison to the mean fibre intake in 
Indonesia, the results in our study reported a lower mean fibre intake (8.80 ± 4.50 g). It is 
important that dietary intakes of fibre are increased in this population, as it may help maintain 
lower levels of HbAC1 levels in individuals carrying more than 9 risk alleles of the B12-GRS. 
Even though our study is the first to report this gene-diet interaction, a meta-analysis conducted 
from 15 randomized studies have shown that high fibre intake can reduce HbAC1 levels in type 
2 diabetic subjects [449]. High fibre intake is generally recommended to reduce the risk of 
gestational diabetes (GDM) in pregnant women [450]. It has been shown that each 10g/day 
increment in total fibre intake, corresponds to a 26% reduced risk of GDM [450]. It is possible 
that high dietary fibre may increase satiety and consequently reduce total energy intake [451, 
452]. Increased dietary fibre intake may also affect glucose homeostasis, by delaying gastric 
emptying, resulting in a slower absorption of glucose into the blood stream [450]. Additionally, 
low vitamin B12 status prevents erythropoiesis and prolongs the lifespan of erythrocytes, 
resulting in increased HbA1c levels [453]. This is the first study to provide evidence for an 
interaction between B12-GRS and HbA1c; hence, we do not have any previous studies to 
compare our findings with. 
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Accurately determining obesity has become an exceedingly important step in 
preventing the onset of metabolic syndrome or cardiometabolic diseases, which are brought 
about through excess adiposity. The underestimation of obesity, particularly in young women 
who appear to have a healthy BMI measure, could falsely lead to incorrect conclusions about 
body composition and future risk of diseases associated with increased adiposity, such as breast 
cancer [454]. The ability to measure body fat percentage is currently the preferred method of 
determining body composition over BMI, as it distinguishes between fat and lean body mass 
[455]. To date, little is known about the average body fat percentage in healthy Indonesian 
women. Although, a recent study conducted in 308 Indonesian women of Javanese ethnicity 
living in Yogyakarta Special Region Province (aged between 18-65), reported lower body fat 
% values (33.30 ± 7.70%) compared to our present study  (35.70 ± 7.00 %) [456]. Within our 
study, an interaction between the B12-GRS and protein intake (energy %) on log transformed 
body fat percentage was observed. The exact mechanism of how dietary protein results in a 
more favourable body composition profile in individuals genetically predisposed to vitamin 
B12 deficiency is not known. A previous study conducted in 1,834 participants in Canada 
reported that  high protein diets could reduce overall body fat percentage, even in the absence 
of energy restriction [457]. Further to this, it has been hypothesised that high protein diets 
increase the release of the anorectic gut hormone peptide YY (PYY), thus enhancing greater 
inter-meal satiety and reducing weight gain [458]. This suggestion for a novel interaction of 
protein (energy intake) in relation to body fat distribution in individuals genetically predisposed 
to vitamin B12 deficiency warrants further replication. 
In a review analysing the nutrient intakes of pregnant women in Indonesia, it was 
reported that pregnant Indonesian women generally have protein intakes below the estimated 
average requirements [459]. The association between low protein intake and obesity outcomes 
has attracted interest amongst health care professionals. Observational studies in the USA have 
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reported that body weight and WC were reduced when protein was consumed above the 
recommended daily allowance [0.8 g/kg body weight (BW)] [460]. It has been noted in animal 
models, that pregnant rats consuming a low protein diet were more prone to GDM and to having 
offspring with a low birthweight [461, 462]. In our study, we found a significant interaction 
between the metabolic-GRS and protein energy (%) on log WC, where individuals consuming 
a low protein diet, despite carrying 5 or more risk alleles, had a lower waist to hip ratio 
compared to individuals carrying 4 or less risk alleles.  There are no previous reports of the risk 
variants used in our GRS, but Goni et al [36] found that total protein intake interacted with a 
GRS of 16 obesity/lipid metabolism polymorphisms to modify the effect on body fat mass in 
711 individuals of Caucasian ancestry. In our study, we only observed interaction of the 
metabolic-GRS with WC but not BMI, which suggests that effects of the GRS are likely to be 
on central obesity as opposed to common obesity in Indonesian women. 
Significant interactions between genetic variants and physical activity on obesity traits 
have been reported in several studies from Europe and Asia [463, 464]. However, this is the 
first study to investigate interactions between the two GRSs and physical activity on metabolic 
traits and B12 concentrations in Indonesian women. In our study, as much as 39% of the women 
had low physical activity levels. These findings were much higher than the findings reported 
from another cross sectional study conducted across five major cities in Indonesia, who 
reported that 20% of women had a low physical activity status [465]. Although the majority of 
women in our study were physically inactive, no significant interactions were found between 
the GRSs and physical activity on metabolic traits/B12 status, which could be due to the small 
sample size of our study.  
Major strengths of our study are that this is the first study of its kind to evaluate vitamin 
B12 status among Indonesian women. Furthermore, this study used a comprehensive, 
validated, interviewer administered food frequency questionnaire [440] to measure the long-
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term macronutrient intake of the population. Nevertheless, several limitations of this study need 
to be considered. One of the main limitations of the study is the small sample size (N=117); 
however, we were still able to identify significant associations and gene-lifestyle interactions. 
Measurement errors in dietary assessment are inevitable since self-reported data on dietary 
intake are all subject to bias. We only included dietary data on total energy and macronutrient 
intake, but no data on specific foods or more specific types of micronutrients, which may 
potentially interact with GRS. Circulating concentrations of other vitamin B12 biomarkers, 
such as Holo-transcobalamin (holoTC) or Methylmalonic Acid (MMA) were not measured. 
Furthermore, all the women included in our analysis were of Minangkabau descent, and thus it 
is unknown whether our results can be generalized to other communities in Indonesia. 
6.6 Conclusion 
In conclusion, our study showed a significant effect of the B12-GRS on HbA1C 
concentrations, through the influence of a low dietary fibre intake. Additionally, our study 
failed to provide evidence for an impact of metabolic-GRS on lowering B12 concentrations. 
After correction for multiple testing, none of the interactions were statistically significant; 
hence, further replication studies utilizing larger sample sizes are needed to confirm our 
findings, before public health recommendations and personalised nutrition advice can be 
developed for Minangkabau Indonesian women. 
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Chapter 7  
A genetic approach to investigate the relationship between vitamin 
B12 status and cardio-metabolic traits in response to changes in 
dietary fat composition in 
adults with moderate cardiovascular disease risk   
For this study, I collected and transferred the blood serum samples from the freezer in the 
Department of Food and Nutritional Sciences at the University of Reading to Royal Berkshire 
Hospital (Reading, UK) for vitamin B12 analysis. In addition, I organised the genotyping of 
the selected genetic variants at the LGC Genomics, UK. I was involved in generating and 
cleaning the dataset to perform statistical analysis. I developed the analysis plan, ran the entire 
statistical analysis using the SPSS software and wrote the first draft of the manuscript. I revised 
the manuscript based on the comments from all the co-authors. This paper has been submitted 
to the journal ‘Lipids in Health and Disease’. 
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Authors: Shelini Surendran, Michelle Weech, Kim G. Jackson, Julie A. Lovegrove and Karani 
S. Vimaleswaran  
 
7.1 Abstract 
Background: Low vitamin B12 status has been reported to be a risk factor for several 
cardiometabolic traits such as obesity, diabetes and cardiovascular disease (CVD). Animal 
models have shown that the modification of dietary fat intake can affect vitamin B12 status. 
Hence, we investigated whether vitamin B12- and metabolic disease-related genetic variants 
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modify vitamin B12 concentrations and cardiometabolic traits in response to replacement of 
saturated fatty acids (SFA) with monounsaturated (MUFA) or n-6 polyunsaturated (PUFA) 
fatty acids.  
Methods: This describes a secondary analysis of the Dietary Intervention and VAScular 
function (DIVAS) study. The DIVAS study was a randomized, single-blind, parallel-
group dietary intervention, in which 119 men and women aged 21-60 y from the United 
Kingdom with moderate CVD risk followed one of three isoenergetic diets rich in SFA, MUFA 
or n-6 PUFA for 16 weeks. Genetic risk scores (GRS) based on three vitamin B12 associated 
single nucleotide polymorphisms (SNPs) (B12-GRS) and six metabolic SNPs (metabolic-
GRS) were constructed.  
Results: After the 16-week intervention, post-hoc tests indicated no significant interactions 
between changes in vitamin B12 concentrations and the three dietary groups and the B12- and 
metabolic-GRSs . For the metabolic-GRS, individuals with 6 or more risk alleles showed a 
significant reduction in 24-hour ambulatory systolic blood pressure after the MUFA diet (n = 
13; -7± 8 mm Hg) compared to the SFA (n = 15; 2 ± 7 mm Hg /or n-6 PUFA dietary groups (n 
= 16; 2 ± 9 mm Hg) (Pinteraction = 0.012). However, this interaction was not considered 
statistically significant after correction for multiple testing.  
Conclusions: In summary, this post-hoc analysis demonstrated a greater sensitivity of the 
metabolic-GRS to dietary fat composition with a 9 mmHg lower 24-hour ambulatory systolic 
blood pressure observed following substitution of SFA with MUFA, but not n-6 PUFA. 
However, our findings failed to provide evidence for an impact of the B12-GRS on 
cardiometabolic traits. Further large intervention studies incorporating prospective genotyping 
are required to confirm or refute our findings.  
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7.2 Introduction 
Vitamin B12 is an essential micronutrient associated with the one carbon metabolic 
pathway, a cycle related to the synthesis of DNA, protein and lipids [72, 466]. In recent years, 
new functional roles of vitamin B12 have emerged, linking the water-soluble vitamin to various 
non-communicable diseases. Observational studies have provided evidence for an association 
of low serum B12 concentrations with unfavourable metabolic phenotypes, including future 
type 2 diabetes (T2D) [70], insulin resistance [67], cardiovascular disease (CVD) [10, 115], 
obesity[84] and dyslipidaemia [9]. The basis of low vitamin B12 concentrations and its 
association with these metabolic phenotypes is still under debate and could be the result of 
several mechanisms. It has been hypothesised that low vitamin B12 leads to adipocyte 
dysfunction by modulating lipid metabolism and enhancing cellular inflammation [467]. 
Furthermore, vitamin B12 insufficiency has been shown to disturb the methylation of genes 
involved in the regulation of cholesterol biosynthesis, such as sterol regulatory element binding 
transcription factor 1 (SREBF1) and LDL receptor, consequently increasing the expression of 
cholesterol biosynthesis in adipose tissue  [468]. On the other hand, it has been suggested that 
vitamin B12 deficiency is more prevalent in obese subjects due to increased vitamin B12 
demands secondary to an increased  surface area of the body [84, 91] or as a result of 
individuals consuming a diet low in micronutrient density [92].   
At present the true prevalence of vitamin B12 deficiency in the United Kingdom is 
currently unknown. A recent nationwide survey  reported the estimated prevalence of vitamin 
B12 deficiency (≤150 pmol/L) in 299 women of childbearing age (19-36 yrs) to be 12.4% 
[469]. In addition, a cross sectional analysis involving 689 men in the UK (226 omnivores, 231 
vegetarians and 232 vegans) reported that 52% of vegans, 7% of vegetarians and 0.44% of 
omnivores were vitamin B12 deficient (<118 pmol/L) [470]. Vitamin B12 concentrations of 
individuals are highly heterogenous, with interindividual variability persisting as a result of 
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environmental and genetic factors [14]. Several single nucleotide polymorphisms (SNPs) in 
the fucosyltransferase 2 (FUT2) gene have shown associations with circulating vitamin B12 
and, to date, rs492602 and rs602662 have been the most extensively studied [14]. Furthermore, 
recent studies have shown suggestive associations between variants of FUT2 with diabetes 
(Type 1 and Type 2) and BMI [16, 255-257]. Given that obesity and being overweight may 
modulate the status of vitamin B12 [7, 84], it is important to examine the role of genes involved 
in obesity-related traits with vitamin B12 status. 
In the Dietary Intervention and VAScular function (DIVAS) study, the isoenergetic 
replacement of 9.5–9.6% total energy (TE) dietary saturated (SFAs) with cis-monounsaturated 
(MUFAs) fatty acids for 16 weeks in 195 UK adults at moderate CVD risk resulted in beneficial 
effects on lipid biomarkers and ambulatory night-time blood pressure [471]. Given that the 
modification of dietary fat intake has been shown to affect vitamin B12 status in rats [472], this 
post-hoc analysis presents additional outcome measures from the DIVAS study exploring the 
effect of dietary fat composition on vitamin B12 status in individuals with moderate CVD risk. 
To investigate whether genetic polymorphisms contribute to any observable changes in vitamin 
B12 status and cardiometabolic disease risk markers, a retrospective post hoc analysis of the 
DIVAS study was conducted. We examined whether nine SNPs (6 metabolic SNPs and 3 
vitamin B12 SNPs) modified the response of vitamin B12 concentrations and cardiometabolic 
traits, after substitution of SFA with MUFA or polyunsaturated fatty acids (n-6 PUFA) in 119 
participants at moderate CVD risk. 
7.3 Methodology 
7.3.1 Study participants 
  The DIVAS study was a single-blinded, parallel, randomised controlled trial. A 
detailed description of the study criteria and methods has been previously published 
elsewhere [471, 473]. In brief, non-smoking men and women, aged between 21 and 60 years 
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with moderate risk of CVD, were recruited from Reading, UK and the surrounding area in 
three cohorts between November 2009 and July 2012. A scoring tool [473] was used to 
determine the presence of single or multiple CVD risk factors, including elevated fasted 
measures of serum total cholesterol (TC) and glucose, low high-density lipoprotein (HDL) 
cholesterol, raised blood pressure, increased BMI or waist circumference (WC), and a family 
history of premature myocardial infarction or T2D. Participants who were eligible had a risk 
score of ≥2 combined points, reflecting a moderate CVD risk (≥50% above the population 
mean). Other criteria for exclusion were the presence of abnormal fasting blood biochemistry, 
and taking dietary/vitamin supplements or medication for hypertension, raised lipids, or 
inflammatory disorders [473]. Table 33 shows the characteristics of the study participants at 
baseline. 
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Table 33: Baseline characteristics of study participants in the whole group and stratified by sex 
Characteristics n 
Total 
participants 
n Men n Women P value * 
Age (years) 119 47 ± 9 53 48 ± 9 66 46 ± 9 0.257 
BMI (kg/m2) 119 26.4 ± 4.0 53 26.7 ± 3.5 66 26.2 ± 4.3 0.494 
WC (cm) 111 90.7 ± 11.9 49 96.2 ± 11.1 62 86.4 ± 10.8 <0.0001 
WHR 100 0.87 ± 0.09 39 0.94 ± 0.07 61 0.82 ± 0.06 <0.0001 
24 h Ambulatory Systolic BP (mm Hg) 97 122 ± 11 39 126 ± 9 58 120 ± 11 0.007 
24 h Ambulatory Diastolic BP (mm Hg) 97 75 ± 8 39 78 ± 7 58 74 ± 7 0.019 
Total Cholesterol (mmol/L) 109 5.61 ± 1.09 47 5.81 ± 1.09 62 5.45 ± 1.07 0.090 
HDL Cholesterol (mmol/L) 109 1.54 ± 0.36 47 1.37 ± 0.32 62 1.68 ± 0.33 <0.0001 
LDL Cholesterol (mmol/L) 109 3.80 ± 0.98 47 4.11 ± 0.97 62 3.57 ± 0.93 0.004 
TAG (mmol/L) 109 1.29 ± 0.60 47 1.64 ± 0.60 62 1.02 ± 0.45 <0.0001 
Glucose (mmol/L) 109 5.12 ± 0.43 47 5.24 ± 0.44 62 5.03 ± 0.40 0.008 
Insulin (pmol/L) 119 1.40 ± 0.24 53 1.43 ± 0.25 66 1.37 ± 0.22 0.097 
HOMA-IR 109 1.09 ± 0.71 47 1.25 ± 0.89 62 0.97 ± 0.49 0.054 
Vitamin B12 (ng/L) 96 413.5 ± 161.6 42 413.1 ± 171.7 57 413.8 ± 155.3 0.982 
Data shown are represented as means ± SD, wherever appropriate. P values for the differences in the means between men and women. P values 
were calculated by using an independent t-test  
BMI body mass index, BP blood pressure, HDL high- density lipoprotein cholesterol, HOMA-IR homeostasis model assessment—insulin 
resistance, LDL low- density lipoprotein cholesterol, TAG triacylglycerol, WC waist circumference, WHR waist to hip ratio
275 
The West Berkshire Local Research ethics committee (09/ H0505/56) and the 
University of Reading Research Ethics Committee (09/40) gave a favourable ethical opinion 
for conduct, and each volunteer gave written informed consent before participating. The trial 
was registered at www.clinicaltrials.gov as NCT01478958. All protocols and procedures 
were performed according to the Declaration of Helsinki. In our retrospective analysis, 119 
of the 195 participants who completed the DIVAS study consented to genetic analysis and were 
included in the present study. Only 96 participants had samples available for vitamin B12 
analysis. 
7.3.2 Study design and diets  
A detailed description of the DIVAS study design and methods has been reported elsewhere 
[471, 473]. Clinical visits took place at the Hugh Sinclair Unit of Human Nutrition, University 
of Reading, during weeks 0 (baseline; V1) and 16 (after intervention; V2) [471]. The 
participants were randomly assigned to one of three 16 weeks of dietary intervention diets, 
based on a minimization program that matched for age, sex, BMI, and total CVD risk score. 
The three isoenergetic intervention diets (%TE target compositions, SFA:MUFA:n–6 PUFA) 
were rich in SFAs (17:11:4), MUFAs (9:19:4), or n–6 PUFAs (9:13:10). All three intervention 
diets provided 36% TE from total fat, and intakes of other macronutrients were unchanged. 
After the intervention, a greater SFA exchange than the target 8% TE was achieved: SFA vs 
MUFA was 9.5% TE and SFA vs n-6 PUFA was 9.6% TE [473]. Dietary intakes were 
determined from 4-d weighed diet diaries completed at baseline (week 0) and during the 
intervention (weeks 8 and 16), which were analysed by using Dietplan 6.6 (Forestfield 
software).  
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7.3.3 Anthropometric measurements and biochemical parameters 
In brief, volunteers attended the Hugh Sinclair Unit of Human Nutrition (University of 
Reading) at baseline (visit 1) and week 16 (visit 2) after an overnight fast. Study participants 
were asked to refrain from alcohol or organised exercise regimens 24 h before visits. 
Participants were provided with a low fat (<10 g fat) evening meal to standardise short-term 
fat intake and only drank low-nitrate water during this time. After a 12 h overnight fast, a blood 
sample was taken at each visit.  
Serum vitamin B12 concentrations were measured using an electrochemiluminescence 
immunoassay (ECLIA) kit on a Roche 6000 series e601 immunoassay analyser (Roche 
Diagnostics GmbH, Hoffmann-La Roche ltd, Mannheim, Germany) at Royal Berkshire 
Hospital. Fasting serum glucose and lipids (TC, triacylglycerol (TAG), and HDL cholesterol) 
were measured using an ILAB600 clinical chemistry analyser (reagents and analyser: Werfen 
UK Ltd). The LDL cholesterol concentration was calculated using the Friedewald formula 
[343]. Fasting plasma insulin levels were determined by commercial ELISA kits (Dako Ltd, 
High Wycombe, UK). The homeostasis model assessment of insulin resistance (HOMA-IR) 
was calculated using the fasting glucose and insulin data [fasting insulin (pmol/L) x fasting 
glucose (mmol/l)]/135] [474].  
At weeks 0 and 16, BMI was calculated as weight (in kg) divided by the square of body 
height (m). Height was recorded to the nearest 0.5 cm using a wall-mounted stadiometer and 
weight was measured using a digital scale (Tanita Europe) using standard settings (standard 
body type and 1 kg for clothing). Twenty-four hour ambulatory blood pressure (ABP) was 
measured every 30 min from 07:00 to 21:59 and every 60 min from 22:00 to 06:59, 
approximately 48 h before the clinical visits, using A/A grade automated oscillometric ABP 
monitors (A&D Instruments Ltd.). Participant activity forms which contained the recordings 
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of participants’ sleep times, were used to calculate the mean 24-h day and night blood pressure 
measurements [471]. 
7.3.4 SNP selection and genotyping 
In total, nine SNPs were examined in the present study. SNPs for vitamin B12-GRS 
were selected using the tagSNP approach. TagSNPs in the gene fucosyltransferase 2 (FUT2) 
were selected using genotype data from the International HapMap collected in individuals of 
Northern and Western European ancestry (CEU) (HapMap Data Rel 27 Phase 2+3, Feb 09, 
NCBI B36 assembly, dbSNP b126). The Haploview software V3.3 
(http://www.broadinstitute.org/haploview/haploview-downloads) was used to assess the 
linkage disequilibrium (LD) structure between SNPs. Tagger software was used to select 
tagSNPs with the ‘pairwise tagging only’ option and an r2 threshold of >0.8 (±10kb upstream 
and downstream of the genes). In the tagSNP selection, after excluding SNPs with low minor 
allele frequency (<5%), there were 3 tagSNPs (rs602662, rs492602 and rs16982241) 
representing the common genetic variations across the FUT2 gene. The six metabolic disease-
related SNPs were selected for our analysis based on previously published candidate gene 
association and genome-wide association (GWA) studies for cardiometabolic disease-related 
traits and associations of the SNPs with dietary intake of macronutrients [370-372, 475-481]: 
Fat mass and obesity-associated [FTO]- rs8050136 and rs9939609, Melanocortin 4 Receptor 
[MC4R]- rs17782313 and rs2229616 and Transcription factor 7-like 2 [TCF7L2]- rs7903146 
and rs12255372. 
DNA was extracted from the buffy coat using a QIAamp DNA blood kit (QIAGEN) 
and stored at −20 °C from 119 of the participants who consented for genotyping. The 
genotyping of the SNPs was outsourced to LGC Genomics 
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(http://www.lgcgroup.com/services/ genotyping), which employs the competitive allele-
specific PCR-KASP® assay. 
7.3.5 Statistical analysis 
Statistical analysis was carried out using the SPSS software (version 21; SPSS Inc, 
Chicago, IL, USA). All biochemical outcomes were expressed as means ± standard deviation 
(SD) in the tables and text, and as standard error in the figure. All the tested variables were 
checked for normality prior to statistical analysis; BMI, HOMA-IR and insulin levels were not 
normally distributed in our study population; therefore, the data were natural log-transformed 
prior to analysis. The minor allele frequency was calculated by gene counting. Nine of the 
SNPs were in Hardy Weinberg Equilibrium (HWE) (P > 0.05) (Table 34). HWE was not 
calculated for the SNP MC4R rs2229616 as no minor alleles were present. Independent t-tests 
were used to compare means between men and women at baseline. 
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Table 34: Genotype distribution of vitamin B12-related SNPs and metabolic disease-related SNPs 
Gene rs number Major 
allele 
Minor 
allele 
Common 
Homozygotes   
n (%) 
Heterozygotes n 
(%) 
Rare Homozygotes 
n (%) 
Minor allele 
frequency 
HWE 
P value 
  
FUT2 rs602662 G A 34 (28.6) 60 (50.4) 25 (21.0) 0.46 0.877 
FUT2  rs492602 A G 38 (31.9) 58 (48.7) 23 (19.3) 0.44 0.918 
FUT2  rs16982241 G A 91 (76.5) 26 (21.8) 2 (1.7) 0.13 0.928 
TCF7L2  rs7903146 C T 62 (52.1) 46 (38.7) 11 (9.2) 0.29 0.564 
TCF7L2 rs12255372 G T 66 (55.9) 42 (35.6) 10 (8.5) 0.26 0.378 
MC4R rs17782313 T C 70 (59.8) 38 (32.5) 9 (7.7) 0.24 0.243 
MC4R rs2229616 G A 113 (95.0) 6 (5.0) 0 (0) 0.03 -* 
FTO rs8050136 C A 40 (33.9) 57 (48.0) 21 (17.8) 0.42 0.929 
FTO rs9939609 T A 41 (34.5) 57 (47.9) 21 (17.6) 0.42 0.877 
Abbreviations: HWE; Hardy Weinberg Equilibrium 
* HWE was not calculated for the SNP MC4R rs2229616 as no minor alleles were present. 
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7.3.6 Genetic Risk Score 
The unweighted, risk-allele GRS method was calculated for each participant as the sum of risk 
allele counts across each SNP which predicted vitamin B12 status or metabolic disease risk. 
The B12-GRS was generated from the SNPs in the gene FUT2 (rs602662, rs492602 and 
rs16982241), which have been shown to be associated with vitamin B12 concentrations. 
Furthermore, another unweighted GRS was created using allele markers previously reported to 
be associated with metabolic disease traits. The metabolic-GRS was generated from the SNPs 
in the genes FTO (rs8050136 and rs9939609), TCF7L2 (rs7903146 and rs12255372) and 
MC4R (rs17782313 and rs2229616). A value of 0, 1 or 2 was assigned to each SNP, which 
denotes the number of risk alleles on that SNP. These values were then calculated by adding 
the number of risk alleles across each SNP. The average number of risk alleles per person for 
the B12-GRS was 4 (SD = 1), which ranged from 2 to 6. The sample was stratified, by the 
median into a “low genetic risk group” for those with a GRS ≤ 3 risk alleles (n = 41), and into 
a “high genetic risk group” for those with a GRS ≥ 4 risk alleles (n = 78). For the metabolic-
GRS, the average number of risk alleles per person was 5 (SD = 2), which ranged from 2 to 11. 
The sample was stratified, by the median, into a “low genetic risk group” for those with a 
GRS ≤ 5 risk alleles (n = 68), and into a “high genetic risk group” for those with a GRS ≥ 6 
risk alleles (n = 51). The baseline and week 16 associations for the two GRSs with continuous 
phenotypes were evaluated by the general linear model (GLM). Moreover, potential 
interactions between the two GRSs and dietary intervention on changes in vitamin B12 
concentrations and cardiometabolic traits over the 16-week intervention were analysed by 
using GLM, where an interaction term was included in the model. Potential confounders 
associated with the outcomes were adjusted in all GLM analyses (i.e. age, sex, BMI, and 
ethnicity). When a significant diet x genotype interaction was found, data were split by 
genotype group and analysed further by using GLM. A Bonferroni correction was applied and 
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the significant P value was 0.0019 [0.05/2 GRSs * 13 phenotypic outcomes (vitamin B12, 24 
h ambulatory systolic blood pressure, 24 h ambulatory diastolic blood pressure, total 
cholesterol, HDL cholesterol, LDL cholesterol, TAG, glucose, insulin, HOMA-IR, BMI, WC 
and WHR)]. 
7.4  Results 
Baseline clinical and biochemical characteristics of the individuals from the retrospective 
analysis from the DIVAS study are presented in Table 1.Men had higher WC, WHR, 24 h 
ambulatory systolic and diastolic blood pressures, fasting LDL cholesterol, TAG and glucose 
concentrations (P<0.019) and lower levels of fasting HDL cholesterol (P<0.0001) compared to 
women (Table 33). No significant differences in fasting serum vitamin B12 concentrations (P 
= 0.982) between men (413 ± 171 (ng/L) and women (414 ± 155 (ng/L) were observed in this 
study (Table 33). Additionally, there was no overall   significant difference (P>0.539) 
in dietary vitamin B12 intake (Table 35) and serum vitamin B12 concentrations (Table 35), 
between the dietary intervention groups after the 16-week intervention. 
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Table 35: Reported daily composition of vitamin B12 and serum vitamin B12 at baseline (week 0) and after diets rich in SFAs, MUFAs, 
and n–6 PUFAs (week 16) in adults with moderate risk of cardiovascular disease  
 SFA  MUFA  n-6 PUFA  **P value 
Baseline 
(n=40) 
Post 
(n=39) 
Δ  (n=37) Baseline 
(n=35) 
Post 
(n=34) 
Δ  (n=33)  Baseline 
(n=42) 
Post 
(n=40) 
Δ  (n=40)   
 
0.539 
Dietary vitamin B12  (μg/day) 5.29 ± 
2.20 
5.25 ± 
1.93 
-0.02 ± 
1.65 
4.74 ± 
1.55 
5.22 ± 
2.28 
0.46 ± 2.27 6.89 ± 
6.47 
6.11 ± 
3.32 
-0.86 ± 
7.56 
  *P=0.939   *P=0.254   *P=0.474   
Vitamin B12 (ng/L) Baseline 
(n=27) 
Post 
(n=27) 
Δ  (n=26) Baseline 
(n=27) 
Post 
(n=27) 
Δ  (n=26) Baseline 
(n=36) 
Post 
(n=34) 
Δ  (n=34)  
 
0.188 
384 ± 
164 
384 ± 151 -0.08 ± 
71.66 
395 ± 116 379 ± 
112 
-20.0 ± 
66.4 
457 ± 
182 
436 ± 160 -26.4 ± 
56.5 
  *P=0.995   *P=0.138   *P=0.010   
Values are given as means ± standard deviations. Dietary intakes estimated from 4-d weighed diet diaries at baseline (week 0) and after 
intervention (mean of weeks 8 and 16).  
 *The difference between baseline and Post-intervention intakes were identified by using paired-samples T test. 
** The overall effect of diet based on change from baseline after 16-week intervention was derived by univariate analysis (general linear model) 
for between-group comparisons adjusting for BMI, age, sex and ethnicity. 
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 The genotype distributions of the polymorphisms involved in the B12-GRS and 
metabolic-GRS are shown in Table 34. The participants’ characteristics at the beginning of the 
dietary interventions (week 0) are presented in Table 36 according to the B12-GRS and 
metabolic-GRS scores. There was an association between the B12-GRS and fasting HDL 
cholesterol concentration (Passociation = 0.035), where individuals who carried 4 or more risk 
alleles for vitamin B12 deficiency had higher concentrations ( 1.58 ± 0.37 mmol/L) compared 
to those with 3 or less risk alleles (1.47 ± 0.33 mmol/L). There was a significant association 
between the B12-GRS and fasting TAG concentration (Passociation = 0.016), where individuals 
carrying 4 or more risk alleles for vitamin B12 deficiency had 19.6 % lower TAG levels (1.19 
± 0.56 mmol/L) compared to individuals carrying 3 or less risk alleles (1.48 ± 0.65 mmol/L). 
However, these findings were not significant after correction for multiple testing (Bonferroni 
corrected P>0.0019). None of the variables (including vitamin B12, 24 h ambulatory systolic 
and diastolic blood pressure, total cholesterol, HDL cholesterol, LDL cholesterol, TAG, 
glucose, insulin, HOMA-IR, BMI, WC and WHR) were associated with the metabolic-GRS at 
baseline (Table 36). After 16 weeks of dietary intervention, there was no significant association 
of the B12-GRS and metabolic GRSs with changes in the vitamin B12 concentrations after 
Bonferroni correction (Table 37 and Table 38).  
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Table 36: Association of the B12-GRS and metabolic-GRS with obesity traits and fasting biochemical traits 
 
Number 
of risk 
alleles 
BMI 
(kg/m2) 
WC 
(cm) 
WHR 24 h 
Ambulatory 
SBP (mm 
Hg) 
24 h 
Ambulatory 
DBP (mm 
Hg) 
Total 
cholesterol 
(mmol/L) 
HDL-C 
(mmol/L) 
LDL-C 
(mmol/L) 
TAG 
(mmol/L) 
 Glucose 
(mmol/L) 
 Insulin 
(pmol/L) 
HOMA-
IR 
Vitamin 
B12 
(ng/L) 
Vitamin B12-GRS 
≤3 risk 
alleles 
26.3 ± 
3.4 
91.4 
± 
10.4 
0.87 ± 
0.07 
124 ± 11 76.9 ± 7.3 5.79 ± 1.14 1.47 ± 
0.33 
4.02 ± 
1.03 
1.48 ± 
0.65 
5.18 ± 
0.40 
28.0 ± 
14.05 
1.04 ± 
0.49 
435 ± 
185 
≥4 risk 
alleles 
26.5 ± 
4.2 
90.3 
± 
12.8 
0.87 ± 
0.10 
121 ± 10 74.7 ± 7.6 5.51 ± 1.06 1.58 ± 
0.37 
3.69 ± 
0.94 
1.19 ± 
0.56 
5.06 ± 
0.44 
29.5 ± 
19.2 
1.11 ± 
0.80 
403 ± 
149 
P value 0.657†* 0.207 0.625 0.197 0.219 0.685 0.035 0.367 0.016 0.075 0.729* 0.529* 0.311 
Metabolic-GRS 
≤5 risk 
alleles 
26.1 ± 
3.38 
89.4 
± 
10.8 
0.86 ± 
0.08 
121 ± 10 75.1 ± 7.4 5.66 ± 1.04 1.56 ± 
0.37 
3.84 ± 
0.95 
1.31 ± 
0.58 
5.13 ± 
0.48 
27.7 ± 
12.4 
1.04 ± 
0.50 
411 ± 
144 
≥6 risk 
alleles 
26.9 ± 
4.6 
92.4 
± 
13.1 
0.88 ± 
0.10 
124 ± 11 75.8 ± 7.7 5.54 ± 1.15 1.53 ± 
0.34 
3.76 ± 
1.02 
1.27 ± 
0.64 
5.10 ± 
0.34 
30.8 ± 
22.7 
1.16 ± 
0.92 
417 ± 
185 
P value 0.335†* 0.913 0.947 0.435 0.870 0.309 0.928 0.350 0.142 0.714 0.634* 0.711* 0.784 
 
Values are given as mean ± standard deviation  
P values for differences between ≤3 and ≥4 risk alleles were obtained using linear regression model adjusted for age, BMI, ethnicity and sex 
† P values were obtained by using a general linear model adjusted for age, ethnicity and sex 
*P values were based on the log transformed values 
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Table 37: Changes in anthropometric traits and fasting biochemical traits after dietary intervention over 16 weeks according to the B12-
GRS 
B12-GRS 
SFA diet 
P association 
MUFA diet 
P 
association 
n-6 PUFA diet 
P association P interaction 
 
≤3 risk 
alleles 
 
≥ 4 risk 
alleles 
≤ 3 risk 
alleles 
 
≥ 4 risk 
alleles  
≤ 3 risk 
alleles 
 
≥ 4 risk 
alleles  
Log BMI (kg/m2) 
-0.00 ± 
0.01 
-0.00 ± 
0.01 0.479 † 
0.01 ± 
0.01 
0.01 ± 
0.01 0.530† 
0.00 ± 
0.01 
0.00 ± 
0.01 0.135† 0.900†† 
WC (cm) 
-0.66 ± 
4.99 
-1.11 ± 
3.44 0.770 
-1.91± 
2.88 
-1.51 ± 
3.18 0.545 
-0.43 ± 
2.32 
-0.08 ± 
3.79 0.881 0.798 
WHR 
1.26 ± 
4.29 
-1.57 ± 
3.97 0.115 
-1.87 ± 
4.36 
-0.66 ± 
4.03 0.354 
0.03 ± 
3.78 
0.11 ± 
4.48 0.978 0.166 
24 h Ambulatory systolic blood 
pressure (mm Hg) 
-1.80 ± 
8.32 
1.74 ± 
7.37 0.162 
-4.91 ± 
5.59 
-0.29 ± 
9.57 0.087 
-0.73 ± 
8.84 
1.41 ± 
8.64 0.424 0.822 
24 h Ambulatory diastolic blood 
pressure (mm Hg) 
-0.10 ± 
6.08 
1.48 ± 
4.32 0.156 
-1.82 ± 
4.69 
0.18 ± 
6.48 0.203 
-0.46 ± 
5.87 
-0.28 ± 
6.17 0.869 0.788 
Total cholesterol (mmol/L) 
0.41 ± 
0.64 
0.30 ± 
0.48 0.256 
-0.55 ± 
0.89 
-0.36 ± 
2.73 0.923 
-0.05 ± 
0.71 
-0.33 ± 
1.57 0.704 0.849 
HDL Cholesterol (mmol/L) 
0.64 ± 
2.01 
-0.22 ± 
1.39 0.085 
-0.02 ± 
0.15 
0.01 ± 
0.18 0.987 
0.50 ± 
1.89 
0.05 
±2.04 0.524 0.566 
LDL Cholesterol (mmol/L) 
-0.29 ± 
2.48 
0.54 ± 
1.58 0.392 
-1.28 ± 
3.30 
0.12 ± 
1.92 0.105 
0.14 ± 
3.61 
0.02 ± 
1.81 0.955 0.393 
TAG (mmol/L) 
-0.67 ± 
2.10 
0.34 ± 
1.41 0.123 
-0.01 ± 
0.42 
0.03 ± 
0.33 0.990 
-0.10 ± 
0.29 
-0.85 ± 
2.41 0.344 0.078 
286 
Glucose (mmol/L) 
-0.46 ± 
2.08 
-0.01 ± 
0.32 0.579 
0.05 ± 
0.33 
0.62 ± 
2.13 0.278 
-0.12 ± 
0.46 
-0.20 ± 
1.45 0.763 0.563 
Log Insulin (pmol/L) 
-0.09 ± 
0.28 
-0.01 ± 
0.21 0.098 
-0.01 ± 
0.09 
0.01 ± 
0.19 0.944 
0.02 ± 
0.21 
-0.03 ± 
0.16 0.605 0.331 
Log HOMA-IR 
-0.09 ± 
0.30 
-0.01 ± 
0.22 0.121 
-0.01 ± 
0.10 
0.02 ± 
0.21 0.966 
0.02 ± 
0.24 
-0.02 ± 
0.18 0.612 0.397 
vitamin B12 (ng/L) 
20.52 ± 
75.53 
-9.14 ± 
69.51 0.403 
-37.60 ± 
90.80 
-12.16 ± 
53.71 0.255 
-38.45 ± 
59.12 
-20.57 ± 
55.66 0.210 0.214 
 
P values for association between GRS and changes of means over 16 weeks with one of three diets were obtained by using general linear model 
adjusted for age, sex, BMI, and ethnicity. P values for interaction between genotypes and changes of means over 16 weeks of intervention with 
one of three diets were obtained by using general linear model adjusted for age, sex, BMI, and ethnicity. Values are mean ± SD  
† P values for association between GRS and changes of means over 16 weeks with one of three diets were obtained by using general linear 
model adjusted for age, sex and ethnicity. 
†† P values for interaction between GRS and changes of means over 16 weeks of intervention with one of three diets were obtained by using 
general linear model adjusted for age, sex and ethnicity. 
Abbreviations: BMI body mass index, HDL high- density lipoprotein, HOMA-IR homeostasis model assessment—insulin resistance, LDL- low- 
density lipoprotein, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, SFA saturated fatty acids, TAG triacylglycerol, WC 
waist circumference, WHR waist to hip ratio 
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Table 38: Changes in anthropometric traits and fasting biochemical traits after dietary intervention over 16 weeks according to the 
metabolic-GRS 
 
Metabolic-GRS 
SFA diet 
P association 
MUFA diet 
P 
association 
n-6 PUFA diet 
P 
association 
P 
interaction 
≤ 5 risk 
alleles 
≥ 6risk 
alleles 
≤ 5 risk 
alleles 
≥ 6 risk 
alleles 
≤ 5 risk 
alleles 
≥ 6 risk 
alleles 
Log BMI (kg/m2) 
-0.00 ± 
0.01 
0.00 ± 
0.01 0.843 † 0.01 ± 0.01 0.01 ± 0.01 0.780 † 0.00 ± 0.01 0.00 ± 0.01 0.241 † 0.569 † † 
WC (cm) 
-0.95 ± 
3.77 
-0.94 ± 
4.34 0.404 
-1.60 ± 
3.21 
-1.74 ± 
2.89 0.812 
-0.15 ± 
2.71 
-0.29 ± 
4.09 0.656 0.937 
WHR 
-0.55 ± 
4.79 
-0.79 ± 
3.58 0.311 0.15 ± 4.55 
-2.56 ± 
2.91 0.251 
-0.52 ± 
3.62 0.95 ± 4.88 0.094 0.168 
24 h Ambulatory systolic blood 
pressure (mm Hg) 
-0.11 ± 
8.03 
1.60 ± 
7.49 0.409 1.63 ± 7.33 
-7.00 ± 
7.95 0.007 
-0.56 ± 
8.61 1.92 ± 8.74 0.475 0.012 
24 h Ambulatory diastolic blood 
pressure (mm Hg) 
-0.06 ± 
4.70 
2.27 ± 
4.94 0.348 1.05 ± 6.01 
-2.79 ± 
5.19 0.115 
-1.31 ± 
5.69 0.64 ± 6.27 0.415 0.069 
Total cholesterol (mmol/L) 0.29 ± 0.45 
0.38 ± 
0.61 0.102 
-0.48 ± 
2.75 
-0.33 ± 
0.71 0.947 
-0.43 ± 
1.61 0.09 ± 0.55 0.081 0.781 
HDL Cholesterol (mmol/L) 0.44 ± 1.65 
-0.297 ± 
1.59 0.206 0.03 ± 0.13 
-0.07 ± 
0.21 0.079 0.29 ± 2.52 0.09 ± 0.26 0.874 0.541 
LDL Cholesterol (mmol/L) 0.20 ± 2.77 
0.34 ± 
0.54 0.400 0.30 ± 2.16 
-1.63 ± 
2.76 0.056 
-0.01 ± 
2.47 0.17 ± 2.78 0.960 0.153 
TAG (mmol/L) 0.53 ± 1.67 
-0.44 ± 
1.62 0.071 
-0.04 ± 
0.41 0.12 ± 0.21 0.354 
-0.31 ± 
1.57 
-1.01 ± 
2.45 0.209 0.201 
288 
Fasting blood glucose (mmol/L) 
-0.04 ± 
0.31 
-0.25 ± 
1.61 0.862 
-0.08 ± 
0.20 1.39 ± 2.79 0.024 0.04 ± 0.42 
-0.51 ± 
1.82 0.347 0.006 
Log fasting Insulin (pmol/L) 
-0.05 ± 
0.24 
-0.01 ± 
0.22 0.967 0.02 ± 0.19 
-0.02 ± 
0.12 0.532 
-0.00 ± 
0.20 
-0.02 ± 
0.16 0.950 0.785 
Log HOMA-IR 
-0.06 ± 
0.26 
-0.02 ± 
0.23 0.926 0.03 ± 0.20 
-0.02 ± 
0.13 0.441 0.00 ± 0.22 
-0.02 ± 
0.18 0.822 0.833 
Vitamin B12 (ng/L) 
-14.17 ± 
52.66 
0.08 ± 
38.51 0.437 
-21.29 ± 
88.03 
-54.61 ± 
59.53 0.072 
-17.84 ± 
69.06 
-2.40 ± 
91.26 0.544 0.533 
 
P values for association between GRS and changes of means over 16 weeks with one of three diets were obtained by using general linear model 
adjusted for age, sex, BMI, and ethnicity. P values for interaction between genotypes and changes of means over 16 weeks of intervention with 
one of three diets were obtained by using general linear model adjusted for age, sex, BMI, and ethnicity. Values are mean ± SD  
† P values for association between GRS and changes of means over 16 weeks with one of three diets were obtained by using general linear 
model adjusted for age, sex and ethnicity. 
†† P values for interaction between GRS and changes of means over 16 weeks of intervention with one of three diets were obtained by using 
general linear model adjusted for age, sex and ethnicity. 
Abbreviations: BMI body mass index, HDL high- density lipoprotein, HOMA-IR homeostasis model assessment—insulin resistance, LDL low- 
density lipoprotein, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, SFA saturated fatty acids, TAG triacylglycerol, WC 
waist circumference, WHR waist to hip ratio
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 At 16 weeks, after adjustment for age, sex, ethnicity and baseline BMI, a significant 
interaction between the metabolic-GRS and dietary intervention (SFA vs MUFA vs n-6 PUFA) 
on changes in 24 h ambulatory systolic blood pressure (Pinteraction = 0.012) was observed (Table 
38 and Figure 18). Individuals with 6 or more risk alleles for the metabolic-GRS had 
significantly lower 24 h ambulatory systolic blood pressure levels after the MUFA (n = 13; -7 
± 8 mm Hg) compared with the SFA (n = 15; 2 ± 7 mm Hg; P = 0.033) and n-6 PUFA-rich 
diets (n = 16; 2 ± 9 mm Hg; P = 0.001) (Passociation= 0.009) (Table 38 and Figure 18).  
 
Figure 18: Mean (±SE) of changes in 24 h ambulatory systolic blood pressure following 
three intervention diets [rich in either saturated fatty acids (SFA), monounsaturated fatty 
acids (MUFA), and n-6 polyunsaturated fatty acids (PUFA)] according to the metabolic-
GRS (Pinteraction = 0.012).  
A general linear model analysis was performed with adjustments for age, sex, body mass index, 
and ethnicity. Individuals carrying ≥ 6 risk alleles had lower 24 h ambulatory systolic blood 
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pressure after consuming the MUFA diet compared to the SFA or n-6 PUFA diets (Passociation 
= 0.007). Error bars indicate Standard error. 
 In addition, we also observed an interaction between the metabolic-GRS and the dietary 
fat intervention (SFA vs MUFA vs n-6 PUFA) on changes in fasting glucose concentrations 
(Pinteraction = 0.006) (Table 38), where individuals with 6 or more risk alleles had significantly 
higher fasting glucose concentrations after the MUFA (n = 21; 1.39 ± 2.79 mmol/L) compared 
with the SFA (n = 26; -0.25 ± 1.61 mmol/L; P = 0.045) and n-6 PUFA-rich diets (n = 14; -0.51 
± 1.82 mmol/L; P = 0.045) (Passociation = 0.020). However, these interactions were not 
statistically significant after correction for multiple testing (Table 38).  
7.5 Discussion 
 To our knowledge, this is the first report to investigate the relationship between vitamin 
B12 concentrations and cardiometabolic traits, after replacing dietary SFA with MUFA or n-6 
PUFA in adults at moderate risk of CVD by using a genetic approach. Our findings from this 
retrospective analysis of the DIVAS study failed to show an impact of the B12-GRS on 
cardiometabolic traits in the presence of a dietary intervention manipulating fatty acid intake 
for 16 weeks. However, our analysis showed that individuals carrying 6 or more risk alleles 
(42.9% of the study population) of the metabolic-GRS had significantly lower 24 h ambulatory 
systolic blood pressure after the 16-week replacement of SFA with MUFA. Our findings 
indicate that the metabolic-GRS influences inter-individual variation in 24 h ambulatory 
systolic blood pressure and a 9.5% percentage replacement of SFA with MUFA could 
potentially be implemented as a dietary approach to reduce CVD risk in individuals at increased 
genetic risk.  
 The quantity and quality of fats consumed in the diet are important features that 
influence the risk of hypertension [482]. In a meta-analysis of 9 randomized controlled trials 
which examined the long-term effects (≥ 6 months) of a high-MUFA (>12%TE MUFA) vs 
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low-MUFA (≤12%TE MUFA) diet on markers of CVD risk, it was shown that high-MUFA 
diets significantly reduced systolic and diastolic blood pressures, compared with individuals 
consuming low-MUFA diets [483]. It is important to note that the studies included in the meta-
analysis had inconsistent total energy intakes, furthermore some of the studies compared high 
carbohydrate diets or high protein diets as the comparator, whereas others used high PUFA 
diets [483]. To date, twin studies have demonstrated the heritability of blood pressure to range 
between 39-63% [484], with lower estimates of heritability from the general population (20-
40%) [485]. Our retrospective data analysis demonstrated a significant interaction between 
metabolic-GRS and dietary fat composition on 24 h ambulatory systolic blood pressure in 
adults at moderate CVD risk, where the substitution of SFA with MUFA reduced 24 h 
ambulatory systolic blood pressure despite individuals carrying 6 or more risk alleles compared 
to the SFA and n-6 PUFA-rich diets. Our findings are also in line with previous 
epidemiological studies which have shown that blood pressure is positively correlated with 
high intakes of SFA [486-488] and that the replacement of SFA with n-6 PUFA may not be 
beneficial in reducing blood pressure [489, 490]. Hence, from interpreting our study findings 
it is possible that the replacement of 9.5% of SFA with MUFA might overcome the genetic 
risk of increased blood pressure. [491] MUFA-rich foods, such as oleic acid  (a major 
component of olive oil), have been implicated in lowering blood pressure by modifying 
membrane phospholipid composition and inducing hypotensive effects through the α2-
adrenergic receptor system in rats [492]. Animal studies have reported impaired endothelial 
vasodilator function [493] and an activation of sympathetic nervous system activities [494] in 
rats fed with SFA. It has been suggested that the detrimental effect of SFA on blood pressure 
might be secondary to a decrease in insulin sensitivity,   which is likely to have contributed to 
the activation of the sympathetic nervous system and the resulting blood pressure increase of 
these rats[494, 495]. However, the association between fasting plasma insulin and hypertension 
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have been inconsistent among human studies [496-498]. Linoleic acid, the primary form of 
dietary n-6 PUFA, has previously been shown to induce hypotensive effects and 
hyperpolarization of pig coronary artery vascular smooth muscle cells (VSMC) through a 
mechanism which activates the Na+/K+-ATPase pump. The activation of the Na+/K+-ATPase 
pump alters the membrane potential of VSMC, leading to the relaxation of the coronary arteries 
[499]; but our analysis in humans at moderate risk of CVD was unable to confirm any beneficial 
effect of replacing  9.6% of SFA with n-6 PUFA on blood pressure. Our finding is in 
accordance with a recent systematic review based on five previous human epidemiological (n 
= 33,834), and four intervention studies (n = 483) which also reported conflicting evidence of 
the impact of n-6 PUFA-rich diets on blood pressure [490]. Hence, given the findings from 
our data analysis, it can be assumed that an increase in MUFA in the diet is likely to regulate 
systolic blood pressure among individuals carrying 6 or more risk alleles of the metabolic-
GRS, however, further analysis is required to confirm these findings.  
 Furthermore, the metabolic-GRS was found to modify the association between the 
MUFA rich diet and changes in fasting glucose concentrations. Among individuals consuming 
the MUFA rich diet, those carrying ≥ 6 risk alleles of the metabolic-GRS had a tendency for a 
greater increase in glucose concentrations after 16 weeks compared to individuals consuming 
an SFA or n-6 PUFA rich diet. Even though this contradicts the impact of MUFA on metabolic 
disease outcomes [491, 500], a recent meta-analysis of nine randomized controlled intervention 
trials (n = 1,547) also failed to identify any significant difference in fasting glucose 
concentrations when comparing high- (>12% of Total Energy Consumption) with low-MUFA 
diets (≤12% of Total Energy Consumption) [483]. Hence, MUFA-rich diets may not be 
beneficial in reducing glucose concentrations in individuals at genetic risk of developing 
metabolic disease-related outcomes. Unexpectedly, our data analysis indicated a significant 
reduction in fasting glucose concentrations after 16 weeks amongst those consuming a n-6 
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PUFA-rich or SFA-rich diet when they carried more than 6 risk alleles of the metabolic-GRS. 
However, these findings should be interpreted with caution, given the potentially negative 
effects associated with consuming a high SFA diet [501] and the complex role of factors 
influencing metabolic disease outcomes [502]. This finding was not considered statistically 
significant after correction for multiple testing; hence, further large studies are warranted to 
explore this gene-diet interaction. 
The present study has some limitations. Our data analysis showed an effect of the 
plasma vitamin B12-GRS in the opposite direction to what we expected, where an increased 
genetic risk of vitamin B12 deficiency was positively associated with increased fasting HDL 
cholesterol and decreased TAG at baseline. In addition, our analysis indicated a significant 
fasting glucose increasing effect amongst those replacing 9.5% of SFA with MUFA when they 
carried more than 6 risk alleles of the metabolic-GRS. In attempting to explain these 
discrepancies it is important to note that this study included six individuals who had vitamin 
B12 deficiency (< 200 ng/L), which could likely have influenced these outcomes. Furthermore, 
we were unable to see any associations of the B12-GRS with any of the other outcomes, which 
could be attributed to the small sample size of the study. In comparison to cross-sectional 
studies, randomized clinical trials are often limited by the sample size; in the DIVAS study, 
only 119 participants out of 195 consented for analysis of genetic data and thus the sample size 
for the analysis was limited. Importantly, our data analysis did not measure circulating 
concentrations of other vitamin B12 biomarkers, such as holo-transcobalamin (holoTC) or 
methylmalonic acid. Furthermore, the DIVAS study included an ethnically diverse population 
(Asian-7% and Black- 7%); however, to avoid population stratification, ethnicity was adjusted 
for in the analyses. Even after excluding other ethnic groups and only analysing Caucasian 
individuals, our findings still remained the same (data not shown). One of the main strengths 
of the DIVAS study was that it examined the effects of dietary fatty acid manipulation for a 
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long duration (16 wk) on vitamin B12 concentrations and cardiometabolic traits in a robust 
randomised controlled intervention study. Secondly, the dietary fat manipulation in this 
intervention study had minimal impact on other dietary components and total energy intake, 
effectively negating the confounding effect of these variables on the effects of the GRS on 
dietary response. 
In conclusion, our data analysis was able to show an interaction between the metabolic-
GRS and dietary fat intake on 24 h ambulatory systolic blood pressure. The results suggest a 
greater sensitivity of individuals carrying 6 or more risk alleles (42.9% of the population) to 
dietary fat composition, with an 24 h ambulatory systolic blood pressure lowering effect 
observed following substitution of SFA with MUFA but not with n-6 PUFA. However, our 
analysis was unable to provide evidence for an impact of the B12-GRS on vitamin B12 
concentrations and cardiometabolic traits in response to the 16-week dietary fat intervention. 
Future studies with a larger sample size examining B12-GRS and metabolic-GRS, particularly 
prospectively genotyped dietary intervention studies, are required to confirm the gene-diet 
interactions identified in our study. 
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Chapter 8  
Discussion and conclusion 
8.1 Discussion 
The field of Nutrigenetics has been important in providing evidence for the interaction 
between genes and nutrients in the development of chronic diseases, such as obesity, insulin 
dysregulation and adverse cardiometabolic outcomes. The findings from this thesis has 
contributed to the field of nutrigenetics by demonstrating that genetic heterogeneity in gene-
diet interactions related to vitamin B12 concentrations and metabolic traits exist across 
different ethnic groups. The results in this thesis allow nutritionists to better understand how 
genetic variants related with B12 absorption and metabolism interact with dietary factors in the 
development of metabolic disorders. The field of nutrigenetics will one day allow nutritionists 
to provide personalised dietary recommendations to their patients based on their genotype in 
order to delay or prevent the development of diseases related to low vitamin B12 status. 
Although, several nutrigenetic studies have examined the interaction between genes and 
nutrition on chronic disease outcomes, the findings have yielded inconsistent results due to two 
main factors (i) genetic heterogeneity between individuals and (ii) small sample sizes with 
limited replication, hence, it has not been possible to develop a personalised diet for each ethnic 
group [12]. Up unto now it has been difficult to conduct nutrigenetic studies in less 
economically developed countries, due to the limited infrastructure, funding and expertise  
[12]. This thesis has set out to use a genetic approach to examine the association between 
selected common single nucleotide polymorphisms (SNPs) associated with vitamin B12 
concentrations and SNPs associated with metabolic traits on vitamin B12 concentrations and 
metabolic outcomes in different ethnic groups. Also, the interaction between these SNPs and 
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dietary factors (protein, carbohydrate and fat) on vitamin B12 concentrations and cardio-
metabolic traits was investigated.  
One of the reasons for examining different ethnic groups was to replicate the findings 
from one study into another independent cohort from another population. A total of three 
different study designs from five different populations [Brazilian adolescents, Sri Lankan 
adults, South Asian Indian adults, Indonesian adult women and British adults] were used to test 
our objectives. The studies included in this PhD were: one case-control study [Chennai Urban 
Rural Study (CURES; Asian Indian, n=900)], three cross-sectional cohort studies [Genetics of 
obesity and Diabetes study (GOOD study; Sinhalese Sri Lankan adults, n=109), The 
Minangkabau Indonesia Study on Nutrition and Genetics (MINANG study; Indonesian 
women; n=118) and Brazilian adolescents (n=113)] and a 16 week-dietary randomized, single-
blind, parallel-group dietary intervention [Dietary Intervention and VAScular function 
(DIVAS study; British adults, n=119)]. The general linear regression model was used for 
statistical analysis using the SPSS version 25, to conduct association and interaction analyses. 
Potential confounders such as age, sex and body mass index (BMI) were adjusted wherever 
necessary. A summary of the findings from this thesis is presented below.  
8.1.1 Impact of genes and diet on homocysteine, vitamin B12, folate and lipids in a 
Brazilian adolescent Population 
Cardiovascular diseases (CVD) have remained the leading cause of mortality in Brazil 
and are major causes of disability affecting the quality of life [328, 329]. Genes involved in the 
one carbon metabolism are of particular interest because of their role in CVD [355]. However, 
the interaction between SNPs involved in the one-carbon metabolism pathway and 
macronutrient intake on cardiovascular risk factors in the Brazilian population has not yet been 
investigated. The aim of this study was to examine the association of ten SNPs involved in the 
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one-carbon metabolism pathway [methylenetetrahydrofolate reductase (MTHFR)- rs1801133 
and rs1801131; 5-methyltetrahydrofolate-homocysteine methyltransferase or methionine 
synthase (MTR)- rs1805087 ; 5-methyltetrahydrofolatehomocysteine methyltransferase 
reductase or methionine synthase reductase (MTRR)- rs1801394; transcobalamin 2 (TCN2)- 
rs1801198, catechol-O-methyltransferase (COMT)- rs4680 and rs4633; betaine-homocysteine 
S-methyltransferase (BHMT)- rs3797546 and rs492842; and fucosyltransferase 2 (FUT2)-  
rs602662] with vitamin B12, folic acid, homocysteine and blood lipids [high- (HDL), low- 
(LDL) density lipoproteins, triacylglycerol (TAG) and oxidized-LDL (ox-LDL)], and to 
investigate whether lifestyle factors (dietary factors/physical activity levels) modified the 
association of the SNPs in 113 Brazilian adolescents (aged 10-19 years) with cardiovascular 
risk. 
 The results of this study confirm the association of the fucosyltransferase 2 (FUT2) 
SNP rs602662 with vitamin B12. Additionally, associations were observed between the SNP 
rs4633 at the catechol-O-methyltransferase (COMT) gene with folic acid concentrations and 
finally the SNP rs1801394 at the 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase (MTRR) gene with ox-LDL concentrations. No gene-lifestyle interactions were 
observed on vitamin B12 concentrations. Additionally, none of the vitamin B12 associated 
SNPs interacted with lifestyle factors to influence cardio-metabolic outcomes.  
This study provided evidence for the interactions between COMT SNP rs4680 and 
carbohydrate intake on ox-LDL levels and the FUT2 SNP rs602662 and protein intake on 
homocysteine concentrations. However, upon stratification of participants based on their 
consumption of dietary carbohydrate/protein (low, medium and high intake), no statistically 
significant associations between the SNPs and the outcomes in any of the tertiles were detected, 
which could potentially be due to the small sample size. This is the first study to provide novel 
gene-diet interactions at the COMT and FUT2 gene loci, on ox-LDL and homocysteine 
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concentrations; hence, we have no other studies to compare our findings with. Given that ox-
LDL and homocysteine are well-known independent risk factors for cardiovascular disease 
[24, 354], our findings may have significant public health implications. However, it is 
important to note that after correction for multiple testing, none of these associations and 
interactions were statistically significant.  
The main strength of this study is that SNPs were examined on vitamin B12, folic acid, 
homocysteine and lipid traits during early stages of life when lifestyle and behavioral factors 
have had less time to substantially modify the phenotype and hence, this study on Brazilian 
adolescents has significant importance. Furthermore, this study population is characterized by 
obesity and/or dyslipidemia which make it suitable for a study on lipids. Additionally, little is 
known about gene–diet interactions which influence ox-LDL concentrations, and thus our 
study adds to the limited body of research. After correction for multiple testing, none of the 
SNP–environment interactions were detected. Hence, our findings warrant confirmation in 
larger and well-powered prospective studies, before any public health recommendations can 
be developed for the adolescent Brazilian population. 
8.1.2 Impact of genes and diet on vitamin B12 concentrations and metabolic diseases 
in an Asian Sri Lankan population 
The prevalence of obesity in Sri Lanka has increased markedly in recent years [361], 
with approximately 34.4% of the Sri Lankan adult population being diagnosed as overweight 
or obese [361, 362]. Although, vitamin B12 deficiency has been linked to obesity [7, 84, 85] 
and diabetes [67, 69, 70], no study to date has tested the genetic link between metabolic traits 
and vitamin B12 status in a Sinhalese cohort. Furthermore, no study has investigated the status 
of vitamin B12 within the Sinhalese population. Hence, the objective of this study was to use 
a gene-based approach to explore the relationship between metabolic traits and vitamin B12 
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status in 109 Sinhalese adults (61 men and 48 women, aged 25-50 years), and to investigate 
whether these relationships were modified by lifestyle factors (dietary factors/physical activity 
levels).  
Genetic risk scores (GRS) based on ten metabolic disease-related genetic variants [Fat 
mass and obesity-associated (FTO)- rs9939609 and rs8050136, Melanocortin 4 Receptor 
(MC4R)- rs17782313 and rs2229616, Transcription factor 7-like 2 (TCF7L2)- rs12255372 and 
rs7903146, Potassium voltage-gated channel subfamily J member 11 (KCNJ11)- rs5219, 
Calpain 10 (CAPN10)- rs3792267, rs2975760 and rs5030952] and ten vitamin B12-related 
genetic variants [Methylenetetrahydrofolate reductase (MTHFR)- rs1801133, Carbamoyl-
phosphate synthase 1 (CPS1)- rs1047891, Cubulin (CUBN)- rs1801222, CD320 molecule 
(CD320)- rs2336573, Transcobalamin 2 (TCN2)- rs1131603, Citrate lyase beta like (CLYBL)- 
rs41281112, Fucosyltransferase 2 (FUT2)- rs602662, Transcobalamin 1 (TCN1)- rs34324219, 
Fucosyltransferase 6 (FUT6)- rs778805 and Methylmalonyl-CoA mutase (MUT)- rs1141321] 
were constructed. 
This study confirmed the association between the B12-GRS and serum vitamin B12 
concentrations. However, no association between the B12-GRS and metabolic traits were 
observed. Furthermore, the metabolic-GRS did not show any association with vitamin B12 
concentrations and metabolic traits. The findings in this study have suggested that a genetically 
lowered vitamin B12 concentration may have an impact on central obesity in the presence of a 
dietary influence (protein energy intake %). However, further stratification of participants 
based on their consumption (low, medium and high dietary intake) of dietary protein (energy 
%) did not show statistically significant associations between the GRS and the outcome in any 
of the tertiles, which could account for the small sample size. Additionally, the metabolic GRS 
interacted with carbohydrate energy intake (%) to influence waist to hip ratio levels, where 
individuals carrying more than 9 risk alleles had a higher waist-to-hip ratio among those in the 
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highest tertile of carbohydrate energy percentage. Given that the daily consumption of protein 
is low and carbohydrate intake is high in Sri Lankan adults [380], my findings may have 
significant public health implications in terms of revising dietary guidelines, which could 
prevent central obesity and its related CVD-related outcomes.  
 
8.1.3 Impact of genes and diet on vitamin B12 concentrations and metabolic diseases in 
an Indonesian women population (Minangkabau community) 
Optimal vitamin B12 status is essential for women to maintain adequate maternal health and 
to avoid foetal developmental complications [70, 434]. Additionally, low vitamin B12 
concentrations have shown negative correlations with body mass index (BMI) in healthy 
women [401]. Currently, the data on vitamin B12 status in healthy Indonesian women is 
unknown and the relationship between low vitamin B12 status and obesity related traits has 
yielded conflicting results [93]. Thus, I used a genetic approach to explore the relationship 
between metabolic traits and vitamin B12 status and investigated whether these relationships 
were modified by lifestyle factors (dietary intake or physical activity levels) in an Indonesian 
women population (117 adults, aged 25-60 years). The Minangkabau population from 
Indonesia was selected in this study on the basis that women hold a higher authoritarian role in 
society and that all food choices in the family are dictated by women [438].  
 Genetic risk scores (GRS) based on nine B12-related SNPs [Methylenetetrahydrofolate 
reductase (MTHFR)- rs1801133, Carbamoyl-phosphate synthase 1 (CPS1)- rs1047891, 
Cubulin (CUBN)- rs1801222, CD320 molecule (CD320)- rs2336573, Transcobalamin 2 
(TCN2)- rs1131603, Fucosyltransferase 2 (FUT2)- rs602662, Transcobalamin 1 (TCN1)- 
rs34324219, Fucosyltransferase 6 (FUT6)- rs778805 and Methylmalonyl-CoA mutase (MUT)- 
rs1141321] and nine metabolic disease-related SNPs [Fat mass and obesity-associated (FTO)- 
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rs9939609 and rs8050136, Melanocortin 4 Receptor (MC4R)- rs17782313 and rs2229616, 
Transcription factor 7-like 2 (TCF7L2)- rs12255372 and rs7903146, Potassium voltage-gated 
channel subfamily J member 11 (KCNJ11)- rs5219, Calpain 10 (CAPN10])- rs3792267 and 
rs5030952] were constructed.  
 This study replicated the non-significant findings observed in the Sri Lankan study and 
confirmed the lack of association between the B12-GRS and metabolic traits, and the 
metabolic-GRS with vitamin B12 and metabolic traits. However, unlike in the Sri Lankan 
study, the B12-GRS in the Indonesian population did not show any associations with B12 
concentrations, which could potentially be accounted to the higher mean vitamin B12 status 
observed in the Indonesian study (436 ± 427.18 pmol/L) compared to the Sri Lankan study 
(380.65  ± 132.83 pmol/L). In the Indonesian study, we observed a novel interaction between 
the B12-GRS and dietary fibre intake (g) on glycated haemoglobin. Individuals who consumed 
a low fibre diet (4.90 ± 1.00 g/day) and those who carried ≥9 risk alleles for vitamin B12 
deficiency had significantly higher HbA1C levels compared to those carrying ≤8 risk alleles. 
Previous studies have shown that dietary fibre consumption is low in the Indonesian 
population, and thus our findings are important as it could encourage a consumer education 
campaign centred around encouraging fibre intake to reduce HbA1C levels, which could 
improve glycaemic control in the Indonesian population.  
8.1.4 Impact of genes and diet on vitamin B12 concentrations and metabolic diseases 
in an Asian Indian population 
 Asian Indians exhibit a unique phenotype collectively known as the ‘South Asian 
Phenotype’ which consists of higher levels of total and visceral fat, higher waist circumference 
and an increased susceptibility to Type 2 diabetes [364]. Approximately >12% of the Indian 
population is either overweight or obese [390]. Although there is a strong genetic component 
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to developing the ‘South Asian Phenotype’, consuming an unhealthy diet and leading a 
sedentary lifestyle can further contribute to this phenotype [405, 408]. Several studies have 
implicated that obesity is related to many micronutrient deficiencies including vitamin B12 [6, 
395, 396]. 
Our study examined whether dietary intake and physical activity levels modified 
associations between a GRS using two previously studied FTO SNPs (rs8050136 and 
rs2388405) and vitamin B12 concentrations and metabolic disease-related outcomes in 900 
Asian Indians (300 normal glucose-tolerant individuals, 300 prediabetic and 300 type 2 
diabetes individuals). In this study, participants were randomly recruited from the Chennai 
Urban Rural Epidemiology Study (CURES), a cross-sectional case-control epidemiological 
study conducted on a representative population of Chennai in Southern India [410].  
 To date, the FTO (Fat mass and obesity associated) gene, has been the strongest obesity 
risk loci in several populations [11]. Our study confirmed the association between FTO gene 
variants and obesity traits. A novel finding of this study was the potential association between 
the FTO-GRS and vitamin B12 concentrations, after adjustment for age, sex, BMI and type 2 
diabetes. Carriers of more than one risk allele for the FTO-GRS had lower vitamin B12 
concentrations, compared to individuals carrying zero risk alleles. The mechanism explaining 
the differences in vitamin B12 concentrations in the FTO-GRS could potentially be due to the 
FTO genotypes modulating gut microbiota and inducing metabolic inflammation, consequently 
impairing B12 absorption [6, 432]. Interestingly, associations between obesity-related SNPs 
and vitamin B12 concentrations in other populations investigated in this thesis (Brazil, Sri 
Lanka, UK and Indonesia) were not observed. It is possible that these associations were not 
observed due to the following reasons [322]: (1) difference in effect allele frequencies, (2) 
genetic heterogeneity across different ethnic groups, (3) variance in linkage disequilibrium 
structure and (4) gene-gene and gene-environment interactions (5) Variations in sample sizes 
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of the study (6) number of metabolic-SNPs assessed. Additionally, no significant interactions 
were observed between the FTO-GRS and lifestyle factors (diet and physical activity) in the 
Indian population. 
 Given that low vitamin B12 concentrations in Asian Indians are common [397, 423] 
and that 28-44% of Asians carry at least one copy of the FTO risk allele [415], our study 
highlights the importance of considering obesity as a risk factor for vitamin B12 deficiency 
with implications on the possible targeting of relevant obesity prevention strategies. Following 
such advice could substantially reduce vitamin B12 deficiency among Asian Indians. 
8.1.5 Impact of genes and diet on vitamin B12 concentrations and cardio-metabolic 
diseases in a British population 
Given that the modification of dietary fat intake has been shown to affect vitamin B12 
status in a previous animal study [472], a post-hoc analysis of the Dietary Intervention and 
VAScular function (DIVAS) study was carried out with the aim of replicating similar findings 
in humans. In this study, I investigated whether vitamin B12- and metabolic disease-related 
genetic variants modified vitamin B12 concentrations and cardiometabolic traits in response to 
replacement of saturated fatty acids (SFA) with monounsaturated (MUFA) or n-6 
polyunsaturated (PUFA) fatty acids in British adults at 1.5-fold higher risk of CVD. Genetic 
risk scores (GRS) based on three vitamin B12 related tagSNPs [(FUT2)- rs602662, rs492602 
and rs16982241] representing the entire common genetic variations across the FUT2 gene were 
selected. Furthermore, seven metabolic disease-related genetic variants [(FTO)- rs8050136, 
rs9939609 and rs10163409, (MC4R)- rs17782313 and rs2229616 and (TCF7L2)- rs7903146 
and rs12255372] were constructed. 
No significant associations of the B12-GRS and metabolic-GRS with vitamin B12 
concentrations were observed within the participants. However, it should be noted that the 
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mean vitamin B12 concentrations were lower in participants who carried ≥4 risk alleles of the 
B12-GRS and ≥6 risk alleles of the metabolic-GRS. Our data analysis showed an effect of the 
B12-GRS in the reverse direction to what was expected, where an increased genetic risk of 
vitamin B12 deficiency was positively associated with increased fasting HDL cholesterol and 
decreased TAG at baseline, these findings were not replicated in other study populations which 
had used a different study design (cross-sectional) in my thesis (Brazil, Sri Lanka, India and 
Indonesia). Our findings from this retrospective analysis of the DIVAS study failed to show an 
impact of the B12-GRS on vitamin B12 concentrations and cardiometabolic traits in the 
presence of a dietary intervention manipulating fatty acid intake for 16 weeks. Furthermore, 
the post-hoc tests indicated no significant interactions between changes in vitamin B12 
concentrations and the three dietary groups with the metabolic-GRSs.  
Interestingly, the DIVAS study showed two novel interactions between the metabolic-GRS and 
the dietary fat intervention on metabolic traits. My study demonstrated that isoenergetically 
substituting a high SFA diet with a 9.5% replacement of MUFA had a significant effect on 
lowering ambulatory systolic blood pressure in individuals carrying 6 or more risk alleles 
(43.8% of the study population) of the metabolic-GRS. Additionally, our study indicated the 
metabolic-GRS modified the association between the MUFA-rich diet and changes in fasting 
glucose concentrations. Among individuals consuming the MUFA-rich diet, those carrying ≥ 
6 risk alleles of the metabolic-GRS had a tendency for a greater increase in glucose 
concentrations after 16 weeks compared to individuals consuming an SFA or n-6 PUFA rich 
diet. Further studies are warranted to confirm these results and investigate the mechanisms 
underlying the effect of these genes on blood pressure levels in response to replacing SFA with 
MUFA.  
8.1.6 General trends observed across the study population 
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Differences in macronutrients existed among the five groups studied in this thesis. In general, 
Sri Lankans and Indians had similar macronutrient intakes, whereas Minangkabau women from 
Indonesia had intakes like those of Brazilian adolescents. Carbohydrate intakes as a percentage 
of calories were higher among South Asians (Sri Lankan: 69.6 ± 8.8 % and Indian: 64.3 ± 6.3 
%) than the other groups (Brazil: 47.7 ± 20.6 %, Indonesian: 54.1 ± 9.4 % and British: 49.1 ± 
7.1%) (Table 39). The acceptable macronutrient distribution range (AMDR) for carbohydrate 
in adolescents (aged 14 and over) and adults is 45-65 percent of total energy [503]. The Sri 
Lankan population consumed carbohydrates above the AMDR. Furthermore, the Indian 
population was very close to the upper limit of the acceptable intake of carbohydrates. The 
British, Indonesian and Brazilian population were well within the AMDR for carbohydrate 
intake. The percent of calories from protein was highest among the Brazilian adolescent 
population (17.0 ± 8.4 %) and lowest among the South Asian populations (Sri Lankan: 11.3 ± 
2.3 % and Indian: 11.3 ± 1.1 %). British adults with moderate cardiovascular risk had the 
highest total fat intakes as percentage of calories (34.1 ± 5.4 %), compared to the other 
populations studied (Brazil: 25.4 ± 13.2 %, Sri Lanka: 21.9 ±  5.3%, Indian: 23.8 ±  4.7 and 
Indonesian: 28.9 ±  8.0%) (Table 38). All of the populations in this thesis had macronutrient 
intakes within the AMDR for protein (10-35%) and fat (20-35%) intake [503]. 
 Aspects of the sampling strategy could have affected our comparisons between the five 
groups. Firstly, we did not examine age differences between macronutrient intakes. The 
Brazilian population included only adolescents, whereas in the Sri Lankan population adults 
up to the age of fifty years were included. The Indian, Indonesian and British populations all 
included adults over the age of fifty. It is important to note, that the younger populations are 
more likely to adopt new dietary patterns, as opposed to older populations, making it easier to 
propose dietary advice. Indian adults were sampled in both urban and rural areas, whereas the 
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MINANG study was conducted in a rural area. Further to this, the DIVAS, GOOD and 
Brazilian population were conducted in urban areas.  More future studies, which look at both 
rural and urban populations are needed, as well as controlling for potential confounders such 
as socio-economic factors [504]. Furthermore, the studies did not report what days of the week 
sampling took place. It is important to note, that the nutrient intake in the weekend may vary 
in comparison to the weekdays [505]. 
 The highest levels of insufficient physical activity (<600 MET mins/week using the 
GPAQ) were reported in the CURES study (82.0%), whereas the lowest levels of insufficient 
physical activity levels were reported in the Brazilian adolescent population (31%) (Table 39). 
There are many limitations, which act to limit the generalisability of the physical activity levels 
including: the sample size of the cohort and the inclusion of cohorts with high-risk (DIVAS, 
CURES and the Brazilian population). Additionally, there are inter-cultural differences that 
exist between how ‘moderate’ and ‘vigorous’ physical activity is reported [506]. In the future, 
physical activity should also be measured with the combined use of a piezoelectric pedometer 
and accelerometer, instead of relying on subjective measures.   
 The observations described in this analysis both confirm previous findings and offer 
new-light on population-based differences in vitamin B12 levels. Compared with the 
Indonesian population, South Asians demonstrated lower vitamin B12 concentrations. 
Although the Brazilian adolescent population had indicators of cardiovascular risk, higher 
vitamin B12 concentrations were observed in this population compared with healthy 
participants from the Indian and Sri Lankan population. Furthermore, the lowest levels of 
vitamin B12 across the five populations in this study was from the DIVAS study (Table 39), 
which could be accounted by the populations older age group. It is difficult to generalise these 
findings, as some of the populations included cohorts at risk of disease and furthermore the 
sample size of the population was limited.
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Table 39: Macronutrient Intakes, Biochemical and physical activity levels: A Comparison of the Brazilian, GOOD, CURES, MINANG 
and DIVAS studies 
 
Brazil 
(N=113)a 
Sri Lanka GOOD 
study (n=109) 
India CURES study 
(n=548) 
Indonesia 
MINANG study 
(n=117)b 
DIVAS (n=119)c 
Macronutrient 
Protein (%) 17.0 ± 8.4 11.3 ± 2.3 11.3 ± 1.1 16.9 ± 3.3 15.6 ± 2.9 
Carbohydrate (%) 47.7 ± 20.6 69.6 ± 8.8 64.3 ± 6.3 54.1 ± 9.4 49.1 ± 7.1 
Fat (%) 25.4 ± 13.2 21.9 ± 5.3 23.8 ± 4.7 28.9 ± 8.0 34.1 ±  5.4 
Total Fibre (g) N/A 16.8  ± 8.2 32.2 ± 11.3 8.8 ± 4.5 N/A 
Total energy (Kcal/day) 2522 ± 586 2098  ± 456 2597 ± 773 1774 ± 609 2148 ± 572 
Anthropometric  
Age (yrs) 14 ± 2 38 ± 7 49.39 ± 11.45 40 ± 10 47 ± 9 
BMI (kg/m2) 24.0 ± 4.9 24.6 ± 4.1 26.75 ± 5.04 25.1 ± 4.2 26.4 ± 4.0 
WHR N/A 0.92 ± 0.11 0.90 ± 0.09 N/A 0.87 ± 0.09 
Fat (%) N/A 27.25 ± 7.37 N/A 35.70 ± 7.00 N/A 
24 h Ambulatory Systolic 
BP (mm Hg) 
N/A 120 ± 15 129 ± 20 113 ± 9 122 ± 11 
24 h Ambulatory diastolic 
BP (mm Hg) 
N/A 75 ± 16 80 ± 12 77 ± 6 75 ± 8 
Biochemical  
Vitamin B12 (pg/ml) 520 ± 232 516  ± 180 417 ± 255  591 ± 579 414 ± 162 
Homocysteine (μmol/l) 7.04 ± 2.99 N/A 13.67 ± 8.09 N/A N/A 
Folic acid (ng/ml) 11.02 ± 3.27 N/A 8.59 ± 5.81 N/A N/A 
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Triacylglycerol (mg/dl) 94.05 ± 54.16 144.19 ± 86.81 146.54 ± 116.88 97.67 ± 42.80 114.16 ± 53.10 
HDL (mg/dl) 46.29 ± 11.79 42.56 ± 8.24 40.89 ± 8.85 58.99 ± 10.20 59.46 ± 13.90 
LDL (mg/dl) 90.28 ± 21.00 134.03 ± 28.60 114.37 ± 35.56 127.77 ± 39.17 146.72 ± 37.84 
VLDL (mg/dl) 18.85 ± 10.82 28.84 ± 17.36 N/A N/A N/A 
Oxidized-LDL (U/L) 6.42 ± 13.69 N/A N/A N/A N/A 
Fasting plasma glucose 
(mg/dl) 
N/A 86  ± 13 116 ± 49 92 ± 20 92 ± 8 
Fasting serum insulin 
(μIU/ml) 
N/A 9.9 ± 7.2 9.23 ± 6.25 32959  ± 26327 4.17 ± 2.52 
Glycated Haemoglobin 
(%) 
N/A 5.4 ± 0.5 6.5 ± 1.7 N/A N/A 
Physical activity levels 
(%) 
 
Low 31 72.5 82.0 39.3 N/A 
Medium 69 19.3 16.2 49.6 N/A 
High 8.3 1.8 11.1 N/A 
aChildren with risk factors for cardiovascular disease were included  
bWomen were included for analysis 
cAdults with moderate risk factors for cardiovascular disease were included 
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Several genetic loci have supported the presence of ethnic differences for metabolic 
traits and vitamin B12 status within the populations studied in this thesis. The FTO rs8050136 
genotype is an example of genetic heterogeneity according to race. The minor allele ‘A’ of the 
SNP rs8050136 was present in 13% of Indian participants vs 23% Indonesian participants 
(Table 40). Although India and Sri Lanka are geographically close, the minor allele was more 
frequent in the Sinhalese population (34%). Furthermore, the prevalence of the rs8050136 
minor allele in the British DIVAS population (42%) was the most prevalent in the population, 
and was in agreement with previous reported values for the Caucasian population 
(https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?do_not_redirect&rs=rs8050136).  
 The FUT2 SNP  rs602662 is one of the most commonly studied variant related to 
vitamin B12 status. The rs602662 SNP is an example of a B12 SNP that has demonstrated 
ethnic specificity, for example, within the Indonesian population the minor allele frequency 
was extremely low (0.03%) in comparison to the DIVAS (46%), GOOD (31%) and Brazilian 
population (41%). Although no genotyping errors were identified, the SNP rs602662 did not 
reach HWE within the Indonesian and Sri Lankan populations (Table 40). It is possible that 
the Hardy-Weinberg equilibrium is not met in South Asian / South East Asian populations. An 
alternative reason could be that the HWE was not reached in these populations, due to the small 
sample size and the possibility of interbreeding (especially as consanguineous marriages are 
common in these populations). 
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Table 40: Genotype frequencies: A Comparison of the Brazilian, GOOD, CURES, MINANG and DIVAS studies 
 
Gene rs number 
Major 
allele 
Minor 
allele 
Common 
Homozygotes  (%) 
Heterozygotes 
(%) 
Rare 
Homozygotes  (%) 
Minor 
allele 
frequency 
HWE ethnicity 
FTO 
rs8050136 C A 291 (75.2) 90 (23.5) 6 (1.6) 0.13 0.749 India 
rs8050136 C A 69 (60.0) 39 (33.9) 7 (6.1) 0.23 0.638 Indonesia 
rs8050136 C A 40 (33.9) 57 (48.0) 21 (17.8) 0.42 0.929 British 
rs8050136 C A 48 (44.0) 47 (43.1) 14 (12.8) 0.34 0.641 Sri Lanka 
rs2388405 T C 342 (83.6) 62 (15.2) 5 (1.2) 0.09 0.259 India 
rs9939609 T A 70 (60.3) 39 (33.6) 7 (6.0) 0.23 0.618 Indonesia 
rs9939609 T A 41 (34.5) 57 (47.9) 21 (17.6) 0.42 0.877 British 
rs9939609 T A 48 (44.0) 47 (43.1) 14 (12.8) 0.34 0.641 Sri Lanka 
MC4R rs17782313 T C 89 (76.1) 26 (22.2) 2 (1.7) 0.13 0.949 Indonesia 
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rs17782313 T C 70 (59.8) 38 (32.5) 9 (7.7) 0.24 0.243 British 
rs17782313 T C 48 (44.0) 50 (45.9) 11 (10.1) 0.33 0.700 Sri Lanka 
rs2229616 G A 116 (99.1) 1 (0.9) 0 (0.0) 0.00 0.963 Indonesia 
rs2229616 G A 113 (95.0) 6 (5.0) 0 (0) 0.03 0.778 British 
rs2229616 G A 99 (91.7) 9 (8.3) 0 (0) 0.04 0.651 Sri Lanka 
TCF7L2 
rs12255372 G T 97 (82.9) 20 (17.1) 0 (0.0) 0.09 0.312 Indonesia 
rs12255372 G T 66 (55.9) 42 (35.6) 10 (8.5) 0.26 0.378 British 
rs12255372 G T 57 (52.3) 45 (41.3) 7 (6.4) 0.27 0.633 Sri Lanka 
rs7903146 C T 95 (81.9) 21 (18.1) 0 (0.0) 0.09 0.284 Indonesia 
rs7903146 C T 62 (52.1) 46 (38.7) 11 (9.2) 0.29 0.564 British 
rs7903146 C T 45 (41.3) 54 (49.5) 10 (9.2) 0.34 0.274 Sri Lanka 
KCNJ11 
rs5219 C T 55 (47.0) 47 (40.2) 15 (12.8) 0.33 0.329 Indonesia 
rs5219 C T 49 (45.0) 45 (41.3) 15 (13.8) 0.34 0.373 Sri Lanka 
CAP10 rs3792267 G A 108 (91.5) 9 (7.6) 1 (0.8) 0.05 0.123 Indonesia 
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rs3792267 G A 79 (72.5) 24 (22.0) 6 (5.5) 0.17 0.035 Sri Lanka 
rs5030952 C T 77 (66.4) 31 (26.7) 8 (6.9) 0.20 0.063 Indonesia 
rs5030952 C T 101 (92.7) 8 (7.3) 0 (0) 0.04 0.691 Sri Lanka 
rs2975760 T C 66 (60.6) 38 (34.9) 5 (4.6) 0.22 0.874 Sri Lanka 
MUT 
rs1141321 G A 67 (59.3) 40 (35.4) 6 (5.3) 0.23 0.993 Indonesia 
rs1141321 G A 28 (25.7) 60 (55.0) 21 (19.3) 0.47 0.271 Sri Lanka 
FUT6 
rs778805 T C 33 (28.2) 61 (52.1) 23 (19.7) 0.46 0.586 Indonesia 
rs778805 C T 29 (26.6) 53 (48.6) 27 (24.8) 0.49 0.776 Sri Lanka 
TCN1 
rs34324219 C A 117 (100) 0 (0.0) 0 (0.0) 0.00 N/A Indonesia 
rs34324219 C A 107 (98.2) 2 (1.8) 0 (0) 0.01 0.923 Sri Lanka 
FUT2 
rs602662 G A 111 (94.9) 4 (3.4) 2 (1.7) 0.03 0.000 Indonesia 
rs602662 G A 34 (28.6) 60 (50.4) 25 (21.0) 0.46 0.877 British 
rs602662 G A 34 (30.1) 52 (46.0) 24 (21.2) 0.45 0.625 Brazil 
rs602662 G A 60 (55.6) 30 (27.8) 18 (16.7) 0.31 0.000 Sri Lanka 
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rs492602 A G 38 (31.9) 58 (48.7) 23 (19.3) 0.44 0.918 British 
rs16982241 G A 91 (76.5) 26 (21.8) 2 (1.7) 0.13 0.928 British 
TCN2 
rs1131603 T C 117 (100) 0 (0.0) 0 (0.0) 0.00 N/A Indonesia 
rs1131603 T C 107 (98.2) 2 (1.8) 0 (0) 0.01 0.923 Sri Lanka 
rs1801198 G C 60 (53.1) 33 (29.2) 10 (8.8) 0.26 0.100 Brazil 
CD320 
rs2336573 C T 86 (74.1) 29 (25.0) 1 (0.9) 0.13 0.390 Indonesia 
rs2336573 C T 99 (90.8) 10 (9.2) 0 (0) 0.05 0.616 Sri Lanka 
CUBN 
rs1801222 C T 84 (74.3) 27 (23.9) 2 (1.8) 0.14 0.920 Indonesia 
rs1801222 C T 78 (72.2) 29 (26.9) 1 (0.9) 0.14 0.338 Sri Lanka 
CPS1 
rs1047891 C A 48 (41.0) 56 (47.9) 13 (11.1) 0.35 0.579 Indonesia 
rs1047891 C A 56 (51.9) 44 (40.7) 8 (7.4) 0.28 0.873 Sri Lanka 
MTHFR 
rs1801133 C T 92 (79.3) 24 (20.7) 0 (0.0) 0.10 0.214 Indonesia 
rs1801133 C T 89 (81.7) 19 (17.4) 1 (0.9) 0.10 0.990 Sri Lanka 
rs1801133 C T 55 (48.7) 41 (36.3) 12 (10.6) 0.30 0.310 Brazil 
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rs1801131 A C 56 (49.9) 43 (38.1) 13 (11.5) 0.31 0.293 Brazil 
CLYBL rs41281112 C T 105 (96.3) 4 (3.7) 0 (0) 0.02 0.845 Sri Lanka 
BHMT  
rs3797546 T C 67 (59.3) 27 (23.9) 7 (6.2) 0.20 0.081 Brazil 
rs492842 T C 35 (31) 43 (38.1) 27 (23.9) 0.46 0.071 Brazil 
COMT  
rs4680 G A 35 (31) 48 (42.5) 24 (21.2) 0.45 0.335 Brazil 
rs4633 C T 44 (38.9) 51 (45.1) 16 (14.2) 0.37 0.844 Brazil 
MTR rs1805087 A G 77 (68.1) 32 (28.3) 2 (1.8) 0.16 0.521 Brazil 
MTRR rs1801394 A G 45 (39.8) 49 (43.4) 16 (14.2) 0.37 0.655 Brazil 
 
Abbreviations: HWE Hardy-Weinberg equilibrium
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8.1.7 Limitations and strengths 
A major limitation to this thesis was that some of the studies had relatively small sample 
sizes; this may have affected our results by having a wider confidence interval. However, 
despite this limitation, we were still able to observe gene-diet interactions on vitamin B12 and 
cardio-metabolic disease outcomes. In this PhD project, most of the studies employed a cross-
sectional study design (Brazilian adolescents, CURES, GOOD, MINANG) which investigated 
the genetic effects at a single point in time, thus we were unable to examine the causal 
relationship between the SNP–diet interactions on vitamin B12 concentrations and metabolic 
traits. Furthermore, some of the studies might have introduced biases, including the inclusion 
of type 2 diabetes participants in the CURES study (selection bias); however, there was 
adjustment for diabetes status in the statistical analysis. The cross-sectional studies investigated 
gene-diet interactions; where the dietary component was based on macronutrient intake. 
However, no data on specific types of micronutrient was available, and this could have limited 
further potential gene-diet interactions from being observed. Furthermore, the data collected 
from FFQs and physical activity questionnaires, were based on self-reported data and this could 
have led to measurement bias. The data was limited in some of the studies, for example the 
GOOD, MINANG and DIVAS studies did not investigate folate or homocysteine 
concentrations in their participants. Additionally, none of the studies investigated other vitamin 
B12 biomarkers, such as Holo-transcobalamin (holoTC) or Methylmalonic Acid (MMA), 
which have been shown to have greater sensitivity for vitamin B12 status.  
The main strengths of this thesis were that different study designs were employed 
(cross-sectional and intervention) to confirm the observed findings. Three of the cross-sectional 
studies used FFQs (CURES, GOOD, MINANG) [368, 411, 440] that were validated to measure 
long-term macronutrient intake of the population. Vitamin B12 status has not been previously 
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reported in healthy Indonesian women and Sri Lankan adults, thus this thesis was the first to 
investigate vitamin B12 status in Sri Lanka and Indonesia (women only). Further to this, four 
of the studies (CURES, GOOD, MINANG and DIVAS) calculated genetic risk scores (GRS) 
for the risk of vitamin B12 deficiency and cardio-metabolic related traits. The benefits of using 
a GRS as opposed to using a single gene, is that GRS can increase the statistical power of the 
study [387] and can provide better information for disease association compared to the single 
SNPs. The use of the tagging approach allowed me to select three tagSNPs representing the 
entire common genetic variations across the FUT2 gene in the DIVAS study. Furthermore, my 
thesis was the first to report gene-diet interactions on vitamin B12 concentrations and metabolic 
traits in Sri Lanka and Indonesia.  
8.2 Conclusion 
In conclusion, my research identified novel interactions between the B12-GRS and 
dietary factors (protein intake and fibre intake) on central obesity indicators within the Sri 
Lankan and Indonesian populations. Furthermore, the B12-related SNP FUT2 rs602662 
showed a significant interaction with protein intake on homocysteine concentrations (a marker 
of cardiovascular disease) in the Brazilian adolescent population. However, no gene-lifestyle 
interactions on cardio-metabolic outcomes were observed in the British population. Given that 
high fibre and protein diets are recommended for preventing metabolic disease outcomes [460] 
[449], the gene-diet interaction findings observed in my study will have significant public 
health implications, where people carrying risk alleles for vitamin B12 deficiency could be 
advised to alter their diet according to their ethnic background. Interestingly, in the Indian 
population, I found the relationship between vitamin B12 and obesity in the other direction to 
what was observed in the Indonesian, Brazilian and Sri Lankan populations. In the CURES 
Indian study, I found that being genetically predisposed to obesity could in fact lower vitamin 
B12 concentrations, without influence from dietary factors. Ultimately, the findings in this 
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thesis contribute to a better understanding of how genetic variants related to B12 absorption 
and metabolism interacts with lifestyle factors in the progression of metabolic traits (Figure 
19).  
Replications of the findings from this thesis require confirmation from studies with a 
larger population size and must include individuals from different ethnic groups. It is important 
that more randomized controlled trials are carried out in the future, to identify the cause and 
effect of a dietary intervention on a metabolic outcome (based on an individual’s genotype). 
Furthermore, it is important that prospective genotyping is carried out to prevent any issues 
related to having an unbalance in genotype groups, which could confound the results. This 
thesis only addressed vitamin B12 concentrations, and only two of the studies in this thesis 
(Indian and Brazilian) studied folate and homocysteine levels, therefore there is a need to take 
these risk factors into consideration in order to implement dietary strategies to prevent the 
metabolic disease-related outcomes. One of the benefits of this thesis was the use of genetic 
risk scores to provide evidence for the genetic effects of the phenotypes observed and this 
increased the statistical power of our study. It is important that future nutrigenetic studies utilize 
a comprehensive panel of SNPs associated with vitamin B12 or metabolic disease related traits 
to calculate a genetic risk score. 
 In conclusion, my study has demonstrated significant interactions between the B12-
GRS and dietary intake on metabolic traits. However, these gene-diet interactions require 
replication in an independent cohort utilizing a larger number of samples and functional studies 
to understand the role of these interactions at the molecular level are highly warranted before 
implementing personalised nutrition strategies to overcome the burden of metabolic diseases. 
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Figure 19: The main study findings of this thesis 
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8.3 Future prospects 
 In this thesis, I found that the relationship between B12 deficiency and metabolic 
outcomes may be influenced by dietary factors such as protein and fibre intake. It is important 
that the gene-diet interactions observed in this thesis are replicated, before public health 
recommendations can be enforced. Also, it is important to further investigate whether people 
with increased weight require more B12 containing foods, for the possibility of implementing 
B12 deficiency screening programmes in the population. If low vitamin B12 concentrations 
stimulate metabolic diseases through a dietary influence, it is important that mechanistic studies 
are carried out to determine how vitamin B12 interacts with adipose tissue metabolism or how 
epigenetic mechanisms contribute to the epidemic of metabolic diseases. Current literature 
suggests that the genetic profile of an individual can shape the microbiome of the host, and an 
altered gut flora has been associated with vitamin B12 deficiency [14, 264]. This possibly 
requires investigation, given the known link between an altered distribution in gut microbiota 
and obesity. 
 In the future, validation of the findings of this thesis will be carried out by replicating 
the study in a cohort with an increased sample size and power. Moreover, it is difficult to truly 
isolate the macronutrient accountable for any nutrigenetic effects, especially for fat and 
carbohydrates, as one macronutrient usually compensates the other [507]. Therefore, dietary 
intervention studies are more favourable as they place strong emphasis on compliance to the 
dietary exposure. Dietary intervention studies have the potential to avoid measurement bias 
found within FFQs and to uncover relationships between SNPs, diet and metabolic traits. 
Additionally, longitudinal research studies are required to examine the causal relationship 
between the SNP–diet interactions on vitamin B12 concentrations and metabolic traits. Future 
studies should also measure specific dietary micronutrients for more in-depth gene-diet 
interactions to be carried out.   
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Future research should include more long-term, randomised controlled studies that 
robustly measure both body composition (e.g. dual-energy X-ray absorptiometry, magnetic 
resonance imaging and/or computed tomography scans) and body size (e.g. body weight or 
BMI) [93]. Additionally, investigating how different clinical outcomes associated with vitamin 
B12 deficiency is affected by B12 supplements at different doses is another area that requires 
attention. It is also necessary to study the effects of adiposity on vitamin B12 status across all 
body sizes and to measure vitamin B12 status using markers such as homocysteine, 
methylmalonic acid (MMA) and holotranscobalamin. Looking into groups that are more at risk 
of vitamin B12 deficiency, such as elderly individuals, pregnant women, vegetarians, other 
patient groups (e.g. Type 2 diabetes patients taking metformin medication), ethnic minorities 
and elite athletes must also be considered. 
 It is yet to be elucidated whether the relationship between vitamin B12 and cardio-
metabolic traits, can be modified in response to other dietary sources (e.g. fortified foods); such 
evidence will have important implications on setting dietary requirements in a clinical setting. 
Insights from this PhD thesis show promise for the use of personalised nutrition in the area of 
vitamin B12 and obesity, whereby certain vitamin B12-related SNPs may be used to predict an 
individual’s risk of developing metabolic traits and may be modified according to an 
individual’s lifestyle (dietary pattern/physical activity levels).  Nutrigenetic research is 
urgently required, given the importance of developing public health strategies to decrease the 
prevalence and impact of overweight and obesity.  
Although extraordinary improvements have been accomplished in identifying several 
gene-diet interactions, little is known about the underlying cardio-metabolic pathways of these 
gene-diet interactions [508, 509]. Nutrigenomics is an approach which explores the effect of 
specific nutrients on gene expression and their metabolic consequences [510]. The definition 
of nutrigenomics has further extended to ‘nutritional factors which protect the genome from 
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any damage’. Nutrigenomics focuses on the impact of dietary factors on the genome, proteome 
(the complete set of proteins expressed by an organism) and the metabolome (the total number 
of metabolites). Researchers are now able to demonstrate that certain nutritional interventions 
are positive in a select proportion of the population, whilst others show no effect, and some 
may act unfavourably [511]. This field of research, will ultimately help in understanding how 
the diet interacts with metabolic pathways and their role in diet-related diseases [512]. On the 
other hand, nutrigenetics explores the effect of genetic variation on the interaction between a 
particular diet and disease [513]. The role of nutrigenomics and nutrigenetics will help 
revolutionise our ability to design optimal dietary advice for health maintenance and for 
metabolic disease prevention [221]. Currently, a large gap exists between nutrition 
recommendations and an individual’s eating behaviour [514]. Population-based dietary advice, 
where a ‘one size fits all’ approach is given, has been relatively unsuccessful in benefitting the 
patient, due to a myriad of factors including: lack of motivation and failure of patient 
compliance [514]. Evidence now suggests that the use of genetic testing or personalised advice 
as a catalyst, can demonstrate behavioural changes in nutrition [515, 516].  
‘Foodomics’ approaches are becoming increasingly essential tools in preventative 
health care. This approach combine ‘omics’ (i.e. transcriptomics, proteomics, metabolomics) 
technologies  to prevent and treat non-communicable diseases [508]. The ‘Foodomics’ 
approach is used to help understand the gene-based differences among individuals in response 
to specific dietary patterns, and to identify the interactions of bioactive compounds from dietary 
components at a biochemical, molecular and cellular level [517]. An example of the foodomics 
approach was shown in the work of Valdes et al., who studied the effect of rosemary extracts 
on colon cancer cells, using multi-platform ‘omics’ analyses for clarifying the signalling and 
metabolic pathways involved in cancer progression [518].  
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Precision nutrition is another technique that aims to develop more comprehensive 
nutritional recommendations based on an individual’s internal and external environment [519]. 
This approach suggests that it is possible to understand the complex relationship between an 
individual and their food consumption, individuals physical activity level, their food behaviour, 
microbiota, metabolome and their phenotype (health status), in order to offer nutritional 
interventions/ advice which can benefit the individual [510, 519]. As a result, precision 
nutrition requires a greater degree of scientific certainty and replication studies, compared to 
the other methods [510]. 
The majority of studies assessing the link between genetic variation and disease risk 
have been studied in populations with European ancestry (78%). At present, there is a need to 
study more diverse ethnic groups, in order to translate our understanding of genetic disease 
architecture into clinical practice. At present, approximately 85% of the Genotype-Tissue 
Expression project study (examines the genes in tissues obtained from different people and 
studies how inherited changes in genes lead to common diseases) contains samples from 
European descent [207], again highlighting the need for more studies in minority populations. 
At present, the ability to study minority populations have been hindered, and this may be due 
to previous experiences of these populations being exploited/mistrusted in biomedical research 
[207]. In order to generate reliable phenotype data from diverse ethnic groups, it is important 
that less economically developed regions contain adequate funding, equipment for biochemical 
and genetic testing and experienced personnel [207]. 
 In summary, knowledge in the field of nutrigenetics holds a promising future in 
preventing the development of dietary-related chronic diseases. Although, there are many 
studies which show interactions between genes and lifestyle factors, there are inconsistences 
in the evidence given which may limit the application of nutrigenetics to the general public at 
present [514]. There is a need to utilize larger studies that are well-powered and that examine 
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lifestyle/dietary behaviours across various ethnic groups in order to implement personalised 
nutrition. 
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Chapter 9  
Appendices 
9.1 Research plan: The Influence of One‑carbon Metabolism Gene Polymorphisms 
and Gene–environment Interactions on Homocysteine, Vitamin B12, Folate 
and Lipids in a Brazilian Adolescent Population 
 
Main study objective: 
To determine whether 10 SNPs from seven selected candidate genes related to the one-carbon 
metabolism cycle were associated with vitamin B12, homocysteine, folic acid and lipid-related 
outcomes and whether these associations were modified by environmental factors (diet and 
physical activity). 
 1)To work out which genetic model to use for each SNP: additive, dominant or recessive 
2) To test the association between the 10 SNPs and folic acid levels 
3) To test the association between the 10 SNPs and Hcy levels 
4) To test the association between the 10 SNPs and vitamin B12 levels 
5) To test the interaction between the 10 SNPs and dietary factors on folate levels 
6) To test the interaction between the 10 SNPs and dietary factors on Hcy 
7) To test the interaction between the 10 SNPs and dietary factor on vitamin B12 levels 
Previous Studies looking at the association of the 10 SNPs with biochemical traits: 
Gene symbol SNP rs number Vitamin B12 Folate Hcy 
MTHFR  rs1801133  [520] [254, 520-522] 
MTHFR  rs1801131  [523, 524] [523] 
MTR rs1805087  [234]  
MTRR rs1801394  [234]  
TCN2 rs1801198 [285]   
COMT rs4680   [525] 
COMT rs4633   [338] 
BHMT rs492842   It is unknown whether 
this SNP is associated 
with Hcy, although 
previous studies have 
implicated associations 
between the BHMT gene 
and homocysteine. 
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BHMT rs3797546   It is unknown whether 
this SNP is associated 
with Hcy, although 
previous studies have 
implicated associations 
between the BHMT gene 
and homocysteine. 
FUT20 rs602662 [234, 254]   
 
 
Co-variates in this study: 
• Age will be coded according the two age ranges[341] : 
- (10-14 years) = Recoded as 0 
-(15-19 years) = Recoded as 1 
• Gender will be coded 0 (Male) or 1 (Female) [341] 
• BMI was estimated and classified according to the WHO (2007) for BMI/age 
according to gender and was coded  into 4 groups:[341] 
- below 15th percentile=below normal weight -> Recoded as 1 
- between 15th and 85th percentile= normal-weight -> Recoded as 2 
-between 85th and 97th percentile= overweight -> Recoded as 3 
- above 95th percentile=obese. -> Recoded as 4 
 
Plan of action: 
Objective 1: To work out which genetic model to use for each SNP: additive, dominant 
or recessive. 
Aims: Statistical test used: 1) Reason for statistical test used 
2) Outcome of statistical test used 
3) covariates (when appropriate) 
1a) To determine the 
frequencies of each 
of the genotypes, so 
that an appropriate 
genetic model can be 
selected. 
Descriptive 
statistics- 
Frequencies 
1) Reason for test:  exposure variables 
(SNPs)  are categorical variables 
2) To be given the frequencies of the 
common homozygous, heterozygous 
and rare homozygous genotypes. 
Therefore, an appropriate model can 
be given to the SNP: dominant, 
recessive or additive. As well as this, 
the minor allele frequency can be 
calculated. 
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Objective 2: To test the association between the 10 SNPs and Folic acid levels 
2a) Testing the 
association between 
each SNP and folic 
acid levels  
One-Way Anova; 
Post hoc Tukey 
1) Reason for test:  exposure variable (SNP) 
is a categorical variable and the outcome 
variable (folic acid) is a continuous variable.  
2) Outcome of test: Identifying the difference 
of folic acid levels between different 
genotypes (common, heterozygotes and 
rare).     
2b) Adjusting for 
covariates to check if 
the covariates 
influence the 
association between 
each SNP and folic 
acid levels 
Univariate linear 
regression   
1) Reason for test: exposure variable (SNP) 
is a categorical variable and the outcome 
variable (folic acid levels) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
the variants on folic acid levels 
3) Covariates to be adjusted: Age, gender, 
BMI [341]  
Objective 3: To test the association between 10 SNPs and Homocysteine levels (Hcy) 
3a) Testing the 
association between 
each SNP and Hcy 
levels  
One-Way Anova; 
Post hoc Tukey 
1) Reason for test: The exposure variable 
(SNP) is a categorical variable and the 
outcome variable (Hcy levels) is a 
continuous variable.  
2) Outcome of test: Identifying the difference 
of Hcy levels between different genotypes.      
3b) Adjusting for 
covariates to check if 
the covariates 
influence the 
association between 
each SNP and Hcy 
levels. 
Univariate linear 
regression   
1) Reason for test: exposure variable (SNP) 
is a categorical variable and the outcome 
variable (Hcy levels) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
the variants on Hcy levels 
3) Covariates to be adjusted: Age, gender, 
BMI [341] 
Objective 4:To test the association between the 10 SNPs and vitamin B12 (cbl) 
4a) Testing the 
association between 
each SNP and cbl 
levels  
One-Way Anova; 
Post hoc Tukey 
1) Reason for test:  exposure variable (SNP) 
is a categorical variable and the outcome 
variable (cbl levels) is a continuous variable.  
2) Outcome of test: Identifying the difference 
of cbl levels between different genotypes.      
4b) Adjusting for 
covariates to check if 
the covariates 
influence the 
association between 
each SNP and cbl 
levels 
Univariate linear 
regression   
1) Reason for test: exposure variable (SNP) 
is a category variable and outcome variable 
(cbl levels) is a continuous variable  
2) Outcome of test: identifying the impact of 
the variants on cbl levels 
3) Covariates to be adjusted: Age, gender, 
BMI [341] 
Objective 5: To test the association between the 10 SNPs and lipid concentrations 
(TAG, HDL-cholesterol, LDL-cholesterol, and ox-LDL) 
5a) Testing the 
association between 
One-Way Anova; 
Post hoc Tukey 
1) Reason for test:  exposure variable (SNP) 
is a categorical variable and the outcome 
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each SNP and each 
lipid concentration 
variable (each lipid concentration) is a 
continuous variable.  
2) Outcome of test: Identifying the difference 
of lipid concentrations between different 
genotypes.      
5b) Adjusting for 
covariates to check if 
the covariates 
influence the 
association between 
each SNP and each 
lipid concentration 
Univariate linear 
regression   
1) Reason for test: exposure variable (SNP) 
is a category variable and outcome variable 
(each lipid concentration) is a continuous 
variable  
2) Outcome of test: identifying the impact of 
the variants on lipid concentration. 
3) Covariates to be adjusted: Age, gender, 
BMI [341] 
Objective 6: To test the interaction between the 10 SNPs and dietary factors on Folic 
acid levels 
6a) Testing the 
interaction between 
the macronutrient 
and SNPs on folic 
acid levels  
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and the outcome 
variable (folic acid levels) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
the gene variants and the macronutrients: 
carbohydrate, protein and fat on folic acid 
levels. 
3) Covariates to be adjusted: Age, gender, 
BMI [341]. 
6b) Testing to find 
out if high or low 
macronutrients are 
causing the 
interaction 
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and outcome 
variable (Folic acid levels) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
gene variants and the consumption of 
different quantities of the macronutrient on 
folic acid levels 
3) Covariates to be adjusted: Age, gender, 
BMI.[341] 
(Data split based on tertiles of carbohydrate, 
protein and fat) [253] 
Objective 7: To test the interaction between the 10 SNPs and dietary factors on Hcy 
levels 
7a) Testing the 
interaction between 
the macronutrient 
and SNPs on Hcy 
levels  
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and the outcome 
variable (Hcy levels) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
the gene variants and the macronutrients: 
carbohydrate, protein, fat on folic acid levels. 
3) Covariates to be adjusted: Age, gender, 
BMI  [341]. 
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7b) Testing to find 
out if high or low 
macronutrients are 
causing the 
interaction 
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and outcome 
variable (Hcy levels) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
gene variants and the consumption of 
different quantities of the macronutrient on 
Hcy levels 
3) Covariates to be adjusted: Age, gender, 
BMI  [341]. 
(Data split based on: Tertiles of 
carbohydrate, protein and fat) [253] 
Objective 8: To test the interaction between the 10 SNPs and dietary factors on cbl 
levels 
8a) Testing the 
interaction between 
the macronutrient 
and SNPs on cbl 
levels  
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and the outcome 
variable (cbl levels) is a continuous variable. 
2) Outcome of test: identifying the impact of 
the gene variants and the macronutrients: 
carbohydrate, protein, fat on cbl levels. 
3) Covariates to be adjusted: age, gender, 
BMI [341] 
8b) Testing to find 
out if high or low 
macronutrients are 
causing the 
interaction 
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and outcome 
variable (cbl levels) is a continuous variable. 
2) Outcome of test: identifying the impact of 
gene variants and the consumption of 
different quantities of the macronutrient on 
cbl levels 
3) Covariates to be adjusted: Age, gender, 
BMI [341] 
(Data split based on tertiles of carbohydrate, 
protein and fat)[253] 
Objective 9: To test the interaction between the 10 SNPs and dietary factors on lipid 
concentrations (TAG, HDL-cholesterol, LDL-cholesterol, and ox-LDL) 
9a) Testing the 
interaction between 
the macronutrient 
and SNPs on lipid 
concentrations 
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and the outcome 
variable (lipid concentrations) is a 
continuous variable. 
2) Outcome of test: identifying the impact of 
the gene variants and the macronutrients: 
carbohydrate, protein, fat on lipid 
concentrations. 
3) Covariates to be adjusted: age, gender, 
BMI [341] 
9b) Testing to find 
out if high or low 
Univariate linear 
regression 
1) Reason for test: exposure variable (SNP) 
is a categorical variable and outcome 
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macronutrients are 
causing the 
interaction 
variable (lipid concentrations) is a 
continuous variable. 
2) Outcome of test: identifying the impact of 
gene variants and the consumption of 
different quantities of the macronutrient on 
lipid concentrations 
3) Covariates to be adjusted: Age, gender, 
BMI [341] 
(Data split based on: Tertiles of 
carbohydrate, protein and fat)[253] 
SPECIAL NOTES 
When looking at 
carbohydrates, 
proteins and fat in 
grams, you will need 
to adjust for Kcal. If 
you are using energy 
intake of the 
macronutrients you 
do not need to adjust 
for Kcal. 
Compute variables • For Carbohydrate interactions: 
1g of Carbohydrates = 4kcal 
• For Fat interactions: 
1g=9 kcal 
• For Protein interactions: 
1g= 4kcal [526] 
 When significant 
interactions with 
macronutrients are 
detected, further 
investigation will 
take place to 
underline the specific 
type of macronutrient 
responsible for the 
interaction.  
 
 
 
Univariate linear 
regression  
No subgroups of protein and carbohydrates 
were recorded in this data set. 
 
 
For fat interactions: 
• Test for interaction between SNPs 
with saturated fatty acid intake, SNPs 
with monounsaturated fatty acid 
intake and SNPs with 
polyunsaturated fatty acid intake. 
Tertiles will be made for each of 
these sub-groups. 
 
 After carrying out 
the interaction 
analysis using 
Univariate liner 
regression and 
obtaining P values, 
make sure any 
problems due to 
multiple 
comparisons are 
counteracted 
Bonferroni 
Correction 
1) This method adjusts for multiple 
comparison and reduces experiment-
wise error rate in genetic association 
studies[527] 
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9.2  Research plan – A genetic approach to examine the relationship between 
vitamin B12 status and metabolic traits in a South Asian population 
 
Main objectives: 
The purpose of this study is to use a genetic approach to explore the relationship between 
metabolic traits and vitamin B12 status in a Sri Lankan population and to investigate whether 
these relationships were modified by dietary intake.   
 
Hypothesis: 
I will test the hypotheses that low plasma vitamin B12 concentrations caused by genetic 
variants are associated with an increased risk of obesity and type 2 diabetes, and that the effect 
of genetic variants associated with high BMI on obesity traits is partly mediated through the 
reduction of serum vitamin B12 concentration. The latter hypothesis requires that genetically 
increased obesity traits are associated with low vitamin B12 concentration and with increased 
risk of diabetes/obesity traits. 
 
Specific aims: 
 
 
 
 
Diagram representing the study design. The diagram shows four possible associations, and 
four possible interactions. One-sided arrows with unbroken lines represent genetic 
associations and one-sided arrows with broken lines represent interactions between a lifestyle 
factor and GRS on serum vitamin B12/ metabolic traits.   
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1. I will test the association between the metabolic-GRS and vitamin B12 concentrations 
and metabolic disease-related traits.  
2. I will then test the associations between the B12–GRS and vitamin B12 status and 
metabolic disease related traits.  
3. Lastly, I will test whether these genetic associations are modified by lifestyle factors 
(macronutrient intake and physical activity levels).  
 
 
Previous Studies looking at the association of the 10 B12-related SNPs with vitamin B12 
concentrations: 
Gene rs number Studies which show an 
association with vitamin B12 
Methylenetetrahydrofolate 
reductase (MTHFR) rs1801133 
[288] 
Carbamoyl-phosphate 
synthase 1 (CPS1) rs1047891 
[205] 
Cubulin (CUBN) rs1801222 [205, 234, 253] 
CD320 molecule (CD320) rs2336573 [205, 237, 253] 
Transcobalamin 2 (TCN2) rs1131603 [205, 233] 
Citrate lyase beta like 
(CLYBL) rs41281112 
[205, 206] 
Fucosyltransferase 2 
(FUT2) rs602662 
[205, 233, 234, 253, 254, 258, 
260] 
Transcobalamin 1 (TCN1) rs34324219 [205, 233] 
Fucosyltransferase 6 
(FUT6) rs778805 
[205] 
Methylmalonyl-CoA mutase 
(MUT) 
rs1141321 
 
 
[205, 206, 234] 
 
 
Previous Studies looking at the association of the 10 metabolic disease-related SNPs with 
diabetes and obesity traits: 
 
Gene 
 
  
rs number 
 
  
Studies which show 
its association with 
Type 2 diabetes in 
South Asian 
populations 
Studies which 
show its 
association with 
obesity in South 
Asian 
populations 
Calpain 10 (CAPN10) rs3792267 [374, 528]  
Calpain 10 (CAPN10) rs2975760 [528]  
Calpain 10 (CAPN10) rs5030952 [528]  
Potassium voltage-gated 
channel subfamily J member 
11 (KCNJ11) rs5219 
[529]  
Transcription factor 7-like 2 
(TCF7L2) rs12255372 
[372, 373, 530-532]  
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Transcription factor 7-like 2 
(TCF7L2) rs7903146 
[372, 373, 530, 532-
536] 
[479, 537] 
Fat mass and obesity 
associated (FTO) rs9939609 
[538, 539] [370, 479, 539-
546] 
Melanocortin 4 Receptor 
(MC4R) rs17782313 
 [370, 545, 547-
550] 
Fat mass and obesity 
associated (FTO) rs8050136 
 [371, 542, 544, 
546] 
MC4R 
rs2229616 
 [551] (South East 
Asian population) 
 
Disease cut off-values: 
1) Only normal glucose tolerant (NGT) individuals were included in this study. According to the 
World Health Organization (WHO) NGT individuals are those with 2-h plasma glucose value 
< 7.8 mmol/l (140 mg/dl) [552] 
2) Generalized obesity was defined according to the World Health Organization Asia Pacific 
Guidelines for Asians as non-obese (BMI < 25 kg/m2 ) and obese (BMI ≥ 25 kg/m2 )[422]. 
3) Vitamin B12 status is defined as: 
<148 pmol/L (%) – deficient individuals 
148-221 pmol/L- suboptimal individuals  
>221 pmol/L – normal individuals [2] 
 
 
Plan of action: 
Objective 1: To work out whether each SNP was in Hardy-Weinberg equilibrium 
Aims: Statistical test 
used: 
1) Reason for statistical test used 
2) Outcome of statistical test used 
3) covariates (when appropriate) 
1a) Determine whether the 
observed genotype counts are in 
Hardy-Weinberg equilibrium 
(HWE) 
Chi-Squared test 1. Reason for test:  To compare 
observed genotype counts with 
the values expected under 
Hardy-Weinberg  
2. Outcome of statistical test: To 
test whether a population is in 
HWE at a locus [408, 553] 
Objective 2: To produce descriptive statistics for all the sample members who 
completed an assessment on demographics, fasting biochemical and anthropometric 
measurements. 
2a) To determine the 
descriptive statistics of the 
sample members who 
completed an assessment on 
demographics, fasting 
biochemical and 
anthropometric measurements. 
Descriptive 
statistics: 
Descriptives for 
continuous 
variables 
 
Or 
 
Descriptive 
statistics: 
Frequencies for 
1. Reason for statistical test used: To 
determine baseline measures of the 
outcomes of interest (Will be 
discussed in detail in the point below) 
in all participants of the study 
2. Outcome of statistical test used: To 
determine the mean and standard 
deviation of the following 
demographic, anthropometric and 
biochemical variables:  
• Age (yrs) 
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categorical 
variables 
• Height (cm) 
• Weight (kg) 
• BMI (Kg/m2) 
• WC (cm) 
• Hip (cm) 
• WHR  
• Fat (%) 
• Fasting plasma glucose 
(mg/dl) 
• Fasting serum insulin 
(μIU/ml) 
• Glycated Haemoglobin 
(HbA1c) 
• Glucose (mmol/l) 
• Insulin (mg/dl) 
• Vitamin B12 levels 
(pmol/L) 
• Physical Activity 
Levels [Sedentary (%); 
Moderate (%); 
Vigorous (%)] 
• Total energy (kcal/d) 
• Protein (g) 
• Fat (g) 
• Carbohydrate (g) 
• Dietary fibre (g) 
• Polyunsaturated Fatty 
acid (PUFA) (g) 
•  
2b) To stratify the descriptive 
statistics table into men and 
women. 
 
Students t test  1. Outcome of statistical test used: To 
identify if there are any statistically 
significant differences in the 
demographic, anthropometric and 
biochemical variables between the 
tertiles of vitamin B12 concentration 
between men and women in each 
tertile [408]. 
 
Objective 3: To test the association between the B12-GRS and metabolic-GRS on 
fasting biochemical/anthropometric measurements (Vitamin B12, glucose, Insulin, 
Hbac1, vitamin B12, BMI, Fat % and WHR). 
3a) Testing the association 
between the GRSs with fasting 
biochemical/anthropometric 
measurements, whilst adjusting 
for covariates.   
Univariate linear 
regression   
1) Reason for test: exposure variable 
(GRS) is a categorical variable and the 
outcome variable (fasting biochemical 
trait/anthropometric trait) is a 
continuous variable. 
2) Outcome of test: To identify the 
impact of the genetic variants on the 
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levels of the fasting metabolic trait/ 
anthropometric trait. 
3) Covariates to be adjusted: Age, 
gender, BMI  (BMI was not adjusted, 
when BMI was the continuous 
outcome) [341]. 
Objective 4: To test the interaction between the two GRSs (B12-GRS and metabolic-
GRS) and dietary factors on fasting biochemical/anthropometric measurements 
(Vitamin B12, glucose, Insulin, Hbac1, vitamin B12, BMI, Fat % and WHR). 
4a) Testing the interaction 
between macronutrients and 
SNPs on fasting biochemical 
and anthropometric 
measurements. 
Univariate linear 
regression 
1) Reason for test: exposure variable 
(SNP) is a categorical variable and the 
outcome variable (fasting biochemical 
measurement/ anthropometric 
measurement) is a continuous 
variable. 
2) Outcome of test: identifying the 
impact of the gene variants and the 
macronutrients: carbohydrate, protein, 
fat on fasting biochemical 
measurement/anthropometric 
measurement  
3) Covariates to be adjusted: Age, 
gender, BMI [341] 
 
 
4b) Testing to find out if high, 
low or medium consumption of 
these macronutrients are 
causing the interaction  
Univariate linear 
regression 
1) Reason for test: exposure variable 
(SNP) is a categorical variable and 
outcome variable (fasting biochemical 
measurement/anthropometric 
measurement) is a continuous 
variable. 
2) Outcome of test: identifying the 
impact of gene variants and the 
consumption of different quantities of 
the macronutrient on fasting 
biochemical 
measurement/anthropometric 
measurement  
3) Covariates to be adjusted: Age, 
gender, BMI [341].  
 
(Data split based on: Tertiles of 
carbohydrate, protein and fat). 
SPECIAL NOTES: 
When looking at carbohydrates, 
Proteins and Fat in grams, you 
will need to adjust for Kcal. If 
you are using the percentage 
energy intake of the 
Compute 
variables 
• For Carbohydrate interactions: 
1g of Carbohydrates = 4kcal 
• For Fat interactions: 
1g=9 kcal 
• For Protein interactions: 
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macronutrients, you do not 
need to adjust for Kcal, as it has 
already been adjusted for. 
1g= 4kcal [526] 
 When significant interactions 
with macronutrients are 
detected, further investigation 
will take place to underline the 
specific type of macronutrient 
responsible for the interaction.  
 
 
 
Univariate linear 
regression  
if interactions with fat intake are 
significant, then 
• Test for interaction between 
SNPs and saturated fatty acid 
intake, SNPs and 
monounsaturated fatty acid 
intake and SNPs and 
polyunsaturated fatty acid 
intake. Tertiles will be made 
for each of these dietary sub-
groups. 
 
After carrying out the 
interaction analysis using 
Univariate linear regression and 
obtaining P values, make sure 
adjustments are made to P 
values when several dependent 
or independent statistical tests 
are being performed 
simultaneously on a single data 
set. 
Bonferroni 
Correction 
2) This method adjusts for 
multiple comparison and 
reduces experiment-wise error 
rate in genetic association 
studies [527] 
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9.3  Research analysis plan: Evidence for the association between FTO gene 
variants and vitamin B12 concentrations in an Asian Indian population 
 
Main study objective: 
To investigate the association of two previously studied FTO polymorphisms (rs8050136 and 
rs2388405) with vitamin B12 concentrations and metabolic disease-related outcomes and 
examined whether these associations were modified by dietary factors and physical activity. 
 
Abbreviations:  
• BMI: Body Mass Index 
•  WHR: Waist to Hip Ratio 
•  WC: Waist Circumference 
• SNP: Single Nucleotide Polymorphism 
• TG: Triglyceride 
• HDL: High Density Lipoprotein 
• LDL: Low Density Lipoprotein 
• HbAC1: Glycated Haemoglobin 
 Specific aims of study: 
1) Firstly, we assessed the relationship between genetic variants thought to have a role in 
metabolic disease related traits with biochemical and metabolic traits (Homocysteine, folic 
acid, obesity, BMI, waist circumference). 
2) Secondly, we assessed the effect of genetic variants thought to have a role in metabolic 
disease-related traits on serum vitamin B12. 
3) Finally, we tested the interaction between the metabolic disease-related SNPs and dietary 
factors on fasting vitamin B12 levels and (Homocysteine, folic acid, obesity, BMI, waist 
circumference). 
 
Diagram representing the study design  
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Previous Studies looking at the association of the two SNPs with obesity related traits: 
Gene  rs number  
Studies which have previously 
investigated the association of 
this SNP with obesity traits. 
Fat mass and obesity 
associated (FTO) rs2388405 
[418] [419] [420]. 
Fat mass and obesity 
associated (FTO) rs8050136 
[371, 542, 544, 546] 
 
 
Disease cut off-values: 
1. In The CURES 2003 study, diabetes was diagnosed  'based on the past medical 
history, drug treatment for diabetes, and/or using the ADA fasting criteria’ [410]. 
2. Generalized obesity was defined according to the World Health Organization Asia 
Pacific Guidelines for Asians as non-obese (BMI < 25 kg/m2 ) and obese (BMI ≥ 
25 kg/m2 ) [422]. 
3. Vitamin B12 status is defined as: 
<148 pmol/L (%) – deficient individuals 
148-221 pmol/L- suboptimal individuals  
>221 pmol/L – normal individuals [2] 
 
 
Objective 1: To work out whether each SNP was in Hardy-Weinberg equilibrium 
Aims: Statistical test 
used: 
1) Reason for statistical test used 
2) Outcome of statistical test used 
3) covariates (when appropriate) 
1a) Determine whether the 
observed genotype counts 
are in Hardy-Weinberg 
equilibrium (HWE) 
Chi-Squared test 3. Reason for test:  To compare 
observed genotype counts with the 
values expected under Hardy-
Weinberg  
4. Outcome of statistical test: To test 
whether a population is in HWE at a 
locus [408, 553] 
Objective 2: To produce descriptive statistics for the sample members who completed an 
assessment on demographics, fasting biochemical and anthropometric measurements. 
2a) To determine the 
descriptive statistics of 
sample members who 
completed an assessment on 
demographics and 
anthropometric measures of 
the outcomes of interest. 
Descriptive 
statistics: 
Descriptives for 
continuous 
variables 
 
Or 
 
Descriptive 
statistics: 
Frequencies for 
1. Reason for statistical test used: To 
determine demographic and anthropometric 
measures of the outcomes of interest (Will be 
discussed in detail in the point below) in all 
participants of the study 
2. Outcome of statistical test used: To 
determine the mean and standard deviation of 
the following demographic, anthropometric 
and biochemical variables:  
• Age (yrs) 
• BMI (Kg/m2) 
• WC (cm) 
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categorical 
variables 
• WHR  
• Obese cases (%) 
• Fasting plasma glucose 
(mg/dl) 
• Fasting serum insulin 
(μIU/ml) 
• Glycated Haemoglobin 
(HbA1c) 
• Glucose (mmol/l) 
• Insulin (mg/dl) 
• Vitamin B12 levels (pmol/L) 
• PAL [Sedentary (%); 
Moderate (%); Vigorous (%)] 
• Total Carbohydrate energy % 
• Fat energy % 
• Protein energy % 
• Dietary fibre (g) 
 
 
2b) To stratify the 
descriptive statistics table 
into individuals who are 
diabetics, pre-diabetics and 
Normal Glucose tolerance 
individuals (NGT).  
Students t test 1. Reason for statistical test used: To compare 
the mean and standard deviations of 
demographic, anthropometric and 
biochemical variables between each group  
2. Outcome of statistical test used: To 
identify if there are any statistically 
significant differences in the demographic, 
anthropometric and biochemical variables 
between each group (diabetics, pre-diabetics, 
NGT and combined individuals). 
 
Objective 3: To test the relationship between genetic variants thought to have a role in 
metabolic disease with biochemical and metabolic traits (Homocysteine, folic acid, obesity, 
BMI, waist circumference). 
3a) To test for the 
association between the 
GRS and 
biochemical/anthropometric 
trait  
Univariate linear 
regression   
1) Reason for test: The exposure variable 
(GRS) is a categorical variable and the 
outcome variable (biochemical 
trait/anthropometric trait) is a continuous 
variable. 
2) Outcome of test: identifying the impact of 
the variants on the levels of the metabolic 
trait/anthropometric trait  
3) Covariates to be adjusted: Age, gender, 
BMI (BMI was not adjusted, when BMI was 
the continuous outcome). 
-When using the combined group (Diabetics, 
pre-diabetics and NGT), diabetes was 
adjusted as a confounder [341]. 
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Special notes: For the BMI SNPs, the effect 
allele was the allele which raises BMI. This 
allele was compared with BMI raising alleles 
from Speliotes et al. [414, 554] 
Objective 4: To test the effect of genetic variants thought to have a role in metabolic disease-
related traits on serum vitamin B12 
4a) Testing the association 
between the GRS with 
fasting vitamin B12 
concentrations 
 
Univariate linear 
regression 
1) Reason for test: exposure variable (GRS) is 
a categorical variable and the outcome 
variable (vitamin B12 concentrations) is a 
continuous variable. 
2) Outcome of test: identifying the impact of 
the variants on the levels of vitamin B12  
3) Covariates to be adjusted: Age, gender, 
BMI (BMI was not adjusted, when BMI was 
the continuous outcome). 
-When using the combined group (Diabetics, 
pre-diabetics and NGT), diabetes was 
adjusted as a confounder [341]. 
 
Special notes: For the BMI SNPs, the effect 
allele was the allele which raises BMI. This 
allele was compared with BMI raising alleles 
from Speliotes et al. [414, 554] 
Objective 6: Testing the interaction between the metabolic disease-related SNPs and dietary 
factors on vitamin B12 levels 
6a) Testing the interaction 
between macronutrients and 
SNPs on vitamin B12 levels 
in each group  
Univariate linear 
regression 
1) Reason for test: The exposure variable 
(GRS) is a categorical variable and the 
outcome variable (vitamin B12 levels) is a 
continuous variable. 
2) Outcome of test: identifying the impact of 
the gene variants and the macronutrients: 
carbohydrate, protein, fat on vitamin B12 
levels  
3) Covariates to be adjusted: Age, gender, 
BMI [341] 
 
-When using the combined group (Diabetics, 
pre-diabetics and NGT), diabetes was 
adjusted as a confounder. 
 
6b) Testing to find out if 
high, low or medium 
consumption of these 
macronutrients are causing 
the interaction  
Univariate linear 
regression 
1) Reason for test: The exposure variable 
(GRS) is a categorical variable and the 
outcome variable (vitamin B12 levels) is a 
continuous variable. 
2) Outcome of test: identifying the impact of 
gene variants and the consumption of 
different quantities of the macronutrient on 
vitamin B12 levels. 
368 
 
3) Covariates to be adjusted: Age, gender, 
BMI [341].  
-When using the combined group (Diabetics, 
pre-diabetics and NGT), diabetes was 
adjusted as a confounder. 
(Data split based on: Tertiles of carbohydrate, 
protein and fat) [253]. 
SPECIAL NOTES: 
When looking at 
carbohydrates, proteins and 
fat in grams, you will need 
to adjust for Kcal. If you are 
using the percentage energy 
intake of the 
macronutrients, you do not 
need to adjust for Kcal, as it 
has already been adjusted 
for. 
Compute 
variables 
• For carbohydrate interactions: 
1g of carbohydrates = 4kcal 
• For fat interactions: 
1g=9 kcal 
• For protein interactions: 1g= 4kcal 
[526] 
 When significant 
interactions with 
macronutrients are detected, 
further investigation will 
take place to underline the 
specific type of 
macronutrient responsible 
for the interaction.  
 
 
 
Univariate linear 
regression  
For fat interactions: 
• To Test for the interaction between 
SNPs with saturated fatty acid intake, 
SNPs with monounsaturated fatty 
acid intake and SNPs with 
polyunsaturated fatty acid intake. 
Tertiles will be made for each of these 
sub-groups. 
 
After carrying out the 
interaction analysis using 
Univariate linear regression 
and obtaining P values, 
make sure adjustments are 
made to P values when 
several dependent or 
independent statistical tests 
are being performed 
simultaneously on a single 
data set. 
Bonferroni 
Correction 
3) This method adjusts for multiple 
comparison and reduces experiment-
wise error rate in genetic association 
studies [527] 
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9.4  Research plan – A nutrigenetic approach for investigating the relationship 
between vitamin B12 status and metabolic traits in Indonesian women 
(Replication of the Sri Lankan GOOD study) 
 
Main objectives: 
The aim of the present study was to explore the relationships between metabolic traits and 
vitamin B12 status in a cohort of healthy Indonesian women and to investigate whether these 
relationships were modified by dietary intake using a genetic approach.   
 
Hypothesis: 
I will test the hypotheses that low plasma vitamin B12 concentrations caused by genetic 
variants are associated with an increased risk of obesity and type 2 diabetes, and that the effect 
of genetic variants associated with high BMI on obesity traits is partly mediated through 
reduction of serum vitamin B12 concentration. The latter hypothesis requires that genetically 
increased obesity traits are associated with low vitamin B12 concentration and with increased 
risk of diabetes/obesity traits. 
 
Specific aims: 
 
 
 
Diagram representing the study design: The diagram shows four possible associations, and 
four possible interactions. One-sided arrows with unbroken lines represent genetic 
associations and one-sided arrows with broken lines represent interactions between a lifestyle 
factor and GRS on serum vitamin B12/ metabolic traits.   
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1. I will test the association between the metabolic-GRS and vitamin B12 concentrations 
and metabolic disease-related traits (glucose, insulin, HbA1c, BMI, WC, body fat 
percentage) 
2. I will then test the associations between the B12 –GRS and vitamin B12 status and 
metabolic disease related traits.  
3. Lastly, I will test whether these genetic associations are modified by lifestyle factors 
(macronutrient intake and physical activity levels).  
 
 
Previous Studies looking at the association of the 10 B12-related SNPs with vitamin B12 
concentrations: 
Gene SNP rs number Studies which show an 
association with vitamin 
B12 
Methylenetetrahydrofolate 
reductase (MTHFR) rs1801133 
[288] 
Carbamoyl-phosphate 
synthase 1 (CPS1) rs1047891 
[205] 
Cubulin (CUBN) rs1801222 [205, 234, 253] 
CD320 molecule (CD320) rs2336573 [205, 237, 253] 
Transcobalamin 2 (TCN2) rs1131603 [205, 233] 
Fucosyltransferase 2 
(FUT2) rs602662 
[205, 233, 234, 253, 254, 258, 
260] 
Transcobalamin 1 (TCN1) rs34324219 [205, 233] 
Fucosyltransferase 6 
(FUT6) rs778805 
[205] 
Methylmalonyl-CoA mutase 
(MUT) 
rs1141321 
 
 
[205, 206, 234] 
 
 
Previous Studies looking at the association of the 10 metabolic disease-related SNPs with 
diabetes and obesity traits: 
 
Gene 
 
  
SNP rs number 
 
  
Studies which show its 
association with Type 
2 diabetes in South 
Asian populations 
Studies which show its 
association with 
obesity in South Asian 
/ South East Asian 
populations 
Calpain 10 (CAPN10) rs3792267 [374, 528]  
Calpain 10 (CAPN10) rs5030952 [528]  
Potassium voltage-
gated channel 
subfamily J member 11 
(KCNJ11) rs5219  
[529]  
Transcription factor 7-
like 2 (TCF7L2) rs12255372 
[372, 373, 530-532]  
Transcription factor 7-
like 2 (TCF7L2) rs7903146 
[372, 373, 530, 532-
536] 
[479, 537] 
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Fat mass and obesity 
associated (FTO) rs9939609 
[538, 539] [370, 479, 539-546] 
Melanocortin 4 
Receptor (MC4R) rs17782313 
 [370, 545, 547-550] 
Fat mass and obesity 
associated (FTO) rs8050136 
 [371, 542, 544, 546] 
MC4R rs2229616  [551] 
 
 
Disease cut off-values: 
4) Only normal glucose tolerant (NGT) individuals were included in this study. 
According to the World Health Organization (WHO) NGT individuals are those with 2-h 
plasma glucose value < 7.8 mmol/l (140 mg/dl) [552] 
5) Generalized obesity was defined according to the World Health Organization Asia 
Pacific Guidelines for Asians as non-obese (BMI < 25 kg/m2 ) and obese (BMI ≥ 25 kg/m2 
)[422]. 
Vitamin B12 status is defined as [2]: 
<148 pmol/L (%) – deficient individuals 
148-221 pmol/L- suboptimal individuals  
>221 pmol/L – normal individuals 
 
Plan of action: 
Objective 1: To work out whether the SNPs are in Hardy Weinberg 
Aims: Statistical test 
used: 
1) Reason for statistical test used 
2) Outcome of statistical test used 
3) covariates (when appropriate) 
1a) Determine whether the 
observed genotype counts are in 
Hardy-Weinberg equilibrium 
(HWE) 
Chi-Squared test 1.Reason for test:  To compare 
observed genotype counts with the 
values expected under Hardy-
Weinberg  
2. Outcome of statistical test: To 
test whether a population is in 
HWE at a locus [408, 553] 
Objective 2: To produce descriptive statistics for all the sample members who 
completed an assessment on demographics, fasting biochemical and anthropometric 
measurements. 
2a) To determine the 
descriptive statistics of the 
sample members who 
completed an assessment on 
demographics, fasting 
biochemical and 
anthropometric measurements. 
Descriptive 
statistics: 
Descriptives for 
continuous 
variables 
 
Or 
 
Descriptive 
statistics: 
Frequencies for 
categorical 
variables 
1. Reason for statistical test used: To 
determine baseline measures of the 
outcomes of interest (Will be 
discussed in detail in the point below) 
in all participants of the study 
2. Outcome of statistical test used: To 
determine the mean and standard 
deviation of the following 
demographic, anthropometric and 
biochemical variables:  
• Age (yrs) 
• Height (cm) 
• Weight (kg) 
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• BMI (Kg/m2) 
• WC (cm) 
• Hip (cm) 
• WHR  
• Fat (%) 
• Fasting plasma glucose 
(mg/dl) 
• Fasting serum insulin 
(μIU/ml) 
• Glycated Haemoglobin 
(HbA1c) 
• Glucose (mmol/l) 
• Insulin (mg/dl) 
• Vitamin B12 levels 
(pmol/L) 
• Physical Activity 
Levels [Sedentary (%); 
Moderate (%); 
Vigorous (%)] 
• Total energy (kcal/d) 
• Protein (g) 
• Fat (g) 
• Carbohydrate (g) 
• Dietary fibre (g) 
• Polyunsaturated Fatty 
acid (PUFA) (g) 
•  
2b) To stratify the descriptive 
statistics table into men and 
women. 
 
Students t test  1. Outcome of statistical test used: To 
identify if there are any statistically 
significant differences in the 
demographic, anthropometric and 
biochemical variables between the 
tertiles of vitamin B12 concentration 
between men and women in each 
tertile [408]. 
 
Objective 3: To test the association between the B12-GRS and metabolic-GRS on 
fasting biochemical/anthropometric measurements (Vitamin B12, glucose, insulin, 
HbA1c, BMI, WC, body fat percentage) 
3a) Testing the association 
between the GRSs with fasting 
biochemical/anthropometric 
measurements, whilst adjusting 
for covariates.   
Univariate linear 
regression   
1) Reason for test: exposure variable 
(GRS) is a categorical variable and the 
outcome variable (fasting biochemical 
trait/anthropometric trait) is a 
continuous variable. 
2) Outcome of test: To identify the 
impact of the genetic variants on the 
levels of the fasting metabolic trait/ 
anthropometric trait. 
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3) Covariates to be adjusted: Age, 
gender, BMI  (BMI was not adjusted, 
when BMI was the continuous 
outcome) [341]. 
Objective 4: To test the interaction between the two GRSs (B12-GRS and metabolic-
GRS) and dietary factors on fasting biochemical/anthropometric measurements 
(Vitamin B12, glucose, insulin, HbA1c, BMI, WC, body fat percentage) 
4a) Testing the interaction 
between macronutrients and 
SNPs on fasting biochemical 
and anthropometric 
measurements. 
Univariate linear 
regression 
1) Reason for test: exposure variable 
(SNP) is a categorical variable and the 
outcome variable (fasting biochemical 
measurement/ anthropometric 
measurement) is a continuous 
variable. 
2) Outcome of test: identifying the 
impact of the gene variants and the 
macronutrients: carbohydrate, protein, 
fat on fasting biochemical 
measurement/anthropometric 
measurement  
3) Covariates to be adjusted: Age, 
gender, BMI [341] 
 
 
4b) Testing to find out if high, 
low or medium consumption of 
these macronutrients are 
causing the interaction  
Univariate linear 
regression 
1) Reason for test: exposure variable 
(SNP) is a categorical variable and 
outcome variable (fasting biochemical 
measurement/anthropometric 
measurement) is a continuous 
variable. 
2) Outcome of test: identifying the 
impact of gene variants and the 
consumption of different quantities of 
the macronutrient on fasting 
biochemical 
measurement/anthropometric 
measurement  
3) Covariates to be adjusted: Age, 
gender, BMI [341].  
 
(Data split based on: Tertiles of 
carbohydrate, protein and fat). 
SPECIAL NOTES: 
When looking at carbohydrates, 
Proteins and Fat in grams, you 
will need to adjust for Kcal. If 
you are using the percentage 
energy intake of the 
macronutrients, you do not 
Compute 
variables 
• For Carbohydrate interactions: 
1g of Carbohydrates = 4kcal 
• For Fat interactions: 
1g=9 kcal 
• For Protein interactions: 
1g= 4kcal [526] 
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need to adjust for Kcal, as it has 
already been adjusted for. 
 When significant interactions 
with macronutrients are 
detected, further investigation 
will take place to underline the 
specific type of macronutrient 
responsible for the interaction.  
 
 
 
Univariate linear 
regression  
if interactions with fat intake are 
significant, then 
• Test for interaction between 
SNPs and saturated fatty acid 
intake, SNPs and 
monounsaturated fatty acid 
intake and SNPs and 
polyunsaturated fatty acid 
intake. Tertiles will be made 
for each of these dietary sub-
groups. 
 
After carrying out the 
interaction analysis using 
Univariate linear regression and 
obtaining P values, make sure 
adjustments are made to P 
values when several dependent 
or independent statistical tests 
are being performed 
simultaneously on a single data 
set. 
Bonferroni 
Correction 
3. This method adjusts for 
multiple comparison and 
reduces experiment-wise error 
rate in genetic association 
studies [527] 
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9.5 Analysis plan: A genetic approach to investigate the relationship between 
vitamin B12 status and cardiometabolic traits in response to changes in dietary 
fat composition in adults with moderate cardiovascular disease risk   
 
  
Hypothesis:  
 
The modification of dietary fat intake has been shown to affect vitamin B12 status in rats [472], 
this post-hoc analysis will present additional outcome measures from the DIVAS study 
exploring the effect of dietary fat composition on vitamin B12 status in individuals with 
moderate CVD risk. The main of this study is to investigate whether genetic polymorphisms 
contribute to any observable changes in vitamin B12 status and cardiometabolic disease risk 
markers, a retrospective post hoc analysis of the DIVAS study will be conducted. Thus, in the 
current study I will aim to investigate whether nine SNPs (6 metabolic SNPs and 3 vitamin 
B12 SNPs) modified the response of vitamin B12 concentrations and cardiometabolic traits, 
after substitution of SFA with MUFA or polyunsaturated fatty acids (n-6 PUFA) in 119 
participants at moderate CVD risk. 
 
 
Objectives:  
 
To prove this hypothesis, we will   
 
• Examine association between (6 metabolic SNPs and 3 vitamin B12 SNPs) 
and changes 13 phenotypic outcomes (vitamin B12, 24 h ambulatory systolic blood 
pressure, 24 h ambulatory diastolic blood pressure, total cholesterol, HDL cholesterol, LDL 
cholesterol, TAG, glucose, insulin, HOMA-IR, BMI, WC and WHR) after a 16-weeks 
dietary fat intervention. 
• Investigate interaction between 6 metabolic SNPs and 3 vitamin B12 SNPs and the 
three intervention diets on changes in 13 phenotypic outcomes after 16-weeks intervention.  
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Plan of action: 
 
Objectives   Statistical 
test   
Fixed factor   Dependent factor   Covariates   
Association   General Linear 
regression   
The metabolic-GRS was generated 
from the SNPs in the genes FTO 
(rs8050136 and rs9939609), TCF7L2 
(rs7903146 and rs12255372) and 
MC4R (rs17782313 and rs2229616). 
 
The B12-GRS was generated from the 
SNPs in the gene FUT2 (rs602662, 
rs492602 and rs16982241). 
Changes in vitamin B12 
concentrations and cardiometabolic 
traits (24 h ambulatory systolic blood 
pressure, 24 h ambulatory diastolic 
blood pressure, total cholesterol, 
HDL cholesterol, LDL cholesterol, 
TAG, glucose, insulin, HOMA-IR, 
BMI, WC and WHR) at baseline (visit 
1) and after 16 weeks (visit 2) in  
Age, gender, BMI, and 
ethnicity [13]  
Interaction   General Linear 
regression   
The metabolic-GRS was generated 
from the SNPs in the genes FTO 
(rs8050136 and rs9939609), TCF7L2 
(rs7903146 and rs12255372) and 
MC4R (rs17782313 and rs2229616). 
 
The B12-GRS was generated from the 
SNPs in the gene FUT2 (rs602662, 
rs492602 and rs16982241) 
 
The three-intervention diet (group 1 
high SFA diet, group 2 high MUFA 
diet, and group 3 High PUFA diet)  
Changes in vitamin B12 
concentrations and cardiometabolic 
traits at baseline (visit 1) and after 16 
weeks (visit 2). 
Age, gender, BMI, and 
ethnicity [13]  
 
